title,nn
age,27197
gender,20950
region of enrollment,15406
"sex: female, male",7312
race (nih/omb),3762
"race/ethnicity, customized",3531
"age, customized",3046
ethnicity (nih/omb),2640
weight,873
height,642
body mass index (bmi),542
body mass index,492
"gender, customized",437
bmi,291
body weight,190
eastern cooperative oncology group (ecog) performance status,164
"sex/gender, customized",163
duration of diabetes,121
education,112
smoking status,107
fasting plasma glucose (fpg),106
hba1c,95
race/ethnicity,86
systolic blood pressure,86
marital status,84
diastolic blood pressure,78
smoking classification,77
race and ethnicity not collected,75
race,68
histology,65
diagnosis,62
ethnicity,60
glycosylated haemoglobin (hba1c),59
smoking history,58
glycosylated hemoglobin (hba1c),56
hypertension,53
waist circumference,53
hcv rna category,50
ecog performance status,48
il28b status,48
menopausal status,45
diabetes,44
fasting plasma glucose,44
hcv rna,43
triglycerides,41
parity,39
performance status,39
total cholesterol,39
hcv genotype,38
heart rate,38
body surface area (bsa),36
hemoglobin a1c,33
weight (kg),33
gestational age,32
gleason score,32
body surface area,30
smoking,30
disease stage,29
eastern cooperative oncology group performance status,29
karnofsky performance status,29
employment status,28
fitzpatrick skin type,28
alcohol classification,26
estimated glomerular filtration rate (egfr),25
fasting glucose,25
hiv-1 rna,25
tobacco use,25
diabetes duration,24
diabetes mellitus,24
hemoglobin,24
hemoglobin a1c (hba1c),24
alcohol consumption,23
stage,23
baseline weight,22
cell type,22
cirrhosis status,21
hemoglobin a1c (a1c),21
lesion characteristics,21
alcohol use,20
blood pressure,20
cd4 cell count,20
serum creatinine,20
birth weight,19
disease duration,19
education level,19
prior chemotherapy,19
bmi (body mass index),18
body mass index (bmi) continuous,18
coronary artery disease,18
fasting insulin,18
medical history,18
pathological diagnosis,18
disease status,17
eastern cooperative oncology group (ecog) performance status (ps),17
geographic region,17
height (cm),17
primary diagnosis,17
stage of prostate cancer,17
cardiac history,16
cd4 count,16
diabetes status,16
female reproductive status,16
histologic type,16
montgomery ã…sberg depression rating scale (madrs) total score,16
type of surgery,16
years of education,16
caffeine consumption,15
creatinine,15
diabetes type,15
glucose,15
history of hypertension,15
hiv-1 rna category,15
alanine aminotransferase (alt),14
baseline bmi,14
c-reactive protein,14
comorbidities,14
current smoker,14
forced expiratory volume in 1 second (fev1),14
income,14
karnofsky performance status (kps),14
ldl-c concentration,14
primary tumor site,14
region enroll,14
time since diagnosis,14
tumor grade,14
albumin,13
baseline hba1c,13
cigarettes per day,13
clinical global impression - severity scale score,13
employment,13
hyperlipidemia,13
region,13
tumor type,13
apolipoprotein b concentration,12
cardiac risk factors,12
clinical stage,12
duration of rheumatoid arthritis,12
hamilton anxiety scale total score,12
hiv disease status,12
insulin,12
metabolic syndrome,12
non-high-density lipoprotein cholesterol (non-hdl-c) concentration,12
prostate specific antigen (psa),12
prostate volume,12
body temperature,11
caffeine classification,11
cancer stage,11
congestive heart failure,11
creatinine clearance,11
duration of disease,11
fev1,11
hormone receptor status,11
left ventricular ejection fraction,11
lesion characteristic: lesion location,11
primary disease,11
prior therapy,11
2-hour postprandial plasma glucose (ppg),10
bmi (kg/m^2),10
bmi (kg/m2),10
body-mass index,10
c-reactive protein (crp),10
calculated ldl-c in mg/dl,10
calculated ldl-c in mmol/l,10
cluster of differentiation 4 (cd4) cell count,10
donor type,10
duration of asthma,10
genotype,10
history of diabetes,10
history of smoking,10
intraocular pressure,10
karnofsky performance score,10
karnofsky performance status scale,10
left ventricular ejection fraction (lvef),10
number of metastatic sites,10
number of prior therapies,10
prior surgery,10
pulse,10
skin type,10
time since prostate cancer diagnosis,10
tumor stage,10
alcohol status,9
complications,9
curative intent,9
depression,9
disease stage at study entry,9
disease type,9
duration of surgery,9
eastern cooperative oncology group (ecog),9
eastern cooperative oncology group performance status (ecog ps),9
etiology,9
fasting blood glucose,9
glucose excursion,9
hdl,9
hiv status,9
lesion characteristic: target lesion vessel,9
platelet count,9
previous treatment,9
primary site,9
primary tumor type,9
prior radiotherapy,9
qrs duration,9
total bilirubin,9
total cholesterol/hdl-c ratio,9
triglycerides (tg),9
adiponectin,8
alt,8
atrial fibrillation,8
breakdown of complications,8
cancer type,8
cause of amblyopia,8
cd4+ t-cell count,8
country,8
diabetes history,8
duration of type 2 diabetes,8
dyslipidemia,8
ecog (eastern cooperative oncology group) performance status,8
educational level,8
egfr,8
ejection fraction,8
expanded disability status scale (edss) score,8
fasting c-peptide,8
fpg,8
glomerular filtration rate (gfr),8
healthcare category,8
ldl cholesterol,8
madrs,8
menopause status,8
montgomery-asberg depression rating scale (madrs) total score,8
phosphorus,8
prior chemotherapy regimens,8
prior treatment,8
pulse rate,8
serum testosterone levels,8
smoker,8
stage of disease,8
swollen joint count,8
tender joint count,8
alcohol history,7
alkaline phosphatase,7
annual income,7
apolipoprotein b/apolipoprotein a-1 ratio,7
baseline platelet count,7
body height,7
body mass index (kg/m^2),7
body mass index (kg/m2),7
cardiac index,7
cd4 cell count category,7
cgi-s,7
cholesterol,7
co-morbidities,7
corrected calcium,7
daytime nasal symptoms score,7
diastolic bp,7
estimated glomerular filtration rate,7
estrogen receptor status,7
fasting triglycerides,7
forced vital capacity (fvc),7
grade,7
hba1c (%),7
hepatitis c virus (hcv) genotype,7
highest level of education,7
il28b genotype,7
indication,7
karnofsky score,7
leptin,7
lesion characteristics: american college of cardiology (acc)/american heart association (aha) class,7
lesion location,7
married,7
mean number of micturitions per 24 hours,7
ms subtype,7
number of target lesions,7
number of tender joints,7
nyha class,7
pah etiology,7
positive and negative syndrome scale (panss) total score,7
pregnancy status,7
primary language,7
progesterone receptor status,7
rai stage,7
site of metastasis,7
systolic blood pressure (sbp),7
systolic bp,7
temperature,7
time since initial diagnosis,7
total testosterone,7
tumor location,7
type of cancer,7
type of diabetes,7
weight group,7
who performance status,7
agecategorical,6
alanine aminotransferase,6
asthma,6
baseline glycosylated hemoglobin (hba1c),6
bmi category,6
"bmi, continuous",6
cd4+ cell count,6
chemotherapy regimen,6
clinical global impressions of severity scale (cgi-s),6
conditioning regimen,6
dermatology life quality index (dlqi),6
diastolic blood pressure (dbp),6
disease,6
disease diagnosis,6
disease site,6
distance visual acuity in amblyopic eye,6
distance visual acuity in fellow eye,6
duration of psoriasis,6
ecog,6
ecog performance status (ps),6
ecog ps,6
employed,6
estradiol,6
ethnic origin,6
fasting serum glucose,6
fvc,6
glycated hemoglobin,6
glycosylated hemoglobin a1 (hba1c),6
gravidity,6
gynecologic oncology group (gog) performance status,6
hamilton rating scale for depression-17 items (hamd-17) total score at randomization,6
hba1c (hemoglobin a1c),6
hdl-c,6
hepatitis c virus (hcv) rna,6
history of alcohol consumption,6
initial pathological diagnosis,6
insurance status,6
international prognostic scoring system (ipss),6
karnofsky performance-status score,6
language,6
ldl,6
ldl-c,6
lesion characteristic - pre-procedure thrombolysis in myocardial infarction (timi) flow,6
lesion length,6
lipoprotein(a) concentration,6
low-density lipoprotein cholesterol (ldl-c),6
mean level of urgency,6
mean number of nocturia episodes per 24 hours,6
montgomery-asberg depression rating scale (madrs) total score at randomization,6
new york heart association (nyha) classification,6
nicotine use,6
nighttime symptoms score,6
number of ms relapses,6
number of swollen joints,6
pain,6
performance score,6
predisposition to hypersensitivity,6
presence of medical history,6
previous surgery,6
primary site of disease,6
prior radiation,6
prior radiation therapy,6
prior therapies,6
pulmonary vascular resistance,6
renal function,6
rheumatoid factor (rf) status,6
sitting systolic blood pressure,6
statin use,6
stratification factor: ldl-c level,6
stroke,6
target disease severity,6
time since most recent ms relapse onset,6
total cholesterol (tc),6
tumor site,6
waist/hip ratio,6
weight (lbs),6
17-item hamilton depression rating scale (hamd-17) total score,5
alcohol,5
apolipoprotein b,5
apolipoprotein b/apolipoprotein a1 ratio,5
asa class,5
asa physical status,5
background pah therapy,5
basal insulin daily dose,5
baseline body mass index,5
baseline diastolic blood pressure,5
baseline eastern cooperative oncology group (ecog) performance status,5
baseline fasting plasma glucose,5
baseline height,5
baseline hemoglobin,5
beck depression inventory,5
birthweight,5
bone age,5
cardiomyopathy,5
central retinal thickness,5
child-pugh score,5
cigarettes smoked per day,5
cirrhosis,5
concomitant drug,5
concomitant medications,5
current tobacco use,5
daytime eye symptoms score,5
duration of illness,5
duration of infertility,5
duration of oab symptoms,5
duration of pain,5
duration of psoriatic arthritis,5
educational attainment,5
erythrocyte sedimentation rate (esr),5
expanded disability status scale (edss),5
fasting blood plasma glucose (fpg),5
fasting glucagon,5
fat mass,5
general medical history,5
glycated hemoglobin (hba1c),5
glycosylated hemoglobin a1c (hba1c),5
ham-a,5
hba1c (glycosylated haemoglobin),5
hdl cholesterol,5
health literacy,5
heart failure,5
hematocrit,5
hepatitis c virus rna distribution,5
high-density lipoprotein cholesterol (hdl-c),5
high density lipoprotein,5
histologic grade,5
history of myocardial infarction,5
hospital anxiety and depression â€“ depression subscale,5
household income,5
insulin sensitivity,5
insurance,5
ldl-cholesterol,5
lesion characteristic: percent diameter stenosis,5
luteinizing hormone (lh),5
lvef,5
mean volume voided per micturition,5
measurable disease,5
metformin daily dose,5
no. of prior lines of therapy,5
nodal status,5
nulliparous,5
number of prior relapses,5
parathyroid hormone,5
patient health questionnaire-9,5
plasma human immunodeficiency virus (hiv) ribonucleic acid (rna),5
platelets,5
postvoid residual volume (pvr),5
presence of complications,5
prior hcv treatment,5
prior stroke,5
respiratory rate,5
screening hba1c,5
seated systolic blood pressure,5
serum urate,5
sheehan disability scale (sds) total score,5
stroke type,5
sweat chloride,5
t stage,5
total ige,5
tumor histology,5
type of overactive bladder (oab),5
very low-density lipoprotein cholesterol (vldl-c) concentration,5
viral load,5
visual acuity,5
waist,5
weight continuous,5
white blood cell count,5
world health organization (who) functional class,5
xanthine/caffeine consumption,5
years since diagnosis,5
2-hour postprandial glucose,4
24-item hamilton depression scale total score,4
age at td diagnosis,4
age customized,4
age group,4
antiplatelet therapy,4
apache ii score,4
atopic dermatitis total score,4
background oral antidiabetic agent (oad),4
baseline body mass index (bmi),4
baseline intraocular pressure,4
baseline national eye institute 25-item visual function questionnaire (nei vfq-25) total score,4
baseline pain score,4
baseline systolic blood pressure,4
basis for pathological diagnosis,4
bipolar subtype,4
body fat,4
body mass,4
body mass index (bmi) category,4
"body mass index, continuous",4
borg dyspnea index,4
breakdown of medical history,4
breast cancer history,4
cardiac history: ejection fraction,4
cardiac output,4
cardiovascular disease,4
"cd4 count, continuous",4
cd4%,4
cd4+ t cell count,4
cgi-s score,4
clinical global impression - severity of illness (cgi-s),4
clinical t stage,4
complication,4
corrected calcium phosphorus product (cca x p),4
current smokers,4
current smoking,4
diabetic complications,4
disease histology,4
disease status at transplantation,4
drinks per day,4
drug abuse,4
duration of diabetes mellitus,4
duration of hypertension,4
eastern cooperative oncology group (ecog) performance status score,4
ecog performance score,4
epworth sleepiness scale (ess),4
extent of disease,4
fagerstrom test for nicotine dependence,4
fasting plasma glucose (fpg) at baseline,4
fasting plasma insulin (fpi),4
fat free mass,4
fev1 (% predicted),4
fev1 percent predicted,4
fev1/fvc,4
forced expiratory volume in 1 second (fev1) % predicted,4
free testosterone,4
french-american-british (fab) classification,4
fsh,4
functional independence measure,4
gestational age at enrollment,4
glomerular filtration rate,4
glycated hemoglobin a1c (hba1c),4
ham-d-24,4
hbv dna,4
hcv rna (log10 iu/ml),4
hdl-cholesterol,4
health assessment questionnaire - disability index (haq-di),4
height continuous,4
hemoglobin concentration,4
hemoglobin level,4
hepatitis b e antigen (hbeag),4
hepatitis b e antigen (hbeag) status at baseline,4
her2 status,4
high-density lipoprotein cholesterol,4
highest education level,4
hispanic,4
histological subtype,4
histopathological grade,4
history of atrial fibrillation,4
history of stroke,4
hoehn and yahr stage,4
hospital anxiety and depression â€“ anxiety subscale,4
human epidermal growth factor receptor 2 (her2) status,4
hypercholesterolemia,4
hysterectomy,4
imatinib status,4
immunoglobulin variable heavy chain (igvh) mutation status,4
injury severity score,4
international federation of gynecology and obstetrics (figo) stage,4
international federation of gynecology and obstetrics (figo) stage - recurrent/persistent,4
international normalized ratio (inr),4
international organization for standardization (iso) nicotine level,4
international prognostic scoring system (ipss) score,4
international prostate symptom score (ipss),4
international staging system (iss),4
iv drug history,4
karyotype,4
lactate dehydrogenase (ldh),4
length of hospital stay,4
lens status,4
lesion characteristic: pre-procedure thrombolysis in myocardial infarction (timi) flow,4
level of education,4
level of injury,4
liver cirrhosis,4
living situation,4
low density lipoprotein cholesterol (ldl-c) in mg/dl,4
luteinizing hormone,4
m-stage at study entry,4
mallampati score,4
maternal education,4
mean (sd) distance visual acuity in amblyopic eye,4
mean (sd) distance visual acuity in fellow eye,4
mean arterial pressure (map),4
mean number of pads used per 24 hours,4
mean number of urgency episodes (grade 3 or 4) per 24 hours,4
mechanism of injury,4
metastatic sites,4
montgomery asberg depression rating scale (madrs),4
new york heart association (nyha) class,4
new york heart association (nyha) functional class,4
number of participants categorized into the indicated child-pugh (cp) class,4
obesity,4
occupation,4
opioid use,4
parameters of hematologic response,4
percent predicted forced expiratory volume in 1 second (fev1),4
peripheral vascular disease,4
physician global assessment,4
pittsburgh sleep quality index,4
pr interval,4
previous radiotherapy,4
primary clinical diagnosis,4
primary disease site,4
primary tumor,4
prior hcv treatment experience,4
prior treatment for diabetic macular edema,4
procedure type,4
prostate-specific antigen (psa),4
prostate specific antigen,4
psa,4
psoriasis area and severity index (pasi) score,4
quadriceps strength,4
"race, customized",4
racial group,4
relationship status,4
renal disease,4
response to prior hcv treatment,4
resting energy expenditure,4
rheumatoid factor status,4
rhinoconjunctivitis quality-of-life score,4
risk factors,4
schiff sensitivity score at baseline,4
serum albumin,4
serum calcium,4
serum creatinine (mg/dl),4
serum phosphorus,4
sheehan disability scale (sds),4
site,4
sitting diastolic blood pressure (sidbp),4
stage at diagnosis,4
stage at primary diagnosis,4
stage at study entry,4
starting dose,4
stratification,4
study site,4
sulfonylurea group,4
surgical procedure,4
systolic blood pressure (mmhg),4
tanner stage,4
target disease,4
testosterone,4
time from diagnosis of type 2 diabetes,4
time from initial diagnosis,4
time since first diagnosis of multiple sclerosis (ms),4
tiotropium (tio) use stratum,4
total international prostate symptom score (ipss),4
triglyceride,4
triglyceride concentration,4
tumor size,4
"tumor, node, metastasis (tnm) disease stage",4
type 2 diabetes,4
type of pain,4
waist-to-hip ratio,4
weight in kilograms,4
weight loss last 6 months,4
"weight, continuous",4
world health organization (who) classification,4
young mania rating scale (ymrs) total score,4
zubrod performance status,4
% predicted expiratory volume in 1 second,3
2-hour post-meal glucose (2-hr pmg),3
2-hour postprandial c-peptide,3
2-hour postprandial glucagon,3
2-hour postprandial proinsulin,3
6-minute walk distance,3
abdominal circumference,3
aberrant behavior checklist,3
age at diagnosis,3
age at onset,3
age of onset,3
alanine aminotransferase (alat),3
alcohol used,3
allergic rhinitis,3
american society of anesthesiologists (asa) class,3
anemia,3
ann arbor stage,3
apache ii,3
asa,3
asa score,3
aspartate aminotransferase (ast),3
asthma control questionnaire (acq),3
asthma quality of life questionnaire (aqlq),3
asthma symptom utility index (asui),3
at least one diabetic late complication,3
atopic dermatitis,3
attention deficit hyperactivity disorder (adhd) subtype,3
average 7-point self-monitored plasma glucose (smpg),3
b-symptoms,3
background oral antidiabetic agent,3
baseline aims total dyskinesia score,3
baseline best corrected visual acuity (bcva),3
baseline categorical pain rating scale,3
baseline diffusing capacity of the lung for carbon monoxide (dlco),3
baseline ecog performance status,3
baseline estimated glomerular filtration rate (egfr),3
baseline expanded disability status scale (edss) score,3
baseline fasting plasma glucose (fpg),3
baseline forced expiratory volume in 1 second (fev1),3
baseline glycosylated hemoglobin (hba1c) category,3
baseline hcv rna,3
baseline hcv rna category,3
baseline headache severity,3
baseline hemoglobin a1c (hba1c),3
baseline hiv-1 rna,3
baseline hiv-1 rna category,3
baseline instantaneous nasal symptom score (inss),3
baseline los angeles (la) classification grade for erosive esophagitis (ee),3
baseline pain intensity,3
baseline reflective nasal symptom score (rnss),3
baseline reflective total nasal symptom score (rtnss),3
beck anxiety inventory,3
beta-2 microglobulin at baseline (in mg/l),3
bilirubin,3
bipolar diagnosis,3
blood urea nitrogen,3
blood urea nitrogen (bun),3
bmi categorical,3
"bmi, categorical",3
body-mass index (bmi),3
body mass index group,3
body weight at baseline,3
bone marrow involvement,3
bprs total score,3
breakdown of complications of heart disease,3
breakdown of complications of liver damage,3
breakdown of complications of renal damage,3
breakdown of complications of stroke-related disease,3
breakdown of diabetic complications,3
breast cancer stage,3
brief pain inventory (bpi) average pain score,3
c-peptide,3
c reactive protein,3
calculated bmi,3
campus,3
cancer diagnosis,3
cd38 status,3
cd4 cells count,3
cd4 counts,3
cd4 nadir,3
ces-d,3
chads2 score,3
child pugh status,3
chronic hypertension,3
chronic kidney disease (ckd) status,3
chronic obstructive pulmonary disease,3
cigarette pack years,3
clinical attachment level,3
clinical global impression of severity (cgi-s),3
clinical n stage,3
cluster of differentiation (cd4) cell count,3
complications of allergic disease,3
complications of dyslipidemia,3
complications of heart disease,3
complications of heart failure,3
complications of hypertension,3
complications of hyperuricemia,3
complications of liver damage,3
complications of malignant tumor,3
complications of renal damage,3
complications of stroke-related disease,3
congestive heart failure (chf),3
corticosteroid therapy,3
currently employed,3
cytogenetics,3
daily cc consumption at screening,3
daily dose of metformin,3
days since diagnosis of prostate cancer,3
degree of hepatic dysfunction,3
degree of renal dysfunction,3
dermatology life quality index (dlqi) score,3
diagnosis type,3
diastolic blood pressure (mmhg),3
disease extent,3
disease localization,3
dlco,3
dlqi score,3
dominant current site of metastasis/relapse,3
drinking risk level (drl),3
duration of bph,3
duration of diagnosed diabetes,3
duration of oa,3
duration of plaque psoriasis,3
duration since diagnosis,3
dysmenorrhea,3
eastern cooperative oncology group,3
eastern cooperative oncology group (ecog) performance status (ps) at baseline,3
eastern cooperative oncology group (ecog) score,3
eastern cooperative oncology group performance status (ecog),3
ecog status,3
eczema area and severity index (easi) score,3
ed duration,3
erectile dysfunction (ed),3
ethnic group,3
fasting cholesterol,3
fasting plasma insulin,3
fasting proinsulin,3
fasting serum glucose (fsg),3
fecal calprotectin,3
fertility status,3
fitzpatrick score,3
fluorescence in situ hybridization (fish) abnormalities,3
follicle stimulating hormone (fsh),3
forced expiratory volume in 1 second,3
forced vital capacity,3
forced vital capacity (fvc) percent predicted,3
functional assessment of cancer therapy-general (fact-g),3
gamma-glutamyl transferase (ggt),3
geriatric depression scale (gds),3
gestational age (weeks),3
gestational age in weeks,3
gfr,3
global assessment of functioning (gaf),3
glycosylated haemoglobin a1c (hba1c),3
hamilton anxiety rating scale (ham-a),3
hamilton depression rating scale (ham-d),3
hamilton depression scale (ham-d17) total score,3
hamilton psychiatric scale for depression-17 item (ham-d17) total score,3
hand dominance,3
hba1c (glycosylated haemoglobin a1c),3
hba1c (mmol/mol),3
hbv genotype,3
hdl-c concentration,3
health-related complications,3
health assessment questionnaire disability index (haq-di),3
health status,3
height (m),3
hepatitis b e antibody (hbeab) at baseline,3
hepatitis b surface antigen (hbsag) status at baseline,3
hepatitis b virus (hbv) infection status,3
hepatitis c virus (hcv) infection status,3
high-density lipoprotein (hdl) cholesterol,3
high density lipoprotein cholesterol (hdl-c),3
high sensitivity c-reactive protein (hscrp),3
hip circumference,3
histologic diagnosis,3
history of allergies,3
history of allergy,3
history of brain metastases,3
history of congestive heart failure,3
history of coronary artery disease,3
history of depression,3
history of hyperlipidemia,3
history of myocardial infarction (mi),3
history of transient ischemic attack (tia),3
hiv-1 rna (copies/ml),3
hiv-1 rna categories,3
hiv-1 rna category (copies/ml),3
homa-ir,3
hospital anxiety and depression scale (hads),3
housing,3
il-6,3
il28 genotype,3
inflammatory lesion count,3
initial composite symptom score,3
injury severity score (iss),3
insomnia severity index,3
insomnia severity index (isi),3
intact parathyroid hormone (ipth),3
intereye acuity difference,3
interleukin 28b (il28b) genotype,3
international prognostic index (ipi),3
investigatorâ€™s global assessment (iga) score at baseline,3
iss stage,3
kras status,3
lactage dehydrogenase at baseline (u/l),3
ldl-c in mg/dl,3
ldl-c in mmol/l,3
left ventricular (lv) mass,3
left ventricular internal dimension (lvid) diastole,3
length,3
lesion calcification,3
lesion characteristic: lesion length,3
lesion characteristics: target lesion vessel,3
lipid profile,3
liver biopsy fibrosis score,3
living arrangement,3
low-density lipoprotein,3
low-density lipoprotein (ldl) cholesterol,3
low-density lipoprotein cholesterol (ldl-c) concentration,3
low-density lipoprotein cholesterol (ldl-c) in mmol/l,3
low density lipoprotein,3
low density lipoprotein cholesterol,3
low density lipoprotein cholesterol (ldl-c),3
lumbar spine t-score,3
lv diastolic volume,3
lv systolic volume,3
lvid systole,3
lymph node status,3
madrs total score,3
madrs: baseline total score,3
mass,3
maximum percent fall in forced expiratory volume in 1 second (fev1) post-exercise challenge,3
mean (sd) intereye acuity difference,3
mean gradient,3
mean number of incontinence episodes per 24 hours,3
mean subjective total sleep time (ststm),3
mechanical ventilation,3
medical complications,3
medications,3
metastases,3
metformin dose,3
metformin use at screening,3
mini-mental state examination (mmse) score,3
mini mental state examination (mmse),3
mini mental status exam,3
mitral regurgitation,3
model for end-stage liver disease (meld) score,3
modified rankin scale,3
modified total sharp score (mtss),3
montgomery-asberg depression rating scale (madrs),3
mutation status,3
n stage,3
need for î²-agonist rescue medication following exercise challenge,3
new york heart association (nyha) heart failure classification,3
nicotine dependence,3
number of non-target lesions,3
number of participants with pain severity score,3
number of previous major depressive disorder (mdd) episodes,3
number of prior regimens,3
number of prior treatments,3
number of relapse episodes in the preceding 2 years,3
number of study eyes,3
nyha classification,3
nyha functional class,3
obsessive compulsive disorder,3
obstructive sleep apnea,3
operative time,3
pack-years,3
participant global assessment,3
participant pain assessment,3
pasi score,3
pblac score (assessment of menstrual blood loss),3
peak gradient,3
percent diameter stenosis,3
percentage body fat,3
peripheral arterial disease,3
peripheral vascular history,3
"plasma hiv-1 rna, categorical",3
"plasma hiv-1 rna, continuous",3
platinum-free interval,3
platinum sensitivity,3
pre-bronchodilator forced expiratory volume in the first second (fev1),3
pre-pregnancy bmi,3
presence of diabetes,3
previous alpha-blocker therapy,3
previous anti-diabetic treatment,3
previous chemotherapy,3
previous duration of rosacea,3
previous myocardial infarction,3
previous pci,3
previous radiation therapy,3
previous treatment - chemotherapy,3
previous treatment - surgery,3
previously treated for alcohol dependence,3
primary tumor diagnosis,3
prior allogeneic hematopoietic stem cell transplantation (hsct),3
prior hysterectomy,3
prior panretinal scatter photocoagulation,3
prior regimens,3
prior systemic therapy,3
prior treatment for amblyopia at enrollment,3
prior treatments,3
prolactin,3
psoriasis area and severity index (pasi),3
psoriasis area severity index (pasi),3
ptsd checklist (pcl),3
pulmonary disease,3
qualifying airway reversibility,3
quality of life,3
re-transplant,3
recipient cytomegalovirus status,3
refractive error in amblyopic eye (spherical equivalent/diopters),3
religion,3
renin-angiotensin-aldosterone system polymorphism,3
risk group,3
sds,3
seasonality,3
serum prostate-specific antigen levels,3
serum testosterone level,3
sites of metastases,3
sites of metastatic disease,3
sitting diastolic blood pressure,3
six-minute walk distance (6mwd),3
six minute walk distance,3
sleep efficiency,3
sleep quality,3
social responsiveness scale,3
sore throat pain intensity scale (stpis),3
specimen weight,3
spleen volume,3
splenomegaly,3
stage of disease (iss),3
stage of disease at study entry,3
stool consistency,3
stratification by opioid dose,3
stratification factor,3
stratification factor: low-density lipoprotein cholesterol (ldl-c) level,3
stratification factor: region,3
surgery,3
swollen joint count of 66 evaluable joints,3
tactile sensitivity - tactile threshold at baseline,3
tender joint count of 68 evaluable joints,3
time of basal insulin injection,3
time since diabetes diagnosis,3
time since first diagnosis for bipolar,3
time since first relapse,3
time since start of current depressive episode,3
total alcohol consumption (tac) g alcohol/day,3
total body weight,3
total hip t-score,3
total insulin daily dose,3
total monthly heavy drinking days (hdd),3
total ocular surface staining (toss) score,3
trauma,3
trunk fat,3
tumor burden,3
type of current transplant,3
type of diabetes mellitus,3
type of diagnosis,3
type of hearing loss,3
type of stroke,3
type of transplant,3
type of tumor,3
unresolved spinal litigation,3
"weight, categorical",3
"weight, kg",3
who (world health organization) functional class,3
womac pain score,3
years since stroke,3
zap-70 status,3
17p deletion in cll cells,2
2-hour post-meal glucose,2
2-hour post meal glucose (2-hr pmg),2
2-hour postprandial plasma insulin,2
2-hour postprandial proinsulin-to-insulin ratio,2
25-hydroxyvitamin d,2
25(oh) vitamin d,2
36-item short-form health survey (sf-36),2
5-year gail risk,2
6-minute walk test,2
6-minute walking distance,2
6 minute walk test,2
a1c (hemoglobin a1c),2
abdominal pain,2
absolute cd4 count,2
absolute eosinophil count,2
acne,2
activated partial thromboplastin time (aptt),2
acute physiology and chronic health evaluation ii (apache ii) score,2
adcs-adl - 19 items: baseline total score,2
additional antihypertensive treatment at baseline,2
adiposity,2
administration of 3-hydroxy 3-methylglutaryl coenzyme a (hmgcoa) reductase inhibitor,2
age at first live birth,2
age at initial peanut allergic reaction,2
age at menarche,2
age at onset of menopause,2
age at shunt palliation,2
age of asthma onset,2
age of onset of illness,2
airway blood flow (qaw),2
ais and neurological level,2
alcohol intake,2
alcoholism,2
alkaline phosphatase (u/l),2
allergen test,2
alt (multiples of uln),2
alt category,2
alt normal at baseline,2
american joint committee on cancer (ajcc) stage at study entry,2
american society of anesthesiologists physical status,2
american spinal injury association (asia) score,2
amputation etiology,2
anatomical brain abnormality (by neuroimaging),2
angina,2
antibody to hbeag (anti-hbe),2
anticonvulsant use,2
antipsychotic (weight gain risk),2
anxiety,2
aortic insufficiency,2
apache iii score,2
apnea-hypopnea index (ahi),2
apolipoprotein a-i,2
aromatase inhibitor,2
arterial hypertension,2
asa status,2
asia impairment scale (ais),2
aspartate aminotransferase,2
"asthma attack severity based on asthma prevention and management guideline 2003, japan",2
asthma control test (act) score,2
asthma diagnosis duration,2
asthma duration,2
asthma severity,2
atrial arrhythmia history,2
attention-deficit/hyperactivity disorder (adhd) subtype,2
attention deficit hyperactive disorder,2
auc for percent change from pre-exercise measurement fev1 in l 0-60 mins after exercise challenge,2
augmentation index (aix),2
average 7-point self monitored plasma glucose (smpg),2
average drinks per drinking day,2
average length of menstrual cycle,2
average pain intensity,2
average spherical equivalent between the eyes,2
b symptoms (fever),2
b symptoms (night sweats),2
b symptoms (weight loss),2
basal insulin treatment duration,2
baseline 6 minute walk distance (6mwd),2
baseline a1c,2
baseline alanine aminotransferase (alt) above the upper limit of the normal (uln) range,2
baseline best corrected visual acuity (bcva) letter scores,2
baseline body mass index category,2
baseline body weight,2
baseline c-reactive protein (crp),2
baseline cd4+ cell count,2
baseline cd4+ count,2
baseline cholesterol,2
baseline clinical diagnosis,2
baseline creatinine,2
baseline diastolic blood pressure (dbp),2
baseline disease activity â€“ categorical,2
baseline disease activity â€“ crohnâ€™s disease activity index (cdai),2
baseline dyspnea index,2
baseline eastern cooperative oncology group (ecog) performance score,2
baseline edss score,2
baseline fecal calprotectin,2
baseline forced expiratory volume in one second (fev1),2
baseline glycosylated haemoglobin (hba1c) at baseline,2
baseline hba1c category,2
baseline hcv ribonucleic acid (rna),2
baseline hemoglobin a1c (a1c),2
baseline hemoglobin concentration,2
baseline hemoglobin concentration per treatment group,2
baseline high density lipoprotein (hdl) cholesterol,2
baseline in psoriasis area and severity index (pasi),2
baseline individual reflective ocular symptom score (ross) in subjects with (rtoss) â‰¥5.0,2
baseline instantaneous total nasal symptom score (itnss),2
baseline knodell necroinflammatory score,2
baseline laxative response status,2
baseline lesion characteristics: presence of calcification,2
baseline lesion characteristics: reference vessel diameter,2
baseline lesion characteristics: treated limb,2
baseline lesion type,2
baseline liver volume,2
baseline low density lipoprotein (ldl) cholesterol,2
baseline lower urinary tract symptoms (luts) severity,2
baseline medical history,2
baseline multiple myeloma stage,2
baseline platelet counts,2
baseline platelet counts per treatment group,2
baseline retinal thickness by optical coherence tomography (oct),2
baseline severity,2
baseline six-minute walk distance (6mwd),2
baseline spleen volume,2
baseline systolic blood pressure (sbp),2
baseline temperature,2
baseline total lesion size,2
baseline total testosterone level,2
baseline viral load: absolute value,2
baseline vitamin d level,2
baseline western ontario and mcmaster universities osteoarthritis index (womac) pain subscale score,2
basis for diagnosis,2
bdi,2
beck anxiety inventory (bai),2
beck anxiety inventory (bai) total score,2
beck depression inventory-ii total score,2
beck depression inventory (bdi),2
beck depression inventory (bdi) total score,2
beck depression inventory score,2
"beck depression inventory score, categorical",2
benign prostatic hyperplasia (bph) severity,2
best corrected visual acuity,2
best corrected visual acuity (bcva),2
beta2 microglobulin,2
binet stage,2
binge eating scale,2
birth height,2
birth weight (grams),2
bishop score,2
black race,2
bleeding on probing,2
bleeding on probing (bop),2
blood eosinophil count,2
blood eosinophils,2
blood pressure (bp),2
blood pressure diastolic,2
blood pressure systolic,2
blunt trauma,2
bmi (grouped),2
"bmi (kg/m^2), continuous",2
bmi at enrollment,2
bmi categories,2
bmi z-score,2
body mass (kg),2
body mass index (bmi) at baseline,2
body mass index (bmi) at screening,2
body mass index (bmi) categories,2
body mass index (bmi) group,2
body mass index (bmi) percentile,2
body mass index categorization,2
body mass index class,2
body mass index continuous,2
body mass index percentile,2
"body mass index, categorical",2
body weight (kg),2
bone metastases,2
bone mineral density,2
bone pain,2
bone remodelling,2
bowel movement,2
bp,2
brain metastases,2
brain metastasis,2
brca status,2
breakdown of drugs,2
brief pain inventory - interference (bpi-i),2
brief pain inventory (bpi) 24-hour average pain score,2
brief pain inventory (bpi) average pain,2
brief pain inventory (bpi) interference,2
brief pain inventory severity: average pain score (bpi-s: average pain),2
brief pain inventory severity: least pain score (bpi-s: least pain),2
brief pain inventory severity: pain right now score (bpi-s: pain right now),2
brief pain inventory severity: worst pain score (bpi-s: worst pain),2
brief psychiatric rating scale (bprs) total score,2
bsa (m2),2
bulky disease,2
c-reactive protein (crp) level,2
ca-baseline,2
ca 125 status,2
caffeine use,2
calculated creatinine clearance,2
cancer,2
cancer site,2
cardiac index (ci),2
cardiovascular history,2
cardiovascular risk factors,2
cause of end-stage renal disease,2
cause of liver disease,2
cd4,2
cd4 cell count (/âµl),2
cd4 cell count at entry,2
cd4 count category,2
"cd4 count, categorical",2
cd4 percent,2
cd4 percentage,2
cd4+,2
cd4+ cell count category,2
cd4+ count,2
cdrs-r subscale scores,2
central activation ratio (car),2
central corneal thickness,2
central diastolic blood pressure (cdbp),2
central subfield thickness,2
central subfield thickness on optical coherence tomography,2
central systolic blood pressure (csbp),2
cgi-s baseline severity score,2
charlson comorbidity index,2
charlson index,2
chemotherapy,2
chemotherapy type,2
chest x-ray at screening,2
child-pugh class,2
children's depression rating scale-revised (cdrs-r) total score,2
children's yale-brown obsessive compulsive scale modified for pdd,2
children's yale-brown obsessive compulsive scale modified for pervasive developmental disorders,2
chronic obstructive pulmonary disease (copd) severity,2
cibic-plus: baseline severity score,2
cigarette smoking history,2
clinical global impression-attention deficit hyperactivity disorder-severity scale,2
clinical global impression-attention deficit hyperactivity disorder-severity scale (cgi-adhd-s),2
clinical global impression-severity,2
clinical global impression-severity (cgi-s),2
clinical global impression - severity scale (cgi-s) score,2
clinical global impression of severity (cgi-s) score,2
clinical global impressions of severity (cgi-severity) score,2
clinical global impressions scale-severity of illness (cgi-s) score,2
clinical m stage,2
clinical staging,2
clinician-reported submental fat rating scale (cr-smfrs) rating,2
clinician administered ptsd scale,2
cluster determinant 4 (cd4) cell count,2
cmv status,2
cognitive status,2
comorbidity index,2
complete spontaneous bowel movement (csbm),2
composite symptoms score,2
composition of most recent passed stone,2
concomitant implantable device delivering therapy,2
concomitant medication,2
concomitant morbidities in the past,2
copd,2
copd disease characteristics,2
corneal fluorescein staining (cfs),2
coronary artery disease (cad) category,2
corrected serum calcium,2
corrected total serum calcium,2
cough,2
current alcohol use,2
current anxiety disorder,2
current cd4,2
current employment,2
current employment status,2
current endocrine therapy,2
current medications used for pulmonary and/or allergy conditions,2
current smoking status,2
cystatin c,2
cystic fibrosis questionnaire - revised (cfq-r) respiratory symptoms scale (rss) score,2
cytogenetic risk,2
d-dimer,2
daily dose of metformin prior to dosing of metact combination tablets,2
daily dose of pioglitazone prior to dosing of metact combination tablets,2
daily insulin dose,2
daily mcc consumption at screening,2
daytime asthma symptom score,2
dbp,2
degree of tympanic membrane bulging,2
details of organic dysmenorrhea,2
dexa total fat,2
dheas,2
diabetes mellitus (including impaired glucose tolerance),2
diabetic status,2
diagnosis of diabetes,2
diagnosis: reflux disease,2
dialysis status,2
dialysis vintage,2
diarrhea,2
difficulty swallowing scale (dss),2
direct bilirubin,2
disease activity score using c-reactive protein (das28-crp),2
disease characteristic - erythema,2
disease characteristic - percent bsa (extent of psoriasis),2
disease characteristic - plaque thickness,2
disease characteristic - scaling,2
disease characteristic - subject's global assessment,2
disease characteristics,2
disease group,2
disease location,2
disease risk index (dri),2
disease state,2
disease status at study entry,2
disease subtype,2
distant metastasis,2
does participant consume caffeine?,2
dominant metastatic site,2
donor age,2
donor relation,2
donor source,2
dose level,2
double-blind baseline clbp intensity vas,2
double-blind baseline sleep interference by pain scale,2
draining fistula at baseline,2
drinking habits,2
drinking status,2
drinks per drinking day,2
duration of a disease,2
duration of constipation,2
duration of copd (chronic obstructive pulmonary disease),2
duration of crohn's disease - categorical,2
duration of crohn's disease (cd),2
duration of current episode,2
duration of diabetes at study entry,2
duration of diabetes in years,2
duration of diabetic neuropathy,2
duration of dialysis,2
duration of disease category,2
duration of epilepsy,2
duration of hearing loss,2
duration of infection,2
duration of insomnia,2
duration of lupus nephritis,2
duration of mds,2
duration of morning stiffness,2
duration of multiple sclerosis (ms),2
duration of opioid therapy,2
duration of opioid use,2
duration of osteoarthritis since diagnosis,2
duration of parkinson's disease,2
duration of ra,2
duration of rheumatoid arthritis (ra),2
duration of rheumatoid arthritis (ra) disease,2
duration of tourettes syndrome,2
"duration of type 2 diabetes, categorical",2
duration of uveitis,2
duration on opioid therapy,2
duration since diagnosis of chronic low back pain,2
durie-salmon classification,2
durie-salmon multiple myeloma staging at screening,2
dyskinesias,2
dyspareunia,2
e2,2
eastern cooperative group performance status (ecog ps) at study entry,2
eastern cooperative oncology group (ecog) performance,2
eastern cooperative oncology group (ecog)performance status,2
eastern cooperative oncology group performance score,2
eastern cooperative oncology group performance status scale (ecog ps),2
ecog (eastern cooperative oncology group),2
ecog (performance status),2
ed etiology,2
ed severity,2
edss,2
education (years),2
education years,2
egfr based on modification of diet in renal disease (mdrd) formula,2
electronic-early treatment diabetic retinopathy study visual acuity letter score,2
elevated ldh (lactate dehydrogenase),2
emotional stress,2
epoprostenol dose,2
eq-5d,2
erectile dysfunction,2
erectile dysfunction (ed) duration,2
erectile dysfunction (ed) severity,2
erosion score,2
estimated glomerular filtration rate [egfr],2
estimated time of onset of symptoms at screening,2
estrogen receptor,2
etiology of fecal incontinence,2
etiology of pulmonary arterial hypertension (pah),2
european questionnaire 5 dimensions (eq-5d) total score,2
euroscore,2
ever breastfed,2
excessive bleeding,2
exercise,2
exercise per week,2
exercise stage of change,2
exhaled nitric oxide,2
expanded disability status scale,2
expanded disability status scale at screening (edss),2
expect to remain sexually active,2
extent of resection,2
eye affected,2
fagerstrã¶m score,2
fagerstrom test for nicotine dependence score,2
falls,2
family history of osteoporosis,2
family history of seizures,2
fasting (non-random) serum cholesterol,2
fasting (non-random) serum triglyceride,2
fasting blood glucose (fbg),2
fasting body weight,2
fasting glucose (mg/dl),2
fasting hdl cholesterol,2
fasting ldl cholesterol,2
fasting plasma glucose (fpg) continuous,2
fasting proinsulin-to-insulin ratio,2
fat-free mass,2
femoral neck bmd t-score,2
femoral neck t-score,2
fev1 % predicted,2
fev1 (forced expiratory volume in one second),2
fev1 (l),2
fev1 reversibility % increase,2
fev1 reversibility increase,2
fev1% predicted,2
fev1/fvc ratio,2
fibrinogen,2
figo stage,2
final diagnosis,2
first phase of insulin secretion,2
fitzpatrick skin scale,2
fluctuations,2
follicle-stimulating hormone,2
follicle stimulating hormone,2
forced expiratory volume at one second (fev1),2
forced expiratory volume in 1 second (fev1) percent predicted,2
forced expiratory volume in 1s (fev1),2
forced expiratory volume in one second (fev1),2
forced vital capacity (fvc) % predicted,2
former smoker,2
fraction of inspired oxygen,2
fracture type,2
french-american-british (fab) classification of mds,2
frequency of hot flashes,2
frequent and excessive bleeding,2
frequent bleeding,2
fructosamine,2
ftnd score,2
function,2
functional status,2
fvc % predicted,2
fvc % predicted category,2
gait freezing,2
gastroesophageal reflux disease,2
generalized anxiety disorder 7 (gad-7) score,2
geographical region,2
geriatric depression scale,2
german cockroach-specific serum immunoglobulin e (ige) levels,2
german cockroach-specific serum immunoglobulin subclass 4 (igg4) levels,2
gestation age,2
gestational age at birth,2
gestational age at delivery,2
gingival recession depth,2
glaucoma medications,2
gleason sum,2
global assessment of function (gaf),2
global assessment of functioning,2
global individual signs score (giss),2
glycemic status,2
glycosylated haemoglobin,2
glycosylated haemoglobin a1 (hba1c),2
glycosylated hemoglobin (hba1c) category,2
glycosylated hemoglobin (hba1c) level,2
glycosylated hemoglobin a1 (hba1c) continuous,2
glycosylated hemoglobin a1c (a1c),2
grading of adenocarcinoma,2
graft source,2
gross tumor volume,2
growth hormone (gh),2
ham-a: baseline total score,2
ham-d6 total score,2
hamilton anxiety rating scale (hama) total score,2
hamilton depression rating scale,2
hamilton depression scale,2
hamilton rating scale for depression,2
hamilton rating scale for depression (ham-d) total score at baseline,2
hamilton rating scale for depression (hrsd),2
hand grip,2
hba1c stratum,2
hbv dna by pcr,2
hbv prevalence of birth country,2
hcv genotype subtype,2
health insurance,2
health insurance status,2
heart disease,2
heart rate (hr),2
height (in),2
height standard deviation (sd) score,2
height standard deviation score (sds),2
"height, categorical",2
"height, mean",2
helicobacter pylori (h. pylori) status,2
helicobacter pylori infection,2
hemiparesis,2
hemisphere,2
hemorrhoid grade,2
hepatic disease,2
hepatitis b surface antigen (hbsag),2
hepatitis b surface antigen status,2
hepatitis b virus (hbv) deoxyribonucleic acid (dna),2
hepatitis b virus (hbv) dna,2
hepatitis c (hcv) rna,2
hepatitis c virus (hcv) genotype/ subtype,2
hepatitis c virus genotype,2
hepatitis c virus rna,2
hepatocellular carcinoma,2
hepatomegaly,2
her2,2
her2 expression,2
high-density lipoprotein cholesterol (hdl-c) concentration,2
high-sensitivity c-reactive protein,2
histological classification,2
histology of primary diagnosis,2
histopathologic type,2
histopathology,2
history of af,2
history of asthma,2
history of cancer,2
history of congestive heart failure (chf),2
history of diabetes mellitus,2
history of extraintestinal manifestations,2
history of fistulizing disease,2
history of ischemic stroke,2
history of motion sickness,2
history of percutaneous coronary intervention (pci),2
history of peripheral vascular disease,2
history of peripheral vascular disease (pvd),2
history of pneumonia,2
history of prior surgery for crohn's disease,2
history of suicide attempt,2
history of transient ischemic attack,2
history of vomiting with pregnancy,2
history previous therapy of breast cancer,2
hiv-1 rna (log10 copies/ml),2
hiv-1 rna level,2
hiv-1 rna viral load category,2
"hiv-1 rna, categorical",2
hiv antiretroviral therapy (art) status,2
hiv rna,2
hiv rna distribution at baseline,2
hiv rna viral load,2
hiv viral load,2
hla match,2
"hoehn-yahr ""off""",2
hoehn & yahr stage,2
homa ir,2
homeostasis model assessment for beta-cell function (homa-beta),2
hormonal receptor status,2
hospitalization status,2
hot flash frequency,2
housing status,2
human leukocyte antigen (hla) match,2
hypertension requiring medication,2
"if drinker, amount consumed",2
igf-1 standard deviation (sd) score,2
ighv mutation,2
il28b,2
immunoglobulins,2
immunophenotype,2
impaired glucose tolerance,2
incontinence episodes per week,2
incontinence type,2
index event classification,2
indication for prescription of pantoprazole,2
indication for surgery,2
inflammatory acne lesion count,2
influenza infection,2
influenza infection within 1 year,2
influenza type,2
influenza vaccination status,2
initial sbp,2
injury severity score (for trauma subjects),2
insomnia severity index (isi) score,2
insulin use,2
intact parathyroid hormone,2
intact parathyroid hormone level,2
interleukin 28b (il28b),2
interleukin 6 (il-6),2
international federation of gynecology and obstetrics (figo) recurrent/persistent disease,2
international federation of gynecology and obstetrics (figo) stage recurrent/persistent,2
international organization for standardization (iso) nicotine yield,2
international prognostic index risk category,2
international staging system classification,2
intrinsic qrs width,2
investigator's global assessment (iga) score,2
investigator global assessment (iga) score,2
investigators static global assessment (isga),2
ipth-baseline,2
ischemic heart disease (ihd),2
ishak fibrosis,2
j-tpeakc (heart rate corrected j-tpeak interval),2
jak2 v617f mutation status,2
joint space narrowing (jsn) score,2
kansas city cardiomyopathy questionnaire (kccq),2
karnofsky performance scale (kps),2
karnofsky performance status-baseline,2
karnofsky performance status scale (kps),2
kidney stone passage,2
lactate dehydrogenase,2
lactate dehydrogenase (ldh) at study entry,2
lansky play score,2
latency to onset of persistent sleep (lps),2
ldh,2
lean body mass,2
left atrial diameter,2
left ventricular end-systolic volume (lvesv),2
length of illness,2
lens status (clinical examination),2
lesion characteristic-percent diameter stenosis,2
lesion characteristic: percent diameter stenosis by qca,2
lesion characteristics by quantitative cornary angiography,2
level of encephalopathy,2
level of menstrual symptoms,2
lh,2
limb fat,2
literacy,2
liver disease,2
liver metastasis,2
liver volume,2
location,2
location of pain,2
location of primary tumor,2
log10 hiv-1 rna viral load,2
logistic european system for cardiac operative risk evaluation (euroscore),2
low-density lipoprotein cholesterol,2
low density lipoprotein-c,2
low density lipoprotein - cholesterol (ldl-c),2
"low density lipoprotein - cholesterol (ldl-c), categorical",2
low density lipoprotein cholesterol (ldl-c):high density lipoprotein cholesterol (hdl-c) ratio,2
low high density lipoprotein - cholesterol (hdl-c),2
lower urinary tract symptoms (luts) severity,2
lv ejection fraction,2
lymph-node status,2
lymphoma type,2
lymphovascular invasion,2
major depression,2
mammographic breast density,2
marriage,2
married or living with partner,2
maximum stimulated growth hormone,2
mean (sd) spherical equivalent refractive error in amblyopic eye,2
mean (sd) spherical equivalent refractive error in fellow eye,2
mean body mass index (bmi),2
mean diurnal intraocular pressure (iop) at baseline,2
mean expanded disability status scale (edss) score,2
mean height,2
mean number of relapses within the past 12 months,2
mean number of relapses within the previous 3 years,2
mean number of urgency episodes per 24 hours,2
mean number of urgency incontinence episodes per 24 hours,2
mean psoriasis area and severity index (pasi) score,2
mean pulmonary artery pressure,2
mean pulmonary artery pressure (mpap),2
mean subjective time to sleep onset (stsom),2
measures of handicap (chart),2
median baseline cd4+ cell count,2
median baseline hiv-1 rna level,2
median baseline serum prostate-specific antigen levels,2
median baseline serum testosterone levels,2
median cd4 count,2
medication,2
medication adherence,2
melanoma type,2
menopause,2
metastasis,2
metastatic site,2
migraine,2
mini-mental state examination,2
mini-mental state examination (mmse),2
mini mental state exam,2
mmse score,2
mmse stratum,2
montgomery asberg depression rating scale,2
montgomery asberg depression rating scale (madrs) total score,2
months since diagnosis,2
months since last menstrual period,2
months since stroke,2
months since symptom onset,2
montreal cognitive assessment,2
motzer risk factors,2
mouth opening,2
multidimensional assessment of fatigue,2
multiple gestation,2
multiple myeloma stage before study entry,2
multiple myeloma subtype,2
myocardial infarction,2
nadir cd4 cell count,2
nadir cluster of differentiation 4 (cd4),2
national institutes of health stroke scale score,2
national institutes of health stroke scale score (nihss),2
nationality,2
neck circumference,2
neck circumference (cm),2
neither social security income/social security disability insurance recipient,2
neurologic/renal history,2
neurological history,2
neutropenic,2
new york heart association,2
new york heart association (nyha) functional capacity,2
new york heart association class,2
nhl duration,2
nihss,2
no. of days taking rescue therapy,2
non-hdl-c,2
non-hdl cholesterol,2
non-hodgkin's lymphoma diagnosis/histopathology,2
non-inflammatory acne lesion count,2
non-service-connected pension,2
nonsteroidal anti-inflammatory drug (nsaid) use,2
npi: baseline total score,2
nulligravid,2
number of anti-hypertensive medications,2
number of antihypertensive medications per patient,2
number of births,2
number of children,2
number of cigarettes per day,2
number of cigarettes smoked per day,2
number of diabetic retinopathy (dr) study eyes per participant,2
number of disease sites,2
number of heart failure medications,2
number of inflammatory lesions,2
number of inflammatory lesions per participant at baseline,2
number of lesions,2
number of lesions (target + non-target),2
number of metastatic organs,2
number of organ dysfunctions,2
number of organs involved,2
number of pack-years smoked,2
number of participants,2
number of participants categorized into the indicated genotype for hepatitic c virus (hcv),2
number of participants on chemotherapy,2
number of participants on radiotherapy,2
number of participants with categorical body mass index (bmi),2
number of participants with hysterectomy/oophorectomy,2
number of participants with normal or elevated baseline values for alanine aminotransferase (alt),2
number of participants with or without previous interferon (ifn) use,2
number of participants with pain severity score measured on a rating scale,2
number of participants with prior radiation therapy,2
number of participants with the indicated baseline cd4+ cell count,2
number of participants with the indicated baseline hiv-rna level,2
number of participants with the indicated body mass index (bmi),2
number of participants with the indicated center for disease control (cdc) classification,2
number of participants with the indicated fibrotest/acti test (fibrosure) score,2
number of participants with the indicated smoking status,2
number of pregnancies,2
number of prior chemotherapy regimens,2
number of prior systemic therapies,2
number of relapses,2
number of seizure foci,2
number of short-acting beta-agonist puffs (saba) daily,2
number of vaginal births,2
numeric pain rating scale (nprs),2
ocular surface disease index (osdi),2
office diastolic blood pressure,2
office heart rate,2
office systolic blood pressure,2
optical coherence tomography central subfield thickness,2
optical coherence tomography retinal volume,2
oral contraceptive use history,2
origin of cancer,2
origin of tumor,2
other complications,2
other food allergies,2
p-baseline,2
pacemaker,2
pain catastrophizing scale (pcs),2
pain intensity score,2
pain intensity score by visual analog scale (vas),2
paindetect questionnaire,2
pancreatic primary tumor location,2
panss general psychopathology subscale score,2
panss negative subscale score,2
panss positive subscale score,2
panss total score,2
parameter of hematologic response - bone marrow plasma cells > 30%,2
parameter of hematologic response - urine m-spike >= 200 mg/24 hours,2
parathyroid hormone (pth),2
parent's marital status,2
parkinson's disease duration,2
paroxysmal atrial fibrillation,2
participant counts by gleason score,2
participant diagnosis,2
participant drinking status,2
participants with columbia suicide-severity rating scale (c-ssrs) total score,2
participants with prior anti-myeloma (mm) therapies,2
participants with sexual dysfunction,2
past hormone therapy use,2
pathology,2
patient assessment of treatment satisfaction,2
patient global assessment,2
patient global impressions of severity scale (pgi-s),2
patient health questionnaire-9 (phq-9),2
patient oriented eczema measure (poem),2
patient status,2
pc20,2
pd-l1 expression,2
pd duration,2
peabody picture vocabulary test,2
peak flow rate (ml/sec),2
peak urine flow rate (qmax) category,2
peak vo2,2
peanut ige,2
pediatric quality of life enjoyment and satisfaction questionnaire (pq-les-q) total score,2
penetrating trauma,2
percent body fat,2
percent of body surface area (bsa) involved in psoriasis,2
percent predicted normal fev1,2
percentage of cd4 cells,2
percentage of glycosylated fraction of hemoglobin a1c,2
peripheral blood perfusion impaired,2
peripheral blood perfusion normal,2
peripheral diastolic blood pressure (pdbp),2
peripheral systolic blood pressure (psbp),2
pharmacotherapy for current major depressive episode,2
phenotypic sensitivity score,2
physical activity,2
physical function,2
physical function (health assessment questionnaire disability index [haq-di]),2
physician's global assessment (pga),2
physician's global assessment of psoriasis,2
physician global assessment (pga) of disease activity,2
physician global evaluations,2
pittsburg sleep quality index (psqi),2
pittsburgh sleep quality index (psqi) score,2
pkd genotype,2
plasma glucose level,2
plasma hbv dna level,2
plasma human immunodeficiency virus type 1 (hiv-1) ribonucleic acid (rna) level,2
plasma viral load,2
positive and negative syndrome scale,2
post-bronchodilator fev1,2
post-bronchodilator fev1 predicted,2
post-bronchodilator fev1/forced vital capacity (fvc),2
post-menopausal,2
post-traumatic stress disorder,2
post-void residual volume,2
postmenopausal,2
postvoid residual volume,2
postvoid residual volume (prv),2
pre-art hiv-1 viral load,2
pre-bronchodilator fev1 predicted,2
pre-pregnancy body weight,2
pre-procedure thrombolysis in myocardial infarction (timi) flow,2
pre-therapy antipsychotic usage,2
premorbid intelligence quotient (iq),2
preop work status,2
preoperative cnc word score - treated ear,2
presence of fever,2
presence of pseudomonas aeruginosa (pa),2
presence of tophus,2
previous abdominal surgery,2
previous asthma therapy,2
previous brain or epilepsy surgery,2
previous breast cancer surgery,2
previous endarterectomy,2
previous hormonal therapy,2
previous mi,2
previous oad treatment,2
previous prostatectomy,2
previous skeletal-related event stratification factor,2
previous therapy,2
previous transplant,2
previous treatment - hormone therapy,2
previous treatment - radiation therapy,2
previous vaginal births,2
previous vaginal deliveries,2
previously treated for alcohol withdrawal symptoms,2
primary disease stage,2
primary site of cancer,2
primary tumor location,2
primary type,2
prior abdominal surgery,2
prior adjuvant chemotherapy,2
prior adjuvant therapy,2
prior anti-vegf injections,2
prior bevacizumab,2
prior cancer surgery,2
prior cardiovascular event,2
prior consumption of drugs affecting coagulation system,2
prior lamivudine or ftc treatment,2
prior laser for diabetic macular edema,2
prior mi,2
prior myocardial infarction,2
prior number of chemotherapy regimens,2
prior panretinal photocoagulation,2
prior peribulbar triamcinolone for diabetic macular edema,2
prior stem cell transplant,2
prior tamoxifen,2
prior tamoxifen therapy,2
prior taxane therapy,2
prior therapeutic surgery for epilepsy,2
prior vagal nerve stimulator (vns),2
prior vitrectomy for diabetic macular edema,2
procedure time (min),2
progesterone receptor,2
prolonged and excessive bleeding,2
prolonged and frequent bleeding,2
prolonged bleeding,2
"prolonged, frequent and excessive bleeding",2
proprotein convertase subtilisin/kexin type 9 (pcsk9) concentration,2
prostate cancer type,2
proteinuria by urinalysis (dipstick),2
psa (ng/ml),2
psoriasis area and severity index,2
pth,2
ptsd checklist,2
pulmonary arterial hypertension (pah) etiology,2
pulmonary function measures,2
pulse wave velocity,2
qol-b respiratory symptom score,2
qtc (fridericia's heart rate corrected qt interval),2
qualifying acute coronary syndrome (acs) event,2
quality of life (qol) related to urinary symptoms,2
quality of life questionnaire for bronchiectasis (qol-b) respiratory symptoms domain score,2
quality of life vr-36,2
race class,2
radiotherapy delivery modality,2
rai stage at screening,2
randomization stratum,2
rapid estimate of adult literacy in medicine-sf (realm-sf),2
reason for end stage liver disease,2
recipient cmv status,2
regimen,2
relapsed versus de novo metastasis,2
renal function at baseline,2
residence type,2
respiration,2
resting heart rate,2
resting metabolic rate,2
retinal volume on optical coherence tomography,2
retinopathy severity,2
rheumatoid factor,2
right atrial pressure,2
right atrial pressure (rap),2
riluzole use,2
saint george's respiratory questionnaire (sgrq) symptoms component score,2
sbp,2
scoring atopic dermatitis (scorad) score,2
screening baseline pain over the last 24 hours,2
sds total baseline score,2
seated diastolic blood pressure,2
seizure onset location,2
self-monitored fasting plasma glucose,2
serum bicarbonate,2
serum creatinine at baseline (in mg/dl),2
serum creatinine level,2
serum dihydrotestosterone (dht),2
serum fsh,2
serum î²2 microglobulin,2
serum lh,2
serum phosphorous,2
serum potassium,2
serum prostate-specific antigen,2
serum prostate-specific antigen (psa) levels,2
serum prostate-specific antigen level,2
serum protsate-specific antigen (psa) levels,2
serum psa,2
serum sodium,2
serum testosterone,2
serum testosterone (t),2
setting of prior chemotherapy,2
severity of constipation,2
severity of dependence scale,2
severity of erectile dysfunction (ed),2
severity of infection,2
severity score,2
sexually active,2
sexually active with a female partner,2
sf-36 mental component,2
sf-36 physical component,2
sheehan disability scale (sds) - total score,2
sheehan disability scale (sds) family,2
sheehan disability scale (sds) social,2
sheehan disability scale (sds) work,2
short form -12 (sf-12) health survey,2
short physical performance battery,2
shunt on cardiopulmonary bypass,2
sib: baseline total score,2
site of disease,2
site of metastases,2
site of primary tumor,2
site(s) of metastases,2
sites of metastasis,2
skin photo type,2
skin phototype,2
skin pigmentation,2
sleep apnea,2
smokers,2
smoking habit,2
smoking habits,2
smoking history (pack years),2
society of thoracic surgeons (sts) risk score,2
sperm concentration,2
spherical equivalent,2
spherical equivalent refractive error in amblyopic eye,2
spo2,2
spontaneous bowel movements per week,2
stage at initial diagnosis,2
stage of hypertension,2
status of major depressive episode (mde),2
stem cell source,2
steroid use,2
stratification factor: cinacalcet use within 8 weeks of randomization,2
stratification factor: international staging system (iss) stage,2
stratification factor: route of bortezomib administration,2
stratification factor: screening serum parathyroid hormone (pth),2
stratum,2
stroke location,2
stroke onset,2
stroke symptom onset to intravenous rt-pa start,2
structural heart disease,2
sts score,2
study eye,2
study region,2
subject global assessment per vas,2
subject global evaluations,2
submental fat (smf) rating,2
sulfonylurea use,2
supplemental oxygen required at screening,2
surgery duration,2
surgical approach,2
surgical screw type,2
swollen joint count at baseline,2
swollen joints,2
swollen throat scale (swots),2
symptom score,2
symptomatic status,2
t-stage,2
tactile threshold at baseline,2
tear film break-up time (tfbut),2
tender joints,2
thyromental distance,2
time from diagnosis of advanced /metastatic melanoma to first vem1 phase dose,2
time from diagnosis to enrollment,2
time from first documented metastasis/relapse to study entry,2
time from first pathologic diagnosis,2
time from initial chronic myeloid leukemia (cml) diagnosis,2
time from initial diagnosis to study entry,2
time from ms diagnosis,2
time from primary diagnosis to study entry,2
time since diagnosis of diabetes,2
time since first diagnosis of multiple sclerosis [ms],2
time since first multiple sclerosis (ms) diagnosis,2
time since first progression,2
time since hiv diagnosis,2
time since itp diagnosis,2
time since pah diagnosis,2
time since stroke,2
time to recovery from maximal percent fall,2
tinnitus handicap inventory,2
tnf-alpha,2
tnm stage,2
tobacco use during pregnancy,2
tobacco used,2
tobacco user,2
total acne lesion count,2
total alkaline phosphatase (alp),2
total bilirubin (mg/dl),2
total blood volume,2
total body fat,2
total cholesterol/high-density lipoprotein cholesterol ratio,2
total daily beta-agonist use,2
total daily off time,2
total hospital anxiety depression scale (hads),2
total insulin dose,2
total insulin secretion,2
total led,2
total lung capacity,2
total score on the fagerstrom test for nicotine dependence,2
total sequential organ failure assessment score,2
total sleep time,2
total time on art,2
total unified parkinson's disease rating scale (updrs),2
tpeak-tend interval,2
transferrin saturation,2
transfusion dependence,2
treatment indication,2
treatment modality,2
treatment modality of fviii therapy before enrollment,2
treatment regimen,2
treatment type,2
tremor,2
triglycerides (tgs),2
triglycerides levels,2
"triglycerides, categorical",2
tsh,2
tumor node metastasis (tnm) stage,2
type ii diabetes,2
type of anesthesia,2
type of delivery,2
type of fviii product used before enrollment,2
type of index event,2
type of insurance,2
type of migraine,2
type of multiple sclerosis,2
type of presenting acute coronary syndrome,2
type of primary immunodeficiency,2
type of uveitis,2
ulcer area,2
ulcer size,2
underlying disease,2
updrs,2
updrs-adl score during off time,2
updrs motor score during on time,2
uric acid,2
urinary 11-dtxb2,2
urinary albumin:creatinine ratio,2
urinary pgi2-metabolite,2
urinary urgency,2
urine albumin/creatinine ratio,2
urine protein/creatinine ratio,2
va benefits recipient,2
vaginal deliveries,2
vas,2
ventilator status,2
vessel diameter,2
veteran status,2
visual-acuity score and snellen equivalent,2
visual analog scale (vas),2
visual analogue scale,2
vitamin e,2
volume voided/micturition,2
vomiting,2
waist circumference (cm),2
"waist circumference, categorical",2
wakefulness after persistent sleep onset (waso),2
weekly dose of methotrexate (mtx),2
weekly frequency zolpidem consumption,2
weekly mean of 24-hour average pain severity,2
weekly mean of 24 hour average pain severity,2
weekly number of csbm,2
weekly number of sbm,2
weight at baseline,2
weight categorical,2
weight categories,2
weight category,2
"weight, customized",2
"weight, mean",2
western ontario and mcmaster universities osteoarthritis index (womac) total score,2
who stage,2
who/ecog performance status,2
womac,2
womac function,2
womac pain,2
womac vas pain subscore,2
womac vas physical function subcore,2
womac vas stiffness subscore,2
womac vas total score,2
worker's compensation,2
world health organization (who) functional class at time of transition,2
world health organization (who) performance status,2
world health organization 5-item well-being index (who-5),2
wound size,2
wound size >5cm^2,2
wound size â‰¤5cm^2,2
wound surface area,2
wound type,2
years in practice,2
years of heavy drinking,2
years of opioid use,2
years since last menstruation at baseline,2
years since pah diagnosis,2
young mania rating scale (ymrs),2
zbmi,2
# chronic obstructive pulmonary disease (copd) exacerbations in 30 days prior to screening,1
# cigarettes smoked per day,1
# cigs smoked in past 30 days,1
# of day of induction at onset of hyperglycemia,1
# of days drinking in last 28 days,1
# of partners,1
# of previous cesarean births,1
# of sex acts,1
# of unprotected partners,1
# of unprotected sex acts,1
# packs currently smoked per day,1
# participants currently employed,1
# participants who report previous use of smoking cessation medication,1
# participants who smoke first morning cigarette within 5 minutes,1
# participants with less than 3 quit attempts,1
# participants with longest period of abstinence from smoking- less than 1 week,1
# quit attempts in the past,1
% body surface area,1
% cd30 expression by visual immunohistochemistry (vihc),1
% days alcohol use in past week,1
% days drinking,1
% days heavy alcohol use in past week,1
% days heavy drinking,1
% days of heavy drinking,1
% days w/1+interlock test failures,1
% federal poverty line,1
% predicted fev1 (visit 2),1
% predicted fev1 at screening,1
% reversibility in fev1 (visit 2),1
% reversibility in fev1 (visit 3),1
% time esophageal ph<4,1
% total time ph < 4,1
%predicted amount of air expired in the first second during a forced expiration pre broncho-dilator,1
(non-high-density lipoprotein cholesterol (non-hdl-c),1
0-180 min post prandial glucose auc,1
1-hour post-prandial glucose auc,1
"1,5-anhydro-d-glucitol (1,5-ag)",1
"1,5 anhydroglucitol (1,5 ag)",1
10 meter walk test,1
10 year coronary heart disease (chd) risk,1
10/36 spatial recall - 1st trial,1
10/36 spatial recall - delayed recall,1
10/36 spatial recall - total,1
100% kinetic field,1
11-dehydrothromboxane b2,1
12-lead electrocardiogram (ecg),1
120-min post prandial glucose,1
120-minute postprandial glucose (ppg),1
17-item hamilton depression rating scale (hamd-17) anxiety/somatization score,1
17-item hamilton depression rating scale (hamd-17) anxiety/somatization subscale score,1
17-item hamilton depression rating scale (hamd-17) bech subscale score,1
17-item hamilton depression rating scale (hamd-17) core score,1
17-item hamilton depression rating scale (hamd-17) maier score,1
17-item hamilton depression rating scale (hamd-17) maier subscale score,1
17-item hamilton depression rating scale (hamd-17) retardation score,1
17-item hamilton depression rating scale (hamd-17) retardation subscale,1
17-item hamilton depression rating scale (hamd-17) sleep score,1
17-item hamilton depression rating scale (hamd-17) sleep subscale score,1
17-item hamilton depression rating scale total score,1
17 item hamilton depression rating scale (hamd-17) - maier subscale,1
17 item hamilton depression rating scale total score(hamd-17),1
17 item hamilton rating scale for depression (ham-d17) total score,1
17p deletion and/or tp53 mutation,1
18 years and above,1
1st degree relative with osteoporosis,1
2-hour c-peptide area under the curve result in response to standardized mixed meal tolerance test,1
2-hour glucose excursion,1
2-hour plasma glucose,1
2-hour post-meal glucose (2 hr pmg),1
2-hour post-meal glucose (pmg),1
2-hour post-oral glucose tolerance test (ogtt),1
2-hour post-prandial glucose auc,1
2-hour post meal glucose (2-h pmg),1
2-hour postload plasma glucose (2-h pg),1
2-hour postprandial glucose(2hppg),1
2-hour postprandial plasma insulin (ppi),1
2-hr glucose (impaired glucose tolerance),1
2-hr glucose diabetes mellitus,1
2 -hour c-peptide area under curve result in response to standardized mixed meal tolerance test,1
2 hour c-peptide,1
2 hour glucose,1
2 hour plasma glucose,1
2 hour plasma glucose concentration,1
2 minute walk test time,1
2 symptoms,1
"2,3-dinor-6-keto-pgf1alpha",1
24-h urinary d-chiroinositol (dci) (nmol/day),1
24-h urinary myo (nmol/day),1
24-hour ambulatory diastolic blood pressure,1
24-hour ambulatory systolic blood pressure,1
24-hour average back pain score,1
24-hour dbp,1
24-hour diastolic blood pressure (dbp),1
24-hour mean diastolic ambulatory blood pressure,1
24-hour mean systolic ambulatory blood pressure,1
24-hour plasma glucose (auc/duration),1
24-hour sbp,1
24-hour systolic blood pressure (sbp),1
24-hour urinary calcium,1
24-hour urinary oxalate,1
24-hour urine uric acid,1
24-hour urine uric acid categories,1
24-hour urine volume,1
24-hour vulvar pain,1
24-hour weighted mean plasma glucose (24hr-wmg),1
24-hour worst back pain score,1
24-hr ambulatory diastolic bp,1
24-hr ambulatory heart rate,1
24-hr ambulatory systolic bp,1
24-hr daytime diastolic blood pressure,1
24-hr daytime heart rate,1
24-hr daytime systolic blood pressure,1
24-hr diastolic blood pressure average,1
24-hr heart rate average,1
24-hr nighttime diastolic blood pressure,1
24-hr nighttime heart rate,1
24-hr nighttime systolic blood pressure,1
24-hr systolic blood pressure average,1
24-hr urine phosphate,1
24-month predicted survival probability,1
24 h hot flash score,1
24 hour creatinine clearance,1
24 hour proteinuria,1
24 hour urine calcium,1
25-hydroxyvitamin d level,1
25-oh vitamin d,1
25-oh vitamin d (ng/ml),1
25 oh vitamin d,1
25(oh)d at screening,1
25(oh)d serum level,1
25(oh)vit d,1
25oh vitamin d,1
25vit d (ng/ml),1
28-day partial seizure frequency,1
28-day seizure rate,1
28-joint disease activity score of c-reactive protein (das28[crp]),1
28 day seizure frequency in subjects with <= 6 and > 6 seizures during baseline period,1
2hppg,1
3-hour post-prandial glucose auc,1
3 or more prior endocrine therapies,1
3 symptoms,1
30 day mortality,1
30 day readmission,1
36-item short form health survey (sf-36) quality of life,1
36-item short form health survey (sf-36) quality of life (qol),1
36 items short form survey instrument (sf-36v) mental scale,1
"3mse score, 0-100 scale, mean",1
4 symptoms,1
5-fu (intraperitoneal chemoinfusion) dose per session,1
5-hydroxytryptamine type 3 receptor antagonist,1
5-meter gait speed,1
5 or more drinks of alcohol on 1 occassion-past 3 months,1
5 timed chair stands,1
50-foot walk test contralateral vas pain score,1
50-foot walk test vas pain score,1
50 point pain and interfence with activity scale,1
5q- (31-33) chromosomal abnormality,1
6-minute walk distance (6mwd),1
6-minute walk distance (6mwd) at baseline,1
6 minute walk,1
6 minute walk test (mwt),1
6 minute walking distance (6mwd) category,1
6 mwt,1
6.5 degrees tritan threshold,1
"6mwd, feet",1
7-day point prevalence abstinence,1
7-point self-monitored plasma glucose (smpg),1
7 day physical activity recall,1
72-hour incontinence episode frequency (ief),1
72 hour auc-180,1
75 foot laps completed,1
8 foot walk,1
"a fracture in spine lumbar 1, lumbar 2, lumbar 3, lumbar 4 and t-score â‰¤-2.0",1
ä°ntraoperative blood loss,1
ä°ntraoperative red cell transfusion,1
a1c (%),1
a1c baseline,1
aaq anger attacks,1
abc-hyperactivity,1
abc-inappropriate speech,1
abc-irritability,1
abc-lethargy,1
abc-stereotypy,1
abcb1 genotype,1
abdominal aortic aneurysm size,1
abdominal bloating,1
abdominal discomfort,1
abdominal distention,1
abdominal fat mass,1
abdominal obesity,1
abdominal pain- screening,1
abdominal pain duration,1
abdominal pain severity score,1
"abdominal pain severity, categorical",1
aberrant behavior checklist (abc),1
aberrant behavior checklist total score,1
"aberrant behavior checklist, hyperactivity",1
ability to use toilet at baseline,1
able to ambulate 10 meters in < 12 seconds,1
abnormal involuntary movement scale - non-global total score,1
abnormalities by fish,1
abo blood group,1
abo blood type,1
above average change of getting hiv,1
abscess location,1
abscess size,1
absence of t cell reaction to all vaccine peptides,1
absolute cd4 (cluster of differentiation 4) count,1
absolute cd4 at delivery,1
absolute lymphocyte count,1
absolute lymphocyte count at baseline,1
absolute neutrophil count,1
absolute neutrophil count at baseline (in 1000/ul),1
absolute neutrophil counts,1
acceptability of acupuncture,1
acceptability of hand held fundus photograph in comparison to traditional photgraph,1
access side,1
access to child's record,1
access type,1
access vein,1
accident type,1
accommodative convergence over accommodation (ac/a) ratio,1
accommodative lag,1
accompanying symptoms of the primary disease,1
acculturation score,1
ace-i/arb use,1
ace-inhibitors therapy,1
ace inhibitor,1
ace inhibitor/arb use,1
acellular dermal matrix used (antisepsis side),1
acellular dermal matrix used (control side),1
acetaminophen,1
acne history,1
acne lesion counts,1
acq-6 score,1
acq6,1
acquired immune deficiency syndrome clinical trials group symptom distress module(sdm) overall score,1
acquired immunodeficiency virus (aids),1
acromegaly symptoms,1
acs index event,1
"actinic keratoses, imiquimod side",1
"actinic keratoses, observation side",1
"actinic keratoses, total",1
actinic keratosis baseline severity index,1
action research arm test (arat),1
active a / active w,1
active dorsiflexion,1
active duty military,1
active tobacco use,1
active uveitis,1
active vitamin d use,1
activities of daily living,1
activities of daily living - hoarding,1
activities of daily living (adl),1
activities of daily living (adl) 2 weeks prior to admission,1
activity level,1
actual number of work hours (staff),1
actual zdv exposure during pregnancy,1
acupuncture discomfort (vas),1
acupuncture experience,1
acute benzodiazepine use (does not include daily use),1
acute copd exacerbation requiring hospitalization or ed visit within previous 12 mo,1
acute coronary syndrome (acs) present,1
acute myeloid leukemia (aml) source,1
acute myeloid leukemia (aml) type,1
acute otitis media severity of symptoms (aom-sos) score,1
acute physiologic and chronic health evaluation (apache) ii score,1
acute physiologic and chronic health evaluation (apache) iii,1
acute physiologic and chronic health evaluation iii score,1
acute physiology and chronic health evaluation (apache) ii score,1
"acute physiology and chronic health evaluation (apache) ii score (minimum 0, maximum 71)",1
acute physiology and chronic health evaluation (apache) score,1
acute physiology and chronic health evaluation ii (apache ii),1
acute physiology and chronic health evaluation ii score,1
acute physiology and chronic health evaluation(apache) ii score,1
acute symptomatic dvt of the leg and/or pe as assessed by investigator,1
acy ghr,1
acyl ghrelin,1
adalimumab response failure type,1
adas-cog-orientation test (adas-cog-ot): baseline efficacy scores,1
adas-cog score,1
adascog,1
adcs-adl,1
adcs-adl score,1
addiction severity index (asi) composite scores,1
additional components of resection,1
additive euroscore,1
adenocarcinoma differential of primary tumor,1
adenocarcinoma of the prostate and no radiographic evidence of metastatic disease,1
adenovirus 5 antibody,1
adequate antidepressant use,1
adhd-rs-iv: hyperactivity/impulsivity subscore,1
adhd-rs-iv: inattention subscale score,1
adhd category,1
adhd rating scale,1
adhd rating scale-iv-parent:investigator rated hyperactivity subscale score,1
adhd rating scale-iv-translated in japanese parent version: investigator administered/scored,1
"adhd rating scale-iv parent version: investigator administered & scored, total score",1
adhd rating scale 4th edition,1
adhd treatment status,1
adherent to heart failure medication,1
adhrs-iv-parent: inv. inattention subscale score,1
adhrs-iv-parent: inv. total scores,1
adipose tissue at baseline,1
adipose tissue collagen i deposition,1
adis specific phobia avoidance rating,1
adis specific phobia clinical severity rating,1
adis specific phobia fear rating,1
adjacent carcinoma in situ present,1
adjusted diffusing capacity of the lung for carbon monoxide,1
adjusted total surface area (length x width x proportion of skin involved,1
adjuvant chemotherapy,1
adjuvant radiation therapy (antisepsis side),1
adjuvant radiation therapy (control side),1
adjuvant treatment,1
adl on admission,1
administration of antipyretics,1
admission functional independence,1
admission incentive spirometry (is) volume,1
admission pain score,1
admitted with cardiac diagnosis,1
admitting service,1
adnexal pathology,1
ads scores,1
adult attention-deficit/hyperactivity disorder quality of life 29 - life outlook subscale,1
adult attention-deficit/hyperactivity disorder quality of life 29 - psychological health subscale,1
adult attention-deficit/hyperactivity disorder quality of life 29 - relationship subscale,1
adult attention-deficit/hyperactivity disorder quality of life 29 - total score,1
adult attention deficit hyperactivity disorder (adhd) investigator symptom rating scale (aisrs),1
adult cadaver donor nyberg grade,1
adult olt recipients,1
adult patients with plaque psoriasis >10% bsa,1
adult separation anxiety - 27 scale,1
adult state hope scale,1
adult t-cell leukemia (atl) cells/mm^3 in the peripheral blood,1
adult wellbeing scale,1
advanced airway,1
aerobic efficiency,1
aerobic exercise,1
aetiology of infertility,1
af duration,1
af treatment at enrollment,1
affect perception,1
affected eye,1
affected side,1
affective control scale (acs),1
after exercise- heart rate,1
age-adjusted charlson comorbidity index,1
age-categorical,1
age - part 1 population,1
age (categorical),1
age (statistics),1
age (years) (categorical),1
age >65 years,1
age 1st drinking (years),1
age 1st hypomanic episode,1
age 1st major depressive episode,1
age asthma onset,1
age at asthma onset,1
age at beginning of long term follow-up period,1
age at chronic kidney disease diagnosis,1
age at diagnosis of autosomal dominant polycystic kidney disease (adpkd),1
age at diagnosis of autosomal dominant polycystic kidney disease (yrs),1
age at diagnosis of prostate cancer,1
age at enrollment,1
age at epilepsy onset,1
age at epilepsy onset (years),1
age at first cigarette,1
age at first cocaine use (years),1
age at first diagnosis of schizophrenia,1
age at first episode,1
age at first major depressive disorder (mdd) episode,1
age at first major depressive episode,1
age at first sexual intercourse,1
age at first substance use,1
age at hiv-1 diagnosis,1
age at immigration,1
age at index stroke,1
age at index tcd,1
age at initial egg allergic reaction,1
age at initial milk allergic reaction,1
age at menopause,1
age at onset of adhd,1
age at onset of attention-deficit/hyperactivity disorder (adhd),1
age at onset of binge eating disorder (bed),1
age at onset of diabetes,1
age at onset of disease,1
age at onset of eczema,1
age at onset of hearing loss,1
age at onset of hypophosphatasia symptoms,1
age at onset of menopause by category,1
age at onset of restless legs syndrome,1
age at onset of seizures,1
"age at onset, bipolar i disorder",1
age at parkinson's disease onset,1
age at post-prandial hypoglycemia diagnosis,1
age at primary diagnosis,1
age at radiotherapy,1
age at receipt of bacille calmette-guerin (bcg) vaccination (days),1
age at regular substance use,1
age at rheumatoid arthritis diagnosis,1
age at schizophrenia/schizoaffective disorder diagnosis,1
age at sexual debut,1
"age at starting vasomotor symptoms (vms), years of age",1
age at study enrollment,1
age at surgery,1
age at the start of treatment,1
age at time of onset of first episode,1
age at time of randomization,1
age by sex,1
age categories,1
age categorization females only,1
"age categorization, female only",1
age characterization female only,1
age classification,1
age continuous in follicular lymphoma sub-population,1
"age customized, by disease type",1
age first live birth,1
age first smoked,1
age first treated for depression,1
age first treated for mania/hypomania,1
age in years,1
age of depression onset,1
age of epilepsy onset,1
age of fibromyalgia diagnosis,1
age of first cigarette,1
age of first episode of mdd,1
age of first major depressive disorder (mdd) episode,1
age of mania/hypomania onset,1
age of onset of asthma,1
age of onset of mood symptoms,1
age of onset of psychiatric illness,1
age of onset of regular drinking,1
"age of onset, mean age",1
age of participants,1
age of participants by 10-year age groups,1
age of schizophrenia/schizoaffective disorder diagnosis,1
age of smoking initiation,1
age of smoking onset,1
age of subjects with prior history of herpes labialis outbreak,1
age of the donor,1
age of type 1 diabetes diagnosis,1
age of vascular access graft,1
age of wound,1
age smoked daily,1
age started smoking,1
age started smoking regularly,1
age strata,1
age stratification at randomization,1
"age, categorical: adult population",1
"age, categorical: pediatric population",1
"age, categorical: period 2 (trial enrollment, induction art)",1
"age, categorical: period 3 (randomization to once vs twice daily abc+3tc)",1
"age, categorical: period 4 (randomization to stop versus continue cotrimoxazole)",1
"age, continuous, compliant participants",1
"age, continuous: period 2 (trial enrollment, induction art)",1
"age, continuous: period 3 (randomization to once vs twice daily abc+3tc)",1
"age, continuous: period 4 (randomization to stop versus continue cotrimoxazole)",1
agecategoricalother,1
agents given to prevent gvhd at the time of enrollment,1
agents given to treat gvhd more than 3 days before enrollment in the study,1
agents given to treat gvhd within 3 days before or after enrollment,1
aging male syndrome questionnaire,1
agitation-calmness evaluation scale (aces),1
agitation-calmness evaluation scale (aces) score,1
aha-defined hypertension,1
ahi,1
ahi - events/hour,1
ahi (apnea-hypopnea index),1
ahi (events/hour),1
ahi sitting,1
ahi standing,1
ai sensitivity,1
aids at entry,1
air transport,1
airway blood flow,1
airways reversibility with albuterol,1
"ajcc melanoma tumor, node, metastasis (tnm) stage at study entry",1
ajcc stage,1
aki identified by icd10 codes of n17,1
alabama parenting questionnaire (apq),1
alanine aminotransferase (alt) (u/l),1
alanine aminotransferase (alt) level at baseline,1
alanine aminotransferase (alt); upper limit of normal (uln) = 34 u/l,1
alanine aminotransferase level,1
"alanine aminotransferase, continuous",1
alanine aminotransferease (alt),1
alanine transaminase,1
albumin-adjusted calcium,1
albumin-corrected calcium,1
albumin-to-creatinine (a/cr) ratio,1
albumin at baseline (in mg/dl),1
albumin level,1
albumin plasma concentration,1
alcohol-related consequences score - imbibe,1
alcohol abuse,1
alcohol abuse or alcohol dependence,1
alcohol consumption - abstemious,1
alcohol consumption history,1
alcohol dependence scale,1
alcohol drinker,1
alcohol drinkers,1
alcohol drinking,1
alcohol history (drinking alcohol-containing beverages most days),1
alcohol history (drinking alcohol-containing beverages nearly every day),1
alcohol intake in last six months,1
alcohol servings/day,1
alcohol usage,1
alcohol use (drinks/week),1
alcohol use at baseline,1
alcohol use diagnosis,1
"alcohol use disorder, past 36 months",1
alcohol use disorders identification test,1
alcohol use during pregnancy,1
alcohol use identification test (audit),1
alcohol use severity (audit score),1
alcohol use severity by audit,1
"alcohol, smoking, and substance involvement screening test score",1
alcoholc,1
alcoholic history,1
alcoholism severity,1
alfa-1-acid glycoprotein plasma concentration,1
alfa-fetoprotein,1
algometer-induced pressure pain,1
alk status,1
alkaline hematin value at baseline,1
alkaline phosphatase level,1
all cytogenics,1
all lesion characteristics,1
all lesion ulceration area,1
all patients with fungal catheter-related blood stream infections were potential study subjects,1
all ulcerated lesions,1
allergen sensitivity,1
allergic rhinitis diagnosis duration,1
allergies,1
allogeneic bone marrow transplant (bmt)/hematopoietic stem cell transplant (hsct),1
alpha-1 antitrypsin phenotype,1
alpha-fetoprotein (afp) (ivrs),1
alpha-fetoprotein (afp) (rave),1
alpha-glucosidase inhibitor use,1
alpha-tocopherol,1
alpha fetoprotein level,1
alpha1-pi concentration,1
alpha1 acid glycoprotein (agp),1
als-functional rating scale-r (alsfrs),1
als family history,1
als functional rating scale-revised (alsfrs-r),1
als functional rating scale - revised (alsfrs-r) total score,1
alsfrs-r total score,1
alt (u/l),1
alt as multiple of uln,1
alternate frontal systems z-score,1
alternate psychomotor function z-score,1
alternate verbal memory z-score,1
"alzheimer's disease assessment scale-cognitive subscale (adas-cog11) score (n=507, 533)",1
alzheimer's disease assessment scale - cognitive portion,1
alzheimer's disease assessment scale - cognitive subscale (adas-cog11),1
alzheimer's disease assessment scale - cognitive subscale (adas-cog11) score,1
alzheimer's disease cooperative study activities of daily living (adcs-adl) inventory score,1
alzheimer's disease cooperative study activities of daily living inventory (adcs-adl),1
"alzheimer's disease cooperative study activities of daily living inventory score (n=505, 529)",1
alzheimer's disease cooperative study/activities of daily living inventory,1
alzheimers disease (ad)/mild cognitive impairment (mci),1
ambient temperature,1
amblyopia cause,1
ambulation at baseline,1
ambulation distance,1
ambulatory capacity,1
ambulatory without assistance,1
american college of rheumatology (acr) functional status classification,1
american joint committee on cancer (ajcc) stage at baseline,1
american rheumatism association functional class,1
american society of anaesthesiologists (asa) classification,1
american society of anaethesiology physical status score,1
american society of anesthesiologist (asa) classification,1
american society of anesthesiologist (asa) physical status,1
american society of anesthesiologist classification,1
american society of anesthesiologists (asa)-physical state (2-5),1
american society of anesthesiologists (asa) category,1
american society of anesthesiologists (asa) classification,1
american society of anesthesiologists (asa) physical status classification,1
"american society of anesthesiologists (asa) physical status, categorical",1
american society of anesthesiologists (asa) preoperative classification,1
american society of anesthesiologists (asa) status,1
american society of anesthesiologists physical classification system (asa) class,1
american society of anesthesiologists physical status (asa),1
american society of anesthesiologists physical status class,1
american society of anesthesiologists physical status classification 1,1
american society of anesthesiologists physical status classification 2,1
american society of anesthesiologists physical status score,1
american society of anesthesiologists status (asa),1
american society of anesthesiology (asa) physical status,1
american society of anesthesiology (asa) physical status classification,1
american society of anesthesiology classification,1
amh,1
amh less than 24 pmol/l,1
aml disease classification,1
aml onset: de novo,1
aml onset: secondary,1
amount of alcohol consumed if current drinker,1
amount of cigarette smoking as pack-year,1
amount of computer use,1
amount of physical activity/week,1
amount of pre-randomization outpatient occupational therapy,1
ampef (peak expiratory flow),1
amputees,1
amyotrophic lateral sclerosis functional rating scale-revised (alsfrs-r),1
"ana-positive, n (%)",1
ana(+),1
anaesthesia duration,1
anaesthesia time,1
anal incontinence (ai),1
anal resting tone,1
anal sex in the previous 3 months,1
anatomic location,1
anatomic location of cvc,1
anatomic site of primary diagnosis,1
anatomical area of ablation,1
anatomical location of primary lesion,1
anc at baseline,1
anc prior to randomization,1
ancestry,1
androgenic alopecia,1
anemia symptoms,1
anesthesia time,1
anesthesia type,1
anesthetic volume (in ml),1
angina categories,1
angina pectoris,1
angiolymphatic invasion present,1
angiotensin ii antagonists,1
angiotensin ii concentration (atii) [uric acid],1
angiotensin ii concentration (atii) [vitamin d],1
anisometropia,1
anisometropia at randomization,1
ankle-brachial index,1
ankle brachial index (abi),1
ankylosing spondylitis disease activity score (asdas),1
ankylosing spondylitis quality of life scale (asqol) at baseline,1
ann arbor staging,1
ann arbor staging system of lymphoma,1
annexin v+ microparticles,1
annual household income,1
"annual household income:$20,000 or less",1
annual income (sd),1
annual income (us dollars),1
"annual income <$30,000",1
anorectal manometry - pressures,1
anorectal manometry - volumes,1
antecedent hematologic disorder,1
antecedent hematological disorder (ahd),1
antenatal corticosteroids,1
antenatal steroids,1
anterior vaginal - prolapse repair,1
anti-adalimumab antibody status,1
anti-adalimumab antibody status at screening,1
anti-aqp4 antibody serostatus,1
anti-ccp2 status,1
anti-cyclic citrullinated peptide 2 (ccp2) status,1
anti-cyclic citrullinated protein (anti-ccp) antibodies,1
anti-dementia therapy,1
anti-deoxyribonucleic acid (anti-dna) antibodies,1
anti-dsdna,1
anti-hla lymphocytotoxic antibodies against <25% a reference panel,1
anti-hormone therapy,1
anti-hyperglycemic medications,1
anti-hypertensive treatment,1
anti-hypertensives (class),1
anti-hypertensives (number),1
anti-hypertensives (type),1
anti-inflammatory treatment,1
anti-mitochondrial antibody,1
anti-mullerian hormone,1
anti-nuclear antibodies,1
anti-platelet aggregation and anti-coagulant drugs,1
anti-polyribosylribitol phosphate (prp) antibody titer before primary immunization,1
"anti-scl 70-positive, n (%)",1
anti-seizure meds for migraine prevention,1
anti-tnf treatments,1
anti mullerian hormone (amh),1
antiandrogen use,1
antiarrhythmic drugs,1
antibody to hbeag (hbeab),1
antibody to hbsag (hbsab),1
anticholinergic use at screening,1
anticipated difficult airway,1
anticipated pain,1
antidepressant exposure in current episode,1
antidepressant taken prior to duloxetine switch,1
antidepressant treatment history form (athf-current),1
antidiabetic medications per patient,1
antiemetics taken in last month,1
antihypertension medication within 28 days,1
antihypertensive medication at enrollment,1
antihypertensive medications,1
antihypertensive treatment,1
antimulerian hormone (amh),1
antiplatelet drug or anticoagulant drug,1
antiplatelet drugs,1
antipsychotic medication chlorpromazine equivalents,1
"antipsychotic medication dose, chlorpromazine (cpz)",1
"antiretroviral (arv) regimen at entry, categorical",1
antiretroviral (arv) treatment at entry,1
antiretroviral experienced,1
antiretroviral regimens combined with atv/r,1
antiretroviral therapy usage,1
antiretroviral therapy used (stratification),1
antiretroviral treatment within previous 6 months,1
antithrombin (at) activity level < or equal to 60%,1
antithrombin (at) activity level <60%,1
antithymocyte globulin treatment,1
antral follicle count,1
anuric,1
anxiety (>=10 on gad7),1
anxiety (beck anxiety index: bai),1
anxiety disorder,1
anxiety sensitivity index (asi),1
any comorbidity,1
any condomless anal intercourse with an hiv-discordant partner in last 3 months,1
any current medicationï¼œexcluding antidiabetic drugs,1
any diabetes mellitus complications,1
any historical fracture at age â‰¥ 55 years,1
any incontinence,1
any lifetime major depressive episode,1
any metastatic disease,1
any preoperative mri injury,1
any previous cardiovascular event,1
any previous child with birth defect,1
any prior exposure to heat shock protein 90 (hsp90) inhibitors,1
any prior hepatitis b medication,1
any prior history of bone marrow abnormalities,1
any prior use of docetaxel,1
any psychiatric comorbidity,1
any relevant medical conditions,1
any risk factor for stent thrombosis,1
any smoker in household,1
"any sti excluding trichomoniasis, #",1
"any sti, #",1
any substance use,1
aon signs and symptoms at screening or baseline,1
aortic cross-clamp time,1
aortic cross clamp time,1
aortic regurgitation,1
aortic regurgitation (moderate or severe),1
aortic stenosis,1
aortic valve area (ava),1
aortic valve area (effective orifice area),1
aortic valvular regurgitation,1
apache ii score (at study entry),1
apathy evaluation scale,1
apathy evaluation scale - clinician rated version (aes-c) total score,1
"apathy, aes",1
apgar,1
apgar score at 5 minutes,1
apgar scores @ 1 minute,1
apgar scores @ 10 minutes,1
apgar scores @ 5 minutes,1
apixaban/matching placebo dose at randomization,1
"apnea-hypopnea index (ahi), categorical",1
"apnea-hypopnea index (ahi), events/hr, continuous",1
apnea hypopnea index (ahi) (event/hour),1
apnea type at enrollment,1
apnea+hypopnea index,1
apneaâ€“hypopnea index,1
apnoea-hypopnoea index (ahi),1
apo e4 carrier,1
apo lipoprotein a-i (apo a-i),1
apo lipoprotein b (apo b),1
apo lipoprotein b (apo b):apo lipoprotein a-i (apo a-i) ratio,1
apoe4 status,1
apolipoprotein a,1
apolipoprotein a-i:apolipoprotein b ratio,1
apolipoprotein a1,1
apolipoprotein b (apo b),1
apolipoprotein b:apolipoprotein a-i ratio,1
apolipoprotein e îµ4 status,1
apolipoprotein e4 carrier,1
apoprotein a,1
apoprotein b,1
appearance anxiety inventory (aai),1
appearance of ulcer (clean-based),1
"appearance of ulcer (oozing, bleeding)",1
appetite,1
applicable aura symptoms for qualifying migraine,1
aptt at baseline n=(57;20;27;98;34;33;96;33;29;57;484),1
aqueous humor flow,1
arachidonic acid (aa),1
arch drop,1
arch rigidity,1
are you currently married?,1
area-under-the-curve (c-peptide/glucose) / homa-ir,1
area of choroidal neovascularization (cnv),1
area under plasma glucose concentration curve from time 0.5 hours to 4.5 hours (glu-auc0:30-4:30h),1
area under the curve (auc) glucose (mg*min/dl),1
area under the curve from 0 to 20 minutes (auc0-20),1
area under the curve of glucose (aucg),1
area under the curve of insulin (auci),1
area under the fev1 percent change from baseline time curve for 0-60 mins after exercise challenge,1
argininosuccinate synthetase (ass) assay result,1
arm dominance,1
arm motor ability test (amat),1
aromatase inhibitor therapy,1
arousal index,1
arousal index (ari),1
art experience,1
art regimen at entry,1
arterial blood pressure,1
"arterial blood pressure, continuous",1
arterial hypertension (n),1
"arterial hypertension, categorical",1
arthritis,1
"arthritis self-efficacy score, function",1
"arthritis self-efficacy score, other symptoms",1
"arthritis self-efficacy score, pain",1
asa (american society of anesthesiologists scores),1
asa classification,1
asa health classification,1
asa physical status classification,1
asa physical status in patients who completed study,1
asa physical status iv,1
asa physical status patient classification,1
asa status i,1
asa status ii,1
asa status iii,1
asa status iv,1
asa(american society of anesthesiologists ) scores,1
ascites,1
ascites present,1
asepsis total scores,1
asi-3,1
"asi alcohol composite score, baseline",1
asia classification,1
asia impairment scale,1
asia impairment scale score,1
aspartate aminotransferase (ast) (u/l),1
aspartate aminotransferase level,1
"aspartate aminotransferase, continuous",1
aspirin,1
aspirin sensitivity,1
aspirin use,1
ass assay result,1
assessable joints at baseline,1
assessment of abdominal pain (gi symptom component) grade,1
assessment of behã§et's disease symptoms (other than gi symptoms) grade,1
assessment of diarrhea (gi symptom component) grade,1
assessment of myometrial perfusion,1
assessment of other symptoms (gi symptom component) grade,1
assistive device,1
associated medical conditions,1
associated symptom of the primary disease,1
associated systemic inflammatory disease,1
association for methodology and documentation in psychiatry (amdp-5) item 112 (nausea) score,1
ast (u/l),1
asthma characteristics,1
asthma control questionnaire (acq) overall score,1
asthma control questionnaire (acq5) score at study entry,1
asthma control test score,1
asthma exacerbation in last 12 months,1
asthma exacerbation within the last 12 months,1
asthma exacerbations in previous 12 months,1
asthma exacerbations in the previous 12 months,1
asthma medication use,1
asthma quality of life questionnaire (aqlq) score,1
asthma scores,1
asthma severity according to global initiative for asthma (gina),1
asthma status (mild-to-moderate persistent asthma),1
asthma symptom utility index,1
asthma symptom utility index (asui) score,1
astigmatism,1
at least 1 qualifying tg category > 885 mg/dl,1
at least 2 male sex partners in the past 3 months,1
at least one concurrent mood or anxiety disorder,1
atm status,1
atopy,1
atopy (phadiatop â‰¥ 0.35 kua/l),1
atrial arrhythmias,1
atrial fibrillation (af) duration,1
atrial fibrillation history,1
atrial fibrillation type,1
atrial flutter condition,1
atrioventricular-block (av-block),1
atrioventricular (av) node ablation concomitantly with the micra procedure,1
attachment style questionnaire,1
attempted sucide,1
attended childbirth classes,1
attending public school,1
attending specialty,1
attention-deficit/hyperactivity disorder (adhd) subtype current,1
attention-deficit/hyperactivity disorder (adhd) subtype: current episode,1
attention-deficit/hyperactivity disorder (adhd) subtype: lifetime episode,1
attention-deficit/hyperactivity disorder rating scale-iv-parent version- total score,1
attention-deficit/hyperactivity disorder rating scale-iv-parent version:investigator-administered,1
attention-deficit/hyperactivity disorder rating scale-iv (adhd-rs-iv) total score,1
attention-deficit/hyperactivity disorder rating scale-iv (adhd-rs-iv): total score,1
attention-deficit/hyperactivity disorder rating scale (adhd-rs) total score,1
attention-deficit/hyperactivity disorder subtype,1
attention deficit hyperactive disorder (adhd) subtype,1
attention deficit hyperactivity disorder (adhd) rating scale total,1
attention deficit hyperactivity disorder rating scale,1
attention deficit hyperactivity disorder rating scale-iv total score,1
attention deficit hyperactivity disorder rating scale - am,1
attentional bias as assessed by score on the stroop task,1
"attitudes and beliefs: ""if a person is receiving va benefits and starts working for pay ...""",1
atypical,1
atypical antipsychotic drug augmentation trials,1
auc glucose,1
auc insulin (mg*min/ml),1
auc insuline,1
audiometry,1
audit score,1
auditory hallucination rating scale,1
auscan function score (0-100),1
auscan pain (0-100),1
auscan stiffness score (0-100),1
autism diagnostic interview-revised (adi-r),1
autoantibody status,1
autologous transplant,1
autonomic dysreflexia,1
av (atrioventricular) block,1
av junctional arrhythmia history,1
average baseline seizure frequency per 28 days,1
average baseline testosterone,1
average bmi,1
average clinical attachment level (cal),1
"average cycle 17-35 days, inclusive",1
average daily hydrocodone equivalent dose,1
average daily number of stools,1
average daily opioid dose in morphine equivalents,1
average daily prednisone dose,1
average daily time to on,1
average daily use of short-acting beta-agonist therapy (saba) in past 3 days,1
average daytime (9:00 to 21:00) ambulatory systolic blood pressure (sbpday),1
average dose of medication taken,1
average drinks per week,1
average drinks/day,1
average duration of obstructive symptoms (months),1
average duration of parkinson's disease,1
average fatigue over the last week,1
"average flow 3-10 days, inclusive",1
average frequency of hot flashes per day,1
average functional status,1
average glycated albumin,1
average hba1c,1
average hot flashes per day,1
average insulin glargine daily dose,1
average j0 between the eyes,1
average j45 between the eyes,1
average line days,1
average modified gingival index score,1
average national institutes of health chronic graft versus host disease (cgvhd) score at baseline,1
average number of cigarettes participants smoked per day,1
average number of cigarettes smoke per day,1
average number of cigarettes smoked per day,1
average number of cigarettes smoked per day in the previous 7 day period at baseline,1
average number of hours worked for pay per week,1
average number of migraine attacks per month,1
average number of times other measures were used,1
average numeric pain rating scale (nprs),1
average of all blood glucose,1
average overall pain,1
average ovulatory hcg provided,1
average pain,1
average pain intensity (api),1
average pain intensity during past 24 hours at baseline,1
average pain level,1
average pain over the last 24 hours,1
average pain score,1
average pain severity,1
average participant age +/- sd,1
average probing depth (pd),1
average suvmax,1
average time since injury,1
average total daily insulin dose per body weight at baseline (pre-treatment),1
average years of smoking,1
averaged pain,1
avg %-change from pre-exercise baseline fev1 after 1st î²-agonist use & prior to 2nd î²-agonist use,1
avg computer use,1
aware of exclusive breastfeeding message,1
ax continuous performance test task d-prime,1
axial length,1
axial length - cataractous eye,1
axial length - fellow eye,1
axillary lymph node metastases,1
"axillary lymph node metastases, customized",1
axillary lymph node status before nct,1
axillary nodal evaluation,1
axillary surgery,1
axis 1 primary diagnosis,1
azbio sentences,1
aztreonam minimum inhibitory concentration (mic) for pseudomonas aeruginosa (pa),1
b-blockers therapy,1
b-raf proto-oncogene (braf) status,1
b-type natriuretic peptide (bnp),1
b-type natriuretic peptide (pro-bnp),1
b symptoms,1
b1-fmean,1
b1-fpeak,1
b1-imax,1
b1-imean,1
b1-si,1
bachelors degree or more education,1
back pain,1
back stiffness score,1
background antiretroviral regimen,1
background or prior disease,1
background therapy,1
"bacterial growth prior disinfection (colony forming unit/cm^2, log10 transformed)",1
bacterial vaginosis infection,1
bacteriology,1
bai,1
baked egg tolerant,1
balance,1
balance ability,1
balloon dilation of biliary sphincter,1
ballooning grade,1
balp-baseline,1
barbeau class b or c,1
barcelona stage,1
barnes akathisia rating scale total score,1
barratt impulsivity questionnaire,1
"barrett's esophagus segment length, pre-ablation",1
barriers score,1
barthel index score,1
basal egp,1
basal fsh,1
basal localization,1
base deficit (bd),1
base excess/base deficit,1
baseline % of predicted fev1,1
baseline % predicted fev1,1
baseline % predicted fev1 (visit 4),1
baseline (day 1) karnofsky performance score (kps),1
baseline (visit 3) benign prostatic hyperplasia severity,1
baseline (visit 3) lower urinary tract symptoms (luts) severity,1
baseline 23-item toxicity score,1
baseline 24-hour ambulatory diastolic blood pressure,1
baseline 24-hour ambulatory systolic blood pressure,1
baseline 24-hour blood pressure data by arm,1
baseline 24-item ham-d total score,1
baseline 6-minute walk distance,1
baseline 6mwd,1
baseline actinic keratosis lesion count,1
baseline acute physiology and chronic health evaluation ii (apache ii) score,1
baseline air blast hypersensitivity score,1
baseline alanine aminotransferase (alt) above the upper limit of the normal range (uln),1
baseline alanine transaminase (alt),1
baseline als functional rating scale - revised (alsfrs-r) total,1
baseline alsfrs-r total score,1
baseline am instantaneous total nasal symptom score (itnss),1
baseline am reflective total nasal symptom score (rtnss),1
baseline ambulatory blood pressure,1
baseline ankle pain at rest,1
baseline ankle pain upon weight bearing,1
baseline antidepressant medication use,1
baseline antiretroviral medications - protease inhibitors,1
"baseline anxiety, self-report",1
baseline apolipoprotein-b,1
baseline aranesp dose,1
baseline aranesp route,1
baseline area of choroidal neovascularization (cnv),1
baseline area of leakage,1
baseline aspartate aminotransferase (ast),1
baseline assessment regarding the bothersomeness with abdominal bloating,1
baseline assessment regarding the bothersomeness with abdominal discomfort,1
baseline assessment regarding the bothersomeness with constipation,1
baseline assessment regarding the overall satisfaction with bowel habits,1
baseline asthma control questionnaire (acq),1
baseline auc for glucose,1
baseline auc insulin,1
"baseline average nausea, day1",1
baseline average pain intensity,1
baseline average total daily zolpidem dosage,1
baseline axial length,1
baseline baseline reflective ocular symptom score (rtoss) in subjects with rtoss â‰¥5.0,1
baseline beck depression inventory,1
baseline benign prostatic hyperplasia (bph) lower urinary tract symptom (luts) severity,1
baseline best corrected visual acuity,1
baseline best corrected visual acuity (bcva) in study eye,1
baseline best corrected visual acuity (bcva) letter score,1
baseline biochemical markers of bone metabolism,1
baseline biochemical markers of bone resorption and bone formation,1
baseline blood hemoglobin,1
baseline blood pressure,1
baseline bmi (continuous),1
baseline bmi category,1
baseline bmi group,1
baseline bmi percentile,1
baseline bmi z-score,1
baseline boiled milk wheal,1
baseline bone marrow blast category,1
baseline bone mineral density,1
baseline bone mineral density t-score of each anatomic site,1
baseline brief pain inventory (bpi) interference scores,1
baseline c reactive protein level,1
baseline ca 19-9,1
baseline cancer antigen 19-9 (ca19-9),1
baseline cancer types,1
baseline cardiac left ventricular mass index (lvmi),1
baseline cd4,1
baseline cd4 cell counts,1
baseline cd4 count,1
baseline cd4 counts,1
baseline cd4 percentage,1
baseline cd4+ cell count level,1
baseline cd4+ t-cell count,1
baseline cd8 counts,1
baseline cd8+ t-cell count,1
baseline cdrs-r,1
baseline center for epidemiologic studies depression (ces-d) scores,1
baseline central foveal thickness in fellow eye,1
baseline central foveal thickness in study eye,1
baseline central retinal thickness by optical coherence tomography (oct),1
baseline central subfield thickness,1
baseline central venous catheter in place,1
baseline cgi severity,1
baseline characteristics and risk factors,1
baseline child-pugh turcotte (cpt) score,1
baseline choroidal neovascularization (cnv) size,1
baseline chronic kidney disease stage,1
baseline cirrhosis,1
baseline clinical copd questionnaire score all participants,1
baseline clinical global impression - severity (cgi-s) total score,1
"baseline clinical institute withdrawal assessment of alcohol scale, revised (ciwa-ar)",1
baseline clinical m stage,1
baseline clinical n stage,1
baseline clinical stage,1
baseline clinical t stage,1
baseline cluster of differentiation four (cd4) count,1
baseline cns-bfs total score,1
baseline cns lability scale total score,1
baseline cocaine use (days per week),1
baseline cold symptom score,1
baseline colon motility index,1
baseline colon ph,1
baseline colon transit time,1
baseline colonic geometric center at 24 hours,1
baseline combined liver and spleen volume,1
baseline copd assessment test (cat) total score,1
baseline copeptin,1
baseline corticosteroid (prednisone) dose,1
baseline count of painful/tender joints,1
baseline cowâ€™s milk ige,1
baseline cpd,1
baseline cramps in previous 24 hours,1
baseline cramps in previous 30 days,1
baseline creatinine (mg/dl),1
baseline creatinine level,1
baseline crohn's disease activity index score,1
baseline crp - categorical,1
baseline crying time in minutes,1
baseline cuff blood pressure,1
baseline cytogenetics,1
baseline cytokine levels (log-transformed values),1
baseline daily mean pain intensity (mpi) scores,1
baseline daily metformin hcl use,1
baseline daily step count; mean,1
baseline demographics,1
baseline dental plaque score,1
baseline depression score,1
baseline dermatology-specific quality of life index (dlqi) total score,1
baseline dexa areal bone mineral density t-score,1
baseline diabetes therapy,1
baseline diastolic blood pressure (dbp) hypertension severity category,1
baseline diastolic blood pressure (dbp) values (abpm),1
baseline diffusion capacity of carbon monoxide (dlco),1
baseline discomfort,1
baseline disease activity,1
baseline disease activity score (das) 28 (erythrocyte sedimentation rate [esr]),1
baseline disease characteristics,1
baseline disease history,1
baseline distance walked in 6-minute walk test (6mwt),1
baseline distance walked in the 6-minute walk test (6mwt),1
baseline documentation regarding hypertension,1
baseline documentation regarding left ventricular dysfunction,1
baseline documentation regarding stroke,1
baseline documentation regarding symptomatic heart failure,1
baseline documentation regarding symptomatic heart failure or left ventricular dysfunction,1
baseline documentation regarding the atrial fibrillation,1
baseline documentation regarding transient ischemic attack,1
baseline documentation regarding transient ischemic attack or stroke,1
baseline donor site size,1
baseline drug and device therapy,1
baseline dyspnea index (bdi),1
baseline dyspnea index (bdi) focal score,1
baseline dyspnea index score,1
baseline eastern cooperative oncology group (ecog),1
baseline eastern cooperative oncology group (ecog) performance,1
baseline eastern cooperative oncology group (ecog) performance status (ps),1
baseline eastern cooperative oncology group (ecog) performance status (ps) score,1
baseline echocardiogram measures by arm - augmentation index,1
baseline echocardiogram measures by arm - ejection fraction,1
baseline echocardiogram measures by arm - pulse wave velocity,1
baseline ecog,1
baseline ecog status,1
baseline edema measure,1
baseline edss total score,1
baseline ee grade (la classification),1
baseline egfr categories (ml/min/1.73 m^2),1
baseline electrocardiogram findings,1
baseline eortc qlq-pr25 scores during cycle 1,1
baseline epileptic discharges per 30 minutes,1
baseline eq-5d,1
baseline estimated glomerular filtration rate (egfr) category,1
baseline estimated glomerular filtration rate (egfr) from local lab,1
"baseline estimated glomerular filtration rate, egfr",1
baseline excess weight,1
baseline expanded disability status scale [edss] score,1
baseline extraintestinal manifestations,1
baseline ezetimibe use,1
baseline fasting blood glucose,1
baseline fasting blood sugar,1
baseline fasting serum glucose,1
baseline fasting serum total cholesterol (tc),1
baseline fasting serum triglycerides,1
baseline fecal calprotectin - categorical,1
baseline fecal incontinence medication,1
baseline ferritin,1
baseline fev 1 (l),1
baseline fev1,1
baseline fev1 (percent predicted),1
baseline fev1 if participant has copd,1
baseline for dimension 'bodily pain (bp)' of the sf-36 qol scale,1
baseline for dimension 'general health (gh)' of the sf-36 qol scale,1
baseline for dimension 'mental health (mh)' of the sf-36 qol scale,1
baseline for dimension 'physical functioning (pf)' of the sf-36v2â„¢ (sf-36) quality of life (qol),1
baseline for dimension 'role limitation due to emotional problems (re)' of the sf-36 qol scale,1
baseline for dimension 'role limitation due to physical problems (rp)' of the sf-36 qol scale,1
baseline for dimension 'social functioning (sf)' of the sf-36 qol scale,1
baseline for dimension 'vitality (vt)' of the sf-36 qol scale,1
baseline for the mental component scale (mcs) of the sf-36 qol scale,1
baseline for the physical component scale (pcs) of the sf-36 qol scale,1
baseline forced expiratory volume in 1st second (fev1) (% predicted),1
baseline forced expiratory volume in one second (fev1) percentage predicted,1
baseline forced vital capacity,1
baseline fvc,1
baseline gastric emptying time,1
baseline gd-enhanced lesions,1
baseline gfr,1
baseline gingivitis score,1
baseline gleason grade (higher grade indicates more pathologic atypia),1
baseline glucose,1
baseline glucose levels,1
baseline glycated hemoglobin a1c (hba1c),1
baseline glycosylated hemoglobin,1
baseline glycosylated hemoglobin (hba)1c category,1
baseline gross motor function measure (gmfm-66) score,1
baseline haemoglobin a1c (hba1c),1
baseline hamilton rating scale for anxiety,1
baseline hamilton rating scale for depression with 17 items,1
baseline hamilton rating scale for depression with 21 items,1
baseline hamilton rating scale for depression with seven items,1
baseline hba1c levels,1
baseline hbv dna,1
baseline hbv subtype,1
baseline hcv rna level,1
baseline heart rate,1
baseline heart rate variability (sdnn),1
baseline height sds,1
baseline hemoglobin a1c (hba1c) categories,1
baseline hepatitis b deoxyribonucleic acid (hbv dna),1
baseline hepatitis b e antibody,1
baseline hepatitis b e antigen,1
baseline hepatitis b surface antigen,1
baseline hepatitis b virus (hbv) dna below 169 copies/ml,1
baseline hepatitis b virus deoxyribonucleic acid (hbv dna),1
baseline hepatitis c virus (hcv) rna,1
baseline hiv-1 rna categorial,1
baseline hiv-1 rna level,1
baseline hiv rna values,1
baseline hiv viral load category,1
baseline homeostatic model assessment-beta cell (homa-b),1
baseline homeostatic model assessment-insulin sensitivity (homa-s),1
baseline hrsd score,1
baseline hrsd score for follow-up study,1
baseline hypercalcemia of malignancy (hcm) symptoms,1
baseline hyperpigmentation score,1
baseline hypertension,1
baseline ic,1
baseline igf-1 sds (standard deviation score),1
baseline iief scores during cycle 1,1
baseline in-plane diameter of the largest calcium oxalate stone,1
baseline in body surface area (bsa) total score,1
baseline in nail psoriasis severity index (napsi) total score,1
baseline in participants achieving psoriasis area and severity index (pasi) score,1
baseline in patient's global assessment (patga) total score,1
baseline in psoriasis scalp severity index (pssi) total score,1
baseline in quick inventory of depressive symptomatology self report 16 items (qids-sr16) score,1
baseline in short form (36 items) health survey sf-36 total score,1
baseline in static physician global assessment (spga),1
baseline in static physician global assessment (spga) score,1
baseline in subcutaneous administration assessment questionnaire (sqaaq),1
baseline in work productivity activity impairment questionnaire-psoriasis (wpai-pso) total score,1
baseline incat score,1
baseline index knee pain scores,1
baseline index leg pain intensity,1
baseline individual instantaneous ocular symptom score (ioss) in subjects with (itoss) â‰¥5.0,1
baseline individual instantaneous ocular symtom score (ioss) in subjects with (itoss) â‰¥5.0,1
baseline infection category,1
baseline inr,1
baseline instantaneous total ocular symptom score (itoss) in subjects with (itoss) â‰¥5.0,1
baseline instantaneous total ocular symptoms scores (itoss)] for onset of nasal improvement,1
baseline instantaneous total ocular symtom score (itoss) in subjects with itoss â‰¥5.0,1
baseline instanteous total nasal symptom score (itnss),1
baseline instrumental activities of daily living (iadl),1
baseline insulin levels,1
baseline intact parathyroid hormone (ipth),1
baseline international prostate symptom scores (ipss),1
baseline interval of paracentesis,1
baseline intraocular pressure on caffeinated coffee visit,1
baseline intraocular pressure on decaffeinated coffee visit,1
baseline intraretinal fluid,1
baseline inventory of depressive symptoms- clinician rated (screen),1
baseline investigator global assessment (iga),1
baseline iop,1
baseline karnofsky's performance score,1
baseline karnofsky performance status,1
baseline karnofsky performance status (kps),1
baseline laboratory measures by arm - crp,1
baseline laboratory measures by arm - triglyceride and hdl,1
baseline lactate dehydrogenase (ldh),1
baseline lactate dehydrogenase (ldh) level,1
baseline lactate dehydrogenase level,1
baseline lactate dehydrogenase value,1
baseline ldh greater than 2 times upper limit of normal,1
baseline left ventricular ejection fraction (lvef),1
baseline left ventricular end diastolic volume (lvedv),1
baseline left ventricular end systolic volume (lvesv),1
baseline left ventricular mass indexed to height (lvmi),1
baseline length of menstrual cycle,1
"baseline lesion characteristics as determined by the angiographic core laboratory, itt analysis set",1
baseline lesion characteristics: % occluded,1
baseline lesion characteristics: diameter stenosis,1
baseline lesion characteristics: lesion length,1
baseline lesion characteristics: percent of lesions with flow limiting dissection,1
baseline lesion characteristics: percent of lesions with perforation requiring intervention,1
baseline lesion characteristics: percent of lesions with re-entry into true lumen (site reported),1
baseline lesion characteristics: target lesion length,1
baseline liver volume per treatment group,1
baseline log10 colony forming units (cfu) of m. tuberculosis per ml sputum,1
baseline log10 hiv viral load,1
baseline log10(hiv rna viral load) in copies/ml,1
baseline log10(human immunodeficiency virus (hiv) ribonucleic acid (rna) viral load (vl)),1
baseline low-density lipoprotein cholesterol (ldl-c),1
baseline low back pain intensity,1
baseline low density lipoprotein-cholesterol (ldl-c) allocation strata,1
baseline low density lipoprotein cholesterol (ldl-c) strata,1
baseline lte4 (pg/mg cr),1
baseline luteal phase daily rating of severity of problems score,1
baseline lymphoma diagnosis,1
baseline maximal oxygen consumption (vo2 max) at peak exercise,1
baseline maximum tolerated volume,1
baseline maximum urinary flow (qmax),1
baseline mayo score,1
baseline mean arterial pressure,1
baseline mean hamilton rating scale for depression (ham-d17),1
baseline mean intraocular pressure (iop),1
baseline mean score for constipation symptom 'anorectal obstructions/blockade',1
baseline mean score for constipation symptom 'manual manoeuvre',1
baseline mean score for constipation symptom 'sensation of incomplete evacuation',1
baseline mean score for constipation symptom 'stool quality',1
baseline mean score for constipation symptom 'straining',1
baseline measures - timing of treatment,1
baseline measures for neurometabolites based on mrs,1
baseline measures of stroke symptom severity,1
baseline medication,1
baseline medications - nucleoside analogs,1
baseline memorial sloan kettering (msk) acquired immune deficiency syndrome (aids) dementia scale,1
baseline mental component score of the short form-36 questionnaire,1
baseline metformin dose,1
baseline methemoglobin blood level,1
baseline methotrexate (mtx) dose,1
baseline methotrexate dose,1
baseline methotrexate use,1
baseline microalbuminuria (mau),1
baseline milk extract wheal,1
baseline mini-mental state examiniation (mmse) score,1
baseline minnesota living with heart failure questionnaire (mlhf-q) summary score,1
baseline model for end-stage liver disease (meld) score,1
baseline modified local scoring atopic dermatitis (scorad),1
baseline motivation,1
baseline mskcc risk group (ivrs),1
baseline mucociliary clearance rate,1
baseline multiple organ dysfunction score,1
baseline multiple sclerosis functional composite (msfc) score,1
baseline nausea at its worst,1
baseline new york heart association (nyha) functional class,1
baseline night time mean pain intensity (mpi) scores,1
baseline nihss,1
baseline normalized urinary glycosaminoglycan (gag) level,1
baseline normalized urine glycosaminoglycans (gag) levels,1
baseline nrs (numerical rating scale) burning sensation score,1
baseline number of complete spontaneous bowel movements (csbms),1
baseline number of polyps,1
baseline number of spontaneous bowel movements (sbms),1
baseline nyha class,1
baseline odi,1
baseline opiate use,1
baseline opioid medication for back pain,1
baseline opioid use (morphine equivalents),1
baseline oral/inhaled corticosteroid use,1
baseline osmolarity,1
baseline overall neurological assessment,1
baseline overall score (osc) of pac-qol,1
baseline oxygen therapy use,1
baseline p. aeruginosa sputum density,1
baseline pah medication,1
baseline pain intensity (0-10 nprs),1
baseline pain intensity by categorical scale,1
baseline pain intensity by visual analog scale,1
baseline pain intensity score (nprs),1
baseline pain intensity visual analogue scale score,1
"baseline pain intensity, mm",1
baseline pain levels (visual analog scale - vas) day 1,1
baseline pain numerical rating scale (nrs) score,1
"baseline pain tolerance, self report",1
baseline participant's global assessment of ankle injury,1
baseline participant assessment of normal function/activity,1
baseline participant assessment of pruritis,1
baseline participants,1
baseline passive joint range of motion (jrom),1
baseline patient-reported pain diary score,1
baseline percent predicted forced expiratory volume in 1 second (fev1),1
baseline percent predicted forced vital capacity (fvc),1
baseline percentage duration with an intragastric ph >= 4 during the entire 24 hours on day 1,1
baseline period proteinuria,1
baseline personal and social performance (psp) total score,1
baseline pet scan,1
baseline pge-m (ng/mg cr),1
baseline physical component score of the short form-36 questionnaire,1
baseline physician global assessment of ankle injury,1
baseline plasma cd4+ cell count,1
baseline plasma globotriaosylceramide (gb3),1
baseline plasma human immunodeficiency virus-1 (hiv-1) ribonucleic acid (rna),1
baseline polysomnography recorded sleep parameters,1
baseline population,1
baseline positive and negative syndrome scale (panss) total score,1
baseline predicted height,1
baseline predicted height standard deviation score (sds),1
baseline prolactin,1
baseline prostate-specific antigen (psa),1
baseline prostate-specific antigen (psa) - reported by site,1
baseline proteinuria level,1
baseline protoporphyrin ix level,1
baseline psa (ng/dl),1
baseline psa (prostate specific antigen) levels,1
baseline psoriasis area and severity index (pasi) score,1
baseline psychopathology ratings,1
baseline ptsd symptomatology,1
baseline pulmonary exacerbation rate,1
baseline pulmonary function,1
baseline pulmonary function: diffusion capacity,1
baseline pulmonary hypertension (ph) per interactive voice response system (ivrs),1
baseline pulse rate,1
baseline quality of life measures by arm - ess,1
baseline quality of life measures by arm - phq-8,1
baseline quality of life measures by arm - saqli,1
baseline quality of life measures by arm - short form health survey (sf-36),1
baseline raas status,1
baseline range of motion (rom) percent (of predicted),1
baseline rbc transfusion burden (units/28days),1
baseline reflective total ocular symptom score (rtoss) in subjects with (rtoss) â‰¥5.0,1
baseline renal impairment category,1
baseline resting blood pressure data by arm,1
baseline rhinoconjunctivitis quality of life questionnaire (rqlq) in subject with rqlq(s) score â‰¥3.,1
baseline rhinoconjunctivitis quality of life questionnaire [rqlq(s)] â‰¥3.0,1
baseline rhinoconjunctivitis quality of life questionnaire score [rqlq (s)] )â‰¥3.0,1
baseline s. aureus infection strain,1
"baseline sadness, self-report",1
baseline saint georges respiratory questionnaire score,1
baseline score in 17-item hamilton rating scale for depression,1
baseline score in beck depression inventory,1
baseline score in greene climacteric scale,1
baseline sedative,1
baseline seizure frequency per day,1
baseline seizure frequency per week,1
baseline self-reported skin behaviors,1
baseline serum creatinine,1
baseline serum level of cancer-antigen 125 (ca-125),1
baseline serum loxl2,1
baseline serum urate,1
baseline serum urate categories,1
baseline serum urate level units,1
baseline serum uric acid (sua),1
baseline severity (first attack),1
baseline sf-36 pcs,1
baseline shock,1
baseline short form-36 (sf-36) total scores,1
baseline sij pain,1
baseline six-minute walk distance,1
baseline six minute walk distance,1
baseline size of polyps in mm,1
baseline small bowel motility index,1
baseline small bowel ph,1
baseline small bowel transit time,1
baseline smoking rate,1
baseline smoking rate (cigarettes per day),1
baseline smoking status,1
baseline spasticity numerical rating scale (nrs) score,1
baseline spasticity numerical rating scale (nrs) score phase b,1
baseline sperm concentration,1
baseline spleen volume per treatment group,1
baseline splenectomy status,1
baseline spores cfu,1
baseline stage,1
baseline stage of hypertension,1
baseline strata,1
"baseline stress, self-report",1
baseline subscore'worries and concerns (wcc)' of patient assessment of constipation-qol(pac-qol),1
baseline subscore 'physical discomfort (phd)' of pac-qol,1
baseline subscore 'psychosocial discomfort (psd)' of pac-qol,1
baseline subscore 'satisfaction (sat)' of pac-qol,1
baseline sum of longest diameters (sld) of target lesions by investigator assessments,1
baseline symptom score,1
baseline symptom scores,1
baseline systolic blood pressure (sbp) hypertension severity category,1
baseline systolic blood pressure (sbp) values (abpm),1
baseline t2 lesion volume,1
baseline tactile hypersensitivity score,1
baseline third agent,1
baseline time to sputum culture positivity (ttp) in liquid culture media,1
baseline tobacco used per week,1
baseline total (composite) western ontario and mcmaster universities osteoarthritis index (womac) sc,1
baseline total bilirubin,1
baseline total cholesterol to high density lipoprotein cholesterol ratio,1
baseline total colony forming units (cfu),1
baseline total fain-tolosa-marin tremor rating scale (trs),1
baseline total international prostate symptom scores (ipss),1
baseline total meibomian gland score,1
baseline total osdi score,1
baseline total oss score,1
baseline total prostate volume (tpv),1
baseline total testosterone (tt) (ng/dl),1
baseline total western ontario and mcmaster universities osteoarthritis index (womac) score,1
baseline transepidermal water loss (tewl) mean,1
baseline transferrin saturation,1
baseline triglycerides,1
baseline uganda neuropsychological test battery summary measure (u np sum),1
baseline unheated milk wheal,1
baseline urate concentration (pua),1
baseline urinary albumin/creatinine (a/cr) ratio,1
baseline value for chloride (normalized value),1
baseline value for potassium (normalized value),1
baseline value for sodium (normalized value),1
baseline value of high density lipoprotein-c,1
baseline value of low density lipoprotein-c,1
baseline value of total cholesterol,1
baseline value of triglycerides,1
baseline values for apolipoprotein b (apo b),1
baseline values for high-density lipoprotein cholesterol (hdl-c),1
baseline values for ldl-c:hdl-c,1
baseline values for low-density lipoprotein cholesterol(ldl-c),1
baseline values for non hdl-c,1
baseline values for total cholesterol (tc),1
baseline values for triglycerides (tg),1
baseline vas pain score (mm),1
baseline vas scores,1
baseline vc% predicted max,1
baseline vcss,1
baseline vegetative cells cfu,1
baseline venous thromboembolism,1
baseline viral load: : log scale,1
baseline viral load: log scale,1
baseline viral suppression,1
baseline visual acuity,1
baseline visual acuity by randomization strata,1
"baseline visual acuity, logmar",1
baseline visual analog scale (vas) pain rating,1
baseline vit d level (ng/ml),1
baseline vitamin d,1
baseline volume to fullness,1
baseline waist circumference,1
baseline walking speed,1
baseline weekly zolpidem dosage,1
baseline weight (lbs),1
baseline weight category,1
baseline western ontario and mcmaster universities osteoarthritis index (womac) function subscore,1
baseline western ontario and mcmaster universities osteoarthritis index (womac) stiffness subscore,1
baseline who functional classification,1
baseline who performance status,1
baseline whole gut transit time,1
baseline ymrs score,1
baseline z-scores of the lumbar spine (l2-l4) and femoral neck,1
baselinen best corrected visual acuity (bcva) in fellow eye,1
basic health literacy screen,1
basis for most recent pathological diagnosis,1
basis of diagnosis,1
basis of fap diagnosis,1
basline pulmonary function (fev1),1
basline systolic blood pressure,1
basophils in bone marrow,1
basophils in peripheral blood,1
bath ankylosing spondylitis disease activity index (basdai),1
bath ankylosing spondylitis disease activity index (basdai) at baseline,1
bath ankylosing spondylitis disease activity index (basdai) score,1
bath ankylosing spondylitis disease activity index >4,1
bath ankylosing spondylitis functional index (basfi) at baseline,1
bclc (barcelona clinic liver cancer) stage,1
bclc staging,1
bdd-y-bocs,1
bdi-ii depressive symptom scores,1
bdi-ii score,1
bdi (beck depression inventory) score,1
became deaf age 3 or younger,1
beck's depression inventory,1
beck depression inventory- severe depression score,1
beck depression inventory- total score,1
beck depression inventory-ii,1
beck depression inventory-ii (bdi-ii),1
beck depression inventory - ii (bdi-ii),1
beck depression inventory - past 2 weeks,1
beck depression inventory ii (bdi-ii) total score,1
beck depression inventory ii (bdi),1
beck depression inventory ii(bdi-ii),1
"beck depression inventory score, continuous",1
"beck depression inventory, 2nd edition",1
"beck depression inventory, second edition",1
beck hopelessness scale,1
"beck scale for suicide ideation, current",1
"beck scale for suicide ideation, worst",1
beck suicide ideation scale,1
before-school functioning questionnaire,1
before adjuvant treatment,1
behavior (clinical scale),1
behavior rating inventory of executive function-adult version self report- organization of materials,1
behavior rating inventory of executive function-adult version self report - behavioral regulation,1
behavior rating inventory of executive function-adult version self report - emotional control,1
behavior rating inventory of executive function-adult version self report - gec,1
behavior rating inventory of executive function-adult version self report - inconsistency,1
behavior rating inventory of executive function-adult version self report - infrequency,1
behavior rating inventory of executive function-adult version self report - inhibit,1
behavior rating inventory of executive function-adult version self report - initiate,1
behavior rating inventory of executive function-adult version self report - metacognition index,1
behavior rating inventory of executive function-adult version self report - negativity,1
behavior rating inventory of executive function-adult version self report - plan/organize,1
behavior rating inventory of executive function-adult version self report - self monitor,1
behavior rating inventory of executive function-adult version self report - shift,1
behavior rating inventory of executive function-adult version self report - task monitor,1
behavior rating inventory of executive function-adult version self report - working memory,1
behavioral skills,1
beliefs consistent with female empowerment in relationships,1
beliefs supportive of hiv stigma,1
bellmunt prognostic factors,1
bellmunt score,1
benefits score,1
benign prostatic hyperplasia impact index (bii),1
benign prostatic hyperplasia impact index (bphii),1
benzodiazepine taken in last month,1
berg balance,1
berg balance scale,1
best-corrected visual acuity,1
best baseline response,1
"best corrected visual acuity (bcva), assessed by etdrs chart",1
best corrected visual acuity (etdrs),1
best corrected visual acuity at baseline mean+sem (letter score),1
best distance visual acuity in the amblyopic eye at randomization,1
best distance visual acuity in the fellow eye at randomization,1
best forced expiratory volume in one second (fev1)/best forced vital capacity (fvc) ratio,1
best interocular eye visual acuity difference at randomization,1
best response from prior systemic treatment,1
best response of last prior treatment regimen for osteosarcoma,1
best response prior to induction therapy,1
best response to prior systemic therapy,1
best response to salvage therapy pre-asct,1
beta-2 microglobulin,1
beta-2 microglobulin at study entry,1
beta-2 microglubilin,1
beta-blocker,1
beta-blocker intake,1
beta-blocker intake at randomization,1
beta-blocker medication in regimen,1
beta-blocker use,1
beta-blockers for migraine prevention,1
beta-cell function assessed by homeostasis model assessment for beta-cell function (homa-beta),1
beta 2-micro-globulin,1
beta 2 microglobulin,1
beta 2 microglobulin at registration,1
beta 2 microglobulin at study entry,1
beta amyloid imaging findings,1
beta cell function (disposition index),1
bifurcated lesion,1
bifurcation lesion (per participant),1
biguanide use,1
bilateral obstruction,1
bilateral uveitis,1
bile acid sequestrant use,1
biliary atresia splenic malformation (basm),1
biliary cancer site,1
biliary sphincterotomy,1
biliary stent,1
biliary stent present,1
biliary strent placement,1
bilirubin level,1
binet stage at screening,1
bioavailable testosterone,1
biochemistry,1
biochemistry - alanine transaminase (alt),1
biochemistry - alkaline phosphatase,1
biochemistry - aspartate transaminase (ast),1
biochemistry - c-reactive protein (crp),1
biochemistry - creatinine,1
biochemistry - glutamyl transferase,1
biochemistry - potassium,1
biochemistry - total bilirubin,1
biochemistry - urea,1
biochemistry - values: sodium,1
biochemistry haemoglobin,1
biolog hot flash monitor (physiological measure),1
biopsy gleason score (percent),1
bipolar i disorder,1
birth-weight,1
birth place,1
birthplace,1
bis-11 total score,1
bisphosphonate use,1
bisphosphonate use at study entry,1
bladder carcinoma in situ,1
bladder diary: # leaks,1
bladder diary: # micturations,1
bladder diary: # nocturia episodes,1
bladder outlet obstruction index (booi),1
bladder primary,1
bladder primary tumor,1
bladder residual urine,1
bladder staging,1
blantyre coma scale,1
blasts in bone marrow,1
blasts in peripheral blood,1
bleeding (y/n),1
bleeding on probing â‰¤ 10%,1
bleeding risk,1
bleeding ulcer size,1
blepharospasm disability scale,1
blinded assessment of facial rhytids,1
blood chemistry: serum creatinine,1
blood chemistry: serum glutamic oxaloacetic transaminase (sgot),1
blood chemistry: serum glutamic pyruvic transaminase (sgpt),1
blood chemistry: thyroid stimulating hormone (tsh),1
blood culture,1
blood diseases,1
blood eosinophil counts,1
blood estradiol level,1
blood flow rate,1
blood follicle-stimulating hormone (fsh) level,1
blood glucose,1
blood glucose level (mmol/l),1
blood glucose meter brand,1
blood lab values,1
blood levels of manganese,1
blood loss,1
blood marker - cysteine,1
blood marker - glutathione,1
blood marker - gpxbc- glutathione peroxidase,1
blood microfilaremia (mf/ml),1
blood neutrophil count (in myelokathexis),1
blood neutrophil levels,1
blood pressure - diastolic,1
blood pressure - systolic,1
blood pressure (systolic blood pressure (sbp) and diastolic blood pressure (dbp)) at baseline,1
blood pressure â‰¥130/85 mmhg,1
blood pressure control,1
blood pressure diastolic mean,1
blood pressure systolic mean,1
blood pressure within 1 wk before randomization,1
"blood pressure, diastolic",1
"blood pressure, mean",1
"blood pressure, systolic",1
blood type,1
blood urea nitrogenï¼ˆnormal values range from 2.8-7.2 mmol/lï¼‰,1
bmc index,1
bmd,1
bmi- z score,1
"bmi (body mass index), mean",1
bmi (m/kg2),1
bmi (n=32),1
bmi (percentile),1
bmi (z-score),1
"bmi [body mass index (<30, â‰¥30 kg/m2)]",1
bmi < 40kg/m^2,1
bmi = <=18-30 kg/m2,1
bmi at baseline,1
bmi categorization,1
bmi category (kg/m^2),1
bmi category at baseline,1
bmi greater than 25,1
bmi group,1
bmi kg/m^2,1
bmi of <30,1
bmi percentile,1
bmi percentiles,1
bmi ranges,1
bmi standard deviation score,1
bmi weight status category (cdc),1
bmi z score,1
"bmi(body mass index), mean",1
bmi(kg/m^2),1
"bmi, customized",1
"bmi, kg/m2",1
bnp,1
body-mass-index,1
body-mass-index (bmi),1
body-mass index (kg/m2),1
body-mass index < 35,1
body-mass index >=30,1
body-mass index percentile (bmi),1
"body-mass index, kg/m2",1
body composition measured by dual energy x-ray absorptiometry,1
body composition: fat mass,1
body composition: lean body mass,1
body fat %,1
body fat (%),1
body fat mass,1
body fat percentage,1
body hair mean score,1
body image quality of life inventory (biqli),1
body mass index-standard deviation score (bmi-sds),1
body mass index (bmi) (kg/m^2),1
body mass index (bmi) at enrollment,1
body mass index (bmi) at randomisation,1
body mass index (bmi) at screening (kg/m^2),1
body mass index (bmi) at transplant,1
body mass index (bmi) at week -2,1
body mass index (bmi) group (kg/m^2) at screening,1
body mass index (bmi) stratification,1
body mass index (bmi) units: kg/m2,1
body mass index (bmi) z-score,1
"body mass index (bmi), categorical",1
"body mass index (bmi), kg/m^2",1
body mass index (bmi): adult population,1
body mass index (bmi): pediatric population,1
"body mass index (bmi, kg/m^2)",1
body mass index (bmi; kg/m^2),1
body mass index (females),1
body mass index (kg/square of m.),1
body mass index (males),1
body mass index [bmi],1
"body mass index 15-54, inclusive",1
body mass index at screening,1
body mass index bmi (kg/m2),1
body mass index calculated during 1st visit,1
body mass index categories,1
body mass index category,1
body mass index in kg/m^2,1
body mass index kg/m^2,1
body mass index n=(1003;992;1995),1
body mass index n=(1146;1163;1151;3460),1
body mass index n=(677;702;692;2071),1
body mass index numerical value,1
body mass index sd score,1
body mass index z-score,1
body mass index(bmi),1
body mass index(bmi) category,1
"body mass index, average",1
"body mass index, customized",1
"body mass index, kg/m^2",1
"body mass index, kg/m^2, mean (sd)",1
"body mass index, kg/m2",1
"body mass index, mean",1
"body mass index, mean (range)",1
"body mass index, mean (sd)",1
"body mass index, self reported",1
body mass index: kg.m^2,1
body surface are (bsa),1
body surface area (bsa) affected by psoriasis,1
body surface area (bsa) at day 1 of visit 1,1
body surface area (bsa) categories,1
body surface area (bsa) continuous,1
body surface area (bsa) involvement with ad,1
body surface area (bsa) involvement with atopic dermatitis,1
body surface area (m^2),1
body surface area at baseline,1
body surface area with psoriasis,1
body surface areaï¼ˆbsaï¼‰,1
"body surface, continuous",1
body weight (bw),1
body weight at birth,1
body weight at enrollment,1
body weight at randomisation,1
body weight at the start of treatment,1
body weight at time of study,1
body weight before surgery,1
body weight in kilograms (kg),1
body weight standard deviation score,1
bond disease only,1
bone-only disease (y/n),1
bone-specific alkaline phosphatase (bap) value from baseline,1
bone age imputed,1
bone density from dxa,1
bone disease,1
bone height,1
bone lesions,1
bone marrow-blasts counts,1
bone marrow aspirate plasma,1
bone marrow blasts (number of blasts/total cells in bone marrow),1
bone marrow cellularity,1
bone marrow cellularity at baseline,1
bone marrow fibrosis,1
bone marrow invasion,1
bone marrow labeling index,1
bone marrow plasmacytosis,1
bone metastasis,1
bone mineral density (bmd) total spine,1
bone mineral density in response to pamidronate,1
bone mineral density measurement in lumbar spine,1
bone mineral density t-score,1
bone mineral density t-score at study 20030216 baseline,1
bone pain grade (ctc version 2.0),1
"bone pain today or during previous 3 days (scale, 0-10)",1
bone specific alkaline phosphatase,1
bone surgical intervention (vs soft tissue surgical intervention),1
boost dose,1
boost field,1
borg dyspnea index (bdi),1
borg dyspnoea score,1
born in the united states,1
boston naming test - 30 item,1
bothersomeness of hot flashes,1
bottle use,1
botulinum toxin status,1
bound voriconazole plasma concentration,1
bowel symptom score (bss),1
box and blocks,1
bpdia,1
bpi-interference average score,1
"bpi average pain (duloxetine n=116, placebo n=119)",1
bpi interference,1
bpi pain intensity,1
bprs-a,1
bprs score,1
bpsys,1
brachytherapy,1
braf status,1
braf v600 mutation status,1
brain-derived neurotropic factor,1
brain gd+ lesions before first dose,1
"brain injury (giii/iv intraventricular hemorrhage , periventricular leukomalacia, hypoxic ischemic e",1
brain marker - glutamine and myo-inositol,1
brain marker - glutathione and glutamate,1
brain metastasis present,1
brain natriuretic peptide,1
brain natriuretic peptide (bnp),1
brain natriuretic peptide level,1
brainstem/cerebellar at onset,1
breakdown according to eastern cooperative oncology group (ecog) performance status,1
breakdown by estrogen receptor (er) status,1
breakdown by human epidermal growth factor (her-2 neu) status,1
breakdown by progesterone receptor (pr) status,1
breakdown for prior treatment for prostate cancer,1
breakdown of complications (tabulated in duplicate),1
breakdown of complications of allergic disease,1
breakdown of concomitant antidiabetic medications,1
breakdown of concomitant antihyperlipidemic drugs,1
breakdown of concomitant antihypertensive medications,1
breakdown of disease-free interval,1
breakdown of other concomitant medication,1
breast cancer,1
breast cancer subtype,1
breast density of participants with no prior mammogram,1
breast field separation,1
breast volume,1
breastfed,1
breastfeeding,1
breastfeeding status,1
breech presentation,1
breslow's thickness,1
brian total score,1
brief,1
brief cope inventory adaptive coping subscale,1
brief cope inventory maladaptive coping subscale,1
brief fear of negative evaluation scale,1
brief pain inventory- interference score,1
brief pain inventory- severity score,1
brief pain inventory-interference (bpi-i) average subscale score,1
brief pain inventory-severity (bpi-s) average pain,1
brief pain inventory-severity (bpi-s) average subscale score,1
brief pain inventory - short form (bpi-sf) average pain score,1
brief pain inventory - short form interference score,1
brief pain inventory (bpi),1
brief pain inventory (bpi)-severity average pain in the last week,1
brief pain inventory (bpi) - pain severity,1
brief pain inventory (bpi) average 24-hour pain score,1
"brief pain inventory (bpi) average interference (duloxetine n=116, placebo n=119)",1
brief pain inventory (bpi) interference scores,1
brief pain inventory (bpi) mean interference score,1
brief pain inventory (bpi) questionnaire,1
brief pain inventory (bpi) severity,1
brief pain inventory (bpi) severity scores,1
brief pain inventory (bpi) severity: average pain score,1
brief pain inventory 24-hour average pain score,1
brief pain inventory 24-hour average pain severity,1
brief pain inventory average pain,1
brief pain inventory average pain rating,1
brief pain inventory interference,1
brief pain inventory severity,1
"brief pain inventory, worst pain",1
brief psychiatric rating scale,1
brief psychiatric rating scale anxiety depression score-baseline,1
brief psychiatric rating scale negative symptom score-baseline,1
brief psychiatric rating scale positive symptom score-baseline,1
brief psychiatric rating scale total score-baseline,1
brief psychiatry rating scale,1
brief questionnaire of smoking urges (qsu-brief),1
brief symptom inventory,1
bright future somewhat/very unlikely,1
bristol scale,1
bronchus sign,1
brown assessment of beliefs scale (babs),1
brown attention deficit disorder scale,1
bruce exercise group,1
bsa - body surface area,1
bsa score,1
bsap,1
"bsi score, baseline",1
buccal plate thickness,1
bulbar onset,1
bulky disease (â‰¥5 cm on at least one baseline index lesion),1
bulky disease (cm),1
bun,1
buprenorphine dose at 24 weeks if gestation,1
buprenorphine dose at 28 weeks if gestation,1
buprenorphine dose at 32 weeks if gestation,1
buprenorphine dose at 36 weeks if gestation,1
burden severity (continuous),1
burkholderia spp colony-forming units (cfu) in sputum,1
burn size,1
bvas/wg,1
bypass time,1
bystander cpr,1
c-peptid(normal values range from 0.78-5.19 ng/ml),1
c-peptide (ng/ml),1
c-peptide area under the curve (auc) response to a mixed meal tolerance test (mmtt) at baseline,1
c-peptide auc(0:30-4:30h),1
c-reactive protein (crp) (n=10),1
c-reactive protein (crp) level at baseline,1
c-reactive protein (crp) serum level,1
c-reactive protein at baseline (in mg/dl),1
c-reactive protein mg/dl,1
c-reactive protien serum level,1
c-terminal telopeptide of type i collagen,1
c reactive protein plasma concentration,1
ca-125,1
ca-125 units per milliliter at baseline for all patients,1
ca 19-9 (tumor marker),1
ca125 at enrollment,1
ca19-9 (tumor marker levels),1
cad/cvd/pad,1
caffeine or xanthine use,1
cag larger allele repeat length,1
cag smaller allele repeat length,1
calcaneal valgus angle,1
calcification,1
calcium (corrected),1
calcium absorption fraction,1
calcium and/or vitamin d supplement,1
calcium serum level,1
calculated low density lipoprotein cholesterol (ldl-c) in mmol/l,1
calculated mean daily insulin dose,1
calculated or direct low-density lipoprotein cholesterol,1
calculated panel reactive antibodies (cpra),1
calgary depression scale (cds) total score,1
california tobacco survey: inhale deeply,1
calorie requirements,1
canadian functional class,1
cancer (ca),1
cancer and leukemia group b (calgb) prognostic score,1
cancer antigen 125 (ca125),1
cancer clinical stage,1
cancer diagnosis: extension phase,1
cancer diagnosis: initial treatment phase,1
cancer of liver italian program (clip),1
cancer stage & type,1
cancer stage (tnm),1
cancer stage by tumor type,1
cancer stage of diagnosis,1
cancer subtypes,1
cancer treatment,1
cancer type or histologic subtype,1
cancer type stratification factor,1
cannabis cigarettes per day,1
cannabis use (number of days per week),1
cannulated ijv diameter (cm),1
capillary blood hco3,1
capillary blood pco2,1
capillary blood ph,1
capillary blood po2,1
capillary glucose level,1
caprini score,1
caps,1
caps-d score (primary outcome),1
caps total,1
capsular pain,1
car available to drive child to school,1
carbon monoxide breath level,1
carbon monoxide exposure,1
carbon monoxide reading,1
carcinoembryonic antigen (cea),1
carcinogen exposure (creatinine adjusted nnal),1
carcinoma stage at initial diagnosis,1
cardiac arrhythmias,1
cardiac catheterization during index admission,1
cardiac diagnosis,1
cardiac disease,1
cardiac history-ejection fraction,1
cardiac history-left ventricular ejection fraction,1
cardiac history - left ventricular ejection fraction,1
cardiac history: left ventricular ejection fraction,1
cardiac lesion,1
cardiac medications,1
cardiac resynchronization therapy,1
cardiac risk factor,1
cardiomyopathy etiology,1
cardiomyopathy type,1
cardiopulmonyar bypass time,1
cardiovascular (cv) risk group,1
cardiovascular (cv) risk group status,1
cardiovascular and cerebrovascular events before entry,1
cardiovascular disease (cvd) status,1
cardiovascular disease risk factors,1
cardiovascular fitness (pacer test: fitnessgram),1
cardiovascular medication - anticoagulant,1
cardiovascular medication - beta blocker,1
cardiovascular medication - lipid lowering agents,1
cardiovascular medications - ace inhibitors or arb,1
cardiovascular risk,1
cardiovascular risk category: cardiovascular disease/multiple risk factors (cvd/mrf),1
cardiovascular risk factors (including the existence of a metabolic syndrome),1
cardiovascular sequential organ failure assessment (sofa) score,1
cardiovascular surgical history,1
cared for colonized or infected patient,1
caregiver-reported overall pain (continuous),1
caregiver-reported worst pain (continuous),1
caregiver activity survey,1
caregiver age (continuous),1
caregiver currently smokes,1
caregiver gender (categorical),1
caregiver income (categorical),1
caregiver race/ethnicity (categorical),1
carfilzomib regimen combination,1
carotid artery disease,1
carotid artery stenosis,1
carotid femoral pulse wave velocity,1
cartilage volume in the global knee,1
cartilage volume in the lateral compartment,1
cartilage volume in the medial compartment,1
case definition of post-stroke fatigue,1
case status,1
categorical baseline fecal calprotectin,1
categorical duration of ulcerative colitis,1
categorical infant birthweight (g),1
categorical pain severity rating (psr),1
categorical scores on clinical global impression-improvement [cgi-i],1
categorical tumor size,1
categories of health care,1
categories of healthcare,1
categorization of participants according to body mass index,1
category fluency test (cft): baseline efficacy scores,1
category of hba1c,1
category of primary myelofibrosis,1
category of regional lymph node classification,1
catheter configuration,1
caucasian,1
causative organisms isolated from pretreatment specimens at study entry,1
cause of native kidney disease,1
cause of neutropenia,1
cause of renal disease,1
cause(s) of prior repeated infections,1
cavitation,1
ccl18 levels,1
ccs angina grade iii or iv,1
cct (cranial computed tomography) pathological,1
cd235a+ red cell microparticles,1
cd30 grouping at screening,1
cd34+ cell dose per kilogram (x10^-6),1
cd34+ count (10^6 cells/kg),1
cd38 expression status,1
cd4 absolute count,1
cd4 at inclusion,1
cd4 cell count (cells/mm^3),1
"cd4 cell count (n=13, 9, 3, 7, 32)",1
cd4 cell count at delivery,1
"cd4 cell count, categorized",1
"cd4 cell count, cells/âµl",1
"cd4 cell count, continuous",1
cd4 cells/mm3,1
cd4 count (cells/mm^3),1
"cd4 count (n=16, 13, 10)",1
cd4 count categorical,1
cd4 count continuous,1
"cd4 count, baseline",1
cd4 distribution at baseline,1
cd4 level,1
"cd4 percent (n=16, 14, 11)",1
cd4 percent (percentage of total lymphocytes that are cd4 cells),1
"cd4 percent at screening, categorical",1
cd4 percent categories,1
cd4 percent of total,1
cd4 t-cell activation,1
cd4 t-cell count,1
cd4 t cell count,1
cd4 t cell count/mm^3,1
cd4 t cell percentage,1
"cd4 t cell percentage: period 2 (trial enrollment, induction art)",1
cd4 t cell percentage: period 3 (randomization to once vs twice daily abc+3tc),1
cd4 t cell percentage: period 4 (randomization to stop versus continue cotrimoxazole),1
cd4% at study entry,1
cd4+ cell count (absolute count),1
"cd4+ count (nucleomaxx sample size (n)=80, placebo n=80)",1
cd4+ t-cell count nadir,1
"cd4+ t-cell count, categorical",1
cd4+ t-cell counts,1
cd4+ t lymphocyte counts,1
cd41+ platelet microparticles,1
cd62e+ endothelial microparticles,1
cd8,1
cd8 count,1
cd8+ t-cell activation percent,1
cd8+ t-cell count,1
cdasi activity score,1
cdc classification at study entry,1
cdc hiv clinical classification,1
cdc hiv disease category,1
cddp (intraperitoneal chemoinfusion) dose per session,1
cdr-sob,1
cdr score,1
ceap,1
ceap clinical classification,1
cell-associated hiv-1 rna/dna ratio,1
cell source,1
cellularity,1
center for epidemiologic studies depression scale - revised (ces-d),1
center for epidemiologic studies depression scale (ces-d),1
center for epidemiologic studies depression scale (ces-d) score,1
center of pressure excursion index (3mph),1
center of pressure excursion index at self-selected speed,1
centers for disease control (cdc) classification,1
centers for disease control (cdc) disease category,1
central apnea index (cai),1
central corneal dendritic cell density,1
central fasting plasma glucose,1
central laboratory protein c class,1
central line use,1
central nervous system (cns) metastases,1
central nervous system (cns) penetration score,1
central nervous system metastasis,1
central retinal/lesion thickness (cr/lt),1
central review ck5 status,1
central review egfr status,1
central review er status,1
central review her2/neu status,1
central review ki67,1
central review pr status,1
central subfield macular thickness (um),1
central subfield thickness (csft),1
central subfield thickness on oct,1
central venous access,1
central venous catheter (cvc) type,1
central venous pressure,1
central venous pressure (cvp),1
centralized pathologic diagnosis,1
centromere(+),1
cerebral haemorrhage,1
cerebral infarction,1
cerebral malaria retinopathy (present),1
cerebral vascular accident,1
cerebrospinal fluid beta-amyloid-42,1
cerebrospinal fluid protein,1
cerebrovascular accident (cva),1
cerebrovascular disease,1
certainty of multiple system atrophy (msa) diagnosis,1
certification/license,1
cervical length,1
cervical pain,1
cervical stromal invasion,1
ces-d depressive symptoms,1
ces-d score,1
cf genotype,1
cfl severity as assessed by investigator,1
cfl severity as assessed by the investigator,1
cfq-r respiratory score at day 1,1
cfq-r rss score,1
cgi-bp - depression,1
cgi-bp - overall,1
cgi-bp change from preceding phase score (depression),1
cgi-bp change from preceding phase score (mania),1
cgi-bp change from preceding phase score (overall),1
cgi-bp depression score,1
cgi-bp mania score,1
cgi-bp severity of illness score (depression),1
cgi-bp severity of illness score (mania),1
cgi-bp severity of illness score (overall),1
cgi-bp_os,1
cgi-s status - per protocol population (pp),1
"cgi-s: baseline present study, 13267b",1
cgi-s: baseline severity score,1
cgi-s: baseline total score,1
cgi severity score,1
cgm experience level,1
cha 2 ds 2 vasc score,1
cha2ds2vasc score,1
cha2dsvas score,1
chads-2 score at enrollment,1
chads 2 score,1
champs 18 total score,1
champs activity,1
chang stage,1
change in dosing interval since previous doctor visit,1
change in renal plasma flow (rpf) in response to captopril [vitamin d],1
change in rpf in response to captopril [uric acid],1
change in wound size during run-in phase (%),1
changes in sexual function questionnaire (csfq),1
changes in sexual functioning questionnaire short-form (csfq-14) total score,1
changes in sleep measure,1
chaq - functioning,1
chaq - pain,1
character of diabetic macular edema (dme),1
characterization of first liver lesion type of referral diagnosis,1
characterization of second liver lesion type of referral diagnosis,1
characterization of third liver lesion type of referral diagnosis,1
charlson's comorbidity score,1
charlson comorbidity index (cci),1
charlson comorbidity index (cci) scores,1
charlson comorbidity index score,1
charlson comorbidity index scores,1
charlson comorbidity score,1
charlson comorbidity score (past 12 months),1
charlson score,1
chemistries: albumin,1
chemistries: bicarbonate,1
chemistries: calcium,1
chemistries: creatinine,1
chemistries: phosphate,1
chemistries: total protein,1
chemistries: uric acid,1
chemotherapy agent,1
chemotherapy name,1
chemotherapy received,1
chemotherapy stratification,1
"chemotherapy, multiple agents",1
chest circumference,1
chest circumference (cm),1
chest pain,1
child's asthma severity,1
child's wgs result,1
child-bearing potential,1
child-pugh-turcotte (cpt) score category,1
child-pugh score (stage),1
child attends daycare,1
child bearing potential,1
child disruptive behavior rating scale (cdbrs) parent form,1
child eating behaviour questionnaire,1
child health and illness profile - child edition (chip-ce) - achievement domain,1
child health questionnaire (chaq) - global evaluation,1
child percent overweight (%),1
child pugh classification,1
child z-body mass index,1
childbearing,1
childhood asthma control test (c-act) score,1
childhood onset/adult onset,1
children's aggression scale-parent version,1
children's depression rating scale-revised (cdrs-r),1
children's depression rating scale - revised (cdrs-r) suicidal ideation score,1
children's depression rating scale revised,1
"children's depression rating scale, revised (cdrs-r) total score",1
children's depression ratings scale-revised (cdrs-r) total score,1
children's health survey for asthma - child version,1
children under 18 yr in household,1
children with potential intraoperative dysrhythmias,1
childrenâ€™s global assessment scale (cgas) score - current functioning,1
childrenâ€™s global assessment scale (cgas) total score - current functioning,1
childs-pugh classification,1
chitotriosidase,1
"chlamydia, #",1
chlorpromazine equivalents,1
cholesteryl ester fractional clearance rate,1
cholinesterase inhibitor use at screening,1
chorioamnionitis,1
choroidal neovascularization (cnv) lesion type,1
chromium serum level,1
chromogranin a,1
chromosomal alterations,1
chromosome 1q abnormalities,1
chromosome abnormality,1
chronic,1
chronic bronchitis,1
chronic condition inventory,1
chronic conditions - participant (n=207),1
chronic conditions - participant + dependents (n=107),1
chronic episode of depression (2 or more years),1
chronic graft-versus-host disease onset,1
chronic graft versus host disease (cgvhd) category,1
chronic graft versus host disease (gvhd) present,1
chronic graft versus host disease presentation,1
chronic hemodialysis knowledge survey (cheks),1
chronic hepatitis b,1
chronic hepatitis b (hbv) infection status,1
chronic hepatitis b infection status,1
chronic hepatitis c,1
chronic hepatitis c (hcv) infection status,1
chronic hepatitis c infection status,1
chronic kidney disease (ckd) stage,1
"chronic kidney disease (ckd), stage at baseline",1
chronic kidney disease epidemiology collaboration (ckd epi) egfr (ml/min/m^2),1
chronic kidney disease epidemiology collaboration (ckd epi) egfr (ml/min/m2),1
chronic kidney disease stage,1
chronic liver disease etiology,1
chronic lung disease,1
chronic lung disease at prematurity,1
chronic obstructive pulmonary disease (copd),1
chronic obstructive pulmonary disease (copd) characteristics,1
chronic obstructive pulmonary disease (copd) duration,1
chronic pelvic pain,1
chronic renal disease,1
chronic respiratory insuficiency,1
chronic respiratory questionnaire_dyspnea,1
chronic respiratory questionnaire_fatigue,1
chronic respiratory questionnaire_mastery,1
chronic total occlusion,1
chronic use of medication,1
chronicity,1
cigarette history,1
cigarette smoking during this pregnancy,1
cigarette smoking status,1
cigarettes (per day),1
cigarettes per day (cpd),1
cigarettes smoked per day (cpd),1
cigarettes smoked/day,1
circulating lymphocyte subsets,1
circumference measurement,1
cirrhosis (y/n),1
cirrhosis cause,1
cirrhosis status at screening,1
cisplatin cumulative dose,1
city and state where the study activities took place,1
civil status,1
civilian,1
civiq,1
ciwa-ar score,1
ckd-epi -egfr,1
ckd-epi egfr,1
cl(cr) [creatinine clearance],1
clamp r_d,1
classical hodgkin lymphoma pathologic subtype,1
classification of diabetic macular edema,1
classification of diabetic macular edema on clinical exam,1
classification of idiopathic interstitial pneumonia,1
classification of lung tumor stage,1
classification of surgery,1
clayton sexual functioning questionnaire (csfq),1
cleveland clinic score,1
clicking jaw,1
clindamycin administered in ed,1
clinic dbp,1
clinic sbp,1
clinic visits over 3 years,1
clinical-global impressions - severity (cgi-s),1
clinical activity score,1
clinical administered ptsd scale,1
clinical axillary status,1
clinical characteristics,1
clinical characteristics of study subjects,1
clinical degree,1
clinical dementia rating - global (composite) score,1
clinical dementia rating sum of boxes,1
clinical disease stage,1
clinical disease stage (binet staging system),1
clinical disease stage (international staging system),1
clinical disease status,1
clinical global impression,1
clinical global impression-adhd- severity (cgi-adhd-s),1
clinical global impression-improvement (cgi-i),1
clinical global impression-major depressive disorder-severity (cgi-mdd-s) score,1
clinical global impression-severity (cgi-s) total score,1
clinical global impression-severity of illness [cgi-s] score,1
"clinical global impression-severity of illness, bipolar version (cgi-bp)",1
clinical global impression-severity scale,1
clinical global impression-severity scale (cgi-s),1
clinical global impression - severity (cgi-s),1
clinical global impression - severity (cgi-s) score,1
clinical global impression -severity,1
clinical global impression (cgi) at baseline,1
clinical global impression (cgi) severity,1
clinical global impression for bipolar disorders overall severity,1
clinical global impression of severity (cgi-s) for depression score,1
clinical global impression of severity (cgi-s) scale,1
clinical global impression of severity (cgi-s) status - intent to treat population (itt),1
clinical global impression of severity scale (cgi-s),1
clinical global impression scale-severity (cgi-s) score,1
clinical global impression scale (cgi),1
clinical global impression scale for use in bipolar disorder (cgi-bp) overall score,1
clinical global impression severity (cgi-s),1
clinical global impression severity score- baseline,1
clinical global impressions-attention-deficit/hyperactivity disorder severity scale (cgi-adhd-s),1
clinical global impressions-attention deficit hyperactivity disorder-severity (cgi-adhd-s),1
clinical global impressions-improvement (cgi-i),1
clinical global impressions-severity of depression (cgi-s),1
"clinical global impressions - bipolar version, severity of illness (cgi-bp) overall",1
clinical global impressions - severity,1
clinical global impressions - severity (cgi-s) total score,1
clinical global impressions - severity (cgi-s): adhd score,1
clinical global impressions - severity (cgi-s): combined adhd and odd scores,1
clinical global impressions - severity (cgi-s): odd score,1
clinical global impressions - severity (cgi-severity) score,1
clinical global impressions - severity of attention deficit hyperactive disorder score,1
clinical global impressions (cgi) - baseline,1
clinical global impressions (cgi) score for adhd severity,1
clinical global impressions (cgi) score for sud severity,1
clinical global impressions â€“ severity of illness (cgi-s),1
clinical global impressions â€“ severity of illness (cgi-s) rating,1
clinical global impressions of severity (cgi-s),1
clinical global impressions of severity (cgi-s) scale,1
clinical global impressions of severity score,1
clinical global impressions scale-severity (cgi-s) score,1
clinical global improvement- bipolar (cgi-bp) - mania,1
clinical global improvement-severity,1
clinical global improvement-severity (cgi-s) score,1
clinical global improvement attention deficit hyperactivity disorder severity (cgi-adhd-s),1
clinical global patient impression score,1
clinical history,1
"clinical impression global scale - bipolar total score (cgi-bp-m), continuous",1
clinical institute withdrawal assessment for alcohol (ciwa),1
clinical lymph node stage (n) at initial diagnosis,1
clinical manifestation,1
clinical nodule size (cm),1
clinical opiate withdrawal scale (cows),1
clinical presentation of ua or nstemi,1
clinical severity score units,1
clinical signs and symptoms for modified intent-to-treat (mitt) population,1
clinical signs and symptoms for per protocol (pp) population,1
clinical skin evaluation,1
clinical stage (american joint committee on cancer 7th edition),1
clinical stage (ann arbor staging classification),1
clinical stage (ann arbor staging),1
clinical stage [international staging system (iss) category],1
clinical stage of cancer,1
clinical stage: american joint committee on cancer (ajcc) 2009,1
clinical staging modality,1
clinical target volume,1
clinical tumor stage,1
clinical tumor stage (t) at initial diagnosis,1
"clinically localized t1-3, no, mo adenocarcinoma of the prostate",1
clinician-administered ptsd scale (caps) score,1
clinician-administered ptsd scale severity score (caps),1
clinician-reported submental fat rating scale (cr-smfrs),1
clinician administered posttraumatic scale (caps),1
clinician administered ptsd scale (caps),1
clinician administered ptsd scale (caps2),1
clinician clinic,1
clinician global impression of severity (cgi-s),1
clinician global improvement - severity scale,1
"clinician rated snap swanson, nolan, and pelham rating scale score",1
clinics' annual number of patient admissions per year,1
clinidamycin-resistant propionibacterium acne (p.acne) counts,1
clip (cancer of the liver italian program) score,1
clip score,1
clock drawing test,1
clot complete,1
clot onset time,1
cluster determinant 4 (cd4) cell count (/âµl),1
cluster of differentiation 4 (cd4),1
cluster of differentiation 4 (cd4) categories,1
cluster of differentiation 4 (cd4) distribution,1
cluster of differentiation 4 (cd4)+ t-cell count,1
cluster of differentiation 4 (cd4+) cell counts,1
cluster of differentiation 4 single-positive thymocyte (cd4+ t) cell count,1
cluster of differentiation 8 (cd8),1
clusters of differentiation 4 (cd4) t-cells >400 cells/mm^3,1
clutter image rating,1
cmai,1
cmai - long form: baseline total score,1
"cmv status (donor, recipient)",1
co-morbid cardiovascular disease,1
co-morbid diabetes mellitus,1
co-morbid dyslipidaemia,1
co-morbid hypertension,1
co-morbidity status,1
co-morbidity status and body mass index (bmi),1
co-occurring disorders,1
coagulation disorder,1
coagulation sequential organ failure assessment (sofa) score,1
cobb angle,1
cocaine used,1
cochlear mean dose to each ear (d50),1
coexisting autoimmune diseases,1
coexisting illness,1
cognition (mini cog score),1
cognition (spmsq score),1
cognitive assessment: cvlt,1
cognitive assessment: eowvt standard score,1
cognitive assessment: tmt,1
cognitive failures questionnaire,1
"cognitive flexibility, cwi (color word interference)",1
cognitive function at baseline,1
cognitive gross motor function domain z-score,1
cognitive impairment (>2 on sis),1
cognitive performance score npz-8,1
"cognitive status, exit",1
"cognitive status, exit (quick executive interview)",1
"cognitive strategies questionnaire, catastrophizing scale",1
cognitive/mood conditions,1
cohort distribution,1
coinfected with hepatitis b,1
coinfected with hepatitis c,1
coital pain,1
cold ischemia time,1
cold ischemic time,1
college graduate (subject or primary care giver),1
colon versus rectum,1
colonization with aom pathogens,1
colonoscopy results,1
colonoscopy within past 10 years,1
color trails 1,1
color trails 2,1
colorectal cancer (crc) screening history,1
columbia suicide rating scale (c-ssrs) suicidal behavior,1
coma grade of hepatic encephalopathy,1
combined circumference,1
comfortable contact lens wear time,1
"comfortable gait speed, m/s",1
comfortable walking speed (m/sec),1
comission errors,1
common symptoms at baseline gerneral fatigue,1
common symptoms at baseline impaired concentration,1
communication 1: negative weight-related comments,1
communication 2: observed parent-adolescent communication quality,1
"communication status, bdae (boston diagnositic aphasia examination severity index)",1
communicative effectiveness ratings,1
comorbid conditions,1
comorbid conditions (baseline),1
comorbid diabetes,1
comorbid diagnoses,1
comorbid mood disorder,1
comorbid substance use disorder,1
comorbidities in the past,1
comorbidities: cardiovascular disease,1
comorbidities: diabetes,1
comorbidities: hyperlipidaemia,1
comorbidities: hypertension,1
comorbidity,1
comorbidity - atrial fibrillation before operation,1
comorbidity - diabetes,1
comorbidity - hypertension,1
comorbidity - myocardial infarction within 1 month before operation,1
comorbidity disease index,1
comorbidity index (ci),1
comorbidity index score,1
comorbidity score,1
comorbidity with generalized anxiety disorder (gad),1
comorbidity with major depressive disorder (mdd),1
complete spontaneous bowel movement weekly rate,1
complete spontaneous bowel movements (csbms) per week,1
complete utterances in discourse,1
completed college,1
compliance rate with the diet regimen (at the start of treatment with sonias combination tablets ld),1
compliance rate with the diet regimen (at the start of treatment),1
compliance rate with the exercise regimen (at start of treatment with sonias combination tablets ld),1
compliance rate with the exercise regimen (at the start of treatment),1
compliance status of metformin (within 3 months before switching to metact combination tablets),1
compliance status of pioglitazone (within 3 months before switching to metact combination tablets),1
complications of dlbcl,1
complications of influenza,1
complications of malignant tumor (narrow definition),1
complications of multiple myeloma,1
complications of type 2 diabetes,1
complications related to diabetes,1
complications: breakdown of allergic conditions,1
complications: breakdown of diabetic complications,1
complications: breakdown of heart or cerebrovascular diseases,1
complications: breakdown of lifestyle-related diseases (excluding diabetes mellitus),1
complications: breakdown of liver diseases,1
complications: breakdown of malignant tumors,1
complications: breakdown of renal diseases,1
composite symptoms score (daytime nasal and nighttime symptoms),1
compound muscle action potential (cmap) consistent with lambert-eaton myasthenia (lem) at screening,1
concomitant adenomyosis,1
concomitant conditions,1
concomitant disease,1
concomitant donepezil administration,1
concomitant endoscopic ultrasound with fine needle aspiration (eus/fna),1
concomitant estrogen therapy,1
concomitant factors,1
concomitant glucocorticoid use,1
concomitant hysterectomy,1
concomitant immunosuppressive disease,1
concomitant immunosuppressive medication (ism),1
concomitant itp medication at baseline,1
concomitant medication use,1
concomitant medication with non-biologic disease-modifying antirheumatic drugs (dmards),1
concomitant medication(s),1
concomitant medications acetylcholinesterase inhibitors (achei),1
concomitant medications at baseline,1
concomitant medications in the past 6 months: antidiabetic,1
concomitant medications in the past 6 months: antilipidaemic,1
concomitant medications in the past 6 months: aspirin (81 mg),1
concomitant medications in the past 6 months: cardiovascular,1
concomitant medications in the past 6 months: metformin,1
concomitant medications in the past 6 months: pioglitazone,1
concomitant medications in the past 6 months: thiazolidinedione,1
concomitant medications in the past 6 months: vitamin e,1
concomitant medications: anticonvulsant,1
concomitant medications: antidepressant,1
concomitant medications: antipsychotic,1
concomitant medications: lithium,1
concomitant medications: none,1
concomitant medications: sedative/hypnotic/anxiolytic,1
concomitant medications: stimulant,1
concomitant mtx dose,1
concomitant ocular diseases at baseline,1
concomitant oral anti-diabetic medication,1
"concomitant osteoporosis medication , customized",1
concomitant psychiatric medication,1
concomitant statin use,1
concomitant study medications,1
concomitant systemic diseases at baseline,1
concomitant use,1
concordance,1
concurrent biological therapy,1
concurrent chronic kidney disease,1
concurrent diabetes mellitus,1
concurrent medical conditions,1
concurrent medications,1
concurrent oral contraceptive use,1
concurrent pulmonary embolism,1
concurrent radiation,1
concurrent use of chemotherapy,1
condition with symptoms of multiple myeloma,1
conditioning drug received,1
conditioning protocol interventions,1
conditioning regimen parameter,1
conditions for prescribing 80 mg telmisartan in fixed combination with 25 mg hctz,1
conditions other than asthma,1
condom use during last vaginal intercourse,1
conduction disorder,1
confidence in one's ability to quit,1
confidence in quitting,1
confidence in quitting smoking,1
confidence of one's ability to quit,1
confidence scale,1
confidence to quit smoking,1
confirmed influenza infection result,1
confirmed influenza infection status by central testing,1
confirmed t(4;11) translocation / mll-af4+ all,1
congestive heart failure at baseline,1
"congestive heart failure, high blood pressure, age, diabetes stroke 2 (chads2) score",1
conjunctival bacterial flora,1
conlon symptom score,1
conner's global impression-parent scale,1
conners' adhd rating scale self report (caars-s:sv) total score,1
conners' adult adhd rating scale-inv:sv-j adhd index subscale,1
conners' adult adhd rating scale-inv:sv-j hyperactive/impulsive subscale,1
conners' adult adhd rating scale-inv:sv-j inattentive subscale,1
conners' adult adhd rating scale-inv:sv-j total symptoms score,1
conners' adult adhd rating scale-s:sv-j adhd index subscale,1
conners' adult adhd rating scale-s:sv-j hyperactive/impulsive subscale,1
conners' adult adhd rating scale-s:sv-j inattentive subscale,1
conners' adult adhd rating scale-s:sv-j total symptoms score,1
conners' adult adhd rating scale - investigator rated:screening version total score,1
conners' adult adhd rating scale screening version (caars-inv:sv),1
conners' adult attention-deficit hyperactivity/disorder rating scale-investigator rated: screening v,1
conners' parent rating scale-revised:short form - adhd index subscale,1
conners' teacher rating scale-revised:short form (ctrs-r:s),1
conners adult rating scale,1
constipation,1
constipation duration (mon),1
constipation screening,1
consume caffeine,1
consumption of caffeine,1
consumption of concomitant antidiabetic medications,1
consumption of concomitant antihyperlipidemic drugs,1
consumption of concomitant antihypertensive medications,1
consumption of other concomitant medications,1
contact past month with someone who had ebola,1
contingency naming test (cnt) performance score,1
continuously enrolled in health plan for past 24 months,1
contraception use at time of enrollment,1
contraindications to anticoagulation,1
contralateral carotid condition,1
contrast sensitivity function photopic distance,1
control,1
control of malignant pleural effusions in non small cell lung cancer,1
controlled oral word association test (cowat): baseline efficacy scores,1
conventional cytogenetics,1
conversion to open,1
conway clinical scale,1
cooperative group enrollment,1
copd-cses,1
copd diagnosis,1
copd duration,1
copd participant baseline qol (quality of life) score based on the clinical copd questionnaire (ccq),1
copd/asthma,1
cord gas: base deficit,1
cord gas: ph,1
core body temperature,1
corneal diameter - cataractous eye,1
corneal diameter - fellow eye,1
corneal fluorescein staining score,1
corneal staining,1
corneal thickness measured at 1mm one day post op,1
corneal thickness measured at 2mm one day post op,1
coronary artery bypass graft during index admission,1
coronary artery bypass surgery,1
coronary artery calcification score stratification factor,1
coronary artery disease (cad),1
coronary artery disease (cad) status,1
coronary heart disease,1
coronary heart disease (chd),1
coronary heart disease (chd) risk category,1
coronary heart disease risk category by goal,1
corporal surface (body surface area),1
corrected calcium (cca),1
corrected distance visual acuity,1
corrective cardiac surgery,1
cortical silent period (csp),1
corticosteroid at enrollment,1
corticosteroid use,1
corticosteroid user,1
cortisol,1
cotinine,1
cough reflex sensitivity,1
count of organs with metastasis,1
count of participants,1
count of previous anti-leukemic (non-transplant) treatment regimens,1
countries,1
country stratification factor,1
course of disease (month),1
course of parkinson's disease,1
cpap pressure,1
cpap usage,1
cpfq total score,1
"cpp (mm hg) (n=17, 22)",1
cpss score,1
cpss: self- efficacy for physical functioning (fse score),1
cpss: self-efficacy for pain management (pse score),1
cpy2c19 genotype test (n),1
cr (mg/dl),1
craniospinal radiation doses,1
"creatine kinase (nucleomaxx n=80, placebo n=82)",1
"creatine phosphate kinase, continuous",1
creatinin plasma concentration,1
creatinine (mg/dl),1
creatinine clearance (crcl),1
creatinine clearance (ml/min),1
creatinine clearance category,1
creatinine clearance n=(372;371;411;350;373;1877),1
"creatinine clearance, categorical",1
creatinine clearance/estimated glomerular filtration rate,1
creatinine level,1
"creatinine, continuous",1
"creatinine, mg/dl",1
"creatinineï¼ˆnormal values range from 59-104 mmol/l for male,45-84 mmol/l for femaleï¼‰",1
crepitus,1
criminal history,1
criteria for aon diagnosis,1
crohn's disease (cd) duration,1
crohn's disease activity index,1
crohn's disease activity index (cdai),1
crohn's disease activity index (cdai) score,1
crohn's disease history,1
crohnâ€™s disease activity index (cdai) score at baseline,1
cross-reactive immunologic material (crim) assay result,1
cross clamp duration,1
cross classification of rf status and ccp2 status at baseline,1
cross sectional area of the internal jugular vein,1
crow's feet replicas - area ratio,1
crp,1
crp - categorical,1
crp (mg/dl),1
crt: baseline total score,1
crystalloid therapy,1
csappa adequacy,1
csappa enjoyment,1
csappa predilection,1
csappa total,1
csf aî²42 level,1
"csf cryptococcal antigen titer, 1:xxxx",1
csf ptau level,1
"csf quantitative culture, baseline",1
csf total tau level,1
"cst at baseline, mean+sem (âµm)",1
ct scanner,1
ctx,1
ctx-1,1
cues to action score,1
cuff closure performed by the attending surgeon or the fellow/resident,1
culprit lesion for st elevation myocardial infarction (stemi),1
culture results,1
cumulative crystalloid,1
cumulative illness rating scale (geriatric) total,1
cumulative illness rating scale for geriatrics (cirs-g),1
cumulative vasopressor index (cvi),1
cup shape measure,1
curative intent treatment,1
curative surgery used,1
current alcohol consumption,1
current alcohol consumption by participants,1
current alcohol dependence,1
current alcohol status,1
current amiodarone use,1
current angina,1
current annual income,1
current anti-arrhythmic drug use,1
current aromatase inhibitor,1
current asthma,1
current asthma therapy,1
current b-blocker use,1
current binet stage,1
current bmi,1
current body weight,1
current bosentan use,1
current carotid bruit,1
current chemotherapy,1
current chemotherapy stratification factor,1
current cigarette smoker,1
current cigarette smoker or within past year,1
"current cigarette smoker, categorical",1
"current comorbidity, dysthymia",1
"current comorbidity, generalized anxiety disorder (gad)",1
"current comorbidity, major depressive disorder (mdd)",1
"current comorbidity, panic disorder (pd)",1
current deep venous thrombosis (dvt),1
current depression,1
current diabetes mellitus,1
current dialysis frequency,1
current disease phase,1
current drinkers,1
current eczema,1
current episode - mixed or manic,1
current episode - psychotic or nonpsychotic,1
current estrogen use,1
current height,1
current hormone therapy,1
current illness episode: manic versus mixed,1
current illness episode: psychotic versus nonpsychotic,1
current leukemia diagnosis,1
current living situation,1
current m classification staging,1
current major depressive episode status,1
current major depressive episode with melancholic features status,1
current metformin daily dose,1
current myocardial infarction (mi),1
current n classification staging,1
current nicotine user,1
current pain intensity,1
current pathological diagnosis,1
current pressure ulcer location,1
current pressure ulcer stage,1
current prostate cancer chemotherapy stratification factor,1
current psychiatric diagnoses,1
current pulmonary embolism (pe),1
current rai stage,1
current rectal mesalamine,1
current renal dysfunction,1
current residence of patients,1
current schizophrenia diagnosis,1
current silent ischemia,1
current site of metastasis/relapse,1
current site(s) of metastasis/relapse,1
current smoking behavior,1
current smoking behavior at randomization,1
current smoking habit,1
current smoking rate,1
current social phobia (social anxiety disorder [sad]) status,1
current stable angina,1
current status of disease,1
current t classification staging,1
"current tamoxifen, raloxifene, or aromatase inhibitor treatment",1
current thiopurine,1
current tobacco-cigarette smoker,1
current tobacco user,1
current treatment,1
current treatment for amblyopia at enrollment,1
current treatment for back pain,1
current treatment for diabetes,1
current treatments,1
current tumor diagnosis,1
current unstable angina,1
current use of bisphosphonates,1
current use of hypertensive medication,1
current use of tobacco products by participants,1
current weight,1
current work status,1
currently breastfeeding,1
"currently enrolled in college, university, or junior college",1
currently experiencing hot flashes?,1
currently married,1
currently monitoring blood pressure at home,1
currently on antiretroviral therapy,1
currently on art,1
currently on herceptin treatment,1
currently on hormone therapy,1
currently on intraocular pressure lowering medication for glaucoma or ocular hypertension,1
currently on intraocular pressure lowering medicine for glaucoma or ocular hypertension,1
currently prescribed art,1
currently receiving estrogen therapy,1
currently receiving treatment,1
currently smoking,1
currently taking antidiabetic medication,1
currently tests for hiv on regular basis,1
currrent oral mesalamine,1
curve type using srs classification,1
cutaneous involvement at onset,1
cycle length,1
cyp2c19 genotype of participants,1
cyp2c19 genotyping,1
cyp2c19 phenotype metabolic extent,1
cyp2c19 phenotype metabolic rate,1
cyp2c9 genotyping,1
cyst diameter,1
cystic component,1
cystic fibrosis (cf) genotype,1
cystic fibrosis questionnaire-revised (cfq-r) treatment burden domain (parent),1
cystic fibrosis questionnaire-revised (cfq-r) treatment burden domain score (child),1
cystic fibrosis questionnaire-revised respiratory symptom score (cfq-r rss),1
cystoid abnormalities on optical coherence tomography (oct),1
cystoid abnormality on ocular coherence tomography (oct),1
cystoscopy history,1
cytochrome p450 (cyp)2d6 phenotype,1
cytochrome p450 2d6 (cyp2d6) intermediate and extensive metabolizers,1
cytogenetic complexity,1
cytogenetic risk category,1
cytogenetic risk factor,1
cytogenetic risk group,1
cytogenetics (1998),1
cytogenetics (2001),1
cytogenics for patients with aml/mds,1
cytology,1
cytomegalovirus (cmv) status,1
cytomegalovirus serologic testing,1
cytomegalovirus seropositive,1
cytomegalovirus serostatus,1
d-dimer at baseline n=(56;19;25;88;29;32;85;31;29;63;457),1
d(l)co(sb) - ml/min/mmhg % predicted,1
d(l)co(sb) - ml/min/mmhg observed (single-breath diffusing capacity ),1
dactylitis count,1
daily allergic rhinitis symptom score,1
daily average number of puffs in past 3 days,1
daily basal insulin,1
daily corticosteroid dose stratum,1
daily dose in pioglitazone monotherapy prior to dosing of metact combination tablets,1
daily dose in pioglitazone monotherapy prior to switching to metact combination tablets,1
daily dose of antihyperglycaemic therapy prior to study (international units [iu]),1
daily dose of low-dose aspirin,1
"daily dose of metformin before switching to metact combination tablets,and metact dose assignment",1
daily dose of metformin treatment prior to study (milligrams [mg]),1
"daily dose of pioglitazone before switching to metact combination tablets,and metact dose assignment",1
daily frequency of raynuad's phenomenon attacks,1
daily î²-agonist use,1
daily insulin dose (u/kg/day),1
daily insulin usage,1
daily mean plasma glucose,1
daily metformin dose,1
daily moderate to vigorous physical activity (mvpa),1
daily number of moderate and severe hot flushes,1
daily severity score of hot flushes,1
daily smoking diary,1
daily step counts,1
daily stress impact,1
daily supplemental oxygen use,1
daily total insulin dosage,1
daily total insulin dosage-basal,1
daily total insulin dosage-bolus,1
daily total insulin dose,1
daily total insulin units per patient,1
daily use of alcohol,1
daily use of anti-leukotriene,1
daily use of combined inhaled corticosteroid/long acting beta agonist (ics/laba),1
daily use of inhaled corticosteroid (ics),1
das 28-crp score,1
das28-crp,1
das28-crp (disease activity score based on count of 28 joints and the c-reactive protein),1
dasatinib,1
date rape attitudes,1
day-care exposure,1
day 0 gfr (ml/min per 1.73m^2),1
day 0 random urine protein,1
day 0 snot-16 mean item score,1
"day 1 data: 25 hydroxyvitamind(25ohd),bioavailable 25 hydroxyvitamin d(b25ohd), cathelicidin (ll-37)",1
day 1 data: high-sensitivity c-reactive protein (hs-crp),1
day 1: total body fluid balance (tbb),1
day 3 follicle stimulating hormone,1
day 3 fsh (iu/l),1
day of transfer,1
day urinary frequency,1
day1 interleukin-6 (il-6),1
day1 migration inhibitory factor (mif),1
day1 tumor necrosis factor-î±(tnf-î±),1
days before treatment that index lesion was first noticed,1
days before treatment that index lesion was first noticed (categorical),1
days from admit to randomization,1
days from confirmed aon diagnosis to first dose,1
days from first aon symptom to first dose,1
days of alcohol use in past 30 days,1
days of bleeding/spotting in 30 days prior to enrollment,1
days of cocaine use (prior 28 days),1
days of illness,1
days of symptoms,1
days on drip,1
days on transplant waitlist,1
days post diagnosis,1
days since af is known,1
days since last docetaxel,1
days to radical prostatectomy,1
daytime ambulatory diastolic bp,1
daytime ambulatory heart rate,1
daytime ambulatory systolic bp,1
daytime asthma symptom score (0 [best] to 6 [worst] point scale),1
daytime congestion score,1
daytime drowsiness,1
daytime maximum volume voided (dmaxvv) per micturition,1
daytime nasal itching score,1
daytime rhinorrhea score,1
"daytime sleepiness by epworth sleepiness scale, continuous",1
daytime sneezing score,1
daytime symptom score,1
dbp (diastolic blood pressure),1
de-identified whole blood samples,1
de novo lesion,1
debulking,1
deceased-donor cold ischemia time,1
deceased donor kidney transplant recipients,1
deceased/alive status - alive,1
deceased/alive status - deceased,1
decisional conflict,1
decisional conflict scale,1
"declaration of death to initial intervention, hours",1
decompensated cirrhosis,1
decrease in gfr during baseline period,1
decreased oral intake,1
decubitus ulcer,1
deepest vertical depth,1
defect size by direct balloon sizing,1
degree of anemia,1
degree of hearing loss,1
degree of heel pain at baseline,1
degree of heel pain on the visual analog scale (vas),1
degree of interstitial fibrosis,1
degree of past smoking,1
degree of sleep disorder,1
degree of sleep disorders,1
degree of straining during defecation,1
"dehydration (mild), n",1
delay discounting $10 reward (dd 10),1
delay discounting $100 reward (dd 100),1
deletion chromosome 13,1
deletion of chromosome 17p,1
"delis-kaplan executive function system, letter fluency subtest",1
"delis-kaplan executive function system, trails subtest",1
delivery by cesarean section,1
delivery room resuscitation: bag and mask,1
delivery room resuscitation: chest compressions,1
delivery room resuscitation: cpap,1
delivery room resuscitation: epinephrine,1
delivery room resuscitation: intubation with ventilation,1
delivery room resuscitation: oxygen,1
dementia rating scale,1
dementia rating scale-2,1
dementia rating scale score,1
department,1
dependence scale,1
deployment history,1
depression (>=10 on phq9),1
depression (center for epidemiological studies depression scale: ces-d),1
depression (hopkins symptom checklist-20),1
depression anxiety and stress scale (dass)-anxiety,1
depression anxiety and stress scale (dass)-depression,1
depression anxiety and stress scale (dass)-stress,1
depression hamd,1
depression in a distant relative of the participant,1
depression in a second degree relative of the participant,1
depression in mother or father of participant,1
depression in sibling or child of participant,1
depression score,1
depression screening at baseline,1
"depression severity, categorial",1
depression(cesd-10) score,1
depression/anxiety,1
depressive symptomatology,1
depressive symptoms,1
"depressive symptoms, hamd (hamilton rating scale for depression)",1
depth,1
dermatol pain present,1
dermatology-specific quality of life index (dlqi) score,1
dermatology life quality index (dlqi) total score,1
dermatology quality of life index total score,1
dermoscopy use,1
derogatis affects balance scale (dabs),1
descriptive scale - mean coarse wrinkling,1
descriptive scale - mean mottled hyperpigmentation,1
descriptive scale - mean sallowness,1
descriptive scale -mean fine wrinkling,1
designated organ donor on driver's license,1
desire for help completing an advance directive,1
desire for information about advance directives,1
"desire for risks, benefits, and alternatives information about life-sustaining procedures",1
desired role in decision-making,1
desmopressin substitution,1
details of the history of gastric or duodenal ulcers: site of disease,1
details of the history of gastric or duodenal ulcers: time of emergence,1
details regarding predisposition to hypersensitivity,1
detection of antibodies to cyclic citrullinated antibody peptide,1
detection of either igm-rheumatoid factor or antibodies to cyclic citrullinated peptide,1
detection of igm-rheumatoid factor (igm rf),1
developmental age - bayley cognitive,1
device,1
device size,1
device usage,1
dfss,1
dht level,1
diabetes (dm),1
diabetes (i or ii),1
diabetes (type 2),1
diabetes at the time of transplant,1
diabetes complications,1
diabetes diagnosis at study entry,1
diabetes diagnosis at time of screening,1
diabetes disease characteristics,1
diabetes disease characteristics-types of diabetes,1
diabetes duration (years),1
diabetes duration at baseline,1
diabetes duration prior to 1st transplant,1
diabetes management,1
diabetes medication - incretin mimetics,1
diabetes medication - secretagogues,1
diabetes medication - thiazolidinedione (tzd's),1
diabetes mellitis,1
diabetes mellitus (dm) status,1
diabetes mellitus (n),1
diabetes mellitus duration,1
diabetes mellitus history,1
diabetes mellitus medications,1
diabetes mellitus status,1
diabetes mellitus type,1
"diabetes mellitus, type 1 or 2",1
diabetes risk,1
"diabetes, hypertension, or hyperlipidemia",1
"diabetes, rheumatoid arthritis, smoking = risk factors for healing",1
"diabetes, type-2",1
diabetes/high blood sugar,1
diabetic,1
diabetic (medically treated),1
"diabetic complication at baseline, macroangiopathy",1
"diabetic complication at baseline, nephropathy (common risk factor in uncontrolled diabetes)",1
"diabetic complication at baseline, neuropathy (common risk factor in uncontrolled diabetes)",1
"diabetic complication at baseline, retinopathy (common risk factor in uncontrolled diabetes)",1
"diabetic complication, macroaniopathy",1
"diabetic complication, nephropathy",1
"diabetic complication, neuropathy",1
"diabetic complication, retinopathy",1
diabetic complications at baseline,1
diabetic foot,1
diabetic foot ulcer age,1
diabetic foot ulcer area,1
diabetic medication - biguanides,1
diabetic nephropathy,1
diabetic neuropathy,1
diabetic neuropathy history,1
diabetic retinopathy,1
diabetic retinopathy (dr) level,1
diabetic retinopathy severity,1
diabetic retinopathy severity (etdrs level),1
diabetic retinopathy status,1
diabetic status at entry,1
diabetic status at randomization,1
diabetic status at screening,1
diacerin,1
diagnosed with chlamydia - lifetime,1
diagnosed with chronic pain condition (yes),1
diagnosed with depression (yes),1
diagnosed with genital herpes - lifetime,1
diagnosed with genital warts - lifetime,1
diagnosed with gonorrhea - lifetime,1
diagnosed with hepatitis c - lifetime,1
diagnosed with hpv - lifetime,1
diagnosed with syphilis - lifetime,1
diagnosed with trichomoniasis - lifetime,1
diagnosis - worse eyes,1
diagnosis (participants that did not receive stem cell transplant),1
diagnosis (participants that received stem cell transplant),1
diagnosis (who classification),1
diagnosis at study entry,1
diagnosis by pathology,1
diagnosis disorder (major depressive disorder (mdd) or bipolar disorder (bpd),1
diagnosis leading to ghd,1
diagnosis of aids in the record,1
diagnosis of anaplastic astrocytoma (aa) world health organization (who) grade iii,1
diagnosis of bacterial sexually transmitted infection at enrollment visit,1
diagnosis of chronic lymphocytic leukemia (cll),1
diagnosis of definite nash,1
diagnosis of generalized anxiety disorder (gad),1
diagnosis of lumbar radiculopathy,1
diagnosis of major depressive disorder (mdd),1
diagnosis of major depressive episode,1
diagnosis of moderate to severe interstitial cystitis (ic) with bladder pain for â‰¥ 6 months,1
diagnosis of osteoarthritis (n),1
diagnosis of other brain tumor prior to diagnosis of anaplastic astrocytoma who grade iii,1
diagnosis of ovulatory dysfunction,1
diagnosis of patient participant subset,1
diagnosis of primary tumor at study entry,1
diagnosis of reflux disease,1
diagnosis of relapsed/refractory diffuse large b-cell lymphoma,1
diagnosis of secondary glioblastoma multiforme (gbm) (who grade iv),1
diagnosis per the structured clinical interview for the diagnostic and statistical manual,1
diagnosis to enrollment,1
diagnostic and statistical manual of mental disorders (dsm-iv),1
diagnostic and statistical manual of mental disorders fourth edition subtypes,1
diagnostic and statistical manual of mental disorders fourth edition text revision diagnosis status,1
"diagnostic and statistical manual of mental disorders fourth edition, text revision diagnosis",1
diagnostic apnea-hypopnea index (ahi),1
diagnostic categories,1
diagnostic category,1
diagnostic group: medical,1
diagnostic group: surgery,1
diagnostic group: trauma,1
diagnostic summary,1
diagnostic test of h.pylori. (igg antibody),1
diagnostic type,1
dialysate flow rate,1
dialysis duration,1
dialysis history,1
dialysis modality at enrollment,1
dialysis pre-transplant,1
dialysis therapy,1
dialysis y/n,1
diameter of verrucae at presentation,1
diameter stenosis,1
diaphragmatic hernia length,1
diaphragmatic hernia present,1
diarrhea screening,1
diastolic 24-hr mean ambulatory blood pressure monitoring (abpm),1
diastolic blood pressure (dbp) at time of baseline,1
diastolic blood pressure (mean),1
diastolic blood pressure (mm hg),1
diastolic blood pressure categories,1
diastolic blood pressure percentile,1
diastolic blood pressure(dbp),1
diastolic bp (mmhg),1
diastolic pressure,1
diet,1
diet stage of change,1
dietary behaviour (dhq) - overall score,1
dietary calcium,1
dietary fiber intake,1
dietary folate,1
dietary iron,1
dietary selenium,1
dietary total omega-3,1
dietary vitamin b1,1
dietary vitamin b12,1
dietary vitamin b6,1
dietary vitamin c,1
dietary vitamin e,1
dietary zinc,1
different original medications and dosages,1
differentiation,1
difficult cannulation,1
difficulties in emotion regulation scale (ders),1
difficulty breathing,1
diffuse cutaneous scleroderma,1
diffuse large b-cell lymphoma (dlbcl) subtypes - germinal center b-cell (gcb) and non-gcb,1
diffusing capacity of the lungs for carbon monoxide (dlco),1
diffusion in liters of carbon monoxide (dlco) (percent-predicted),1
digit span backward,1
digit span forward,1
digital rectal exam - anal resting tone,1
digital rectal exam - hemorrhoids,1
digital rectal exam - soft tissue scarring,1
digital skin microvascular blood flow measured by laser doppler imaging (ldi) after cold stimulus.,1
digital skin microvascular blood flow measured by laser doppler imaging (ldi) before cold stimulus,1
dihydrotestosterone,1
dihydrotestosterone (dht),1
direct anti-globulin test,1
direct bilirubin (umol/l),1
direct bilirubin(dbil),1
"disabilities of the arm, shoulder, and hand (dash) questionnaire",1
disability (ssdi or va service connected),1
disability assessment scale (das),1
disability index assessed by the pompe pediatric evaluation of disability inventory (pompe pedi),1
disability level,1
disabled,1
discharge diagnosis,1
discharged home under self-care,1
discontinuation of oxaliplatin while on first-line treatment,1
disease-modifying anti-rheumatic drug (dmard) use,1
disease-modifying anti-rheumatic drug (dmard) use within 6 months of randomization,1
disease activity,1
disease activity at first hpv vaccine dose,1
disease activity before treatment,1
disease activity scale 28 (das 28) c-reactive protein (crp),1
disease activity score,1
disease activity score (based on 28 joint counts) (das28),1
disease activity score (crp),1
disease activity score (das 28),1
disease activity score (das) 28,1
disease activity score (das) 28 (c-reactive protein [crp]),1
disease activity score (das) 28 (using crp levels),1
disease activity score (das28-esr),1
disease activity score (das28),1
"disease activity score 28-4, c-reactive protein (das28-4 [crp])",1
"disease activity score 28-4, erythrocyte sedimentation rate (das28-4 [esr])",1
disease activity score 28-c-reactive protein (das28-crp),1
disease activity score 28-erythrocyte sedimentation rate (das28-esr) score,1
disease activity score 28 -erythrocyte sedimentation rate (das28-esr),1
disease activity score 28 (das-28),1
disease activity score 28 based on c-reactive protein (das28-crp),1
disease activity score based on 28-joints count (das28),1
disease activity score based on 28 joints and erythrocyte sedimentation rate (das28-esr),1
disease activity score c-reactive protein (das 28-crp),1
disease activity score for 28 joints- c-reactive protein (das28-crp),1
disease activity score on 28 joints (das28),1
disease activity score using c-reactive protein (das28[crp]),1
disease activity score using c reactive protein (das28-crp),1
disease activity scores using c-reactive protein (das 28 [crp]),1
disease at diagnosis,1
disease at study entry,1
disease burden,1
disease category,1
disease characteristic- target lesion location,1
disease characteristic - investigator's static global assessment,1
disease characteristic - investigator static global assesssment (isga),1
disease characteristic - target lesion location,1
disease characteristic: basis for diagnosis,1
disease characteristic: disease stage at study entry,1
disease characteristic: eastern cooperative oncology group performance status,1
disease characteristic: time from initial diagnosis to prior chemotherapy failure,1
disease characteristic: time from initial diagnosis to study entry,1
disease characteristic: time from prior chemotherapy failure to study entry,1
disease characteristics - tumor type,1
disease characteristics in the past,1
disease characterstic: pathological diagnosis code,1
disease debuted,1
disease definition - severe or complicated malaria,1
disease duration (years),1
"disease duration, average number of years",1
"disease duration, median (range)",1
disease etiology,1
disease histological class,1
disease history,1
disease location in oral cavity or oropharynx,1
disease measurability,1
disease modifying antirheumatic drug or corticosteroid user,1
disease modifying antirheumatic drug user,1
disease onset,1
disease phase/stage,1
disease profile - type of myelofibrosis (mf),1
disease risk,1
disease risk group,1
disease risk status,1
disease severity,1
disease severity as defined by fev1 percent predicted category,1
disease severity based on forced expiratory volume in 1 second (fev1) % predicted,1
disease severity score - pso,1
disease severity score - ra,1
disease sites,1
disease sites at baseline,1
disease stage (ajcc),1
disease stage at 1st diagnosis,1
disease stage at initial diagnosis,1
disease stage at screening,1
disease stage at time of study entry,1
disease stage entry criteria met,1
disease stage of dlbcl at diagnosis,1
disease stage of the modified hoen and yahr staging scale,1
disease stages,1
disease staging,1
disease status (american society for blood and marrow transplantation guidelines),1
disease status (progressive disease) at hematopoietic stem cell transplant,1
disease status at enrollment,1
disease status at entry,1
disease status at hematopoietic stem cell transplant,1
disease status at study enrollment,1
disease status relative to most recent prior therapy,1
disease sub-type,1
disease sub-type: post-essential thrombocythemia myelofibrosis,1
disease sub-type: post-polycythemia vera myelofibrosis,1
disease sub-type: primary myelofibrosis (pmf),1
disease type at diagnosis,1
disease type by investigator,1
diseases in the past 5 years,1
distal vessel runoff,1
distance from the lesion to the pleural,1
"distance to the va hospital, miles",1
distance traversed (meters) during six minute walk test at baseline,1
distance visual acuity amblyopic eye,1
distance visual acuity in sound eye,1
distance visual acuity in the amblyopic eye at randomization,1
distance visual acuity in the fellow eye at randomization,1
distance walked in 6-minute walk test (6mwt),1
distance walked in 6-minutes,1
distant metastasis (m) at initial diagnosis,1
distribution of age,1
distribution of time since diabetes diagnosis,1
diuretic dose,1
dlqi - dermatology life quality index,1
do you currently have a male sex partner?,1
docosahexaenoic acid,1
docosahexaenoic acid (dha),1
documentation of sd nvp use at birth,1
documented concomitant mutation at the alpha-globin locus,1
dominant disease,1
dominant disease site,1
dominant fibroid volume,1
dominant hand,1
dominant lesion site (target + non-target),1
dominant side,1
dominant site of metastasis/relapse,1
donor,1
donor-recipient hla match,1
donor-recipient sex,1
donor bmi,1
donor creatinine levels,1
donor final serum creatinine,1
donor gender,1
donor match,1
donor match (6/6),1
donor status,1
donor type (hla match),1
"donor type for current kidney transplant, n",1
donor types,1
donor/recipient gender,1
donor/recipient height ratio,1
donor/recipient high-risk cmv serostatus,1
donors,1
dopamine agonist treatment,1
dorsal premotor-motor cortical inhibition (dpmi),1
dorsiflexion,1
dose area product,1
dose frequency,1
dose level of interferon-beta (ifn-beta) based on ivrs,1
dose level of interferon-î²,1
dose level of polyphenon e,1
dose per kg body weight prior to randomization,1
dose tier,1
double-blind baseline chronic lower back pain (clbp) intensity vas,1
double-blind participant's global assessment of back pain status,1
dpp-4 inhibitor usage,1
drain duration,1
drinking,1
"drinking days, past 30",1
driving behavior survey-other report,1
driving behavior survey self-report,1
drug-resistant tb status at entry,1
drug abuse or drug dependence,1
"drug allergies, specifically against iron compounds",1
drug and alcohol treatment history,1
drug attitude inventory (dai-10),1
drug resistance,1
drug/alcohol and hiv/hepatitis screening,1
drugs,1
drugs affecting gi motility,1
dsm-iv attention deficit hyperactivity rating scale (adhd rs),1
dsm-iv diagnosis,1
dsm-iv diagnosis of schizophrenia,1
dsm-iv symptom count,1
dsm-v symptom count,1
dsm iv diagnosis,1
dsst: baseline total score,1
dual-energy x-ray absorptiometry (dxa) measuring apparatus,1
dual energy x-ray absorptiometry (dxa) for lean tissue mass,1
duaration of diabetes,1
duke activity status index,1
duration from historary retinal necrosis,1
duration from initial breast cancer diagnosis to date of metastasis,1
duration knee osteoarthritis,1
duration major depressive episode,1
duration of abuse (years),1
duration of acne,1
duration of acromegaly,1
duration of adhd,1
duration of akinesia (years),1
duration of alcohol recovery,1
duration of alendronate use,1
duration of allergic rhinitis,1
duration of anesthesia (minutes),1
duration of angiotensin antagonist therapy before treatment,1
duration of ankylosing spondylitis,1
duration of ankylosing spondylitis (as) symptoms,1
duration of ankylosing spondylitis (lower back pain and stiffness),1
duration of antibiotic course,1
duration of antihyperglycaemic therapy prior to study,1
duration of antiretroviral therapy: period 3 (randomization to once vs twice daily abc+3tc),1
duration of antiretroviral therapy: period 4 (randomization to stop versus continue cotrimoxazole),1
duration of antiviral courses,1
duration of arvs previously used,1
duration of asthma at baseline,1
duration of atrial fibrillation,1
duration of atrial fibrillation diagnosis (year),1
duration of atropine treatment prior to randomization,1
duration of atv/r use,1
duration of back pain,1
duration of behã§etâ€™s disease,1
duration of benign prostatic hyperplasia lower urinary tract symptoms (bph luts),1
duration of breast cancer from primary tumor diagnosis to informed consent,1
duration of cardiovascular disease,1
duration of central neuropathic pain (cnp),1
"duration of central neuropathic pain (cnp) due to ms (n=118, 120)",1
duration of chronic kidney disease,1
duration of chronic kidney disease (ckd) stage 3 or higher,1
duration of chronic low back pain,1
duration of chronic lower back pain,1
duration of chronic lower back pain since onset,1
duration of coronary artery disease,1
duration of crohn's disease at screening in years,1
duration of crohnâ€™s disease (years),1
duration of current af episode,1
duration of cystoscopy,1
duration of diabetes (12 months' participation),1
duration of diabetes (3 months' participation),1
duration of diabetes (6 months' participation),1
duration of diabetes (years),1
duration of diabetes for established diabetes patients,1
duration of diabetes group,1
duration of diabetes mellitus (years),1
duration of diabetic peripheral neuropathic pain,1
duration of diaebetes,1
duration of diagnosis,1
duration of diagnosis for hydronephrosis,1
duration of diagnosis prior to randomization,1
duration of disease-categorical,1
duration of disease (years),1
duration of disease years,1
duration of dry eye symptoms,1
duration of dvt treatment,1
duration of dyspeptic symptoms,1
duration of erectile dysfunction (ed),1
duration of exposure,1
duration of fabry disease,1
duration of fd,1
duration of fecal incontinence,1
duration of fibromyalgia-related pain â€” yr,1
duration of flash symptoms (months),1
duration of follow-up,1
duration of functional constipation,1
duration of glatiramer acetate,1
duration of glaucoma disease at baseline,1
duration of growth hormone treatment,1
duration of haart prior to study entry,1
duration of heart failure,1
duration of heart failure (time),1
duration of heel pain,1
duration of heel pain at baseline,1
duration of hemianopia,1
duration of hemodialysis,1
duration of herpes zoster-specific complaints (separated into groups),1
duration of hiv infection,1
duration of hospital admission prior to first dose,1
duration of hospitalization parameters,1
duration of hydrocortisone treatment prior to randomization,1
duration of hypertension class,1
duration of hypertension diagnosis,1
duration of hypertention,1
duration of hypothyroidism,1
duration of ibs (years),1
duration of illness (days),1
duration of illness at randomization,1
"duration of illness, mean years (sd)",1
duration of implant use,1
duration of injury in years,1
duration of insulin treatment,1
duration of interstitial lung disease (ild),1
duration of knee pain,1
duration of last episode,1
duration of leg ulceration,1
duration of lid,1
duration of lmwh administration,1
duration of longest af episode,1
duration of low back pain,1
"duration of low back pain in months, mean (sd)",1
duration of lower urinary tract symptoms (luts) secondary to benign prostatic hyperplasia (bph),1
duration of lymphedema prior to study enrollment,1
duration of mcl,1
duration of melanoma,1
duration of metastatic breast cancer from metastasis to informed consent,1
duration of metformin treatment,1
duration of mgd or dry eye diagnosis,1
duration of mood state,1
duration of morning stiffness at baseline,1
duration of ms,1
duration of multiple sclerosis disease,1
duration of multiple sclerosis phase b,1
duration of multiple sclerosis since first symptoms,1
duration of myelodysplastic syndrome (mds),1
duration of myelodysplastic syndrome (mds) at study entry,1
duration of neck/arm pain,1
duration of neuropathic pain,1
duration of nicardipine infusion,1
duration of oab symptoms (months),1
duration of oag,1
duration of opioid dependence,1
duration of osteoarthritis (oa) pain,1
duration of osteoarthritis (oa) pain since onset,1
duration of osteoarthritis pain since onset,1
duration of osteoarthritis symptoms,1
duration of osteoporosis,1
duration of pain [months],1
duration of pain symptoms at baseline,1
duration of painful diabetic peripheral neuropathy (pdpn),1
duration of parkinson's disease diagnosis,1
duration of parkinson's disease since initial diagnosis,1
duration of participant rheumatoid arthritis (ra),1
duration of patching prior to randomization (weeks),1
duration of pd,1
duration of pd (years),1
duration of pd symptoms (years),1
duration of peripheral t-cell lymphoma (ptcl),1
duration of pioglitazone treatment,1
duration of plantar fasciitis,1
duration of present depressive episode,1
duration of previous dry-powder inhaler (dpi) experience,1
duration of previous major depressive disorder (mdd) episode,1
duration of previous mental health care,1
duration of previous metered-dose inhaler (mdi) experience,1
duration of primary disease,1
duration of prior forteo 1.1 pen experience,1
duration of prior pain,1
duration of procedure,1
duration of prophylaxis,1
duration of prostate cancer,1
duration of psoriasis (ps),1
duration of psychosis,1
duration of pulmonary arterial hypertension (pah),1
duration of ra disease,1
duration of regular substance use upon treatment entry,1
duration of rheumatoid arthritis (ra) since diagnosis,1
duration of rheumatoid arthritis (years),1
duration of rheumatoid arthritis diagnosis,1
duration of rhinitis,1
duration of schizophrenia,1
duration of scleroderma,1
duration of secondary hyperparathyroidism,1
duration of severe to profound high frequency hearing loss,1
duration of smoking (years),1
duration of spasticity,1
duration of spasticity phase b,1
duration of spinal cord injury,1
duration of surgery (minutes),1
duration of symptoms(days),1
duration of systemic lupus erythematosus (sle),1
duration of t2dm,1
duration of tamoxifen treatment (years),1
duration of tamoxifen use,1
duration of the current episode,1
duration of the surgery,1
duration of toenail onychomycosis involvement,1
duration of transfusion,1
duration of transfusions,1
duration of treatment with csii (continuous subcutaneous insulin infusion) at study entry,1
duration of treatment with insulin at study entry,1
duration of treatment with previous insulin at study entry,1
duration of type-2 diabetes mellitus (t2dm),1
duration of type 1 diabetes,1
duration of type 2 diabetes mellitus,1
duration of type 2 diabetes mellitus (t2dm),1
"duration of type 2 diabetes, customized",1
duration of ufh administration,1
duration of ulcer,1
duration of ulcerative colitis,1
duration of underlying disease,1
duration of untreated psychosis,1
duration of urinary incontinence,1
duration of vitreous hemorrhage since first documented on clinical exam,1
duration of voc,1
duration of zdv during pregnancy - at delivery,1
duration of zdv during pregnancy - at entry,1
duration since first major depressive disorder (mdd) episode,1
duration since first symptoms,1
duration time,1
duration to maxillomandibular fixation (minutes),1
"duration with schizophrenia, years",1
durie-salmon,1
durie-salmon multiple myeloma stage before study entry,1
durie-salmon stage,1
durie-salmon stage at diagnosis,1
durie-salmon stage at study entry,1
durie-salmon stage of myeloma on diagnosis,1
durie-salmon staging system,1
durie salmon stage,1
durie salmon stage at diagnosis,1
durie salmon staging system,1
dutch eating restraintness score,1
dxa android fat,1
dxa android fat percentile,1
dxa bmd leg,1
dxa bmd spine,1
dxa bmd trunk,1
dxa bone mineral content (bmc),1
dxa bone mineral density (bmd),1
dxa gynoid fat,1
dxa gynoid fat percentage,1
dxa leg fat,1
dxa leg fat percentage,1
dxa total body fat,1
dxa total body fat percent,1
dxa trunk fat,1
dxa trunk fat percentile,1
dyad relationship,1
dyadic adjustment scale (das),1
dyadic adjustment scale (das) - participant (self),1
dyadic adjustment scale (das) - spouse/significant other,1
dynamic gait index,1
dynamic lumbar extension muscular endurance,1
dynamic visual acuity,1
dynamometry,1
dyslipidaemia,1
dyslipidemia requiring medication,1
dysmenorrhea score,1
dysplastic lesions identified,1
dyspnea,1
e-etdrs visual acuity,1
e-etdrs visual acuity letter score,1
e/e' ratio,1
early induction androgen deprivation,1
early treatment diabetic retinopath study retinopathy severity level from photograph grading,1
early treatment diabetic retinopathy study best-corrected visual acuity,1
early treatment diabetic retinopathy study distance visual acuity,1
earned wages outside home,1
earns own income,1
eastern co-operative group (ecog) performance status,1
eastern co-operative oncology group (ecog) performance status,1
eastern co-operative oncology group performance status (ecog ps),1
eastern cooperative group oncology performance status,1
eastern cooperative oncology,1
eastern cooperative oncology (ecog) performance status,1
eastern cooperative oncology group (ecog) performance scale status,1
eastern cooperative oncology group (ecog) performance score,1
eastern cooperative oncology group (ecog) performance status (ps) (data collection system-rave),1
eastern cooperative oncology group (ecog) performance status (ps) at study entry,1
eastern cooperative oncology group (ecog) performance status (ps) before treatment,1
eastern cooperative oncology group (ecog) performance status at enrollment,1
eastern cooperative oncology group (ecog) performance status at randomization of maintenance phase,1
eastern cooperative oncology group (ecog) performance status score (as per ivrs),1
eastern cooperative oncology group (ecog) performance status: extension phase,1
eastern cooperative oncology group (ecog) performance status: initial treatment phase,1
eastern cooperative oncology group (ecog) scale,1
eastern cooperative oncology group (ecog) status,1
eastern cooperative oncology group (ecog) therapy,1
eastern cooperative oncology group (ecog)performance status (ps),1
eastern cooperative oncology group (ecog)pperformance status,1
eastern cooperative oncology group functional status,1
eastern cooperative oncology group performace status (ecog-ps),1
eastern cooperative oncology group performance status (ecog-ps),1
eastern cooperative oncology group performance status (ecog-ps) at baseline,1
eastern cooperative oncology group performance status (ecog ps) 0 vs. 1,1
eastern cooperative oncology group performance status score,1
eastern cooperative oncology group performance status(ecog ps),1
eastern cooperative oncology group performance status] (ecog),1
eastern cooperative oncology group scale performance status,1
eastern cooperative oncology group score (ecog),1
eastern cooperative oncology group(ecog) performance status score,1
eastern cooperative oncology performance status (ecog)],1
eastern cooperative onocology group (ecog) perfomance status,1
eastern cooporative oncology group (ecog) performance status,1
eastern oncology cooperative group (ecog) performance status,1
eastern oncology cooperative group performance status,1
eat-10 score,1
eating disorder symptomology (edeq) - global score,1
"echocardiographic parameter-la diameter, long axis",1
echocardiographic parameter-la volume index,1
echocardiographic parameter-lvef,1
echocardiography,1
echogeicity of the lesion,1
ecog-eastern cooperative oncology group (ecog) performance status,1
ecog-ps,1
ecog (eastern cooperative oncology group) performance status (0-4),1
ecog (eastern cooperative oncology group) performance status 0-1,1
ecog (eastern cooperative oncology group) performance status at randomization,1
ecog at study entry,1
"ecog perfomance score, 0/1/2",1
ecog performance scale,1
ecog performance status (eastern cooperative oncology group performance status),1
ecog performance status (ps)],1
ecog performance status 0-1,1
ecog performance status score,1
ecog ps (eastern cooperative oncology group performance status),1
ecog ps at baseline,1
ecog ps: interactive voice response system (ivrs),1
ecog score,1
ecog score at enrollment,1
ecog stratification group,1
economic classification of countries,1
ect at baseline n=(57;20;27;98;34;33;95;33;29;56;482),1
ectocervical loop size (in mm),1
eczema,1
eczema history,1
ed - duration,1
ed - severity,1
edema,1
edema grade,1
edinburgh postnatal depression scale (epds),1
edss < 2.0 at onset,1
edss > 2.5 at onset,1
edss 2.0-2.5 at onset,1
education (clients),1
education (highest level completed),1
education (highest),1
education (staff),1
education > or = high school,1
education achieved at injury,1
education beyond high school,1
education categories,1
education less than or equal to high school,1
education level- less than high school diploma,1
education level attained,1
education status,1
"education, categorical",1
"education, years",1
education: college grad or more,1
educational degree,1
"educational status, college graduate",1
eeg (electroencephalogram) pathological,1
efficacy population by carrier type (persistent vs intermittent),1
efv plasma concentration,1
egfr at enrollment,1
egfr gene amplification,1
egfr mutation status,1
egg ige,1
egg skin prick test score,1
"egg skin test wheal, median, mm",1
eicosapentaenoic acid,1
eicosapentaenoic acid (epa),1
eight-point capillary plasma glucose profiles,1
ejaculate volume,1
ejection fraction (%),1
ejection fraction index < 7 days after index mi,1
ekg (electrocardiogram),1
ekg on admission,1
el escorial criteria (eec),1
elapsed time from collapse until:,1
elasticity,1
elective operation,1
elective surgery,1
electrical impedance (ohms) at 0 weeks,1
electrocardiogram (ecg),1
"electrocardiogram (ecg), abnormal/normal",1
electronic early treatment diabetic retinopathy study visual acuity,1
electronic early treatment diabetic retinopathy visual acuity score,1
elevated baseline cancer antigen 19-9(ca19-9) > 2x upper limit of normal (uln),1
elevated d-dimer(n),1
elevated lactate dehydrogenase (ldh),1
elevated ldh,1
elevated serum lactate dehydrogenase (ldh) level,1
eligibility stratum,1
eligibility to receive treatment with bevacizumab,1
embryos transferred,1
emergency care,1
emergency department visits during 6 months before index admission,1
emesis,1
"emetic response, adverse events, quality of care",1
emetogenicity of chemotherapy in cycle 1,1
emotion mean score,1
empathy for rape victims,1
emphysema on hrct,1
employed (full or part-time),1
employment (clients),1
employment at mgh > 5 years,1
employment status (before caregiving),1
employment status (current),1
employment status (during caregiving),1
employment status/occupation,1
employment: full-time or part-time,1
endoanal ultrasound or magnetic resonance imaging completed,1
endoanal ultrasound/magnetic resonance imaging - extent of sphincter defect,1
endoanal ultrasound/magnetic resonance imaging - sphincter defect,1
endocervical loop size (in mm),1
endocrine therapy,1
endocrine therapy at study entry,1
endocrine therapy elected,1
endometrial thickness,1
endometriosis location,1
endoscopic evidence of gerd,1
endoscopic finding,1
endoscopic intervention required,1
endothelial progenitor cells number,1
endothelium-dependent brachial artery flow-mediated dilatation,1
endotracheal intubation at study entry,1
energy expenditure (kcal/wk),1
energy intake (kcal/day),1
energy levels,1
enfuvirtide (t-20) in background regimen,1
english as a second language,1
engraftment day,1
enjoyment of pleasant events (continuous),1
enlarged kidney,1
eno (exhaled nitric oxide),1
enrolled on a children's oncology group protocol,1
enrolling group,1
enrollment acute gvhd,1
enrollment bmi,1
enrollment by region,1
enrollment disposition,1
enrollment from emergency department,1
enrollment logmar bscva,1
entry cd4,1
"entry plasma hiv rna viral load, copies/ml",1
enzyme-inducing anti-epileptic drug (eiaed) status,1
eortc qlq-c30,1
eortc qlq breast cancer module (br23),1
eosinophil count,1
epds score at intake,1
epds screen (edinburgh prenatal depression scale),1
epic sexual bother subscale (prostate-specific quality of life),1
epidermal growth factor receptor (egfr),1
epidermal growth factor receptor (egfr) by immunohistochemistry,1
epidermal growth factor receptor (egfr) mutation group,1
epidermal growth factor receptor (egfr) mutation status,1
epidural,1
epidural catheter removal time if any inserted,1
epilepsy history - aura,1
epilepsy history - autonomic seizure,1
epilepsy history - dialeptic seizure,1
epilepsy history - motor seizure,1
epilepsy history - number of seizures,1
epileptic history - special seizure,1
epiphora,1
epiretinal membranes present,1
episcleral venous pressure,1
episodes of homelessness,1
episodes of vaginal intercourse in the past 7 days,1
episodic anxiety scale,1
"epogen dose, units/week",1
epworth sleepiness scale score,1
epworth sleepiness score,1
eq-sd score at baseline,1
eq vas,1
er/pgr,1
er/pr/her 2 neu status,1
erectile dysfunction (ed) - etiology,1
erectile dysfunction (ed) etiology,1
erectile dysfunction history - duration,1
erectile dysfunction history - etiology,1
erectile dysfunction severity,1
erosive esophagitis present,1
erythema,1
erythema index,1
erythema intensity score at baseline,1
erythema rating,1
erythromelalgia mutations s241t,1
erythromycin-resistant lesion count,1
esa dose,1
esa pre-treatment,1
esi acuity level,1
esophagitis severity,1
esr (mm/hr),1
ess total score,1
established diagnosis of fat malabsorption syndromes,1
estimated blood loss,1
estimated blood loss (ebl),1
estimated blood loss (in ml),1
estimated duration of infection at baseline,1
estimated duration of the disease,1
estimated gestational age of fetus,1
estimated gfr,1
estimated glomerular filtration rate (ckd-epi equation),1
"estimated glomerular filtration rate (egfr) <60 ml/min per 1.73m^2, n (%)",1
estimated glomerular filtration rate (egfr) categories,1
estimated glomerular filtration rate (egfr) category,1
"estimated glomerular filtration rate (egfr), ml/min per 1.73m^2, mean (sd)",1
estimated glomerular filtration rate according to creatinine (egfrcreat),1
estimated glomerular filtration rate using the cockcroft-gault equation,1
estimated glomerular filtration rate(egfr),1
estimated number of bleeds for the 6 months preceding enrolment in registry,1
estimated pre-fracture vertebral body height,1
estimated severity of illness from pain and fever history only,1
estimated total calorie requirement,1
estrogen-receptor (er) status,1
estrogen-receptor status,1
estrogen and progesterone receptor status,1
estrogen receptor (er),1
estrogen receptor (er) result,1
estrogen receptor (er) status,1
estrogen receptor (er) status of primary tumor,1
estrogen receptor (er) status of the isolated local or regional recurrence,1
estrogen receptor (er)/progesterone receptor (pr)/ her2 status,1
estrogen receptor and progesterone receptor status,1
estrogen receptor positivity (er+),1
estrogen receptor status at metastatic diagnosis,1
estrogen status,1
estrone,1
etdrs (early treatment diabetic retinopathy study) visual acuity,1
etdrs bcva letters,1
etdrs retinopathy severity level (etdrs description),1
ethiology,1
ethnic group: white or caucasian,1
ethnic latina/hispanic,1
ethnicity origin,1
"ethnicity, customized",1
etiologies of epilepsy,1
etiology of chronic kidney disease,1
etiology of chronic pancreatitis (cp),1
etiology of ckd,1
etiology of end stage renal disease (esrd),1
etiology of epilepsy,1
etiology of erectile dysfunction (ed),1
etiology of esrd,1
etiology of subjects,1
etoposide use,1
etravirine in background regimen,1
euglycemic clamps,1
euro quality of life-5 dimensions questionnaire (eq-5d) score,1
euro quality of life-5 domain,1
european-quality of life-5 dimension instrument-3 levels (eq-5d-3l),1
european cooperative oncology group (ecog) performance status,1
european cooperative oncology group performance status,1
european league against rheumatism (eular) sjogrenâ€™s syndrome disease activity index (essdai) score,1
european quality of life 5 dimensions (eq5d) questionnaire index,1
european quality of life 5 dimensions (eq5d) questionnaire visual analogue scale (vas),1
european quality of life questionnaire 5d (eq-5d) qol vas,1
euroqual eq-5d-5l,1
euroscore > 6 (high risk for early mortality for cardiac surgery),1
eus features of chronic pancreatitis,1
evaluable participants,1
evaluation - 16-item quick inventory of depressive symptomatology (qids16) total score,1
evaluation - 17-item hamilton depression rating scale (hamd-17) total score,1
evaluation - 24-item hamilton depression rating scale - item 12:somatic symptoms/gastrointestinal,1
evaluation - 24-item hamilton depression rating scale - item 18b:diurnal variation-severity,1
evaluation - 24-item hamilton depression rating scale - item 19: depersonalization and derealization,1
evaluation - 24-item hamilton depression rating scale - item 21:obsessional and compulsive symptoms,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 1:depressed mood,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 10:anxiety (psychic),1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 11:anxiety (somatic),1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 13:somatic symptoms/general,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 14:genital symptoms,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 15:hypochondriasis,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 16:loss of weight,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 17:insight,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 18a:diurnal variation,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 2:feelings of guilt,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 20:paranoid symptoms,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 22b:helplessness,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 23b:hopelessness,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 24b:worthlessness,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 3:suicide,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 4:insomnia early,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 5:insomnia middle,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 6:insomnia late,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 7:work and activities,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 8:retardation,1
evaluation - 24-item hamilton depression rating scale (hamd-24) - item 9:agitation,1
evaluation - 24-item hamilton depression rating scale (hamd-24) anxiety/somatization subscale score,1
evaluation - 24-item hamilton depression rating scale (hamd-24) bech subscale score,1
evaluation - 24-item hamilton depression rating scale (hamd-24) maier subscale score,1
evaluation - 24-item hamilton depression rating scale (hamd-24) retardation subscale score,1
evaluation - 24-item hamilton depression rating scale (hamd-24) sleep subscale score,1
evaluation - 24-item hamilton depression rating scale (hamd-24) total score,1
evaluation - brief profile of mood states (bpoms),1
evaluation - clinical global impressions of severity scale (cgi-s) score,1
evaluation - massachusetts general hospital cognitive and physical functioning questionnaire,1
evaluation - pain numerical rating scale (nrs) score item 1,1
evaluation - pain numerical rating scale (nrs) score item 7,1
evaluation - sheehan disability scale (sds) item 1,1
evaluation - sheehan disability scale (sds) item 2,1
evaluation - sheehan disability scale (sds) item 3,1
evaluation - sheehan disability scale (sds) total score,1
evaluation - social adaptation self-evaluation scale (sass) total,1
evaluation of bleeding at target area before randomization,1
evaluation tool of children's handwriting,1
"evaluation, by histone î³h2ax analysis, of the effect of an oral dose of 200 mg of methylene blue",1
evaluator's global severity score (egss),1
ever been a perpetrator of teen dating violence,1
ever been a victim of teen dating violence,1
ever been tested for hiv,1
ever breast fed,1
ever experienced uti in life,1
ever had a boyfriend/girlfriend,1
ever had a psychiatric diagnosis,1
ever had anal sex,1
ever had oral sex,1
ever had vaginal sex,1
ever incarcerated,1
ever known someone who died from aids,1
ever received drug therapy,1
ever received sui treatment,1
ever smoked?,1
ever smokers,1
ever spoken to a doctor about pms,1
ever used a home hiv test,1
ever used gay mobile application,1
evidence of a colonized wound on the lower extremity.,1
evidence of metastatic disease,1
evoked compound muscle action potentials,1
evoked pain,1
exacerbations,1
exacerbations past 12 months before study start.,1
examination anxiety,1
excess weight,1
exclusionary medication washout,1
exercise duration,1
exercise endurance time at the beginning of fluticasone propionate,1
exercise endurance time at the beginning of placebo treatment,1
exercise heart rate,1
exercise stages of change,1
exercise stress echocardiography with strain,1
exercise time,1
exercise tolerance assessed by 6 minute walking test,1
exercising regularly,1
exhaled carbon monoxide,1
exhaled carbon monoxide (co) level,1
exhaled carbon monoxide (eco),1
"expanded disability status scale ([edss], n=118, 120)",1
expanded disability status scale (edss)- phase b,1
expanded disability status scale (edss) at baseline,1
expanded disability status scale at screening,1
expanded disability status score (edss) score,1
expected pain for iud insertion,1
experience with other vaccine,1
experienced a uti in the past 12 mo,1
experienced stressful life event,1
experiencing cardiogenic shock,1
expert opinion of active disease,1
expired carbon monoxide,1
"expired co, ppm",1
exposed bone,1
exposed to etanercept,1
exposed to other children,1
exposure to biofuels,1
exposure to other children,1
expression of hormone receptors,1
expression of the lewis y antigen in tumor tissue,1
extended mini-mental state exam,1
extent of bronchiectasis,1
extent of cancer,1
extent of disease at baseline,1
extent of disease at diagnosis,1
extent of disease at study entry,1
extent of operation (right/left/total),1
extent of recurrence,1
extent of residual disease,1
extent of surgery,1
external anal sphincter defect extent,1
external anal sphincter defects,1
extracranial disease at enrollment,1
extracranial metastases,1
extrahepatic disease (ivrs),1
extrahepatic disease (rave),1
extrahepatic metastasis status,1
extrahepatic spread,1
extraintestinal manifestations at baseline,1
extramedullary disease involvement,1
extranodal disease sites,1
extrapyramidal scores/abnormal involuntary movement-baseline,1
extrapyramidal scores/barnes akathisia rating scale (bars) global clinical assessment-baseline,1
extrapyramidal scores/simpson-angus-baseline,1
extravascular sites,1
extubation time (min),1
exudate handling,1
eyelash length,1
eysenck impulsivity scale,1
ezetimibe use,1
"f-, a-, and s-words",1
fab classification,1
fab subtype,1
fabi/bolton score,1
facial skin self-evaluation,1
facit fatigue scale,1
fact-fatigue score,1
fact advanced prostate symptom index (fapsi) -8 score from baseline,1
factor viii activity; factor viii inhibitor titer,1
fagerstrã¶m test for nicotine dependence (ftnd),1
fagerstrã¶m test for nicotine dependence score,1
fagerstrom,1
fagerstrom test for nicotine dependence- 6 item,1
fagerstrom test for nicotine dependence (ftnd),1
fagerstrom test for nicotine dependence (ftnd): time to first cigarette after waking,1
fagerstrom test for nicotine dependence: ability to refrain from smoking where it is forbidden,1
fagerstrom test for nicotine dependence: cigarettes a day,1
fagerstrom test for nicotine dependence: frequency of smoking during first hours after waking,1
fagerstrom test for nicotine dependence: most difficult cigarette to give up,1
fagerstrom test for nicotine dependence: smoking when ill,1
fagerstrom test of nicotine dependence,1
fagerstrom test of nicotine dependence (ftnd),1
fagstrom test for nicotine dependence,1
fahn tolosa marin tremor rating scale,1
failed antidepressants medications,1
failed fecal incontinence conservative therapy,1
failure to attain systolic blood pressure target for 2 consecutive hours during 2-24 hours,1
failure to attain systolic blood pressure target within 2 hours,1
fair or poor health,1
fair or poor self-reported health,1
falls self-efficacy,1
falls self-efficacy scale,1
falls self-report,1
familial adenomatous polyposis (fap) status,1
familial history (fh) of alcoholism,1
familial predisposition to hypersensitivity,1
familiar history of diabetes (n),1
familiar with guidelines,1
familiarity with needle sensation,1
family assessment measure iii (fam) dyadic relationship scale (drs) - participant (self),1
family assessment measure iii (fam) dyadic relationship scale (drs) - spouse/significant other,1
family history of alzheimer's disease,1
"family history of asthma,",1
family history of asthma/reactive airway disease,1
family history of atopy,1
family history of cardiovascular disease,1
family history of coronary artery disease,1
family history of coronary artery disease (cad),1
family history of cvs disease,1
family history of depression,1
family history of diabetes mellitus,1
family history of essential tremor,1
family history of hepatitis b carrier,1
family history of lung cancer,1
family history of marfan,1
family history of mental illness,1
family history of migraine,1
family history of ms,1
family history of oa,1
family history of parkinson's disease,1
family history of pca,1
family history of skin cancer,1
family history related to skin disease,1
family history risk,1
family income,1
family monthly income,1
fast acting insulin,1
fast stage (categorical),1
fast walking speed,1
fasting (non-random) serum high-density lipoprotein-cholesterol (hdl-c),1
fasting (non-random) serum high density lipoprotein-cholesterol (hdl-c),1
fasting (non-random) serum low-density lipoprotein-cholesterol (ldl-c),1
fasting (non-random) serum low density lipoprotein-cholesterol (ldl-c),1
fasting blood glucose (bg),1
fasting blood glucose at the start of treatment with metact combination tablets,1
fasting blood glucose categories,1
fasting blood glucose level,1
"fasting blood glucose, continuous",1
fasting blood plasma (fpg) glucose,1
fasting blood sugar serum level,1
fasting free fatty acids,1
"fasting glucose (nucleomaxx n=82, placebo n=82)",1
fasting glucose(normal values range from 3.9-6.1 mmol/l),1
fasting glucose/insulin ratio (gir),1
fasting hdl-cholesterol,1
fasting hemoglobin a1c,1
"fasting high-density lipoprotein (hdl) (nucleomaxx n=82, placebo n=80)",1
fasting high-density lipoprotein (hdl) cholesterol,1
fasting high-density lipoprotein cholesterol (hdl-c),1
fasting insulin (ulu/ml),1
fasting insulin at the start of treatment with metact combination tablets,1
fasting insulin serum level,1
"fasting lactate (nucleomaxx n=76, placebo n=75)",1
fasting ldl-cholesterol,1
fasting leptin concentration,1
fasting lipid panel,1
fasting lipids,1
fasting lipoproteins,1
"fasting low-density lipoprotein (ldl) (nucleomaxx n=73, placebo n=67)",1
fasting low-density lipoprotein (ldl) cholesterol,1
fasting low-density lipoprotein cholesterol (ldl-c),1
fasting non-hdl cholesterol,1
"fasting non-high-density lipoprotein (non-hdl) (nucleomaxx n=77, placebo n=69)",1
fasting non-high density lipoprotein (hdl) cholesterol,1
fasting plamsa glucose (fpg),1
fasting plasma glucose (fpg) at randomisation,1
fasting plasma glucose (fpg) level,1
fasting plasma glucose (mg/dl),1
fasting resting metabolic rate,1
fasting serum 7 alpha-hco,1
fasting serum insulin,1
fasting serum lipids,1
fasting total-cholesterol,1
fasting total cholesterol,1
"fasting total cholesterol (nucleomaxx n=82, placebo n=81)",1
fasting total cholesterol (tc),1
fasting triacylglycerol (tag),1
"fasting triglycerides (nucleomaxx n=82, placebo n=81)",1
fat %,1
fat as percentage of total body composition,1
fat mass (kg),1
fat mass from dxa,1
father's level of education,1
father height,1
fatigue,1
fatigue-visual analog scale (vas) score,1
fatigue (baseline)-brief fatigue inventory (bfi),1
fatigue (baseline)-international classification of diseases version 10 (icd-10),1
fatigue assessment scale,1
fatigue scale,1
"fatigue score, continuous",1
fatigue severity scale score >40,1
fatigue severity score (fss),1
favorable cytogenetics (at initial diagnosis),1
fbg,1
fear of movement level,1
fecal calprotectin - categorical,1
fecal calprotectin (fc) levels at baseline,1
fecal incontinence episodes,1
fecal incontinence quality of life (fiqol) scale 1 - lifestyle,1
fecal incontinence severity index (fisi) at baseline,1
fecal incontinence treatment history (failed modalities),1
feeding mode,1
feeding regimen,1
feeding stratum,1
feeding tube,1
fef 25-75,1
fef25-75 % predicted,1
felony convictions,1
female age,1
female age category,1
"female age, continuous",1
"female age, customized",1
female child bearing potential,1
female sub-typing - menopausal state,1
female: child bearing potential,1
femoral neck areal bone mineral density (dxa),1
femoral neck bmd,1
femoral neck t-score â‰¤ -2.5,1
femoral total t-score â‰¤ -2.5,1
feno,1
fentanyl,1
ferritin,1
ferritin concentration,1
fertility status of female participants,1
fertility status: adult population,1
fetal anomaly,1
fetal hemoglobin,1
fetal presentation,1
fetal weight (g),1
fetal weight (kilograms),1
fev 1,1
fev1 % predicted at day 1,1
fev1 %predicted,1
fev1 (% predicted after bronchodilator use),1
fev1 (% predicted before bronchodilator use),1
fev1 (l) percent predicted,1
fev1 at randomisation,1
fev1 before albuterol use (% predicted),1
fev1 before albuterol use (l),1
fev1 fall % predicted with exercise,1
fev1 percent of predicted,1
fev1 percent of predicted category,1
fev1 post-bronchodilator,1
fev1 post-bronchodilator categories,1
fev1 postbd,1
fev1 postbd %pred,1
fev1 pre-bronchodilator,1
fev1 reversibility,1
fev1 score (thoracic),1
fev1% pred,1
fev1(l) (forces expiratory volume) observed,1
"fev1, % of predicted",1
"fev1, liters",1
fev1/fvc %-predicted,1
fev1/fvc % ratio,1
fev1/fvc (% predicted after bronchodilator use),1
fev1/fvc (% predicted before bronchodilator use),1
fev1/fvc (%),1
fev1/fvc (forced expiratory volume at one second/forced vital capacity),1
fev1/fvc at screening,1
fev1/fvc percentage,1
fev1/fvc postbd,1
fev25-75,1
fevâ‚,1
fever duration,1
ff-vep conduction block in the affected eye at baseline,1
ff-vep latency in the fellow eye at baseline,1
fi symptom duration,1
fibrate use,1
fibroblast growth factor 23 (fgf-23),1
fibroid related symptoms,1
fibromyalgia impact,1
fibromyalgia impact questionnaire,1
fibromyalgia impact questionnaire (fiq),1
fibromyalgia impact questionnaire (fiq) subscale scores,1
fibromyalgia impact questionnaire (fiq) total score,1
fibromyalgia impact questionnaire (fiq) total scores,1
fibrosis (ishak score),1
fibrosis score,1
fibrosis stage,1
fibrotestâ® score,1
figo (international federation of gynecology and obstetrics) stage,1
figo (international federation of gynecology and obstetrics) stage - recurrent/persistent,1
figo (international federation of gynecology and obstetrics) stage recurrent/persistent,1
figo stage at diagnosis,1
fim motor scale,1
finances,1
financial capacity instrument - total,1
financial class - insurance type,1
financial status,1
fine motor function domain z-score,1
fine motor/nonverbal function domain z-score,1
fio2,1
fiq score,1
fiqol scale 2 - coping/behavior,1
fiqol scale 3 - depression/self-perception,1
fiqol scale 4 - embarrassment,1
first-line chemotherapy regimen,1
first glasgow coma scale score assessed upon hospital emergency department (ed) arrival,1
first medical contact,1
first observed total bilirubin,1
first postnatal gas: base deficit,1
first postnatal gas: ph,1
first rhythm,1
first salvage,1
first transplant,1
fish,1
fish detection of del (11q22-23),1
fish detection of del (13q14),1
fish detection of del (17p13),1
fish detection of immunoglobulin heavy chain (igh)/cyclind1 (ccnd1) (bcl1) t (11; 14),1
"fisher scale (n=10, 13)",1
fistzpatrick skin type,1
fitzpatrick,1
fitzpatrick skin classification,1
fitzpatrick skin tone,1
fitzpatrick skin type score,1
fitzpatrickâ€™s sun-reactive skin type,1
flap reconstruction,1
flexibility assessment: extension (angle),1
flexibility assessment: extension (visual analog scale ([vas]),1
flexibility assessment: rotation (angle),1
flexibility assessment: rotation (vas),1
flexibility assessment: side-to-side (angle),1
flexibility assessment: side-to-side (vas),1
flipi,1
flipi risk category,1
flow-mediated vasodilation (fmd),1
flt (fms-like tyrosine kinase 3) and npm1 (nucleophosmin) gene status,1
flt and npm1 status,1
flt3 itd mutation status,1
flt3 mutation,1
flt3 mutational subtype,1
fluid intake-fluid output,1
fluid severity,1
fluorescein staining score â± sd,1
fluorescence in situ hybridization (fish) detection of trisomy 12,1
fluoresence intensity,1
fluoroscopy time,1
fmd,1
follical-stimulating hormone (fsh),1
follicle-stimulating hormone (fsh),1
follicle-stimulating hormone level,1
follicular lymphoma international prognostic index (flipi),1
follicular lymphoma international prognostic index (flipi) risk group,1
follicular lymphoma prognostic index (flipi),1
follow-up time,1
follow up method,1
fontaine classification,1
food impaction > 5 minutes,1
foot and ankle ability measure,1
foot and ankle ability measure-sport,1
foot length sitting,1
foot length standing,1
foot posture index,1
forced expirator volume in the first second of expiration (fev1)/fvc ratio,1
forced expiratory flow 1 sec,1
forced expiratory flow 1 sec as a percentage of predicted,1
forced expiratory flow 25% to 75% (fef25-75),1
forced expiratory flow at 25% to 75% forced vital capacity (fef 25%-75%),1
forced expiratory flow at 25% to 75% of the forced vital capacity (fef25%-75%),1
forced expiratory flow from 25 to 75 % (fef2575%) % predicted,1
forced expiratory volume (fev1),1
forced expiratory volume (fev1) (max %-predicted),1
forced expiratory volume (fev1) percent predicted,1
forced expiratory volume at 1 second (fev1),1
forced expiratory volume at one second (fev1) % predicted,1
forced expiratory volume at one second.,1
forced expiratory volume at one second/forced vital capacity (fev1/fvc),1
forced expiratory volume in 1 second (fev1%pred.),1
forced expiratory volume in 1 second (fev1) (%predicted),1
forced expiratory volume in one second (fev1) (in liters),1
forced expiratory volume in one second (fev1) on day 1,1
forced expiratory volume in one second (fev1) percent (%) predicted,1
forced vital capacity (fvc) (percent-predicted),1
forced vital capacity (fvc)(in liters),1
forearm's active range of movement,1
forearm's passive range of motion,1
formal education,1
former nicotine user,1
former treatment for infertility,1
forrest class,1
foveal center involvement,1
fpg categorization,1
fraction of exhaled nitric oxide (feno),1
fraction of inspired oxygen at enrollment,1
fracture history,1
fracture status,1
fracture type (open or closed),1
fragility fracture,1
frailty index,1
framingham hard coronary heart disease,1
framingham score at baseline,1
frax score,1
frc (l) (functional residual capacity) observed,1
frc percent of liters predicted,1
free elastase during the run-in phase,1
free fatty acids (ffa),1
free serum testosterone,1
free t4,1
free testosterone (pmol/l),1
free testosterone level,1
free thyroxine (t4),1
french-american-british classification (fab),1
"french, american, british (fab) classification",1
frequency of abdominal pain,1
frequency of belching,1
frequency of bloating,1
frequency of daily dosing of metformin prior to dosing of metact combination tablets,1
frequency of defecations,1
frequency of diarrhea,1
frequency of fecal incontinence at baseline,1
frequency of flatulence,1
frequency of heart burn,1
frequency of involved disease sites,1
frequency of lack of appetite,1
frequency of less than 2 bowel movements per week,1
frequency of more than 2 bowel movements per day,1
frequency of nausea,1
frequency of sex in current or most recent relationship,1
frequency of vaginal intercourse,1
frequency of vomiting,1
fresh oral fluid samples with known hiv reactivity,1
frontal midline theta activity- amplitude,1
frontal midline theta activity- frequency,1
frontal systems function domain z-score,1
fsh at screening,1
fsh baseline concentration,1
fsh/lh,1
ft4,1
fugl-meyer assessment,1
fugl-meyer assessment (fma),1
fugl-meyer assessment score,1
fugl-meyer score,1
fugl-meyer upper extremity motor assessment,1
fuhrman grade,1
full range of saint louis university mental status scores,1
function- forward reach,1
function-walking distance,1
functional activities questionnaire,1
functional ambulation classification (0-5),1
functional assessment of cancer therapy-fatigue (fact-f) score,1
functional class of disease,1
functional diarrhea or diarrhea-predominant irritable bowel syndrome (ibs),1
functional independence measures (tfim),1
functional outcome of sleep questionnaire,1
functional reach assessment,1
"functioning, global assessment of functioning scale",1
fungal infection type,1
future interest for surgical specility,1
fvc %-predicted,1
fvc (% predicted after bronchodilator use),1
fvc (% predicted before bronchodilator use),1
fvc (% predicted),1
fvc (forced vital capacity),1
fvc postbd,1
fvc postbd %pred,1
"fvc, liters",1
fviii trough level at baseline,1
fx:c at diagnosis (iu/dl),1
gabapentinoid (gabapentin/ pregabalin) naive,1
gad antibody positive,1
gad enhancing lesions at onset,1
gadolinium (gd)-enhancing lesions,1
gadolinium enhancing lesions (t1) at screening,1
gaf,1
gail 5-year projected probability of developing breast cancer,1
gail risk 5-year probability of cancer development,1
gail risk of developing breast cancer within 5 years,1
gait speed,1
gait velocity (cm/sec),1
galveston orientation and amnesia test score,1
gamma-glutamyl transferase,1
gamma-glutamyl transpeptidase (ggt),1
gamma-glutamyltransferase (ggt) (u/l),1
gamma h2ax histone positive,1
gammah2ax histone phosphorylation,1
gastric emptying half life,1
gastric or duodenal ulcer history breakdown,1
gastric or duodenal ulcer history: time of onset,1
gastric outlet obstruction score,1
"gastric ph, median",1
gastroesophageal reflux disease-health-related quality of life (gerd-hrql) total score,1
gastroesophageal reflux disease-health related quality of life (gerd-hrql),1
gastroesophageal reflux disease (gerd),1
gastrointestinal (gi) disease,1
gastrointestinal condition,1
gastrointestinal quality of life index (giqli) score,1
gastrointestinal symptom scale for kids (gissk) - type of stomach problems,1
gastroparesis symptom rating scale score,1
gcs,1
gdm in previous pregnancies,1
gds,1
gds score,1
gender - part 1 population,1
gender at beginning of long term follow-up period,1
gender in follicular lymphoma sub-population,1
gender in patients completing study,1
gender of extension period participants,1
gender of sex partners in last 3 months,1
"gender, by disease type",1
"gender, male/female: compliant participants",1
"gender, male/female: period 2 (trial enrollment, induction art)",1
"gender, male/female: period 3 (randomization to once vs twice daily abc+3tc)",1
"gender, male/female: period 4 (randomization to stop versus continue cotrimoxazole)",1
gene expression score,1
gene expression signature,1
gene mutations,1
general cardiovascular history,1
general health status,1
general medical history: cardiac arrhythmia(s),1
general medical history: ecg abnormalities,1
general medical history: other (non-asd) cardiac disease,1
general medical history: previous cardiac surgery,1
general self-efficacy scale,1
general sleep disturbance,1
generalised anxiety disorder (gad)-7,1
generalized anxiety disorder,1
generalized anxiety disorder (gad) status,1
genetic alterations,1
genetic risk,1
genetic type,1
genital herpes recurrence in last 12 months,1
genotype of scd,1
genotypes and genetic mutations,1
genotypic sensitivity score,1
geographic area of residence,1
geographic region where the participant lived,1
geometric center (gc) of colonic transit,1
gerd hrql off ppi,1
gerd hrql on ppi,1
gerd symptom severity,1
geriatric depression scale-short form (gds-s),1
geriatric depression scale (continuous),1
geriatric depression scale (gds) total score,1
german cockroach-specific ige fragment antibody binding (fab) activity,1
german cockroach-specific serum ige levels,1
german cockroach-specific serum immunoglobulin g (igg) levels,1
german cockroach prick skin test wheal size,1
german cockroach skin test sensitivity,1
german revised children's quality of life questionnaire (kindl-r): emotional well-being score,1
german revised children's quality of life questionnaire (kindl-r): family score,1
german revised children's quality of life questionnaire (kindl-r): friends score,1
german revised children's quality of life questionnaire (kindl-r): physical well-being score,1
german revised children's quality of life questionnaire (kindl-r): school score,1
german revised children's quality of life questionnaire (kindl-r): self esteem score,1
german revised children's quality of life questionnaire (kindl-r): total quality of life score,1
gestation (weeks),1
gestation at enrollment,1
gestational age-weeks,1
gestational age (ga),1
gestational age (wks),1
gestational age at admission,1
gestational age at cesarean delivery,1
gestational age at enrollement,1
gestational age at enrollment in weeks,1
gestational age at entry,1
gestational age at entry to dipp,1
gestational age at intake,1
"gestational age at nvp dosing, continuous",1
gestational age at randomization,1
gestational age at randomization (weeks),1
gestational age at time of enrollment,1
gestational age diagnosed,1
gestational age insulin started,1
gestational age upon treatment entry,1
"gestational age, categorical",1
gestational diabetes at enrollment,1
gestatonal age,1
gfr status,1
gi symptom diarrhea sub score,1
gi symptoms constipation sub score,1
giant cell tumor disease type,1
gingival index,1
gingival index (gi),1
gingival recession,1
gissk - severity of stomach problems,1
glare recovery,1
glasgow-blatchford score,1
glasgow coma scale (total),1
glasgow coma scale score,1
glasgow coma scale.(gcs),1
glasgow coma score (gcs) prior to enrollment,1
glaucoma diagnosis at baseline,1
glaucoma type,1
"gleason 7 histology, or psa 10-20",1
gleason score (categorical),1
gleason score (higher score is associated with worse outcomes),1
gleason score of 8 or more,1
glioma grade,1
global acroqol score,1
global assessment,1
global assessment of functioning scale,1
global assessment of gastrointestinal (gi) symptoms grade,1
global chronic graft-versus-host disease score,1
global deficit z-score (gds),1
global deterioration scale,1
global initiative for chronic obstructive lung disease (gold) patient group,1
global national institutes of health graft versus host disease (gvhd) score,1
"global neuropsychological deficits (standardized, composite)",1
global pdus (mcp 2-5) score (n=96),1
global severity of acne,1
globotriaosylceramide (gl-3) accumulation in the myocardium,1
globulin,1
glomerular filtration rate (gfr) stratification factor,1
glomerular filtration rate (ml/min/1.73m^2),1
glucagon auc(0:30-4:30h),1
glucocorticoid,1
glucocorticosteroid-refractory status,1
glucocorticosteroid use,1
glucosamine,1
glucose (mg/dl),1
glucose (mmol/l),1
glucose 0',1
glucose 120',1
glucose 2 hours after meal,1
glucose 30',1
glucose 5-hour (hr) total area under the curve (auc),1
glucose 60',1
glucose 90',1
glucose concentration,1
glucose infusion rate (gir),1
glucose levels,1
glucose levels in ogtt,1
glucose tolerance,1
glutamic-oxaloacetic transaminase(ast),1
glutamic-pyruvic transaminase (gpt),1
glutamic-pyruvic transaminase(alt),1
glutathione,1
glycated hemoglobin(normal values range from 4-6 percent),1
glycerinated german cockroach prick skin test wheal size,1
glycosilated hemoglobin,1
glycosylated albumin,1
glycosylated haemoglobin (%)(hba1c),1
glycosylated haemoglobin (hba1c) at baseline,1
glycosylated haemoglobin (hba1c) at screening,1
glycosylated haemoglobin (hba1c) at the start of study treatment,1
glycosylated haemoglobin (hbaa1c),1
glycosylated haemoglobin a1c (hba1c) at randomisation,1
glycosylated hembglobin (hba1c),1
glycosylated hemoglobin,1
glycosylated hemoglobin (a1c),1
glycosylated hemoglobin (hba1c) - interim analysis,1
glycosylated hemoglobin a1c (hba1c) (at start of treatment with sonias combination tablets ld),1
glycosylated hemoglobin a1c (hba1c) at week -2,1
gmfcs level,1
gnrh-agonist duration,1
gog performance status,1
gold classification,1
"gonorrhea, #",1
gorelick dehydration score,1
gout,1
gout flares in the past year,1
gp iib/iiia administration,1
grace acs risk and mortality score,1
grade (histology),1
grade level,1
grade of acute graft-vs-host-disease (gvhd) at diagnosis,1
grade of anterior chamber cells,1
grade of histologic differentiation,1
grade of histological diagnosis,1
grade of hydronephrosis,1
grade of intubating anaesthetist,1
grade of osteoarthritis,1
grade point average previous academic year,1
grading,1
graft-versus-host disease (gvhd) prophylaxis intervention,1
graft-versus-host disease (gvhd) prophylaxis regimen,1
graft vintage,1
granulocyte colony stimulating factor (g-csf) pretreatment,1
grasp-release test,1
gravid,1
gravida,1
gravidity category,1
gravidity: number of previous pregnancies,1
grip strength,1
grip strength affected hand,1
grip strength of both hands,1
grip strength of non-affected hand,1
grooved pegboard dominant,1
grooved pegboard non-dominant,1
gross motor disability assessed by gross motor function measure-88 (gmfm-88),1
gross motor function classification system (gmfcs),1
gross motor function classification system (gmfcs) level,1
gross weight,1
group beta streptococcus colonization,1
growth chart percentiles,1
growth hormone (gh) level,1
growth hormone deficiency (ghd) onset type,1
growth measured by height z-score,1
growth measured by weight z-score,1
gsci- bloating sub score,1
gsci- nausea sub score,1
gsci- satiety sub score,1
gsci total score,1
gsrs,1
gstm1 & gstt1 genotypes,1
gvhd prophylaxis,1
gynecologic oncology group performance status,1
gynecological history,1
h pylori status,1
h. pylori (serum) positive,1
h. pylori infection,1
h. pyori positive,1
haart regimen at enrollment,1
habits timeline followback (tlfb) incidence for use of alcohol,1
habits timeline followback (tlfb) incidence for use of caffeine,1
habits timeline followback (tlfb) incidence for use of drugs,1
habits timeline followback (tlfb) incidence for use of marijuana,1
habits timeline followback (tlfb) incidence for use of nicotine,1
hachinski score,1
had a prior stem cell transplant,1
had at least one historical illness,1
had experience on unsedative upper endoscopy without any contraindication,1
had inpatient stay or emergency department visit in previous 6 months,1
had major depressive disorder (mdd) hospitalizations in the past 24 months,1
had medical history of cardiac surgery,1
had medical history of cardiovascular disorder,1
had medical history of endocrine disorder,1
had medical history of neurodevelopmental disorder,1
had medical history of psychiatric disorder,1
had previous mdd in the past 24 months,1
had prior treatment,1
had splenectomy,1
haematology: haematocrit,1
haematology: haemoglobin,1
haematology: mean corpuscular volume,1
haematology: platelet count,1
haematology: white blood cell count,1
haemodynamic parameter,1
haemoglobin,1
haemoglobin a1c (hba1c),1
haemoglobin concentration at baseline,1
haemophilus influenzae (h influenzae) sensitivity in nasopharyngeal cultures,1
hai,1
hair curliness,1
hair density index measured prior to intervention,1
hair length,1
hair texture,1
ham-a baseline total score,1
ham-a total score,1
"ham-a: baseline present study, 13267b",1
ham-d-17,1
ham-d score,1
hamd total score,1
hamilton-d-17 score,1
hamilton-d-28 score,1
hamilton anxiety rating scale-14 items total score,1
"hamilton anxiety rating scale (hars) total score, continuous",1
hamilton anxiety scale (ham-a) total score,1
hamilton anxiety scale (hama),1
hamilton depression rating scale-17 item (hdrs-17),1
hamilton depression rating scale-17 items total score,1
hamilton depression rating scale (17 item),1
hamilton depression rating scale (24 item),1
hamilton depression rating scale (ham-d) suicide item,1
hamilton depression rating scale (hdrs) score,1
hamilton depression rating scale 17-item,1
hamilton depression rating scale 17 (ham-d-17),1
hamilton depression scale - 17 item version (hamd-17) total score,1
hamilton depression scale 17-item (ham d17),1
hamilton psychiatric scale for depression-17 item (ham-d17) score,1
hamilton psychiatric scale for depression-17 item ham-d17) total score,1
hamilton rating scale for anxiety (hrsa),1
hamilton rating scales of depression,1
hamilton scale for depression,1
hamstring shortening,1
hand status,1
haq disability index,1
haq score,1
hars baseline score,1
has-bled score,1
has a history of congestive heart failure,1
has a history of hyperlipidemia,1
has a history of hypertension,1
has a history of ischemic heart disease,1
has a history of myocardial infarction,1
has a history of obesity,1
has a history of peripheral neuropathy,1
has a history of renal impairment/dialysis,1
has a history of retinopathy,1
has a history of stroke/transient ischemic attack,1
has a history of type 1 diabetes,1
has a history of type 2 diabetes,1
has advance directive,1
has primary care provider,1
has the participant been hospitalized due to depression in the last 4 weeks,1
hb (g/dl),1
hba 1c,1
hba1c % result at visit 1,1
hba1c (%-points),1
hba1c (%) fasting bloodwork,1
hba1c (glycosylated haemoglobin) at baseline,1
hba1c (glycosylated haemoglobin) at randomisation,1
hba1c (ngsp value) at the start of treatment with metact combination tablets,1
hba1c 6-9%,1
hba1c at screening,1
hba1c at screening (day -7),1
hba1c at the start of study treatment,1
hba1c category,1
hba1c level,1
hba1c value at baseline,1
"hba1c, categorical",1
hbeag-negative participants,1
hbeag positive,1
hbeag status,1
hbsag,1
hbv,1
hbv-dna,1
hbv dna at enrollment,1
hbv dna by pcr (log10 iu/ml),1
hbv dna category,1
hbv dna level at baseline,1
hbv dna log 10 copies per ml,1
hbv e antigen (hbeag) status at baseline,1
hcc stage,1
hcv,1
hcv coinfection,1
hcv genotype/ subtype,1
hcv genotypes,1
hcv infected,1
hcv rna at entry,1
hcv rna distribution,1
hcv rna level,1
hcv rna level (iu/ml),1
hcv viral load level,1
"hdl-c levels, continuous",1
hdl cholesterol (<40 male or <50 female),1
hdl cholesterol (mg/dl),1
hdl cholesterol (mmol/l),1
hdl cholesterol concentration (mmol/l),1
hdl function,1
hdl particle concentration (total) (âµmol/l),1
hdl particle size (nm),1
hdl particles,1
hdrs baseline score,1
hdv-rna,1
head abbreviated injury score,1
head motion in degrees,1
headache,1
headache days,1
headache intensity,1
health,1
health-related disability,1
health-related quality of life,1
health-related quality of life (sf-36v2-acute form),1
health and labour questionnaire (hlq) absence from work module,1
health assessment question,1
health assessment questionnaire-disability index (haq-di),1
health assessment questionnaire-disability index (haq-di) score,1
health assessment questionnaire (haq),1
health assessment questionnaire disability index,1
health assessment questionnaire disability index (haq-di) score,1
health care system,1
health care utilization: employment status,1
health care visits,1
health insurance plan,1
health insurance type,1
health literacy (sils),1
health literacy (stofhla score),1
health literacy level,1
health quality of life (qol) as assessed by short form 36 (sf-36),1
health quality of life of excellent or very good,1
health related quality of life (hrqol): baseline assessment sf-36 health domain scores (n=126),1
healthcare utilization status: reimbursement type,1
healthcare worker type,1
healthy,1
healthy volunteers,1
hearing level (better ear),1
hearing level (worse ear),1
hearing screening threshold,1
hearing sensitivity (pure tone thresholds),1
heart attack/coronary/mi,1
heart failure-specific quality of life,1
heart failure (hf) stage,1
heart failure cause,1
heart failure duration,1
heart failure etiology,1
heart failure status,1
heart failure/congestive heart failure,1
heart rate (beats/min),1
heart rate (hr) at baseline,1
heart rate (hr) pre-induction,1
heart rate from physical exam (bpm),1
heart rate variability parameter pnn50,1
heart rate variability parameter rmssd,1
heart rate variability parameter sdnn,1
"heart rate, bpm",1
"heart rate, supine",1
"heart rate, upright",1
"heavy drinking days, past 30",1
heel side,1
height-cm,1
"height (cm) (descriptive analysis, only)",1
height (ft),1
height (inches),1
height (n=32),1
"height 143-148 cm, inclusive",1
height age,1
height at baseline,1
height at inclusion,1
height at screening,1
height at visit 1 (week -1),1
height in centimeters,1
height in centimeters (cm),1
height in inches,1
height of the patients,1
height percentile,1
height sd score,1
height standard deviation score (sds) [lyon],1
height standard deviation score (sds) [national center for health statistics (nchs)],1
height z-score,1
height(female),1
height(male),1
"height, cm",1
"height, continuous",1
"height, customized",1
"height, m",1
"height, thyromental distance, sternomental distance, neck length",1
"height,centimeter (cm)",1
height: adult population,1
height: pediatric population,1
helicobacter pylori (h. pylori) infection at the start of takepron treatment,1
helicobacter pylori status,1
hemagglutination inhibition (hi) (egg-derived) - a/h1n1 at day1 (predose) titer,1
hemagglutination inhibition (hi) (egg-derived) - a/h1n1 titer at day 1(pre-vaccination),1
hemagglutination inhibition (hi) (egg-derived) - a/h3n2 titer at day 1 (pre-vaccination),1
hemagglutination inhibition (hi) (egg-derived) - b titer at day 1 (pre-vaccination),1
hemagglutination inhibition (hi) antibody titer (egg-derived)-a/h1n1 strain,1
hematemesis present,1
hematocrit (volume of red blood cells / total volume of blood),1
hematologic disease burden,1
hematologic malignancy,1
hematologic malignancy status,1
hematology - basophils,1
hematology - eosinophils,1
hematology - hematocrit,1
hematology - hemoglobin,1
hematology - lymphocytes,1
hematology - monocytes,1
hematology - neutrophils,1
hematology - platelet count,1
hematology - red blood cell count,1
hematology - white blood cell count,1
hematology: platelet counts,1
hematology: red blood cell (rbc) counts,1
hematology: white blood cell (wbc) counts,1
hematopoietic cell transplantation (hct) refined disease risk index (dri),1
hematopoietic cell transplantation comorbidity index (hct ci),1
hematopoietic cell transplantation specific comorbidity index (hct-ci),1
hematopoietic stem cell transplantation status,1
hemiparetic side: right/left,1
hemisphere of enrollment,1
hemoglobin-corrected carbon dioxide diffusing capacity (dlco) predicted,1
hemoglobin (g/dl),1
hemoglobin (g/l),1
hemoglobin (hb),1
hemoglobin a1c (%),1
hemoglobin a1c (hba1c) %,1
hemoglobin a1c (hba1c) [national glycohemoglobin standardization program (ngsp)],1
hemoglobin a1c (hba1c) at baseline,1
hemoglobin a1c (hba1c) group,1
hemoglobin a1c (hba1c; a1c),1
hemoglobin a1c at baseline (pre-treatment),1
hemoglobin a1c category,1
hemoglobin adjusted diffusing lung capacity for carbon monoxide (dlco) percent predicted,1
hemoglobin at baseline (in g/dl),1
hemoglobin baseline,1
hemoglobin in peripheral blood,1
hemoglobin(normal values range from 130-175 g/l),1
"hemoglobin, continuous",1
"hemoglobin, g/dl, mean (sd)",1
hemophilic arthropathy,1
hemorrhoids,1
heng prognostic criteria,1
heparin-pf4 (platelet factor 4) od (optical density) test results,1
heparin exposure this admission before day 0: use (or non-use) of low molecular weight heparin,1
heparin exposure this admission before day 0: use (or non-use) of unfractionated heparin (ufh),1
hepatic encephalopathy,1
hepatic trauma at baseline,1
hepatic venous pressure gradient (hvpg),1
hepatitic c virus (hcv) rna,1
hepatitis b (hbsag),1
hepatitis b and c status,1
hepatitis b e-antibody status,1
hepatitis b e antibody (hbeab),1
hepatitis b e antibody negative,1
hepatitis b e antigen (hbeag) positive,1
hepatitis b e antigen (hbeag) status,1
hepatitis b early antigen (hbeag) positive participants,1
hepatitis b flares (acute exacerbation),1
hepatitis b infection,1
hepatitis b or c,1
hepatitis b or c co-infection status,1
hepatitis b surface antigen,1
hepatitis b virus (hbv) dna level at baseline,1
hepatitis b virus (hbv) surface antigen status,1
hepatitis b virus dna (hbv dna) by polymerase chain reaction (pcr),1
hepatitis b virus dna by polymerase chain reaction,1
hepatitis b virus surface antigen,1
hepatitis c (hep c anti-hcv),1
hepatitis c antibody,1
hepatitis c antibody status,1
hepatitis c genotype,1
hepatitis c infection,1
hepatitis c infection status,1
hepatitis c or cirrhosis diagnosis,1
hepatitis c positive,1
hepatitis c viral load,1
hepatitis c virus (hcv) antibody status,1
hepatitis c virus (hcv) co-infection,1
hepatitis c virus (hcv) rna (iu/ml),1
hepatitis c virus rna level,1
hepatitis c virus rna levels,1
hepatitis co-infection,1
hepatitis history,1
her-2 fish,1
her-2/neu status,1
her2-status,1
"her2 (fluorescent in situ hybridization [fish] testing), customized",1
her2 (human epidermal growth factor receptor 2) status,1
her2 fish,1
her2 ihc,1
her2 positive,1
her2 receptor status,1
her2 status - positive,1
her2 status: her2/ihc (local assessment),1
her2/neu status,1
her2/neu status (invasive disease only),1
hernia classification,1
heroin craving questionnaire â€“ short form 14 (hcq-sf-14),1
herpes simplex virus type 1 (hsv-1) status,1
herth hope index,1
hga1c,1
hgb<12 g/dl,1
hgba1c ratio,1
hhie-s (hearing handicap inventory for the elderly - screening),1
hi antibody titer (egg-derived)-a/h3n2 strain,1
hi antibody titer (egg-derived)-b strain,1
hi(egg-derived) - a/h3n2 at day1(predose) titer,1
hi(egg-derived) - influenza b(b) at day1(predose) titer,1
high-density lipoprotein,1
"high-density lipoprotein-cholesterol, continuous",1
high-density lipoprotein (hdl),1
high-risk features (participants that did not receive stem cell transplant),1
high-risk features (participants that received stem cell transplant),1
high-risk patients,1
high-sensitivity c-reactive protein (hscrp),1
high-sensitivity crp,1
high blood pressure/hypertension,1
high density lipoprotein-c,1
high density lipoprotein-cholesterol,1
high density lipoprotein (hdl-c),1
high density lipoprotein (hdl),1
high density lipoprotein (hdl)-cholesterol,1
high density lipoprotein (hdl) cholesterol,1
high density lipoprotein (hdl) risk,1
high density lipoprotein cholesterol,1
high density lipoprotein cholesterol (hdl),1
high density lipoprotein cholesterol(normal values range from 1.04-1.55 mmol/l),1
high density lipoprotein(hdl),1
high grade dysplasia/intramucosal carcinoma,1
high order aberration,1
high risk feature,1
high risk for cardiovascular event based on framingham score,1
high school or higher education,1
high sensitivity c-reactive protein,1
high sensitivity c-reactive protein (hs-crp) level,1
high sensitivity c-reactive protein (hscrp) level,1
highest degree,1
highest education,1
highest educational level,1
highest grade completed in school,1
highest household education level,1
highest single donor-specific antibodies (dsa),1
highly selective c-reactive protein (hs-crp),1
highly sensitive c-reactive protein,1
hill grade,1
hirsutism,1
hirsutism score,1
hispanic or latino,1
hispanic origin,1
histologic classification,1
histologic grade (g),1
histologic grade at baseline,1
histologic subtype,1
"histologic subtype, no.",1
histologic type - leiomyosarcoma,1
histologic type of a breast cancer,1
histologic type of cancer,1
histological analysis (who classification),1
histological category for subgroup analyses,1
histological diagnosis,1
histological diagnosis of primary disease,1
histological features,1
histological subtype (dominant pattern),1
histological subtypes of ra-ild,1
histological tumor grade,1
histological type,1
histological types,1
histologies,1
histology-cell type,1
histology - glioblastoma,1
histology activity index,1
histology at diagnosis,1
histology at diagnosis: final anaysis,1
histology at diagnosis: interim analysis,1
histology glioblastoma,1
histology grade,1
histology of ovarian tumor,1
histology of primary diagnosis: adenocarcinoma,1
histology of specimen,1
histology of the tumor,1
histology of tumor,1
histology of urothelial cancer,1
histology subtype,1
histopathologic grade,1
histopathological diagnosis,1
histopathological diagnosis of osteosarcoma at study entry,1
histopathological grading,1
histopathological tumor size,1
"histopathological tumor size, customized",1
historical best fev1 (% predicted),1
historical chronic obstructive pulmonary disease (copd) exacerbations,1
historical fractures,1
history,1
history - age at first episode,1
history - atypical depression,1
history - how long was last major depressive disorder (mdd) episode,1
history - interval between start of current and remission of last mdd episode,1
history - melancholic depression,1
history - number of previous episodes,1
history - seasonal pattern in major depressive disorder (mdd) if â‰¥3 previous mdd episodes,1
history - time since first episode date,1
history - time since most recent episode,1
history av node ablation,1
history left leg pain,1
history low back pain,1
history of abscess,1
history of acne,1
history of adverse reactions following a previous sedation,1
history of alcohol-responsive tremors,1
history of alcohol (drinking alcohol-containing beverages nearly every day),1
history of anaphylaxis to cow's milk (cm),1
history of anaphylaxis to egg,1
history of angina,1
history of atrial ablation,1
history of atrial fibrillation/flutter,1
history of atrial/ventricular arrhythmia,1
history of bisphosphonate administration,1
history of bleed,1
history of bleeding disorder,1
history of bleeding time,1
history of brain metastates,1
history of cardiac dysrhythmias,1
history of cardiovascular disease,1
history of carotid atherosclerosis,1
history of carotid endarterectomy (cea),1
history of carotid restenosis,1
history of cerebro-vascular accident (cva),1
history of cerebrovascular accident,1
history of cerebrovascular accident (cva),1
history of cerebrovascular disease,1
history of chickenpox,1
history of chronic obstructive pulmonary disease (copd),1
history of chronic pelvic pain,1
history of colon polyps,1
history of colorectal cancer,1
history of combat exposure,1
history of coronary artery bypass graft (cabg),1
history of coronary artery bypass grafting (cabg),1
history of coronary artery disease (cad),1
history of coronary interventions,1
history of coronary revascularization (pci or cabg),1
history of cvd,1
history of decompression sickness,1
history of diabetes mellitus type 2,1
history of diabetes stratification factor,1
history of diabetic macular edema treatment,1
history of diverticulitis,1
history of drinking,1
history of drug or alcohol problem,1
history of dyslipidemia,1
history of dysmenorrhea,1
history of dysrhythmias,1
history of eczema,1
history of electrical cardioversion,1
history of electroconvulsive therapy,1
history of epilepsy,1
history of exacerbations,1
history of fever,1
history of fractures in the last 10 years,1
history of gastric bypass at least 3 months post-op with no continuing complications,1
history of gastroesophageal reflux disease,1
history of gi bleeding,1
history of heart attack,1
history of high cholesterol,1
history of hip fracture?,1
history of household contact with abscess,1
history of hyperlipidemia requiring medication,1
history of hypertension requiring medication,1
history of hyptertension,1
history of infectious uveitis,1
history of inhibitor,1
history of ischemic heart disease,1
history of kidney stone,1
history of kidney stones or cancer,1
history of laboratory-confirmed influenza illness in previous influenza season,1
history of left main disease,1
history of left ventricular hypertrophy,1
history of leg ulceration (months),1
history of lipid disorder,1
history of loop electrosurgical excision procedure,1
history of low back pain,1
history of lower limb varices,1
history of lower limb varices surgery,1
history of major bleeding,1
history of mantle or head and neck radiation,1
history of mood disorders,1
history of most recent zoster,1
history of multivessel disease,1
history of ocular hypertension,1
history of osteopenia,1
history of osteoporosis,1
history of other food allergy,1
history of ovarian cystic disease,1
history of panretinal photocoagulation,1
history of percutaneous transluminal angioplasty (pta),1
history of pharmacological cardioversion,1
history of physical abuse,1
history of post-ercp pancreatitis,1
history of pre-study dialysis,1
history of previous major depressive episode,1
history of previous sphincterotomy,1
history of prior breast biopsy,1
history of prior cin/fn and prior cin/fn treatments,1
history of prior clinical events,1
history of prior ductal carcinoma in situ (dcis) or lobular carcinoma in situ (lcis),1
history of prior stroke,1
history of prus,1
history of psychotherapy,1
history of ptsd,1
history of radiotherapy,1
history of receiving an influenza vaccine,1
history of recent chemotherapy,1
history of recurrent acute otitis media,1
history of recurrent stroke,1
history of renal disease,1
history of repeated infections,1
history of revascularization,1
history of rosacea,1
history of seizure,1
history of sexual abuse,1
history of significant bleeding,1
history of sinusitis,1
history of sleep apnea,1
history of smoking and/or alcohol abuse,1
history of smoking habit,1
history of splenomegaly,1
history of stomach ulcer,1
history of stroke (not qualifying event),1
history of suicide attempts,1
history of surgical resection,1
history of tbi (present or absent) - lifetime osu tbi-id,1
history of thrombotic disorder (td),1
history of tobacco exposure,1
history of transient ischemic attack (tia) or cerebrovasular accident (cva),1
history of transseptal puncture,1
history of treatment for drug/alcohol,1
history of tuberculosis (tb) in mother,1
history of type 1 diabetes mellitus,1
history of type 2 diabetes mellitus,1
history of ulcers,1
history of upper extremity fibromuscular dysplasia (fmd),1
history of urinary tract infections (utis),1
history of urinary tract surgery,1
history of vaginal varicosities,1
history of verbal abuse,1
history of vertebrobasilar occlusive disease,1
history of vt/vf,1
history of vulvar varicosities,1
history or concomitant medical conditions,1
history or prolapse surgery,1
history right leg pain,1
history suggestive of atopy,1
"history, age at first episode",1
"history, met diagnosis of major mood disorder (mdd)",1
"history, number of previous mdd episodes",1
"history, time since most recent mdd episode",1
hiv-1 cerebrospinal fluid (csf) rna viral loads (vl),1
hiv-1 plasma ribonucleic acid (rna) viral loads,1
hiv-1 rna (copies/ml) category,1
hiv-1 rna (viral load),1
hiv-1 rna <50 copies/ml,1
hiv-1 rna categorical,1
hiv-1 rna continuous,1
hiv-1 rna quantitation at entry,1
hiv-1 rna viral load,1
hiv-1 viral load,1
hiv-associated neurocognitive disorder (hand) status,1
hiv-rna,1
hiv-rna at arv start,1
hiv diagnosis,1
hiv dna,1
hiv duration,1
hiv infection,1
hiv positive,1
hiv positive participants,1
hiv positivity,1
hiv rna (copies/ml) at study entry,1
"hiv rna categories (n=3, 2, 9)",1
hiv rna category,1
hiv rna level,1
hiv rna level at baseline,1
hiv rna results (copies/ml),1
hiv rna viral load category,1
"hiv seropositive with viral load < 10,000",1
hiv serostatus,1
hiv status - lifetime,1
hiv status disclosure to anyone,1
hiv status knowledge before pregnancy,1
hiv viral load <40 copies/ml,1
"hiv, #",1
hl,1
hla dr allele - both dr3 and dr4,1
hla dr allele - dr3 only,1
hla dr allele - neither dr3 nor dr4,1
hla dr4 allele only,1
hla mismatch,1
hla typing match score - 1st cord,1
hla typing match score - 1st cord to 2nd cord,1
hla typing match score - 2nd cord,1
hla typing match score - host vs graft (hvg) direction,1
hlq impediments to work module,1
hlq reduced productivity at paid work module,1
hlq unpaid work module: help received with unpaid work,1
hmg coa-reductase,1
hodgkin lymphoma status after end of frontline therapy,1
hodgkin versus non-hodgkin lymphoma,1
"hoehn-yahr ""on""",1
hoehn-yahr off medication,1
hoehn-yahr on medication,1
hoehn-yahr scale,1
"hoehn-yahr, ""on""",1
hoehn & yahr,1
hoehn & yahr scale,1
hoehn and yahr score,1
hollingshead- index of social position,1
hollingshead socioeconomic category,1
holter monitor,1
homa-beta cell,1
homa-î²,1
homa-ir (homeostatic model assessment - insulin resistance),1
homa-s,1
homa at the begining of product intake,1
homa index,1
homa2 %b,1
homa2 %s,1
homa2 ir,1
home asthma medication,1
homeless in last 5 years,1
homeostasis model assessment beta cell index (homa-î²),1
homeostasis model assessment of insulin resistance (homa-ir),1
homeostasis model assessment of insulin resistance (homa-r),1
homeostasis model of assessment - insulin resistance (homa-ir),1
homeostatic assessment of insulin resistance,1
homeostatic model assessment (homa),1
homeostatic model assessment of beta-cell function (homa-beta),1
homeostatic model assessment of insulin resistance (homa-ir),1
"homo receptor positive, her2 negative",1
homocysteine,1
hopkins verbal learning test t-score,1
hopkins verbal memory testâ€“revised,1
horizontal cup to disc ratio,1
hormonal status,1
hormone replacement therapy,1
hormone use,1
hospital,1
hospital-acquired pru,1
hospital admissions during year prior to index admission,1
hospital anxiety and depression,1
hospital anxiety and depression (had) â€“ anxiety subscale,1
hospital anxiety and depression scale - anxiety subscale,1
hospital anxiety and depression scale (hads) - anxiety subscale score,1
hospital anxiety and depression scale (hads) - depression subscale score,1
hospital anxiety and depression scaleâ€”anxiety subscale (hads-a),1
hospital levels,1
hospitalisation day,1
hospitalizations,1
hospitalizations for respiratory symptoms in prior year,1
hospitalizations in past year,1
hospitalized as a result of diagnosis,1
hospitalized in past 12 months,1
host cytomegalovirus (cmv) status,1
hostility towards women,1
hot flash bother,1
hot flash related daily interference,1
hot flash related daily interference scale (hfrdis),1
hot flash score,1
hot flash severity,1
hot flashes,1
hours from intubation to randomization,1
hours of burnout training in past year (staff),1
hours of motivational interviewing training in past year (staff),1
hours/week spent,1
household income as percent of federal poverty level,1
"household income less than $50,000 per year",1
household income per month,1
"household income: not available/refused/don't know, <$50,000, >$50,000",1
housing (clients),1
housing experience (responded yes),1
how long in present relationship,1
hpv genotyping,1
hpv status,1
hpv/p16 status,1
hrsd-17,1
hs-c-reactive protein (hs-crp) serum levels,1
hscl-20 depression severity,1
hscrp,1
hscrp (mg/l),1
hsv-2 infection,1
"hsv-2, #",1
human epidermal growth factor receptor 2 (her-2) status,1
human epidermal growth factor receptor 2 (her-2/neu),1
human epidermal growth factor receptor 2 (her-2/neu) status,1
"human epidermal growth factor receptor 2 (her2) (immunohistochemistry [ihc] scoring), customized",1
human epidermal growth factor receptor 2 (her2) result,1
human epidermal growth factor receptor 2 (her2/neu),1
human epidermal growth factor receptor 2 expression status,1
human epidermal growth factor receptor 2 positivity (her2+),1
human immunodeficiency ribonucleic acid (hiv rna) categories,1
human immunodeficiency virus (hiv) ribonucleic acid (rna) viral load (log10 c/ml),1
human immunodeficiency virus ribonucleic acid (hiv rna),1
human immunodeficiency virus ribonucleic acid (hiv rna) distribution,1
human immunodeficiency virus type 1 (hiv-1) ribonucleic acid (rna),1
human leucocyte antigen (hla) typing match score - gvh direction,1
"human leucocyte antigens (hla) class i (a, b) and class ii (dr) incompatibilities",1
human leukocyte antigen (hla) b27 positive status,1
human leukocyte antigen (hla) match type,1
human papillomavirus type 11 (hpv11) serostatus,1
human papillomavirus type 16 (hpv16) serostatus,1
human papillomavirus type 18 (hpv18) serostatus,1
human papillomavirus type 6 (hpv6) serostatus,1
"hunt and hess scale (n=10, 13)",1
hvpg (mmhg),1
hydration,1
hydronephrosis,1
hydronephrosis present,1
hydroxyurea use at baseline,1
hyper-gender ideology,1
hyperactivity score (clinical scale),1
hyperlipidemia history,1
hyperlipidemia requiring medication,1
hyperlipidemia status,1
hyperliporoteinemia,1
"hypernatremic, n",1
hyperpigmentation,1
hypertension (htn),1
hypertension condition,1
hypertension history,1
hypertension medication,1
hypertension risk,1
hypertension stage,1
hypertension status,1
hypertension treatments prescribed prior to initiation of treatment,1
hypertensive,1
hyperthyroidism,1
hypochlorhydric,1
hypoglycemia percentage of time <70 mg/dl average by group,1
"hyponatraemia, n",1
hypophosphatasia (hpp) phenotype,1
hypophosphatasia phenotype,1
hypopigmentation,1
hypotension,1
hypothalamus mean dose (d50),1
hypothyroidism,1
hypothyroidism/hyperthyroidism,1
î²-2 microglobulin,1
î²-agonist use,1
î²-blocker,1
î² â€“ blocker therapy,1
î²2-microglobulin,1
ib sub-type,1
"ibs-signs and symptoms score, categorical",1
ibs-sss score,1
ibs-subtype,1
ibs-symptom severity scale score,1
ibs symptoms at baseline/ randomisation),1
icd implanted prior to the ablation procedure,1
ice water-induced cold pain and its after-sensation,1
ics (inhaled cortico steroid) use at randomization,1
ics (inhaled corticosteroids) use,1
ics dose (inhaled corticosteroid dose),1
ics pretreatment dose,1
ics/laba therapy,1
icu admission at baseline,1
icu annual patient volume,1
icu history,1
icu mortality rate,1
icu status at randomization,1
ida-hba1c (%),1
ideal body weight,1
ideel treatment inconvenience,1
ideel treatment satisfaction scores,1
ideel treatment score,1
identification of target area for efficacy evaluation,1
ids-c30 item 6 score,1
"if only temporary, removal time of central venous catheter",1
"if taking sleep aids, how frequent?",1
iga,1
ige,1
ige (ku/l),1
igf-1,1
igf-1 sd score,1
igf-i standard deviations score (sds),1
igf binding protein-3 sd score,1
igfbp-3 sds,1
igfr,1
igg antibody level (eu/ml),1
il-13,1
il-28b genotype,1
il-28b rs1297860 genotype,1
il-8,1
ild participant baseline qol score based on clinical copd questionnaire (ccq),1
illness duration in years,1
illness management and recovery scale,1
illness type,1
imaging modality,1
imatinib dose at baseline,1
immune compromised at study entry,1
immune response at enrollment,1
immunocytochemical expression of ki-67,1
immunoglobulin e,1
immunoglobulin heavy chain (igh) type,1
immunoglobulin heavy chain variable region (ighv) mutation status,1
immunoglobulin light chain (igl) type,1
immunoglobulin subtype,1
immunohistochemical subtype,1
immunosuppression,1
immunosuppression therapy other than prednisone at screening,1
immunosuppressive therapy prior to transplant,1
impact of dry eye on everyday life (ideel) treatment effectiveness score,1
impact of dry eye on everyday life symptom-bother (ideel sb) score,1
impact of symptom burden to daily life (by md anderson symptom inventory-korean),1
impact on family scale (fabel): total impact score,1
impact probability of poor outcome,1
impaired fasting glucose,1
impaired fasting glucose (ifg) status,1
impaired fasting glucose and impaired glucose tolerance,1
impairment function,1
"implant distribution maxilla, mandible",1
implant stability measured by resonance frequence analysis,1
implantable cardioverter defibrillator,1
importance of quitting,1
importance of quitting smoking,1
importance of quitting to self,1
improvement in abdominal pain,1
impulsivity score (clinical scale),1
in-patient number,1
in-patient surgery,1
in vitro fertilization (ivf) with this pregnancy,1
inadequate response/intolerance to prior anti-tumor necrosis factor (tnf) agent therapy,1
inattention score (clinical score),1
incidence of ovarian hyperstimulation,1
incidence of prior neoadjuvant or adjuvant therapy (>6 months),1
incision length,1
incisors,1
inclusion body myositis-functional rating scale (ibmfrs) score,1
income categories,1
income category,1
income less than $20k,1
income level,1
incomplete evacuation,1
incontinence,1
incontinence-specific quality of life,1
incontinence at baseline of period 1,1
incontinence episodes/24 hour,1
incontinence episodes/24 hours,1
incontinence frequency,1
incontinence quality of life scale (iqol),1
incontinence severity,1
incontinent,1
incontinent episodes during 24 hours,1
incontinent episodes/day,1
increased tear film,1
index acute coronary syndrome (acs) event type,1
index admission was for st-segment elevation myocardial infarction [stemi],1
index gcs score at randomization,1
index knee,1
index lesion,1
index lesion ulceration area,1
index stroke location,1
index stroke type,1
index ulcer duration (months),1
indiana university school of medicine site,1
indication for cardiac resynchronization therapy defibrillator (crt-d),1
indication for colonoscopy procedure,1
"indication for colonoscopy procedure (screening, surveillance or diagnostic)",1
indication for ercp,1
indication for implantable cardioverter defibrillator (icd),1
indication for lung transplant,1
indication for lvad,1
indication for magnetic resonance imaging (mri),1
indication for mastectomy (antisepsis side),1
indication for mastectomy (control side),1
indication for operation,1
indication for pci,1
indication for placement,1
indication for resection,1
indication for sedation,1
indication for stress testing,1
indication for the surgery,1
indication for the visit,1
indication for transplantation,1
indication for transseptal puncture,1
indication for vaccination,1
indication of catheter,1
indication of induction of labor,1
indication of severe sickle cell disease,1
indications,1
indications for endocrine therapy,1
indications for endoscopic retrograde cholangiopancreatography (ercp),1
indications for stress test,1
indications for surgery,1
indications for the angelâ® catheter placement,1
indigestion screening,1
indocyanine green used to improve visualization,1
indoor tanning attitudes scale,1
indoor tanning frequency,1
indoor tanning intentions scale,1
indoor tanning skin damage susceptibility scale,1
indoor tanning social approval scale,1
indoor tanning willingness scale,1
induction agent,1
induction indication,1
induction to delivery time,1
indwelling device use,1
infant birth weight,1
infant gestational age at delivery,1
infantile hemangioma localization,1
infants <= 24 months of age at enrollment and with a diagnosis of bpd,1
infants <= 24 months of age at enrollment and with hschd,1
infants born <= 35 weeks gestational age and <= 6 months of age at enrollment,1
infants gestational age,1
infarct-related artery,1
infection,1
infection by chlamydia trachomatis,1
infection by neisseria gonorrhoeae,1
infection by trichomonas vaginalis,1
infection in last 6 months,1
infection site,1
infection source,1
infection type,1
infections in the wound at baseline,1
infectious complications,1
infertility,1
infertility duration,1
infertility mean score,1
infertility period,1
inflammation grade,1
inflammatory bowel disease flares in the past 12 months,1
inflammatory bowel disease questionnaire (ibdq),1
inflammatory bowel disease questionnaire (ibdq) score,1
inflammatory bowel disease type,1
inflammatory breast cancer (ibc) or non-ibc locally advanced breast cancer (labc),1
inflammatory lesion (il) counts at baseline,1
inflammatory lesions,1
inflammatory marker,1
inflammatory markers in blood,1
influenza diagnostic test by local testing,1
influenza infection within 5 years,1
influenza type/subtype by central testing,1
influenza vaccination history within 1 year,1
information,1
information processing function domain z-score,1
infusion system spasticity treatment sub-indication,1
inhalation injury,1
inhaled corticosteroid,1
inhaled corticosteroid use at baseline,1
inhaled corticosteroids,1
inhaled corticosteroids or inhaled corticosteroids / long-acting beta 2-agonist use,1
inhaled glucocorticosteroids (ics) pretreatment,1
inhaled glucocorticosteroids (igcs) dose at study entry.,1
inhaled nitrite use in last 3 months,1
inhaled tobramycin use in the previous 12 months,1
"inhibition, cwi (color word interference)",1
inhibitory control (mean % error),1
initial asthma control test (act),1
initial asthma quality of life questionnaire,1
initial bmi,1
initial bmi (kg/m^2),1
initial c-reactive protein,1
initial childbearing age,1
initial daily dose of blopress,1
initial diagnosis of primary tumor (t),1
initial diagnosis: distant metastasis (m),1
initial diagnosis: regional lymph nodes (n),1
initial gait speed,1
initial heart rate (hr),1
initial hematoma volume,1
initial histological diagnosis,1
initial illness severity rating,1
initial intervention to cross clamp,1
initial karnovksy performance score (kps),1
initial m stage at diagnosis,1
initial modified sartorius score,1
initial n classification staging at diagnosis,1
initial procedure,1
initial t classification staging at diagnosis,1
initial treatment type (surgery or radiation),1
initial tumor diagnosis,1
initial tumor location,1
initial viral load,1
initial weight (kg),1
injectable contraception use,1
injection volume,1
injury characteristics: side of fracture,1
injury classification,1
injury level,1
injury location - n(%),1
injury severity score (iss): number of severely injured,1
injury type - n(%),1
inotrope score,1
insomnia severity,1
inspiratory capacity,1
inspirometry volume,1
institution,1
institutional intent to use brachytherapy,1
instrumental activities of daily living (iadl),1
instrumental activities of daily living (iadl) summary score,1
insulin-like growth factor-i (igf-i),1
insulin-like growth factor 1,1
insulin-like growth factor 1 (igf-1),1
insulin-like growth factor 1 (igf-1) level,1
insulin-like growth factor i,1
insulin (uiu/ml),1
insulin auc,1
insulin auc(0:30-4:30h),1
insulin dose group,1
insulin glargine dose,1
insulin infusion,1
insulin level,1
insulin levels in ogtt,1
insulin modality,1
insulin regimen prior to preop arrival,1
insulin requiring diabetes,1
insulin resistance,1
insulin resistance index (homa-r),1
insulin resistance: homeostatic model assessment (homa),1
insulin secretagogues,1
insulin sensitivity (inverse of fasting insulin from ogtt),1
insulin sensitivity (si),1
insulin therapy before admission,1
insulin treatment,1
insulin use (units/kg per day),1
insulin user,1
insulin users,1
insulin(normal values range from 2.08-10.9 î¼u/ml),1
insulin/proinsulin ratio,1
insulinemia,1
insulinogenic index from ogtt,1
insurance (any type),1
insurance coverage,1
insurance status (more than one may apply),1
insurance status (uninsured),1
insured,1
intact cervix?,1
intact primary tumor,1
intact uterus?,1
intelligence quotient (iq),1
intelligence quotient (iq) <70,1
"intend to quit smoking, next month",1
intended pci performed,1
intended pregnancy,1
intensity of baseline hae attack,1
intensive care unit (icu) type,1
intentions to intervene,1
inter-episode recovery,1
interest in spirituality,1
interferon classification,1
interferon eligibility,1
interleukin-6,1
interleukin-6 (il-6),1
interleukin 28b (il-28b) genotype,1
interleukin 6,1
interleukin(il)-6,1
intermediate cytogenetics (at initial diagnosis),1
internal anal sphincter defect extent,1
internal anal sphincter defects,1
internal carotid artery (ica) stenosis â‰¥ 50%,1
internation prostate symptom score (ipss),1
international consultation on incontinence questionnaire-short form (iciq-sf) score,1
international federation of gynecologic and obstetrics (figo) stage,1
"international federation of gynecologic and obstetrics (figo), clinical staging, for cervical carcin",1
international federation of gynecology & obstetrics (figo) disease stage,1
international federation of gynecology and obstetrics (figo) stage at initial surgery,1
international federation of gynecology and obstetrics(figo) ovarian cancer staging at diagnosis,1
international index of erectile function (iief),1
international index of erectile function (iief) - erectile dysfunction severity,1
international index of erectile function (iief) - erectile function domain,1
international index of erectile function (iief) erectile function (ef) domain,1
international normalization ratio,1
international normalized ratio,1
international physical activity questionnaire short form,1
international prognostic index (ipi) risk group,1
international prognostic index (ipi)],1
international prognostic scoring system (ipss) investigator determined,1
international prognostic scoring system (ipss) risk classification,1
international prognostic scoring system (ipss) total score,1
international prognostic scoring system risk (ipss),1
international prostate symptom score,1
international prostate symptom score (ipss) at baseline,1
"international prostate symptoms score, storage subscore",1
"international prostate symptoms score, total",1
"international prostate symptoms score, voiding subscore",1
international renal interest society (iris) ii score at baseline,1
international staging system,1
international staging system (iss) at study entry,1
international staging system (iss) stage of myeloma on diagnosis,1
international staging system (iss); stage (n),1
internet use,1
internet user,1
interocular difference in distance visual acuity,1
interocular eye visual acuity difference at randomization,1
interocular pressure (mmhg),1
interval between magnetic resonance imaging and prostatectomy,1
interval between mi and randomization,1
interval from diagnosis to transplantation,1
interval from transplantation to start of study product administration,1
interval since last transplant,1
intervention requested before enrollment,1
interventions,1
interview language,1
intra-ocular pressure (iop),1
intra-operative bupivacaine liposome injectable suspension,1
intra-operative ketorolac,1
intra-operative methadone,1
intra-operative total opioid,1
intra-thoracic metastasis only,1
intra ocular pressure,1
intracerebral hematoma volume,1
intracerebral hematoma volume greater than 30 cm3,1
intraocular pressure - cataractous eye,1
intraocular pressure - fellow eye,1
intraocular pressure (iop),1
intraocular pressure (iop) - study eye,1
intraocular pressure (iop) at hour 2,1
intraocular pressure (mm hg),1
intraocular pressure left eye,1
intraocular pressure right eye,1
intraocular visual acuity difference at randomization,1
intraoperative bicarbonate,1
intraoperative colloid fluid,1
intraoperative cristalloid fluid,1
intraoperative fentanyl (mcg),1
intraoperative fill volume (antisepsis side),1
intraoperative fill volume (control side),1
intraoperative findings,1
intraoperative fresh frozen plasma transfusion,1
intraoperative management strategy,1
intraoperative mean arterial blood pressure,1
intraoperative oxygen saturation,1
intraoperative partial pressure of arterial oxygen,1
intraoperative partial pressure of carbon dioxide,1
intraoperative ph,1
intraoperative urine output,1
intraoral neuropathy,1
intratesticular dihydrotestosterone (itt-dht),1
intratesticular testosterone (itt-t),1
intravenous (iv) drug history,1
intravenous (iv) drug use,1
intravenous drug history,1
intravenous drug use history,1
intravenous tissue plasminogen activator (t-pa) in patients with cerebral ischemia,1
intraventricular hemorrhage,1
intubated pre-operatively,1
intubation in delivery room,1
inventory of depressive symptomatology,1
inventory of depressive symtomatology-self report (ids-sr),1
investigational drugs,1
investigator's global assessment (iga),1
investigator-assessed sum of daytime and nighttime pruritus/itch scores at baseline,1
investigator-rated individual target behaviors (itb-inv): frequency score,1
investigator-rated individual target behaviors (itb-inv): intensity score,1
investigator assessed acute symptomatic deep vein thrombosis (dvt) of leg or pulmonary embolism (pe),1
investigator assigned performance status,1
investigator global assessment (iga),1
investigator global assessment of acne,1
investigator global assessment of acne severity,1
investigator global assessment of disease activity (0 to 4 - likert scale),1
investigator global health assessment,1
investigator reported body mass index (bmi),1
investigator specialty,1
"investigator(ir) compared to participant(pa)-derived risk level assessment of misuse,abuse,diversion",1
investigatorâ€™s global assessment (iga),1
investigatorâ€™s global assessment (iga) score,1
involvement of >4 nodal sites,1
involvement of regional lymph nodes,1
"iop at baseline, mean+sem (mmhg)",1
ipi risk category,1
ipmn type,1
ipss quality of life (qol) score,1
ipss quality of life score(qol) score,1
ipss risk category,1
ipss storage score,1
ipss voiding score,1
ipth,1
iq,1
iq score,1
iraq or afghanistan veteran,1
iris color,1
iris color (study eye),1
"irls rating scale total score, continuous",1
irritability,1
irritable bowel disease questionnaire (ibdq) score at baseline,1
irritable bowel syndrome - quality of life (ibs-qol),1
ischaemic heart disease or peripheral artery disease,1
ischemic heart disease,1
isga,1
isga-chronic hand dermatitis,1
ishak,1
isi total score,1
islet equivalents infused,1
islet yield,1
ism risk group,1
isometric core muscular endurance,1
isometric lumbar extension muscular strength,1
isotypes,1
iss (injury severity score),1
"iss score (n=30, 27)",1
iss staging,1
itch numeric rating scale (nrs),1
itching score,1
items that require careful examination before vaccination,1
iud type,1
"iv drug history, categorical",1
iv drug use,1
iv site,1
jak-2v617f,1
jankovic blepharospasm rating scale,1
janus kinase 2 (jak2) mutation,1
japan stratification factor,1
jaw,1
jia medications,1
job status,1
jugular venous pressure elevated,1
juniper asthma control,1
juvenile idiopathic arthritis (jia),1
jvc titer at screening,1
kansas city cardiomyopathy overall score,1
kansas city cardiomyopathy questionnaire: overall summary score,1
karnofsky-index,1
karnofsky index,1
karnofsky index (%),1
karnofsky perfomance status (kps),1
karnofsky performance,1
karnofsky performance scale,1
karnofsky performance scale index status,1
karnofsky performance score (kps),1
karnofsky performance status (baseline kps)[1],1
karnofsky performance status (kps) at registration,1
karnofsky performance status (kps) score,1
karnofsky performance status at baseline,1
karnofsky performance status score,1
karnofsky/lansky performance status,1
karnosky performance status,1
katz index,1
kellgren-lawrence grade,1
kellgren-lawrence score,1
kellgren lawrence oa grade,1
kellgren lawrence oa grade >=3 in either knee,1
keratometric power - cataractous eye,1
keratometric power - fellow eye,1
ki-67 (cellular marker for proliferation),1
kiddie schedule for affective disorders - affective disorder,1
kiddie schedule for affective disorders - anxiety disorder,1
kiddie schedule for affective disorders - attention-deficit/hyperactivity disorder (adhd) subtypes,1
kiddie schedule for affective disorders - conduct disorder,1
kiddie schedule for affective disorders - oppositional defiant disorder,1
kiddie schedule for affective disorders - tic disorder,1
kiddie schedule for affective disorders and schizophrenia for school aged children-pl,1
kidney disease,1
kidney failure,1
kidney function,1
kidney stone procedures,1
kidney transplant recipient,1
kidney volume,1
killip class,1
kinesthesia,1
kirsten rat sarcoma-2 virus (kras) mutation status,1
kirsten rat sarcoma (kras),1
kirsten rat sarcoma (kras) mutation status,1
kirsten rat sarcoma gene (kras) mutation status,1
knee effusion,1
knee flexion,1
knee flexion angle,1
knee pain severity with ambulation,1
knee range of motion,1
knee replacement participant,1
knee score,1
knee society score,1
knee strength,1
know someone who died by suicide,1
knowledge about hearing conservation,1
knowledge about immunosuppressives,1
knowledge of hpv vaccine,1
knowledge of informed consent to have sex,1
known coronary artery disease,1
known hereditary renal cell carcinoma mutation,1
koos - adl,1
koos - pain,1
koos - qol,1
koos - sport/rec,1
koos - symptoms,1
koos pain score,1
korean version of attention-deficit/hyperactivity disorder (adhd) rating scale (k-ars) score,1
kps scores,1
kras,1
kras genotype,1
kras mutation,1
kras mutation status at baseline,1
ks stage,1
ksq anger-hostility score,1
kumamoto score,1
kyphosis,1
l- dopa,1
l2-l4 (bmd),1
l2-l4 bmd t-score,1
"l2-l4 bmd t-score, categorical",1
la classification grade,1
lab-score value,1
laba (long acting beta agonist) use at randomization,1
laba / ics use at randomization,1
laba dose (long-acting beta agonists),1
laboratory confirmed influenza,1
laboratory tests,1
laceration length,1
laceration length (cm),1
laceration location: above neck,1
laceration location: below neck,1
lactate dehydrogenase (ldh) levels,1
lactate dehydrogenase (ldh) status,1
lactate dehydrogenase (serum),1
lactate levels,1
lactic dehydrogenase,1
lad coronary vessel,1
landmark grade,1
language concordance with primary care provider,1
language of preference,1
language preference,1
language spoken most often,1
language spoken with friends and family,1
large hdl particles,1
largest lesion size,1
laser doppler imaging blood flow,1
last ingestion of clear liquids (hours),1
last ingestion of solids (hours),1
laterality,1
laterality of acute otitis media,1
laterality of acute otitis media (aom),1
laterality of limb involved,1
latest pre-art viral load,1
lcx coronary vessel,1
ldh elevation,1
ldl-c (1.27-3.12 for normal; ï¼œ2.59 at high risk factors; ï¼œ1.80 at very high risk factors),1
ldl-c (low-density-lipoprotein-cholesterol),1
"ldl-c, continuous",1
ldl-c/hdl-c ratio,1
ldl cholesterol (mg/dl),1
ldl cholesterol (mmol/l),1
ldl cholesterol categories,1
lean %,1
lean body weight,1
lean mass (kg),1
learning skill test (lst) total score,1
leeds enthesitis index,1
leeds sleep evaluation questionnaire (lseq),1
left atrial diameter (lad),1
"left atrial volume index, ml/m^2, mean (sd)",1
left ventricle ejection fraction (echo),1
left ventricular (lv) ejection fraction (%),1
"left ventricular (lv) mass index, g/m^2, mean (sd)",1
"left ventricular (lv) mass,g, mean (sd)",1
left ventricular (lv) measurement,1
left ventricular ejection fraction (%),1
left ventricular ejection fraction (lvef) measurement,1
"left ventricular ejection fraction, %, mean (sd)",1
left ventricular end-diastolic volume (lvedv),1
left ventricular end diastolic pressure (lvedp),1
left ventricular end diastolic volume (lvedv),1
left ventricular end systolic volume (lvesv),1
left ventricular function,1
left ventricular hypertrophy,1
left ventricular mass index (lvmi),1
left ventricular mass indexed to height (lvmi),1
legal knowledge of rape/assault,1
leiomyoma distribution,1
lenalidomide (len) as most recent therapy,1
length (cm),1
length of abstinence from all substances,1
length of barrett's segment,1
length of chemoprophylaxis,1
length of continuous androgen deprivation therapy,1
length of current episode,1
length of current episode in months,1
length of current episode in years,1
length of current illness episode,1
length of current major depressive episode,1
length of current schizophrenic episode,1
length of diagnosis,1
length of gestation,1
length of hospital stay (days),1
length of infertility,1
length of initial hospital stay,1
length of marriage,1
length of menstrual cycle,1
length of operation,1
length of psychiatric illness,1
length of rosacea,1
length of time between initial presence current lesions and treatment,1
length of time diagnosed,1
length of time in treatment prior to delivery,1
length z score,1
lengths of ost before study entry,1
lens status (on clinical exam),1
lens status phakic (clinical examination),1
lesion age,1
lesion characteristic-diameter stenosis,1
lesion characteristic-target vessel,1
lesion characteristic: diameter stenosis,1
lesion characteristics: american college of cardiology (acc)/american heart association (aha),1
lesion characteristics: lesion length,1
lesion characteristics: pre-procedure thrombolysis in myocardial invarction (timi) flow,1
lesion characteristics: reference vessel diameter,1
"lesion characteristics: reference vessel diameter, minimum lumen diameter, length",1
lesion characteristics: size,1
lesion characteristics:lesion based,1
lesion classification: american college of cardiology (acc)/ american heart association (aha),1
lesion composition,1
lesion count,1
lesion data - duration since onset,1
lesion data - number of lesions,1
lesion location (vessel),1
lesion measurements,1
lesion response to induction phase,1
lesion side,1
lesion size (greatest linear dimension),1
lesion size(long axis),1
lesion size(short axis),1
lesion sizes,1
lesion totally occluded,1
lesion type,1
lesional volume,1
lesions that underwent eus-fna,1
"let: lidocaine, epinephrine and tetracaine gel use",1
lethargy,1
leucocyte count,1
leukemia stage,1
leukocyte count,1
leukocytes,1
leukocytosis,1
level of 25-hydroxyvitamin d,1
level of ca19.9,1
level of education in years,1
level of provider performing procedure,1
level of training,1
level(s) treated,1
levels of neck dissection,1
levodopa daily dose,1
levodopa equivalent/day,1
lf microfilaria prevalence,1
lh at screening,1
lh/fsh ratio,1
lidocaine use,1
liebowitz self-rated disability scale,1
liebowitz self-rated disability scale (lsdsr),1
liebowitz social anxiety scale,1
liebowitz social anxiety scale (lsas),1
liebowitz social anxiety scale (lsas) - baseline,1
life-space assessment score,1
life-stage of disease onset,1
lifetime alcohol or substance abuse or dependence,1
lifetime cocaine use (years),1
lifetime depression,1
lifetime episodes of depression,1
"lifetime episodes of depression diagnosed (n=335, n=0, n=301)",1
lifetime kidney stone episodes,1
lifetime major depression (m.d.),1
lifetime risk,1
lifetime trauma exposure,1
lifetime trauma exposure event type,1
light-chain subtype,1
"likert scale rating of mood, anxiety, sleep, pain, and stiffness",1
lilie score at diagnosis (myelofibrosis only),1
lille score,1
limb occlusion pressure,1
limited cutaneous scleroderma,1
limited mobility,1
line of current endocrine therapy,1
line of therapy,1
lines of prior therapy,1
lingual plate thickness,1
lipid-altering drug use,1
lipid-lowering medication adherence,1
lipid-lowering medications per patient,1
lipid-lowering therapy,1
lipid lowering medications,1
lipid modification type/dose at run-in,1
lipids and lipoproteins at baseline,1
lipids: hdl cholesterol,1
lipids: ldl cholesterol,1
lipids: total cholesterol,1
lipids: triglycerides,1
lipodystrophy,1
lipoperoxides,1
lipoprotein (a),1
lipoprotein(a),1
lissamine green staining score â± sd,1
little irrgularity at t0,1
live births,1
lived or traveled internationally,1
liver abnormalities at diagnosis,1
liver biopsy stage,1
liver density,1
liver enzymes,1
liver enzymes: alanine aminotransferase,1
liver enzymes: alkaline phosphatase,1
liver enzymes: aspartate aminotransferase,1
liver enzymes: î³-glutamyl transpeptidase,1
liver enzymes: total bilirubin,1
liver fat percentage by magnetic resonance imaging (mri - dixon method),1
liver function test: alanine aminotransferase (alt),1
liver function test: aspartate aminotransferase (ast),1
liver histology findings: biopsy length,1
liver histology findings: definite steatohepatitis,1
liver histology findings: fibrosis stage,1
liver histology findings: hepatocellular ballooning score,1
liver histology findings: lobular inflammation score,1
liver histology findings: portal inflammation score,1
liver histology findings: steatosis score,1
liver histology findings: total nafld activity score,1
liver involvement,1
liver iron concentration,1
liver iron concentration > 8mg/g dry weight,1
liver metastases,1
liver metastases by principal investigator,1
liver only transplant,1
liver sequential organ failure assessment (sofa) score,1
lives alone,1
lives with other smoker(s),1
living alone,1
living arrangements,1
living children,1
living kidney donor,1
living setting pre-stroke,1
living situation at baseline,1
living status,1
living with a smoker,1
living with family,1
living with pulmonary hypertension (lph),1
ln urine benzoylecgonine conc,1
ln(2-hour postprandial insulin),1
ln(fasting insulin),1
ln(fasting plasma glucose(fpg)),1
ln(hba1c),1
ln(low density lipoprotein(ldl)),1
loa loa microfilarial level,1
loa microfilarial count,1
local hba1c,1
local recurrence,1
local treatment,1
localisation of adenocarcinoma,1
localisation of non-target lesions,1
localisation of target lesions,1
localized urticaria,1
locally advanced,1
location in washington state,1
location of breast cancer,1
location of cyst,1
location of enrollment,1
location of hemorrhage,1
location of infection,1
location of isolated loco-regional recurrence (ilrr),1
location of lesions,1
location of metastasis,1
location of primary operation,1
location of target lesion,1
location of voc,1
locations of current pressure ulcers,1
log 10 transformed human immunodeficiency virus-1 ribonucleic acid (hiv-1 rna),1
log 3-nitrotyrosine (3nt),1
log interleukin (il)-18,1
log of treadmill exercise time,1
log plasma 4-hydroxynonenal (hne),1
log protein carbonyl (pc),1
log tnf alpha,1
log tnf receptor 1,1
log tnf receptor 2,1
log viral load,1
log10 hbv dna by pcr,1
log10 hcv rna,1
log10 hiv-1 rna,1
log10 hiv rna level,1
log10 hiv viral load,1
log10 pseudomonas aeruginosa (pa) colony-forming units (cfus) in sputum,1
log10 viral load,1
log10(rna),1
logarithm of the minimum angle of resolution (logmar) of the study eyes,1
logistic euroscore,1
long-acting muscarinic antagonist(s) (lama) use,1
long-lasting af,1
long acting beta agonist,1
long acting beta agonists,1
long acting muscarinic antagonists,1
longest diameter of ileocecal largest open ulcer,1
longest tumor diameter,1
lorazepam requirement 24 hour prior to study entry,1
lordosis,1
los angeles (la) classification grade for erosive esophagitis (ee),1
los angeles motor scale at hospital arrival,1
loss of motivated behavior ham-d factor,1
lost to follow up (considered non-quitters),1
low-density lipoprotein-c:high-density lipoprotein-c ratio,1
"low-density lipoprotein-cholesterol, continuous",1
low-density lipoprotein (ldl),1
low-density lipoprotein (ldl) lower than 2.5 millimole/liter (mmol/l),1
low density cholesterol (ldl-c),1
low density lipoprotein-cholesterol (ldl-c),1
low density lipoprotein-cholesterol (ldl-c):high density lipoprotein-cholesterol (hdl-c) ratio,1
low density lipoprotein (ldl-c),1
low density lipoprotein (ldl),1
low density lipoprotein (ldl) cholesterol,1
low density lipoprotein (ldl) risk,1
low density lipoprotein cholesterol (ldl-c level),1
low density lipoprotein cholesterol (ldl-cho),1
low density lipoprotein cholesterol (ldl),1
low income,1
low income financial status,1
low transverse-skin incision,1
low transverse-uterine incision,1
lower extremity fugl-meyer motor assessment,1
lower extremity fugl-meyer score,1
lower extremity functional score,1
lower extremity motor score,1
lower gi abnormalities at diagnosis,1
lower left extremity strength,1
lower respiratory tract infection score at the start of treatment,1
lower urinary tract symptom (luts) severity,1
lower urinary tract symptoms severity,1
lowest documented cd4 count,1
ls bmd,1
lsas-performance,1
lumbar level treated,1
lumbar radiculopathy,1
"lumbar spine (l2-l4) bone mineral density (bmd), categorical",1
lumbar spine bmd (g/cm^2),1
lumbar spine bone mineral density (bmd) score,1
lumbar spine bone mineral density (bmd) t-score,1
lumen volume,1
lunch status,1
lund-mackay score (ct scan),1
lund mackay ct stage,1
lung clearance index (lci),1
lung disease,1
lung function,1
lung injury pattern,1
lung metastases,1
lung stage,1
lung volume initiation,1
lutenizing hormone,1
lv end diastolic diameter,1
lv end systolic diameter,1
lv mass,1
lv measurement,1
lvd-resistance substitution,1
lvedv (left ventricular end-diastolic volume),1
lvef % (left ventricle ejection fraction),1
lvef(%),1
"lvef, mean",1
lvesv (left ventricular end-systolic volume),1
lymph node dissection (c1/level vi),1
lymph node evaluation,1
lymph node involvement,1
lymph node size,1
lymphadenopathy,1
lymphatic filariasis antigen prevalence (ict),1
lymphocytes,1
lymphoid tissue collagen i deposition,1
lymphoma disease stages,1
lymphoma sub-types,1
lymphovascular involvement,1
lymphovascular space invasion (lvsi),1
lytic bone lesions,1
m stage,1
maastricht ankylosing spondylitis enthesitis score (mases),1
macroscopic vascular invasion,1
macrovascular invasion,1
macrovascular invasion (ivrs),1
macrovascular invasion (rave),1
macular pigment optical density,1
madbp,1
madrs-10 score,1
madrs-15 score,1
madrs baseline total score,1
madrs score,1
"madrs score, baseline",1
madrs total score at baseline,1
madrs: baseline from lead-in study 13267a (nct01140906),1
"madrs: baseline present study, 13267b",1
magnetic resonance angiographic index,1
magnetic resonance imaging (mri) descriptives,1
"mahler dyspnea index, mean focal score",1
maims,1
maims at screening,1
main language spoken at home,1
main reasons for discontinuing medications before starting fibromyalgia (fm) treatment at baseline,1
maintained on any antidepressant,1
maintained on selective serotonin re-uptake inhibitors (ssri),1
major defect of the levator ani muscle,1
major depressive disorder,1
major depressive disorder (mdd) status,1
major known or suspected human teratogens,1
major organ-systems involved,1
male clinicians,1
male sexual health questionnaire (mshq),1
malignant cause identified,1
malignant melanoma (mm) site,1
mallampati class (n),1
mallampati grade,1
malondialdehyde,1
malondialdehyde (î¼m),1
mammogram prior to study entry,1
manchester health questionnaire (mhq) severity scale at baseline,1
mannitol,1
manual labor,1
manual muscle testing (mmt-8) score,1
manual muscle testing (mmt) score,1
maraviroc in background regimen,1
margin of resection,1
marihuana use (spelling with 'h' used by dea and fda),1
marijuana use,1
marital interaction scale in cancer rehabilitation evaluation system-short form (cares-sf),1
marital status - married,1
"marital status, categorical",1
"marital status: married, other",1
marked kyphosis,1
markers,1
marks aqlq,1
marks asthma quality of life,1
married or living with significant other,1
married status,1
married/living with someone,1
marrow examination for infiltration,1
marrow examination for lymphoid nodules,1
marshall ct scan category,1
martial status,1
masbp,1
masood score,1
massachusetts general hospital - hairpulling scale (mgh-hps),1
massachusetts general hospital cognitive and physical functioning questionnaire (cpfq),1
massachusetts general hospital cognitive and physical functioning questionnaire (mgh-cpfq) total,1
massachusetts general hospital hair pulling scale,1
massachusetts general hospital hairpulling scale,1
maternal age,1
maternal age at delivery,1
maternal body mass index (bmi),1
maternal cd4 t cell count,1
maternal comorbidities,1
maternal experience,1
maternal pre-existing comorbidity,1
maternal serum 25 hydroxy vitamin d (25(oh)d),1
matrics consensus cognitive battery (mccb) excluding misceit managing emotions test),1
matrix metalloprotease (mmp-3),1
mattis-dementia rating scale,1
max e2 level prior to oocyte retrieval,1
max elasticity,1
max stimulated gh,1
maximal detrusor pressure,1
maximal heart rate (hrmax (beats/min)),1
maximal oxygen consumption,1
maximal oxygen consumption (ml/kg/min),1
maximal oxygen consumption (vo2max),1
maximal oxygen uptake,1
maximal oxygen uptake (vo2max (l/min)),1
maximal oxygen uptake (vo2max),1
maximal respiratory exchange ratio (rermax),1
maximal severity of ak at baseline,1
maximal thickness of junctional zone,1
maximal thickness of the endometrium,1
maximal thickness of the myometrium,1
maximum aneurysm diameter,1
maximum aortic-root diameter z-score,1
"maximum aortic-root diameter, cm",1
maximum cramp pain in previous 24 hours,1
maximum cramp pain in previous 30 days,1
maximum dose of nicardipine used,1
maximum drain duration (antisepsis side),1
maximum drain duration (control side),1
maximum expiratory flow,1
maximum expiratory pressure,1
maximum fev1 percent predicted,1
maximum flow rate,1
maximum grip strength average,1
"maximum grip strength, left hand",1
"maximum grip strength, right hand",1
maximum growth hormone (gh) peak on stimulation test,1
maximum initial escalation day dose,1
maximum injection pressure,1
maximum inspiratory flow,1
maximum isometric voluntary contraction testing (mvict) score,1
maximum left pelvic venous caliber,1
maximum lymph node size,1
maximum metabolic equivalents achieved,1
maximum number of asthma symptom days (previous 2 weeks),1
maximum percent fall in fev1 after exercise,1
maximum pituitary adenoma diameter (v1),1
maximum right pelvic venous caliber,1
maximum secretory phospholipase a2 (spla2) value,1
maximum stimulated gh,1
maximum temperature,1
maximum tolerated dose of milnacipran,1
maximum tumor size,1
maximum tumour diameter,1
maximum urinary flow rate (qmax),1
mayo end-stage liver disease (meld) score,1
mayo score,1
mayo score at baseline,1
mayo score for assessment of ulcerative colitis activity,1
mbs-difficult/painful urination at randomization,1
mbs-vaginal and/or vulvar irritation or itching at randomization,1
mbs-vaginal bleeding with sexual activity at randomization,1
mbs-vaginal dryness at randomization,1
mbs-vaginal pain with sexual activity at randomization,1
mcgill pain questionnaire score,1
mcl (ann arbor) stage at diagnosis,1
mcp-1,1
mcs12,1
mdas baseline score,1
mdi - major depression inventory,1
mdma use history,1
mdrd-egfr,1
mds-updrs part ii,1
mds-updrs part iii,1
mds-updrs part iv,1
mds world health organization (who) classification,1
mean (sd) spherical equivalent in amblyopic eye,1
mean (sd) spherical equivalent in fellow eye,1
mean 24-hour ambulatory diastolic blood pressure,1
mean 24-hour ambulatory systolic blood pressure,1
mean 24-hour mean diastolic blood pressure (dbp),1
mean 24-hour mean systolic blood pressure (sbp),1
mean 24-hour weighted mean glucose at baseline,1
mean absolute cd4 count,1
mean age at menopause (sd),1
mean age at onset of attention deficit hyperactivity disorder (adhd),1
mean age at onset of illness,1
mean airway pressure at enrollment,1
mean amplitude of glucose excursion,1
mean aom-sos score,1
mean aortic valve gradient,1
mean arterial blood pressure,1
mean arterial pressure,1
mean arv duration,1
mean baseline 28 joint disease activity score (das 28),1
mean baseline high sensitivity c-reactive protein (hs-crp),1
mean baseline high sensitivity c-reactive protein level,1
mean baseline national institutes of health stroke scale (nihss) score,1
mean baseline plasma soluble p-selectin,1
mean baseline soluble cd40 ligand,1
mean benign prostatic hyperplasia (bph) disease stage scores,1
mean birth weight,1
mean blood glucose,1
mean blood pressure,1
mean blood pressure (mbp) pre-induction,1
mean bmi,1
mean body-mass index,1
mean body mass index,1
"mean body mass index (sd), kg/m^2",1
mean body surface area (bsa) involvement,1
mean cd4,1
mean cd4 count,1
mean cd4+ t-cell count,1
mean cd4+ t-cell counts,1
mean chads-2 score at enrollment,1
mean change in mrss in 1 month prior to baseline,1
mean charlson comorbidity index scores,1
mean cluster of differentiation 4 (cd4) cell count at baseline,1
mean cognitive performance,1
mean conditioned pain modulation (cpm),1
mean corpuscular hemoglobin concentration,1
mean corpuscular volume (mcv),1
mean cost per participant per month,1
mean dermatology life quality index (dlqi) total score,1
mean deviation from normal visual field using the hfa 24-2,1
mean deviation of visual field,1
mean diameter of baseline digital ulcers,1
mean diastolic blood pressure,1
mean diastolic blood pressure (dbp),1
mean disease duration,1
mean diurnal intraocular pressure (iop),1
mean doppler abi,1
mean duration of disease,1
mean duration of epilepsy,1
mean duration of generalized seizure,1
mean duration of partial seizures,1
mean duration of type 2 diabetes mellitus,1
mean embryo transferred,1
mean esophageal eosinophil count,1
mean estimated probability of middle ear effusion,1
mean euro quality of life 5 dimension (eq-5d) utility index scores,1
mean excess body weight,1
mean fasil laxity scale,1
mean functional assessment of chronic illness therapy (facit) fatigue questionnaire total scores,1
mean griffiths photonumeric scale for photodamage score,1
mean hba1c level,1
mean heart rate,1
mean heart rate (hr),1
mean hemoglobin a1c (hba1c),1
mean hemoglobin value,1
mean hiv duration,1
mean hospital anxiety and depression scale (hads) anxiety and depression scores,1
mean impaction score,1
mean incontinence episodes / 24 hours,1
mean insulin glargine dose,1
mean keratanized gingiva (kg) width,1
mean ldl level,1
mean log baseline hiv-1 rna,1
mean medical outcomes study (mos) sleep scale scores,1
mean metformin dose at baseline,1
mean micturitions / 24 hours,1
mean milk volume at entry,1
"mean minimum systolic blood pressure, during the first 2 hours post randomization",1
mean nocturia episodes / 24 hours,1
mean nrs score,1
mean number of actinic keratosis lesions on face,1
mean number of concurrent baseline medications taken for fibromyalgia (fm),1
mean number of daytime incontinence episodes per 24 hours,1
mean number of daytime micturitions per 24 hours,1
mean number of doctor visits,1
mean number of emergency room days,1
mean number of eosinophils per high powered field in esophagus,1
mean number of gadolinium (gd) enhancing lesions,1
mean number of gadolinium(gd)-enhancing t1-weighted lesions,1
mean number of grade 3 or 4 urgency episodes per 24 hours in adolescents,1
"mean number of health care encounters, as a measure of resource utilization",1
mean number of medical appointments,1
mean number of nighttime incontinence episodes per 24 hours,1
mean number of nighttime micturitions per 24 hours,1
mean number of opioids,1
mean number of pads used / 24 hours,1
mean number of pain medications,1
mean number of seizures,1
mean number of stools,1
mean number of swollen joints at baseline,1
mean number of tender joints at baseline,1
mean number of total baseline digital ulcers,1
mean of post meals blood glucose (postprandial),1
mean of pre-meals blood glucose,1
"mean opioid dose, twice daily",1
mean pain level,1
mean pain score,1
"mean pain50, kg/cm^2",1
mean plaque index score,1
mean post-meal maximum glucose,1
mean premedication time (min:sec),1
mean prostate-specific antigen (psa) in ng/ml,1
mean pseudomonas aeruginosa quantitative sputum culture (cfu's/gr of sputum),1
mean psoriasis subject satisfaction questionnaire (pssq) scores,1
mean pulmonary arterial pressure (mpap) at rest,1
mean rdq heartburn score,1
mean sac diameter,1
mean score of aom-sos,1
mean seated diastolic blood pressure,1
mean seated systolic blood pressure,1
mean seizure frequency,1
mean sepsis-related organ failure assessment (sofa) score,1
mean serum creatinine levels,1
"mean serum estradiol, pg/ml",1
mean service connection rating,1
mean simplified acute physiology score ii (sapsii): integer score,1
mean sleep quality score,1
mean spontaneous bowel movements,1
mean standard drinks per week,1
mean subjective time to sleep onset in minutes (stsom),1
mean systolic blood pressure,1
mean systolic blood pressure (sbp),1
mean time from diagnosis,1
mean time interval from initial treatment to pet scan,1
mean time interval from pet scan to surgery/gp study,1
mean time of disease-free interval,1
mean time to percutaneous coronary intervention (pci),1
mean tolerated daily dose of insulin,1
mean total ocular surface staining (toss) score,1
mean urgency episodes (grade 3 or 4) / 24 hours,1
mean urgency incontinence episodes / 24 hours,1
mean urine calcium excreted,1
mean visual acuity,1
mean visual acuity letter score,1
mean volume voided (mvv) per micturition,1
mean watch bp office abi,1
mean weight,1
mean weight per weight group,1
mean worst pain level,1
mean years of education,1
measurable disease category,1
measure of number of organs with graft versus host disease (gvhd),1
median 24 hour pad weight,1
median age,1
median age (range),1
median baseline headache score,1
median baseline nausea score,1
median baseline nihss score,1
median baseline serum prostate-specific antigen levels (ng/ml),1
median baseline serum testosterone levels (ng/ml),1
median days since prior chemotherapy,1
median duration of imatinib treatment,1
median duration of uc,1
median electronic-early treatment diabetic retinopathy visual acuity (letter score),1
median fecal calprotectin immediately before randomization,1
median first cr duration,1
median gravidity (iqr),1
median hiv-1 rna,1
median nihss score (range),1
median number of pads per day,1
median number of previous treatments,1
median number of prior regimens,1
median of duration of remission at baseline,1
median parity (range),1
median pessary months (iqr),1
median pessary size (iqr),1
median prior therapies,1
median psa,1
median sarcoma size,1
median serum testosterone level,1
median standard deviation of systolic blood pressure,1
median t2 lesion # at onset,1
median t2 lesion vol at onset,1
median time from prior chemotherapy,1
median time since adt initiation,1
median time since cml-cp diagnosis,1
median time since first brain metastases (years),1
median time since radiotherapy,1
median time since surgery,1
median tumor size,1
median visual acuity (etdrs),1
medicaid coverage,1
medical and surgical history,1
"medical burden, cirs (cumulative illness rating scale)",1
medical comorbidity,1
medical conditions,1
medical history - acute coronary syndrome/myocardial infarction,1
medical history - chronic obstructive pulmonary disease,1
medical history - deep vein thrombosis,1
medical history - ischemic stroke,1
medical history - pulmonary embolism,1
medical history - venous thromboembolism,1
medical history & concomitant conditions,1
medical history and co-morbidities,1
medical history and concurrent conditions,1
medical history of diffuse large b-cell lymphoma (dlbcl),1
medical history of essential hypertension,1
medical history with or without diabetes,1
medical history/comorbidities,1
medical history: participant has diabetes,1
medical history: participant has had previous myocardial infarction (mi),1
medical history: participant has hyperlipidemia,1
medical history: participant has hypertension,1
medical history: participant is a current smoker (within past 30 days),1
medical insurance,1
medical outcome study sleep scale (mos-ss),1
medical outcome study sleep scale (mos-ss) sleep disturbance baseline measure (weeks 1 and 7),1
medical outcomes study - specific adherence scale,1
medical outcomes study (mos) adhere,1
medical outcomes study 36-item short form (sf36) physical component (pcs) and mental component (mcs),1
medical outcomes study short form-12 mental component score (sf-12 mcs),1
medical outcomes study short form-12 physical component score (sf-12 pcs),1
medical outcomes study short form 12 - mental,1
medical outcomes study short form 12 - physical,1
medical outcomes study sleep scale,1
medical practice setting,1
medical research council dyspnea score,1
medically treated diabetes,1
medicare case-mix weight,1
medicare coverage,1
"medication (nsaids, aspirin, clopidogrel, ticlopidine, steroid)",1
medication adherence by morisky scale,1
medication adherence rating scale,1
medication at enrollment,1
medication history (antihypertensives),1
medication management test (mmt) score,1
medication on admission,1
medication resistance,1
medication stage of change,1
medication treatment failures during current episode,1
medication use -- aspirin,1
medication use -- cox ii inhibitors,1
medication use -- other nsaids,1
medication use -- statins,1
medication use at baseline,1
meets criteria for dsm-iv alcohol dependence,1
meets criteria for dsm-v ad,1
meglitinide use,1
meibomian gland score,1
melancholic,1
melanin index,1
melanoma stage,1
melanoma tumor stage; metastasis classification at study entry,1
melasma started with pregnancy,1
meld and ctp scores,1
"meld, cirrhotics only",1
melena present,1
memorial sloan kettering cancer center risk criteria (mskcc) risk group,1
memorial sloan kettering cancer center risk group (mskcc,1
memorial sloanâ€“kettering cancer center (mskcc) prognostic risk,1
memorial sloane kettering cancer center (mskcc) score,1
memory compensation questionnaire,1
"men who have sex with men (msm), #",1
men: hdl cholesterol,1
menopausal course,1
menopausal stage,1
menopausal status (females),1
menopausal status at cycle 0,1
menopausal status at isolated loco-regional recurrence (ilrr),1
menopause rating scale,1
menopause status of postmenopausal,1
menorrhagia,1
menses frequency,1
menstrual cycle,1
menstrual cycle regularity,1
menstrual pattern,1
menstrual problems mean score,1
menstrual status,1
"menstruation (before the first dose), customized",1
mental component summary score from sf-36,1
mental disorder diagnosis past 36 months,1
mental health-related quality of life,1
mental health index 5 score,1
mental status (mmse),1
menthol,1
mesenteric fat thickness,1
metabolic equivalent,1
metabolic equivalent of task (mets),1
metabolic factors: body-mass index,1
metabolic factors: diastolic blood pressure,1
metabolic factors: fasting serum glucose,1
metabolic factors: glycated haemoglobin a1c,1
metabolic factors: homa-ir,1
metabolic factors: insulin,1
metabolic factors: systolic blood pressure,1
metabolic factors: waist-to-hip ratio,1
metabolic factors: waist circumference,1
metabolic factors: weight,1
metabolic outcomes,1
metastasis site,1
metastatic disease,1
metastatic disease sites,1
metastatic lesions/sites of relapse,1
metastatic site locations,1
metastatic sites (multiple sites possible),1
metastatic sites of disease,1
metastatic sites of disease outside of prostate,1
metastatic stage,1
"metastatis stage, m0",1
metavir fibrosis score,1
metavir score,1
metformin,1
metformin monotherapy or combination therapy at randomisation,1
metformin use at baseline,1
metformin use at enrolment,1
methacholine pc20 (mg/ml),1
methadone maintained,1
methamphetamine use in last 3 months,1
"methemoglobin, %, mean (sd)",1
method of diagnosis of fabry disease,1
method of dialysis at baseline,1
method of initial diagnosis,1
method of insemination,1
method of operation (robotic/endoscopic),1
method of tumor assessment,1
methotrexate,1
methotrexate (mtx) dose at substudy baseline,1
methotrexate dosage,1
methotrexate dose,1
methotrexate usage at registration,1
methotrexate user,1
methoxy polyethylene glycol-epoetin beta dose,1
mfsi-sf fatigue,1
mgfa class,1
mgmt statis,1
mhq emotions at baseline,1
mhq incontinence impact at baseline,1
mhq personal relationships at baseline,1
mhq physical limitations at baseline,1
mhq role limitations at baseline,1
mhq sleep energy at baseline,1
mhq social limitations at baseline,1
michigan neuropathy screening instrument,1
michigan neuropathy screening instrument (mnsi) physical assessment - total score,1
microalbumin in urine,1
microalbumin/creatinine,1
microbiology recovery,1
microfilarial count /ul,1
microneedle,1
micturition-related urgency episodes per 24 hours,1
micturitions per 24 hours,1
micturitions/24 hour,1
micturitions/24 hours,1
mid-luteal progesterone,1
mid-parental target height,1
mid-upper-arm circumference (muac),1
midwall fractional shortening (mfs),1
mild cognitive impairment (mci),1
military rank,1
military service-connected 100%,1
military service-connected benefits for sci,1
milk ige,1
milk skin prick test score,1
millimeter (mm) of clear nail from the lunula,1
mini-blessed (continuous),1
mini-cognitive assessment for dementia,1
mini-international neuropsychiatric interview (mini),1
mini-mental state examination score,1
mini-mental state examinition,1
mini-nutritional assessment score,1
mini drug or alcohol abuse or dependence,1
mini mental score,1
mini mental state exam (mmse),1
mini mental state exam (mmse) total score,1
mini mental state exam score,1
mini mental state examination (mmse) total score,1
mini mental state examination (mmse): baseline efficacy scores,1
mini mental state examination >23,1
mini mental state examination score,1
mini mental status examination (mmse),1
minimal residual disease (blast %) as assessed by bone marrow flow cytometry,1
minimal thickness of the myometrium,1
minimental state exam (mmse),1
minimum hla match score,1
minimum lumen diameter,1
minimum stent diameter (per-patient),1
minimum trust score,1
minnesota living with heart failure questionnaire (mlhf-q) summary score,1
minnesota living with heart failure questionnaire (mlhfq) emotional score,1
minnesota living with heart failure questionnaire (mlhfq) physical score,1
minnesota living with heart failure questionnaire (mlhfq) total score,1
minnesota living with heart failure questionnaire (mlwhf),1
minnesota living with heart failure questionnaire (mnlhf),1
minnesota nicotine withdrawal score,1
minor duct sphincterotomy,1
minority,1
minsao2,1
minute ventilation and carbon dioxide production (ve/vco2 slope),1
minutes per week of moderate-to-vigorous of physical activity (mvpa min/wk),1
minutes per week of moderate-to-vigorous physical activity,1
minutes spent with parkinson disease provider,1
mip-1alpha,1
mipi = mcl international prognostic index score group at enrollment,1
mipi at diagnosis,1
missed at least one dose of cholesterol medication in previous 30 days at baseline,1
missed number of school days (previous 2 weeks),1
"mitral atrial inflow velocity (e), cm/s, mean (sd)",1
"mitral early inflow velocity (e), cm/s, mean (sd)",1
mitral regurgitation (moderate or severe),1
mitral regurgitation (mr),1
mitral stenosis,1
mitral valve deceleration time,1
mitral valve e/a ratio,1
mitral valve inflow (a) velocity,1
mitral valve inflow (e) velocity,1
mitral valve tissue doppler velocity (a'),1
mitral valve tissue doppler velocity (e'),1
mixed histological features present,1
mixed histology,1
mixed venous oxygen saturation,1
mmf prophylaxis,1
mmse,1
mmse ranges,1
mmse total score,1
mmse total score at screening,1
mobile phone ownership,1
mobility - timed get up and go (tug),1
mobility knowledge pretest score,1
moca,1
moca total,1
mode of hbv acquisition,1
mode of hiv infection,1
mode of infection,1
mode of ventilation,1
model for end-stage liver disease (meld) score at baseline,1
moderate renal impairment,1
modified-rodnan skin score,1
modified accâ€“aha lesion class b2 or c,1
modified ann arbor staging,1
modified ashworth scale (mas),1
modified ashworth scale (mas) score,1
modified bajorin risk group,1
modified bishop score (mbs),1
modified bmi,1
modified borg dyspnea scale,1
modified clinical dementia rating scale (cdr),1
modified falls efficacy scale,1
"modified grab score (n=11, 11)",1
modified hoehn-yahr scale,1
modified mallampati classification,1
modified medical research council (mmrc) dyspnea score,1
modified medical research council dyspnea questionnaire,1
modified medical research council dyspnea scale (mmrcds) grade,1
modified mini-mental state examination (3ms),1
modified mini mental status exam (3mse),1
modified nyha/who functional class (fc),1
modified oswestry disability index,1
modified palmoplantar pustulosis area and severity index (m-pppasi),1
modified performance-oriented mobility assessment - gait subtest (mpoma-g),1
modified pulmonary index score (initial),1
modified rai stage,1
modified rankin scale (mrs),1
modified rankin score (mrs),1
modified rodnan skin score (mrss),1
modified rodnan skin score (mrss) at baseline,1
modified schwab & england independence scale,1
modified selena-sledai score,1
modified simpson-angus scale,1
molecular breast imaging prior to study entry,1
monastra ratio,1
monitoring attentional style,1
monoclonal protein type,1
monocyte vitamin d receptor (vdr) expression,1
monosyllabic words,1
montgomery- asberg depression rating scale (madrs) total score,1
montgomery-ã„sberg depression rating scale (madrs) total score,1
montgomery-ã…sberg depression rating scale (madrs),1
montgomery-ã…sberg depression rating scale (madrs) total score at baseline,1
montgomery-asberg depression rating scale,1
montgomery-asberg depression rating scale (madrs) - total score,1
montgomery-asberg depression rating scale (madrs) item 8 score,1
montgomery-asberg depression rating scale total score (madrs),1
montgomery-asberg depression rating score,1
montgomery-asberg depression scale,1
montgomery ã…sberg depression rating scale (madrs),1
montgomery and ã…sberg depression rating scale (madrs),1
"montgomery asberg depression rating scale (madrs) total score, continuous",1
monthly family income <$1800,1
monthly non-service-connected amount,1
monthly non-service-connected pension,1
monthly social security disability insurance benefits,1
monthly social security income benefits,1
months away from work,1
months feeling pain,1
months from chronic graft versus host disease (cgvhd) diagnosis,1
months from diagnosis to transplant,1
months from initial diagnosis to first dose,1
months from initial diagnosis to first dose of ixazomib,1
months from transplant,1
months of pain,1
months of undifferentiated inflammatory arthritis (ua),1
months poststroke onset,1
months since last dose in 20050179,1
months since metastatic disease diagnosis,1
months since primary diagnosis,1
montreal cognitive assessment (moca),1
mood,1
mood and craving scales: hamilton rating scale for depression,1
mood and craving scales: inventory of depressive symptomatology-self-report,1
mood and craving scales: penn alcohol craving scale,1
mood and craving scales: young mania rating scale,1
mood disturbance,1
mood states,1
more than one primary cancer,1
"morisky medication adherence survey, 8-item (mmas-8)",1
morning peak expiratory flow (pef),1
morning peak flow rate (pefr),1
morning stiffness,1
morning systolic and diastolic bp (mmhg),1
morningness/eveningness questionnaire,1
morphine equivalents,1
morphology,1
mos-ss overall sleep index ii baseline measure (weeks 1 and 7),1
most advanced histology,1
most bothersome vulvar and vaginal atrophy (vva) symptom (mbs) by severity (overall [composite]),1
most frequent site of primary malignancy,1
most prevalent co-morbidities among participants in the study,1
most proximal extent of dvt,1
most recent cd4 count,1
most recent hba1c % result,1
most recent pathological diagnosis,1
most recent treatment before enrolment in the study,1
mother's level of education,1
mother height,1
mother tongue,1
"mothers with at least one child with autism, and pregnant before the third trimester",1
motion sickness (vehicle sickness),1
motivation scale,1
motivation: attitudes towards hiv preventive acts,1
motivation: behavioral intentions for hiv prevention,1
motivation: subjective norms regarding hiv preventive acts,1
motor component of glasgow coma score,1
motor development status assessed by alberta infantile motor scale (aims),1
motor fluctuations,1
motor function assessment of hand movement,1
motor impairment of wrist and forearm,1
"motzer category (low, intermediate or high)",1
movement disorder society revision of the unified parkinson's disease rating scale mds-updrs part i,1
moxifloxacin susceptibility,1
mrd level at baseline by central laboratory,1
mri compatibility,1
mri region of main interest,1
mri subcutaneous adipose tissue,1
mri total adipose tissue,1
mri visceral adipose tissue,1
mrt (magnetic resonance tomograhy) pathological,1
ms medication in the past 2 years,1
msdbp,1
mskcc risk group,1
mssbp,1
mu wave frequency,1
mu waves-amplitude,1
mucosal biopsies obtained,1
mucosal denudation,1
mucosal irritation,1
mucous discharge,1
mucous membrane grade,1
multidimensional anxiety scale for children (masc),1
multidimensional assessment of fatigue (maf),1
multidimensional fatigue inventory,1
multidimensional scale of perceived social support,1
multiple-drug-refractory chronic hepatitis b virus patients,1
multiple arteries,1
multiple fenestrations noted,1
multiple fractures of upper and lower limbs at baseline,1
multiple gestations,1
multiple sclerosis (ms) diagnosis subtype,1
multiple sclerosis modifying therapy (ms dmt) use,1
multiple sclerosis neuropsychological screening questionnaireâ€“patient version,1
multiple sclerosis quality of life (ms-qol-54) overall quality of life subsection,1
multiple sclerosis treatment concern questionnaire (mstcq) flu like symptom (fls) score items 13-16,1
multiple sclerosis treatment concern questionnaire (mstcq) global side effects score items 21-23,1
multiple sclerosis treatment concern questionnaire (mstcq) injection site reaction score items 17-20,1
multiple system atrophy (msa) type,1
multiple system atrophy of the parkinsonian subtype (msa-p),1
multiple system atropy subtype,1
muscle mechanical energy expenditure,1
muscle oxidative capacity,1
muscle strength,1
muscle sympathetic nerve activity,1
muscles with trigger point,1
musculoskeletal fractures at baseline,1
musculoskeletal pain,1
mutation (abcc8),1
mutation status at registration,1
mutational status,1
myasthenia gravis-activity of daily living (mg-adl),1
myasthenia gravis foundation of america (mgfa) classification at screening,1
mycophenolate daily dose,1
myeloablative conditioning,1
myelodysplastic syndrome (mds) french-american-british (fab) classification,1
myelodysplastic syndromes world health organization classification,1
myelodysplastic syndromes world health organization classification at study screening,1
myelofibrosis with myeloid metaplasia subtype,1
myeloma type,1
myocardial disease,1
myocardial infarction (mi) duration greater than 3 hours,1
myocardial infarction in history,1
myocardial infarction in the previous 3 months,1
myofascial pain,1
n-acetylcysteine (nac) use,1
n-back task error rate,1
n-back task reaction time,1
n-stage,1
"n-terminal pro-brain natriuretic peptide (nt-probnp), pg/ml, mean (sd)",1
n-terminal prohormone brain natriuretic peptide (nt-probnp),1
n stage - regional lymph nodes,1
n stage of tumor at diagnosis,1
n status,1
nadir cd4,1
nadir cd4 count,1
nadir cd4+,1
nadir cd4+ t-cell count,1
nadir spo2 during 6-min walk while breathing ambient air,1
nafld activity score,1
nafld activity score (nas) liver histology,1
"nail psoriasis severity index (napsi) (n=283, 281, 283)",1
nail psoriasis severity index (napsi) score,1
nart (full scale iq),1
nas score,1
nasal congestion,1
nasal congestion scores,1
nasal congestion upon awakening,1
nasal obstruction symptom evaluation (nose) score,1
nasogastric tube removal day,1
national eye institute 25-item visual function questionnaire (nei vfq-25) total score,1
national eye institute visual function questionnaire-25 (nei-vfq-25) sub-scale scores at baseline,1
national institute of health stroke scale (nihss) at hospital arrival,1
national institute of mental health trichotillomania severity scale,1
"national institutes of health stroke scale score, median (range)",1
nationality of subjects,1
native aorta diameter,1
natriuretic brain pro-peptide,1
natural hair color,1
naturally post menopausal participants,1
nausea/emesis,1
nausea/vomiting,1
near esophoria,1
neck dissection,1
neck extension time,1
neck stiffness,1
need for oxytocin,1
need for vasopressors before angelâ® catheter insertion,1
need of pre-surgery sedation,1
needle gauge used,1
negative logarithm of hydrogen ion concentration in arterial blood (pha),1
negative serum pregnancy test,1
"negative symptoms, brief psychiatric rating scale",1
negative urinary pregnancy test,1
nei vfq-25 + supplement total score,1
"neo five factor inventory of personality, neuroticism subscale (neo-ffi-n)",1
neoadjuvant chemotherapy,1
neonatal birth weight,1
neovascularization on clinical examination,1
nephrectomy,1
nephrectomy laterality,1
nephrotic syndrome history,1
nervousness of acupuncture,1
net household income,1
neurocardiogenic syncope,1
neuroendocrine tumour (net) origin,1
neurologic function status,1
neurologic history,1
neurologic pain,1
neurological impairment,1
neurological/renal history,1
neuropathic pain symptom inventory (npsi),1
neuropsychiatric inventory,1
neuropsychiatric inventory (npi): baseline efficacy scores,1
neuropsychiatric inventory npi),1
neutralising antibody (nab) status,1
neutropenic status,1
neutropenic status: presence or absence of neutropenia,1
neutrophils,1
never married,1
new gd-enhancing lesions during 3-month pre-treatment,1
new modified bishop score,1
new or enlarging t2 lesions during 3-month pre-treatment,1
new postoperative mri injury,1
new york heart association (nyha) chf classification,1
new york heart association (nyha) functional classification,1
new york heart association (nyha) functional status,1
new york heart association [nyha] class,1
new york heart association classification,1
new york heart association classification (nyha),1
new york heart association functional class (nyha class),1
new york heart association functional classification,1
new york heart association group,1
new york heart association heart failure classification (nyha class) n (%),1
"new york heart association, world health organization (nyha/who) functional class",1
newly active lesions during 3-month pre-treatment,1
newly diagnosed versus recurrent disease,1
newly diagnosed with diabetes mellitus at the start of follow-up,1
ngf,1
nh3,1
nhl histology,1
niacin use,1
nicotine,1
nicotine addiction,1
nicotine cravings assessment baseline scores on a visual analogue scale (vas),1
nicotine dependent,1
nicotine pack years,1
nicotine replacement therapy use,1
night urinary frequency,1
nightmare frequency,1
nighttime asthma symptom score (0 [best] to 3 [worst] point scale),1
nih stroke scale,1
nih stroke scale (nihss),1
nih stroke scale at baseline,1
nihss score,1
nihss score strata,1
nimh trichotillomania severity and impairment scale,1
nis+7 score,1
nitric oxide catabolites,1
nniss score,1
no-show rate,1
no effect of nsaid,1
no health insurance plan,1
no immunosuppression,1
no local treatment modality,1
no prior history of cancer in previous 5 years,1
no service-connected/non-service-connected benefits,1
no use of alcohol during pregnancy,1
no. hubs per patient,1
no. of cigarettes/day (past year),1
no. of days with hot flashes (/month),1
no. of lesions,1
no. of nodes identified,1
no. of patients classified by disease subtype,1
no. of previous chemotherapy regimens,1
no. of previous hormonal therapies,1
no. of prior regimens,1
no. of prior therapies,1
no. of urinary tract infections in past 6 months,1
no. of vaginal births,1
no. of years smoked,1
no.of joints with active disease,1
nocturia episodes/ 24 hour,1
nocturia episodes/24 hours,1
nocturnal asthma score,1
nocturnal blood pressure,1
nocturnal hypoxemia,1
nocturnal micturitions per 24 hours,1
nocturnal urine volume,1
"nodal stage, n0",1
nodular lesion count,1
nodule counts,1
non- high density lipoprotein (non-hdl) cholesterol,1
non-alcoholic steatohepatitis (nash) score,1
non-cardiac surgery,1
non-completion rate of all scheduled patients,1
non-completion rate of showing-up patients,1
non-cv (cardiovascular) morbidity at enrollment,1
non-death revised grief experience inventory,1
non-hdl-c/hdl-c ratio,1
non-high-density lipoprotein-c:high-density lipoprotein-c ratio,1
non-high-density lipoprotein cholesterol,1
non-high-density lipoprotein cholesterol (hdl-c),1
non-high density lipoprotein-cholesterol (non-hdl-c),1
non-high density lipoprotein cholesterol (non-hdl-c),1
non-high density lipoprotein cholesterol (non-hdl-c):high density lipoprotein cholesterol (hdl-c) ra,1
non-hodgkin's lymphoma (nhl)-stage,1
non-hodgkin's lymphoma (nhl) histology,1
non-hodgkin's lymphoma (nhl) stage,1
non-inflammatory lesion (nil) counts at baseline,1
non-inflammatory lesion count,1
non-motor symptoms scale (nmss) total score,1
non-opioid drug use disorder diagnosis past 36 months,1
non-small cell lung cancer (nsclc) disease stage at entry,1
non-small cell lung cancer (nsclc) disease type,1
non-small cell lung cancer (nsclc) histology,1
non-small cell lung cancer stage,1
non-steroidal anti-inflammatory drug (nsaid) use,1
non-target lesions,1
non-vellus terminal hair count,1
non-verbal,1
non high-density lipoprotein cholesterol (non-hdl-c),1
non inflammatory lesion count,1
non inflammatory lesions,1
non steroidal anti inflammatory drug use,1
non vitamin k antagonist,1
nonâ€“small-cell lung cancer stage (tnm 6th edition),1
nondrug treatments / procedures for primary diagnosis,1
nonesterified fatty acid,1
nonhigh density lipoprotein-cholesterol (nonhdl-c):high density lipoprotein-cholesterol (hdl-c)ratio,1
noninsulin-dependent diabetes,1
nonparoxysmal af,1
nonsmall-cell lung carcinoma histology,1
norepinephrine,1
normal-to-normal lesion length,1
normal adrenal corticotropic hormone (acth) test,1
normal glucose tolerance,1
normal or underweight (bmi <25 kg/m2),1
normal platelet function,1
normal skin type,1
normalized brain volume at screening,1
normalized liver volume,1
normalized spleen volume,1
"normonatremic, n",1
not admitted to hospital in the last 12 months,1
not using cocaine at intake,1
nottingham extended activities of daily living,1
noun naming,1
novel oral anticoagulant (noac) use,1
npc patients,1
npi,1
npi distress score,1
npi score,1
nprs,1
nsaid use,1
nsaids,1
nsaids/acetaminophen for acute migraine,1
nsclc classification,1
nt-probnp,1
nuclear family + grandparents history of diabetes,1
nuclear family history of diabetes,1
number (no.) of pregnancies,1
number cesarean births,1
number completing study,1
number enrolled participants,1
"number landmark polyps at least 2 mm at baseline screen for evaluable polyps, evaluable participants",1
number meeting goal of 150 moderate-to-vigorous min/week,1
number of 24-hour voids,1
"number of 3,4-dap individual daily doses at randomization",1
number of abdominal pain symptoms,1
number of abdominal symptoms: bloating,1
number of abdominal symptoms: flatulence,1
number of abortions,1
number of active agents in obr,1
number of active antihypertensive medications,1
number of active medications,1
number of aeds at enrollment,1
number of aks,1
number of alcohol servings required for tremor response,1
number of american college of rheumatology (acr) criteria met at screening,1
number of anal intercourse without a condom,1
number of antiepileptic drugs (aeds) used over lifetime,1
number of antiepileptic drugs used,1
number of antihypertensive drug classes being used,1
number of antihypertensive medications,1
number of antiretroviral (arv) classes previously used,1
number of awakenings after sleep onset,1
number of background aeds,1
number of baseline dysplastic lesions,1
number of baseline lesions,1
number of baseline lesions (target + non-target),1
number of baseline lesions (target + non-target) by independent radiological review,1
number of bleeding in the past 1 year,1
number of bleeding sites,1
number of bleeds during last 6 months,1
number of bleeds in last 3 months,1
number of blood glucose measurements per day,1
number of bone lesions,1
number of brain metastases,1
number of bypasses,1
number of cancer indications,1
number of cardiac-related hospital admissions and ed visits in the past 12 months,1
number of caregivers who were spouses,1
number of cases of bi/nap1/027,1
number of cesarean,1
number of cgvhd organ sites,1
number of chf events leading to hospitalizations during 12 months before enrollment,1
number of cigarette pack-years,1
number of cigarettes smoked,1
number of co-morbid conditions,1
number of co-morbidities,1
number of coadministered drugs bound to proteins for more then 70%,1
number of combination chemotherapy cycles,1
number of comorbidities,1
number of concomitant medications for the inclusion diagnosis,1
number of concurrent cgvhd therapies,1
number of copd exacerbations in last 18 months,1
number of copd exacerbations in last year,1
number of current pressure ulcers,1
number of cyp2d6 drugs taken,1
number of daily basal insulin injections at baseline,1
number of daily dosings prior to randomization,1
number of daily medications,1
number of days hospitalized,1
number of days of observation,1
number of days of total body irradiation,1
number of days of work/school missed,1
number of days to assure leak-proof gastrocutaneous tract,1
number of days with night heartburn,1
number of daytime voids,1
number of dc cardioversions in past 4 years,1
number of decompression dives,1
"number of deployments, continuous",1
number of diabetic medications,1
number of diseased vessels,1
number of diseases,1
number of dives,1
number of documented symptomatic atrial fibrillation episodes,1
"number of donor mismatches at hla-a, b, c, and drb1",1
number of donor sites,1
number of doses of study vaccine to be received,1
number of drains (antisepsis side),1
number of drains (control side),1
number of drinking years,1
number of drinks per week,1
number of dry (incontinence-free) days per 7 days,1
number of dry (incontinence-free) nights per 7 days,1
number of exacerbations during 2 - 52 weeks prior to enrollment,1
number of existing vertebral (thoracic [th4] -l4) fractures,1
number of extranodal lesions,1
number of extranodal sites,1
number of failed medications,1
"number of failed treatments (n=335, n=159, n=301)",1
number of fi episodes in 2-week period,1
number of fibroids present greater than 2cm,1
number of fibroids present less than 2 cm,1
number of fine needle aspiration (fna) passes,1
number of first degree relatives with colorectal cancer,1
number of fractures in the past,1
number of gadolinium-enhanced lesions,1
number of gadolinium-enhanced lesions at baseline,1
number of gd+ lesions at baseline,1
number of haemorrhoidal packs removed,1
number of hcc,1
"number of health care encounters, as a measure of resource utilization",1
number of health conditions,1
number of hearing aids,1
number of hiv tests in last year,1
number of hormonal replacements,1
number of hospitalization days for chf at 12 months before enrollment,1
number of hot flashes in 24-hour period,1
number of hours from end of surgery to dosing,1
number of hours patient requires assistance,1
"number of hypertensive participants, n(%)",1
number of implants placed,1
number of incontinent episodes at baseline,1
number of index lesions,1
number of individual lesions,1
number of inhalations of albuterol or levalbuterol in a 24-hour period,1
number of injections per day,1
number of insulin injections/inhalations per day,1
number of islet infusions,1
number of joint bleeds in last 3 months,1
number of joints with active arthritis,1
number of joints with arthritis symptoms,1
number of landmark polyps at baseline sceen,1
number of landmark polyps at least 2 mm at baseline screen,1
number of legs being treated,1
number of lesions at baseline,1
number of lesions per partipant,1
number of lesions per subject,1
number of lesions treated per patient,1
number of lifetime hypomanic episodes,1
number of lifetime kidney stone episodes,1
number of lifetime major depressive episodes,1
number of lifetime suicide attempts,1
number of lines of prior chemotherapy,1
number of lines of prior chemotherapy in metastatic setting,1
number of living children,1
number of lymph node regions,1
number of lymph nodes removed (antisepsis side),1
number of lymph nodes removed (control side),1
number of male condomless anal intercourse partners in last 3 months,1
number of male sex partners in last 3 months,1
number of mdd hospitalizations in the past 24 months,1
number of metastatic disease sites,1
number of metastatic lesions by bone scan,1
number of metastatic sites at screening,1
number of metastatic sites by principal investigator,1
number of metastatic sites/organs,1
number of mg crisis/exacerbation prior to screening,1
number of missing teeth,1
number of neurotoxic agents exposed to,1
number of nights with middle of the night awakening,1
number of nights with sleep disturbances related to gastroesophageal reflux disease (gerd) symptoms,1
number of nocturnal voids,1
number of nodules,1
number of non target lesions,1
"number of obese participants, n(%)",1
number of oral corticosteroid (ocs) courses in the past 6 months,1
number of osteopenic patients,1
number of osteoporotic patients,1
number of outbreaks a year,1
number of pack years,1
number of pack years smoked,1
number of packs per year,1
number of pads used during 24 hours postoperative,1
number of participant records with diagnosis codes for the indicated diseases or disorders,1
number of participants according to blood eosinophil count,1
number of participants achieving the physician global assessment (pga) of psoriasis reponses,1
number of participants at baseline who were taking a biologic drug,1
number of participants at baseline who were taking an anti-tnf drug,1
number of participants at baseline who were taking methotrexate,1
number of participants at each stage of prostate cancer,1
number of participants by category of time since mcnv diagnosis,1
number of participants by number of risk factors for stroke,1
number of participants by stratification factors,1
number of participants concurrently using bisphosphonate,1
number of participants concurrently using trastuzumab,1
number of participants currently working at enrollment,1
number of participants diagnosed with the indicated conditions and using the indicated therapies,1
number of participants evaluated using psoriasis physician satisfaction questionnaire (ppsq),1
number of participants for tanner assessment: females,1
number of participants for tanner assessment: males,1
number of participants given doses in study i1f-je-rhal (nct01253265),1
number of participants having certain methods of diagnosis of invasive aspergillosis,1
number of participants hospitalized because of hip surgery and knee surgery,1
number of participants in the indicated age groups,1
number of participants in the indicated categories per best response to first-line treatment,1
number of participants in the indicated categories per best response to first line treatment,1
number of participants in the indicated soft tissue sarcoma (sts) subgroups at baseline,1
number of participants not using topical preparations,1
"number of participants on beta-blockers, n (%)",1
"number of participants on calcium-channel blockers, n (%)",1
number of participants on insulin therapy,1
"number of participants on loop diuretics, n (%)",1
"number of participants on mineralocorticoid receptor antagonists, n (%)",1
number of participants on oha therapy,1
number of participants on prophylaxis prior to screening,1
"number of participants on statin, n (%)",1
"number of participants on thiazide diuretic, n (%)",1
number of participants on two different chemotherapy regimens.,1
"number of participants onacei/arb, n (%)",1
number of participants per categorical score on clinical global impression-improvement (cgi-i) scale,1
number of participants per weight group,1
number of participants positive for hepatitis b and/or c at baseline,1
number of participants prescribed cholesterol medication at baseline,1
number of participants receiving 8 or more therapy sessions in ptsd or mental health clinics,1
number of participants receiving the indicated at before hit ii with regard to rationale,1
number of participants receiving the indicated heparin treatment prior to hit ii,1
number of participants receiving the indicated type of low-molecular-weight heparin (lmwh),1
number of participants receiving the indicated type of prophylactic treatment,1
number of participants receiving therapeutic treatment for the given indications,1
number of participants receiving thromboembolic prophylaxis for the given indications,1
number of participants receving the indicated at before hit ii (specified) with regard to rationale,1
"number of participants reporting concerns with prescription opioid (op) misuse, abuse or diversion",1
number of participants taking indicated concurrent antiepileptic drug at study entry,1
number of participants that have ever smoked greater than 100 cigarettes - lifetime,1
number of participants undergoing either prophylaxis or therapy,1
number of participants using indicated class of medications or having the indicated comorbidities,1
number of participants who did and did not receive ufh,1
number of participants who had a score of 0-1 in the the eastern cooperative oncology group (ecog),1
number of participants who had nafld activity score (nas) pre/post 24-28 wks. after treatment,1
number of participants who have been to a chronic pain clinic for their current lbp,1
number of participants who have ever seen a chiropractor for lbp,1
number of participants who have ever seen a physical therapist for lbp,1
number of participants who have seen a physician for their current lbp,1
number of participants who indicated that they did or did not have former abortions,1
number of participants who met criteria for major depressive disorder via scid-mdd,1
number of participants who met goal for low-density lipoprotein cholesterol at baseline,1
number of participants who received prior chemotherapy in neoadjuvant/adjuvant setting,1
number of participants who received treatment on this protocol,1
number of participants who smoke,1
number of participants who were art naã¯ve at baseline,1
number of participants who were considered satisfied according to psoriasis subject satisfaction,1
number of participants who were employed prior to the hernia repair,1
number of participants who were postmenopausal,1
number of participants with 4th grade osteoarthritis.,1
number of participants with a history of ppi use,1
number of participants with a positive or negative status for the indicated hormone receptors,1
number of participants with abnormal physical exam results,1
number of participants with acquired immunodeficiency syndrome (aids) at baseline,1
"number of participants with annual income of $35,001 or more",1
number of participants with any visceral metastatic disease and with only non-visceral disease,1
number of participants with asthma,1
number of participants with asthma and chronic obstructive pulmonary disease (copd),1
number of participants with at least one fracture,1
number of participants with atrial fibrillation,1
number of participants with atrial flutter,1
number of participants with background (bg) methotrexate (mtx) use,1
number of participants with baseline plasma hiv-1 rna <=100000 copies/ml and >100000 copies/ml,1
number of participants with baseline retinal perfusion,1
number of participants with bleeding rates in previous 6-9 months,1
number of participants with blood estradiol level,1
number of participants with bmi >= 27 kg/m2 at baseline,1
number of participants with c-reactive protein (crp) levels,1
number of participants with categorical bmi,1
number of participants with categorical score for pain intensity,1
number of participants with centers for disease control and prevention (cdc) classification,1
number of participants with chronic obstructive pulmonary disease (copd),1
number of participants with clinical global impression-improvement (cgi-i) score: clinician,1
number of participants with clinical global impression-improvement (cgi-i) score: participant,1
number of participants with comorbid copd at baseline,1
number of participants with comorbidities,1
number of participants with concomitant antibiotics prescribed,1
"number of participants with coronary artery disease, n (%)",1
number of participants with crohn's disease,1
number of participants with curative intent,1
"number of participants with current continuous positive airway pressure (cpap) use, n (%)",1
number of participants with diabetes mellitus (including subtypes),1
"number of participants with diabetes mellitus, n (%)",1
number of participants with diagnosis of scleroderma,1
number of participants with different exposure days (ed),1
number of participants with disease severity score,1
number of participants with doctor visits,1
number of participants with drug-induced extrapyramidal symptoms scale (diepss) score,1
number of participants with each hepatitis c viral genotype,1
number of participants with emergency room visits,1
number of participants with estrogen receptor positive,1
number of participants with family history of adhd,1
number of participants with fractures before study,1
number of participants with frequent gerd/dysphagia symptoms,1
number of participants with hemoglobin level within the range of 11-12 grams per deciliter (g/dl),1
"number of participants with high n-terminal pro-brain natriuretic peptide (nt-probnp), pg/ml, n (%)",1
number of participants with histopathological grade,1
"number of participants with history of atrial fibrillation, n (%)",1
number of participants with history of barrett's esophagus,1
number of participants with history of gerd,1
number of participants with history of prior stenting,1
number of participants with hiv-1 rna below assay lower limit,1
"number of participants with hyperlipidemia, n (%)",1
number of participants with î²iii-tubulin positive and negative tumors,1
number of participants with indeterminate colitis,1
number of participants with indicated hiv viral load,1
number of participants with international normalized ratio (inr) results,1
number of participants with interstitial lung disease (ild),1
number of participants with known thrombophilia,1
number of participants with low or high viral load,1
number of participants with lymph node involvement,1
number of participants with lymph nodes (lns) of the indicated clinical n stage,1
number of participants with major surgical history on treated knee,1
number of participants with markers of illness severity,1
number of participants with modified diet,1
number of participants with multiple study sites,1
number of participants with mutation types,1
number of participants with naion diagnosis per calendar year,1
number of participants with naion diagnosis per region of united states,1
number of participants with nocturnal and daytime hypoxemia in copd,1
"number of participants with obstructive lung disease, n (%)",1
"number of participants with obstructive sleep apnea, n (%)",1
number of participants with or without previous ifn use,1
number of participants with pacemaker rhythm,1
number of participants with posterior chamber intraocular lenses,1
number of participants with previous adjuvant/neoadjuvant taxane therapy,1
number of participants with previous ischemic stroke,1
number of participants with prior anti-cancer therapy and diagnostic procedures,1
number of participants with prior chemotherapy,1
number of participants with prior therapy for attention-deficit/hyperactive disorder (adhd),1
number of participants with psychiatric comorbidities,1
number of participants with quit smoking history,1
number of participants with relevant co-morbidities,1
number of participants with remission based on ham-d17 score,1
number of participants with retinal perfusion at baseline,1
number of participants with risk factors for stroke,1
number of participants with risk factors of invasive fungal infections,1
number of participants with spleen involvement,1
number of participants with steroid use during the first clinical demyelinating event,1
number of participants with suicidal behavior and / or ideation on columbia suicide severity rating,1
number of participants with the absence or presence of thumb spasticity,1
number of participants with the cytochrome p450 2d6 (cyp2d6) genotype,1
number of participants with the indicated alanine aminotransferase (alt) levels at baseline,1
number of participants with the indicated alcohol consumption (per day),1
number of participants with the indicated anamnestic thromboembolisms,1
number of participants with the indicated baseline hepatitis b (hb) status,1
number of participants with the indicated baseline hepatitis c (hc) status,1
number of participants with the indicated body weight,1
number of participants with the indicated cdc classification of hiv infection,1
number of participants with the indicated copd severity,1
number of participants with the indicated duration of follow-up,1
number of participants with the indicated duration of follow-up from cohort entry to index date,1
number of participants with the indicated duration of follow-up from gprd registration to index date,1
number of participants with the indicated duration of follow-up from gprd study cohort entry to id,1
number of participants with the indicated duration of follow-up from registration to index date,1
number of participants with the indicated duration of their in-hospital stay,1
number of participants with the indicated eastern cooperative oncology group performance status,1
number of participants with the indicated ecog performance status,1
number of participants with the indicated fish results,1
number of participants with the indicated hemorrhagic risk present,1
number of participants with the indicated hormone receptor status,1
number of participants with the indicated ihc results,1
number of participants with the indicated level of adherence to fsc,1
number of participants with the indicated major risk factors or other key characteristics,1
number of participants with the indicated medical conditions in pancreatic cancer cases/controls,1
number of participants with the indicated medical conditions/drug use in renal cancer cases/controls,1
number of participants with the indicated number of former abortions,1
number of participants with the indicated number of former pregnancies,1
number of participants with the indicated number of metastatic sites,1
number of participants with the indicated number of risk factors,1
number of participants with the indicated payer source,1
number of participants with the indicated primary disease at baseline,1
number of participants with the indicated prior therapy,1
number of participants with the indicated reason for the end of lmwh administration,1
number of participants with the indicated reason for the end of ufh administration,1
number of participants with the indicated risk factors for venous thromboembolism,1
number of participants with the indicated saaipi scores,1
number of participants with the indicated stage of disease at initial diagnosis,1
number of participants with the indicated thromboembolic therapy (specified),1
number of participants with the indicated type of former birth,1
number of participants with the indicted hormonal status (er+ and pr+ / er- and pr-),1
number of participants with thrombophilia accompanied by venous thromboembolism (vte) in anamnesis,1
number of participants with time since central retinal vein occlusion (crvo) diagnosis,1
number of participants with total white cell count,1
number of participants with traumatic lesion,1
number of participants with tumor cells of the indicated histologic grade,1
number of participants with tumor node metastasis (tnm) stage,1
number of participants with type a and b hemophilia,1
number of participants with type of surgery,1
number of participants with type of tumor,1
number of participants with ulcerative colitis,1
number of participants with underlying liver disease,1
number of participants with upper-motor-neuron injuries for sci,1
number of participants with urea levels,1
number of participants with urine calcium excreted over 0.3 grams per day (g/day),1
number of participants with vagal nerve stimulator (vns) use,1
"number of participants with zz genotype (a1-pi deficiency), or sz, z / null or other genotype",1
number of particpants with greater than or equal to high school education,1
number of passes,1
number of past antiretrovials used,1
number of past medications,1
number of patient with injury from other mechanisms,1
number of patient with injury from pull mechanism,1
number of patients at each stage of prostate cancer,1
number of patients hospitalized for chf during 12 months before enrollment,1
number of patients implanted,1
number of patients receiving mechanical ventilation,1
number of patients receiving treatment for diabetes,1
number of patients receiving types of medication infusions,1
number of patients with 0 pregnancies,1
number of patients with 1 pregnancy,1
number of patients with 2 pregnancies,1
number of patients with 3 pregnancies,1
number of patients with a semi-annual hba1c assessment (as determined form medicare claims data),1
"number of patients with adenocarcinoma and time since first line therapy in categories (n= 322, 336)",1
number of patients with an annual eye exam (as determined from medical record review),1
number of patients with an annual eye exam (as determined from medicare claims data),1
number of patients with an annual foot exam (as determined from medical record review),1
number of patients with an annual lipid assessment (as determined from medical record review),1
number of patients with an annual lipid assessment (as determined from medicare claims data),1
number of patients with annual blood pressure assessment (as determined from medical record review),1
number of patients with annual hba1c assessment (as determined from medical record review),1
number of patients with annual hba1c assessment (as determined from medicare claims data),1
number of patients with annual renal function test (as determined from medical record review),1
number of patients with anti-recombinant human acid alfa-glucosidase (anti-rhgaa) immunoglobulin g,1
number of patients with blood pressure <130/80 mmhg,1
number of patients with categorical bmi,1
number of patients with hba1c <9 percent,1
number of patients with hypertension,1
number of patients with infectious and noninfectious etiology of fever,1
number of patients with injury from fall mechanism,1
number of patients with insulin therapy at baseline,1
number of patients with insulin therapy at screening,1
number of patients with intend to treat vcfs,1
number of patients with kidney transplant,1
number of patients with ldl cholesterol <100mg/dl,1
number of patients with liver involvement,1
number of patients with metformin use at baseline,1
number of patients with normal/abnormal left ventricular mass (lvm) z-score and lvm index,1
number of patients with one bleeding ulcer,1
number of patients with peripheral-blood (pb) cluster of differentiation 34+ (cd34+) cell count,1
number of patients with previous abdominal surgery,1
number of patients with screening hba1c greater than or equal to 8%,1
number of patients with screening hba1c less than 8%,1
number of patients with sepsis,1
number of patients with single and multiple ulcers,1
number of patients with sulfonylurea use,1
number of patients with sulfonylurea use at baseline,1
"number of patients with target joints, yes/no",1
number of patients with thiazolidinedione (tzd) use at baseline,1
number of patients with ulcers of different sizes,1
number of patients with ventilator use,1
number of positive axillary nodes,1
number of positive lymph nodes,1
number of positive nodes,1
number of pre-admission medications,1
number of pregnancies (males and females),1
number of pregnancies less than 14,1
number of pregnancies unintended,1
number of prescribed drugs for hypertension,1
number of prescribed maintenance medications,1
number of prescription medications,1
number of previous antihypertensive treatments,1
number of previous attacks per subject,1
number of previous autologous hematopoietic stem cell transplants (hsct),1
number of previous cesarean sections,1
number of previous chemotherapy regimens,1
number of previous disease-modifying anti-rheumatoid drugs (dmards),1
number of previous episodes,1
number of previous episodes of depression during participants life,1
number of previous episodes of depression in past 12 months,1
number of previous episodes of mania during participants life,1
number of previous episodes of mania in past 12 months,1
number of previous fresh art cycles [n(%)],1
number of previous hospitalizations,1
number of previous hospitalizations for copd,1
number of previous lifetime mdd episodes,1
number of previous mdd episodes in the past 24 months,1
number of previous mdd episodes within the last 36 months,1
number of previous mdd episodes/exacerbations in the last 24 months,1
number of previous metastatic chemotherapy regimens,1
number of previous metastatic endocrine therapies,1
number of previous migraines,1
number of previous migraines per month,1
number of previous mixed episodes during participants life,1
number of previous mixed episodes in past 12 months,1
number of previous suicide attempts,1
number of previous therapies,1
number of previous therapies for metastatic disease,1
number of previous vertebral fractures,1
number of previously failed aads per subject,1
number of prior anti-angiogenic agents received in the advanced/metastatic setting,1
number of prior anti-myeloma therapies,1
number of prior attacks,1
number of prior cancer therapies,1
number of prior chemotherapies,1
number of prior chemotherapies for metastatic disease,1
number of prior chemotherapy reginmens,1
number of prior hospitalizations,1
number of prior interventions,1
number of prior itp therapies,1
number of prior lines of systemic therapy,1
number of prior lines of therapy,1
number of prior metastatic chemotherapy regimens,1
number of prior non-surgical therapies,1
number of prior platinum-containing treatment lines,1
number of prior pressure ulcer surgeries,1
number of prior pressure ulcers (pru),1
number of prior radiation therapies,1
number of prior radiation treatments,1
number of prior regimens of participants that did not receive stem cell transplant,1
number of prior regimens of participants that received stem cell transplant,1
number of prior regimens to treat multiple myeloma,1
number of prior salvage regimens,1
number of prior salvage therapies,1
number of prior suicide attempts,1
number of prior surgeries,1
number of prior systemic anti-cancer therapies,1
number of prior systemic treatment regimens for gist,1
number of prior therapies (including prior transplant),1
number of prior therapies for recurrent cancer,1
number of prior transcatheter arterial chemoembolization (tace),1
number of prior tumor necrosis factor (tnf) inhibitors,1
number of quit attempts in the past 12 months,1
number of quit attempts in the past year,1
number of regimens,1
number of relapses in 1 year prior to screening,1
number of relapses in 12 months prior to screening,1
number of relapses in 2 years prior to screening,1
number of relapses in 3 years prior to screening,1
number of relapses in last 2 years,1
number of relapses in period within 2 year prior to signing icf,1
number of relatives with breast cancer,1
number of repeats of guanine adenine adenine (gaa) sequence,1
number of resources/rehabilitative devices used,1
number of respiratory-related hospital admissions and ed visits in the past 12 months,1
"number of restorations, categorical",1
number of ribs fractured,1
number of right eyes enrolled,1
number of risk factors,1
number of schizophrenic episodes or exacerbations in the previous 24 months,1
number of second line hormonal therapies received,1
number of sex partners -ever,1
number of sex partners in the past 3 months,1
number of sites of metastastic,1
number of sites of metastatic disease,1
number of smokers in the household,1
number of smoking years for ever smoked,1
number of stents (per-patient),1
number of stools categorized as per consistency,1
number of stools with signs of blood and visible oil or grease,1
number of subjects in each age range having starr procedure,1
number of subjects on concomitant medications,1
number of subjects using anticholinergics,1
number of subjects with abdominal fistulas at screening,1
number of subjects with best corrected visual acuity of 20/40 or better in each eye,1
number of subjects with bipolar subtype diagnosis at baseline,1
number of subjects with fibromyalgia at baseline,1
number of subjects with icu admission at baseline,1
number of subjects with spinal cord injury (sci) or multiple sclerosis (ms),1
"number of surgeries at the time of enrollment, mean+sem",1
number of swollen joints (sjc),1
number of t1 hypointense lesions,1
number of t2 lesions at baseline,1
number of t2 lesions detected in screening mri (magnet-resonance imaging),1
number of target joint,1
number of teeth removed,1
number of text messages received on an average day,1
number of text messages sent on an average day,1
number of the indicated pre-index period copd-related comorbidities,1
number of the indicated pre-index period treatments,1
number of time constant 1 (t1) gadolinium enhanced (gd+) lesions,1
number of time constant 1 (t1) hypointense lesions,1
number of time constant 2 (t2) lesions,1
number of treated lesions,1
number of treated lesions (per-patient),1
number of treated vessels (per-patient),1
number of tumor,1
number of tumors,1
number of unique baseline medications taken for fibromyalgia (fm; newly-initiated and continuing),1
number of urgent care and ed visits in the past year,1
number of vaginal delivery,1
number of vertebral fractures,1
number of vessels treated per patient,1
number of visits in past 2 years,1
number of visits to emergency room or equivalent facility due to depression in the last 4 weeks,1
number of visits to other specialists due to depression in the last 4 weeks,1
number of visits to primary healthcare provider due to depression in the last 4 weeks,1
number of wet nights during baseline,1
number of wet nights during baseline by stratification criteria,1
number of work hours missed due to depression in the last 4 weeks,1
number of work hours missed in the last 4 weeks,1
number of work hours worked per week,1
number of years after menopause,1
"number of years after menopause, categorical",1
number of years at the hscm asthma clinic,1
number of years in oncology/hematology clinical practice,1
number of years obese,1
number of years of education,1
number of years participant has worn a prosthesis,1
number of years participants smoked,1
number of years post kidney transplantation,1
number of years smoked,1
number of years smoked daily,1
number of years with asthma,1
number of years with diabetes,1
number of years: recurrent genital herpes,1
number relatives with breast cancer,1
number sick-listed,1
number subjects with draining cutaneous fistulas at screening,1
number subjects with perianal fistulas at screening,1
number undergoing endoscopic mucosal resection,1
number with undetectable viral load,1
numeracy,1
numeric pain index,1
numeric rating scale (nrs-11),1
numeric rating scale of pain score,1
numerical rating scale (nrs) overall pain score,1
numerical rating scale (nrs) pain score,1
nurse practitioner,1
nursery location,1
nursing home resident,1
nutritional status as assessed by vitamin a and e level,1
nutritional status as assessed by vitamin d level,1
nvp resistance,1
nyha,1
nyha ( functional classification of the new york heart association),1
nyha (new york heart association) classification,1
nyha functional classification,1
nyha heart failure class,1
o2 cost diagram (ocd),1
oacis-s aberrant behavior score,1
oacis-s anxiety score,1
oacis-s general level of autism score,1
oacis-s hyperactivity/inattention score,1
oacis-s nonverbal communication score,1
oacis-s repetitive behavior score,1
oacis-s restricted interests score,1
oacis-s sensory sensitivity score,1
oacis-s social interaction score,1
oacis-s verbal communication score,1
oad use,1
oad use at screening by class,1
ob-gyn asked about pms,1
obese (bmi > 30 kg/m2),1
obesity distribution,1
"obesity, bmi >= 30",1
obestatin concentration,1
objective numeracy (lipkus),1
objective response,1
objective response to prior ipilimumab treatment,1
observational scale of behavioral distress - revised,1
observed myocardial infarction prevalence,1
obsessive-compulsive disorder (ocd) status,1
obstetric history - # of caesarean deliveries,1
obstetric history - # of vaginal deliveries,1
obstetric history - gravidity,1
obstetric history - parity,1
obstructive apnea index,1
obstructive meibomian gland dysfunction (mgd),1
obvious contribution to the uterine blood supply from the ovarian artery,1
occipital alpha waves-amplitude,1
occipital alpha waves-frequency,1
occiput-to-wall distance,1
occlusion,1
ocs dose (oral corticosteroids),1
oct central subfield,1
oct cystoid abnormality (questionable or definite),1
oct subretinal fluid present (questionable or definite,1
ocular alignment,1
ocular surface disease index,1
ocular surface disease index â± sd,1
odi,1
odi preoperatively,1
"odi score, mean",1
ods composite score,1
oestrogen treatment,1
of childbearing potential,1
office diastolic bp,1
office sitting diastolic blood pressure (dbp),1
office sitting systolic blood pressure (sbp),1
office systolic bp,1
official number of work hours (staff),1
ogtt_si (insulin sensitivity from ogtt),1
ohi main type,1
oi medications for prophylaxis,1
oiliness evaluation score,1
omission errors,1
on antidepressant medication,1
on antiretrovirals at entry,1
on antithrombotic therapy at qualifying event,1
on aspirin,1
on demand or prophylaxis regimen,1
on glucose-lowering therapy,1
on insulin,1
on oral agents,1
on other diabetes medications,1
on second generation antipsychotic medication,1
oncological treatment,1
one or more births,1
one or more ed visits in prior year,1
one or more lifetime ed visits,1
one or more prior chemotherapy,1
one or more prior immunotherapy,1
one or more prior radiotherapy regimens,1
one or more prior surgical treatments,1
one or more severe hypoglycemic events in last six months,1
onset age,1
oocytes retrieved,1
oophorectomy,1
oozing/vesiculation.crusting,1
operability,1
operated knee,1
operating room temperature,1
operating time,1
operation,1
operation duration,1
operation performed (pulmonary resection),1
operative shoulder,1
operative side,1
"operative side: left, right",1
operative vaginal delivery,1
opioid craving,1
opioid dose (morphine equivalent),1
"opioid drug use disorder diagnosis, past 36 months",1
opioid experience,1
opioids for acute migraine,1
optic disc area difference,1
optic disc hemorrhage,1
optic neuritis at onset,1
optical coherence tomography (oct) central subfield mean thickness,1
optical coherence tomography (oct) central subfield thickness,1
optical coherence tomography central macular thickness,1
optical coherence tomography cystoid abnormality,1
optical coherence tomography cystoid abnormality (questionable or definite),1
optical coherence tomography machine,1
optical coherence tomography signal strength,1
optical coherence tomography subretinal fluid present,1
optical coherence tomography subretinal fluid present (questionable or definite),1
oral analgesic within 2h prior to study drug,1
oral anti-diabetic drug (oad) type,1
oral anti-diabetic drugs (oads),1
oral antidiabetic treatment combination at study entry,1
oral antiviral (oav) treatment status,1
oral antiviral treatment status,1
oral cavity sub-site,1
oral contraceptive pill compliance,1
oral contraceptive use within 30 days of visit 1,1
oral corticosteroid use at baseline,1
oral corticosteroids usage at registration,1
oral diabetes medication adherence,1
oral glucocorticosteroid (ocs) use at baseline,1
oral glucose tolerance test,1
oral glucose tolerance test (1st hour),1
oral glucose tolerance test (oggt),1
oral glucose tolerance testing - 120 minute glucose,1
oral glucose tolerance testing - fasting glucose,1
oral glucose tolerance testing - fasting insulin,1
oral hygienic index,1
oral infection,1
oral or inhaled steroid use,1
oral pills contraception,1
oral steroids in last 12 months,1
oral/facial angioedema,1
orchiectomy (surgical castration),1
organ failure site,1
organ involvement at randomization,1
organ of origin,1
organ sites,1
organizational structure,1
organoleptic scores,1
organs procured,1
organs transplanted,1
origin,1
origin of pain,1
origin of sepsis,1
original site of primary cancer,1
original study,1
orthopaedic trauma association (ota) fracture type,1
orthopedic procedure,1
orthopedic surgery,1
orthostatic diastolic blood pressure change,1
orthostatic systolic blood pressure change,1
osleocalcin,1
osteoarthritis,1
osteoarthritis knee disease duration,1
osteocalcin,1
osteopenia/osteoporosis before ai start,1
osteoporosis cause,1
ostial lesion,1
oswestry disability index (odi),1
oswestry disability index (odi) score,1
ota fracture classification,1
other adults in the home,1
other anticoagulant,1
other axis 1 disorder in distant relative of participant,1
other axis 1 disorder in parents of participant,1
other axis 1 disorder in second degree relative of participant,1
other axis 1 disorder in sibling or child of participant,1
other baseline characteristics,1
other cancer prior to baseline,1
other central venous catheter (cvc) in place prior to angelâ® catheter insertion,1
other chronic diseases present,1
"other conditions, based upon self-report",1
other diabetes medications,1
other extra-nodal lesions,1
other food allergy,1
other illicit substance use,1
other laboratory results: international normalised ratio,1
other laboratory results: prothrombin time,1
other medical problems at baseline,1
other oral anti-diabetic drugs,1
other prior anti-cancer therapy,1
other prior nervous system disorders,1
other psychiatric disorder,1
other substance use disorder,1
other treatments for diabetes prior to study,1
others,1
outcome,1
outcome expectancies for engaging in rape,1
outcome expectancies for intervening,1
outcome expectations for exercise score,1
outcome of immune tolerance induction (iti) treatment,1
outcome of induction of abortion,1
outcome of induction of labor,1
outpatient,1
outpatients,1
ovarian vein reflux,1
ovarian volume,1
ovaries seen,1
over the knee cast,1
overactive bladder questionnaire,1
overall caries burden at baseline,1
overall disease severity at baseline,1
overall duration of hospital stay,1
overall hand pain,1
overall mean weight,1
overall motzer score,1
"overall number of participants, by phase",1
overall pathologic stage,1
overall response at screening,1
overall stage,1
overall stage of disease,1
overall symptom score,1
overnight change on finger tapping task,1
overt aggression scale-modified (oas-m) (kay et al 1988),1
overt aggression scale-modified (oas-m).,1
owerweight (bmi 25â€“30 kg/m2),1
oxford score (hip or knee as appropriate),1
oxidized-glutathione,1
oxygen consumption,1
oxygen desaturation index (odi4),1
oxygen desaturation type qualifying patient for enrollment,1
oxygen pulse,1
oxygen saturation,1
oxygen support,1
oxygen uptake efficiency slope (oues),1
oxygen use,1
oxygen use at baseline,1
p. aeruginosa tobramycin minimal inhibitory concentration (mic),1
p.s.(performance status)[the eastern cooperative oncology group (ecog) criteria],1
p:f ratio,1
p1np,1
p21 status,1
paced qrs duration,1
pacing indication: permanent atrial fibrillation and high-grade av block,1
"pack-years, smokers only",1
pack years smoking,1
packed rbc (prbc) transfusion burden,1
packs per day currently smoked,1
padc (caregivers assessment of disease control),1
pafio2:fio2 ratio less than or equal to 200 mm hg,1
pagi-sym- gerd sub score,1
pagi-sym- lower abdominal pain sub score,1
pagi-sym- upper abdominal pain sub score,1
pagi-sym nausea/vomiting predominant symptom,1
pah-specific therapy at baseline,1
pah history,1
pah medications at baseline,1
pah subtype,1
pain-related symptoms,1
pain (baseline) visual analog scale (0-10),1
pain (number rating scale),1
"pain (visual analogue score, vas)",1
pain (y/n),1
"pain at its worst in last 24 hours (scale, 0-10)",1
pain bothersome index score at baseline,1
pain catastrophizing score,1
pain during dressing changes,1
pain frequency index score at baseline,1
pain in last 4 weeks (interference with daily activities),1
pain in orthostatic position,1
pain in supine position,1
pain intensity,1
pain intensity-numeric rating scale (pi-nrs),1
pain intensity and back pain disability,1
pain intensity in the past week,1
pain intensity on 100 mm visual analog scale (vas). 0=no pain 100=worst possible pain,1
pain intensity rating,1
pain killer (opioid),1
pain measured by visual analogue scale (vas),1
pain numeric rating scale,1
pain rating index,1
pain rating on the visual analog scale (vas),1
pain relief experienced with as needed analgesics,1
"pain score (numeric rating scale , 0-10)",1
pain score at triage,1
pain scores,1
pain severity,1
pain severity score,1
pain status,1
pain syndrome,1
pain type,1
pain visual analog scale (vas),1
pain visual analog scale at baseline,1
pain visual analogue scale (vas) scores,1
pain when transfer,1
pain with intercourse,1
pain: nirschl staging (0 to 7),1
pain: visual analogue scale (0 to 10),1
paindetect,1
paindetect (0-38),1
pakt statusstatus at registration via central path review,1
palliative performance scale - stratification variable,1
palmoplantar psoriasis surface area ppsa,1
palpable spleen length below the costal margin,1
pancreatectomy,1
pancreatic acinarization,1
pancreatic mass location,1
pancreatic mass size,1
pancreatic stent placement,1
pancreatic tumour location,1
pancreatography,1
panel reactive antibody (pra) group,1
panic attack scale (pas),1
panic disorder severity scale,1
panic disorder severity scale (pdss) - primary outcome,1
panns positive and negative symptom scale,1
panss marder anxiety/depression factor score,1
panss marder disorganized thoughts factor score,1
panss marder factor anxiety/depression symptom score,1
panss marder factor disorganized thought symptom score,1
panss marder factor hostility/excitement symptom score,1
panss marder factor negative symptom score,1
panss marder factor positive symptom score,1
panss marder hostility/excitement factor score,1
panss marder negative symptoms factor score,1
panss marder positive symptoms factor score,1
panss positive and negative subscale scores combined,1
panss total,1
pap test in last four years,1
par with the indicated 1993 center for disease control and prevention (cdc) baseline classification,1
para,1
para-aortic lymph node,1
parameter in clinical decline,1
"parameter of hematologic response - none (non-secretory myeloma, bone marrow only)",1
parameter of hematologic response - serum immunoglobulin free light chain >= 10 mg/dl,1
parameter of hematologic response - serum immunoglobulin free light chain >= 10mg/dl,1
parameter of hematologic response - serum immunoglobulin free light chain >=10mg/dl,1
parameter of hematologic response - serum m-spike >= 1 g/dl,1
parameter of hematologic response - serum m-spike >= 1g/dl,1
parameter of hematologic response - urine m-spike >= 200mg/24 hours,1
parameter of hematologic response: serum immunoglobulin free light chain >= 10 mg/dl,1
parameter of hematologic response: serum m-spike >= 1 mg/dl,1
parameter of hematologic response: urine m-spike >= 200 mg/24 hours,1
parameters of hematologic response - serum m-spike >=1g/dl,1
paraneoplastic syndromes,1
paraprotein,1
paraprotein at study entry,1
parasite count (median),1
parasite counts,1
parathyroid hormone (pth) level,1
parathyroid hormone at baseline,1
parathyroid hormone category,1
parathyroide hormon serum level,1
parent's education,1
parent's employment status,1
parent's relation to child,1
"parent-rated attention-deficit scale (fbb-hks): total score, severity",1
"parent-rated oppositional defiant/conduct disorders scale (fbb-ssv): total score, severity",1
parent body mass index (kg/m^2),1
parent child interaction teaching scale (pcits),1
parent completing questionnaire has degree or higher degree,1
parent education,1
parent employment status,1
parent modeling 1: dietary choices (wcss),1
parent modeling 2: self-monitoring (wcss),1
parent modeling 3: physical activity (wcss),1
parent modeling 4: weight and body concerns,1
parent resource empowerment,1
parent stress index (psi) child domains,1
parent stress index (psi) parent domains,1
parent stress index (psi) total stress and life stress,1
parent weight (lb.),1
parental asthma,1
parental education,1
parental history of myopia,1
parental history of type ii diabetes mellitus,1
parental smoking,1
parenting sense of competence (psoc) scale,1
parenting stress - parenting stress index - third edition (psi-3),1
parents' index of quality of life - atopic dermatitis score,1
paretic side,1
parietal alpha waves-frequency,1
parity (full term pregnancies),1
parity (number of previous live births),1
parity at enrollment,1
parity category,1
parkinson's disease quality of life (pdqol) total score,1
parkinson's disease questionnaire 39 (pdq-39) summary index,1
parotid gland volumes,1
parous,1
paroxysmal af,1
parsonnet score,1
partial mayo score,1
partial mayo score at baseline,1
partial pressure of carbon dioxide (paco2),1
partial pressure of o2 (pao2),1
participant's global assessment visual analog scale at baseline,1
participant's predisposition to hypersensitivity,1
participant-assessed pruritus visual analog scale (vas) score at baseline,1
participant-reported history of cataract,1
participant body mass index,1
participant cancer histology,1
participant characteristics,1
participant classification,1
participant from enrolling institutions,1
participant global assessment of disease status,1
participant opioid status,1
participant or caregiver's assessment of participant's overall well-being,1
participant pain visual analog scale,1
participant rating using the karnofsky/lansky performance status scale,1
participant scores on national institutes of health stroke scale,1
participant social status : current living situation,1
participant social status : current marital status,1
participant weight at baseline,1
participant with prior radiation,1
participant with prior surgery,1
participants' completion of 6 blinded cycles,1
participants' lipase intake in units per day,1
participants by disease phase,1
participants categorized by site of metastasis,1
participants categorized by the number of pack years smoked,1
participants categorized by the number of packs currently smoked per day,1
participants coughing since â‰¥ 3 days at time of enrollment,1
participants diagnosis,1
participants hospitalized for uc in past 12 months,1
participants in the united states,1
participants of participants who have ever had a mri for their current lbp,1
participants on anti-diabetic medications,1
participants on anti-hypertensive medications,1
participants on lipid lowering medications,1
participants on opioid therapy,1
participants on specific medication,1
participants per treatment group,1
participants screened for colon cancer,1
participants summarized by number of adverse prognostic factors,1
participants summarized by number of adverse prognostic factors excluding intermediate karyotype,1
participants who did not receive stem cell transplant disease status(progressive disease)/enrollment,1
participants who received stem cell transplant disease status at enrollment,1
participants who report all or most of my friends smoke,1
participants who used corticosteroids for initial attack,1
participants who were refractory to the most recent previous anti-leukemic treatment,1
participants with 5q(-) (31-33) chromosomal abnormality,1
participants with a alanine aminotransferase (alt) of >2x normal upper limit,1
participants with a well controlled asthma week at study entry.,1
participants with acute exacerbations in past 12 months,1
participants with asthma,1
participants with at least 1 lesion,1
participants with at least one cardiovascular risk factor,1
participants with at least one concomitant disease,1
participants with at least one episode of depression,1
participants with at least one episode of hypomania,1
participants with at least one episode of mania,1
participants with at least one episode of mixed episode,1
participants with at least one thromboembolic risk factor,1
participants with baseline cardiac troponin (central laboratory),1
participants with comorbidities,1
participants with current diagnosis at stage iv,1
participants with diagnosis of cancer type,1
participants with dominant and non-dominent limb involvement,1
participants with epilepsy,1
participants with erosions,1
participants with evidence of osteopenia/osteoporosis,1
participants with extramedullary plasmacytomas,1
participants with fasting blood glucose at the start of treatment with metact combination tablets,1
participants with fasting insulin at the start of treatment with metact combination tablets,1
participants with gonadotrophin stimulated assisted reproductive technology (art) cycle,1
participants with grandparents born in japan,1
participants with hba1c (ngsp value) at the start of treatment with metact combination tablets,1
participants with high calcium++,1
participants with high lactate hydrogenase (ldh),1
"participants with hip diagnosis (n, %)",1
participants with history of nephrolithiasis,1
participants with history of tuberculosis,1
participants with hiv pvl <200 copies/ml,1
participants with hypocomplementemia,1
participants with inadequate response/intolerance to prior anti-tumor (tnf) therapy (infliximab),1
participants with known hiv reactivity,1
participants with lumbar stenosis,1
participants with lytic bone lesions present,1
participants with metastases at study entry,1
participants with moderate psoriasis according to the investigator's global assessment (iga),1
participants with ongoing therapy for uc at enrollment,1
participants with orthostasis,1
participants with perennial allergic rhinitis,1
participants with plasma hiv-1 rna < 400 copies/ml,1
participants with previous anti-leukemic transplant regimens,1
participants with prior anticancer therapy,1
participants with prior antidepressant trials,1
participants with prior antineoplastic therapy,1
participants with prior chemotherapy regimen,1
participants with prior depressive episodes,1
participants with prior medical condition,1
participants with prior radiation therapy,1
participants with prior radiotherapy to brain,1
participants with risk factors,1
"participants with sacral trauma (n, %)",1
participants with significant medical conditions in past 6 months,1
participants with skeletal survey results,1
participants with surgical history,1
participants with the indicated investigational's static global assessment (isga) score at baseline,1
participants with tophi,1
participating site location,1
participation by cohort,1
pasi - (psoriasis area and severity index),1
past-month use,1
past and current tobacco usage,1
past antidepressant use,1
past hearing aid use,1
past history of depression(self reported),1
past lower back surgery,1
past medical history,1
past medication for olp,1
past psychiatric conditions: major depressive disorder,1
past smoker,1
past substance use disorder,1
past work history,1
patching duration at randomization,1
paternal education,1
pathogens isolated at baseline,1
pathologic diagnosis,1
pathologic n stage,1
pathologic subtype,1
pathologic t stage,1
pathologic tumor size,1
pathologic tumor stage,1
pathological diagnosis of osteosarcoma at study entry,1
"pathological diagnosis, customized",1
pathology of thyroid carcinoma,1
pathology subtype,1
patient's global assessment of disease activity,1
"patient's global assessment of disease severity (patga) (n=431, 430, 430)",1
patient's global impressions of improvement (pgi-i) rate,1
patient's global impressions of severity (pgi-s) score,1
patient's location in the hospital upon enrollment,1
patient's pain level 24 hours prior to surgery,1
patient's perception of bladder condition,1
patient-reported overall pain,1
patient-reported performance status,1
patient-reported submental fat rating scale (pr-smfrs),1
patient-reported worst pain (continuous),1
patient-sf36 (short form 36) domain scores,1
patient activation,1
patient alert and oriented,1
patient assessment of flaking,1
patient assessment of itch,1
patient assessment of pain,1
patient assessment of upper gastrointestinal disorders-quality of life (pagi-qol) total score,1
patient body mass index (bmi),1
patient counts by gleason score,1
patient entrance skin dose,1
patient global assessment (1â€“100),1
patient global assessment (ptga),1
patient global assessment (ptga) of disease activity,1
patient global assessment of disease activity - visual analog scale (vas),1
patient global assessment of disease activity (0-to- 100 millimeter visual analog scale),1
patient global assessment of illness (pgai),1
patient global assessment of pain,1
patient global assessment of pain (0- to- 100-mm visual analog scale),1
patient global assessment of psoriasis,1
patient global impression of severity (pgi-s),1
patient global impression of severity (pgi-s) scale,1
patient global impressions of severity (pgi-s) scale,1
patient global impressions of severity (pgi-severity),1
patient health questionnaire-15,1
patient health questionnaire-9 items (phq-9),1
patient health questionnaire (phq-9),1
patient health questionnaire (phq-9) depression score,1
patient health questionnaire (phq),1
patient health questionnaire (phq)-9,1
patient health questionnaire (phq)9 depressive symptoms,1
patient health questionnaire (phq9),1
"patient health questionnaire (range 0 [best] -27[worst]), continuous",1
patient health questionnaire 8 (phq-8),1
patient health questionnaire 9-item (phq-9),1
patient health questionnaire â€“ 9,1
patient health questionnaire â€“ 9 how often,1
patient health questionnaire depression subscale (phq-9),1
patient income (categorical),1
patient pain score,1
patient panel reactive antibody (pra)(%),1
patient perception of bladder condition (pbc/ppbc),1
patient perception of bladder condition (ppbc) at baseline,1
patient perception of intensity of urgency scale (ppius),1
patient pruritis scale (vas),1
patient use of psychotropic medications (categorical),1
"patient weight, kg",1
patient/donor cytomegalovirus (cmv) infection status,1
patient/donor sex match,1
patient: donor gender,1
patientâ€™s global assessment of disease activity- visual analog scale (ptgada-vas),1
patientâ€™s global assessment score,1
patientâ€™s global impressions of severity (pgi-s),1
patients completing survey,1
patients had to meet the ali criteria,1
patients that had been splenectomized,1
patients treated with sagb by solicited teams,1
patients with a second surgery,1
patients with at least one surgery,1
patients with bone metastases,1
patients with current pathological diagnosis,1
patients with diabetes mellitus,1
patients with dryness,1
patients with family history of coronary artery (cad),1
patients with history of diabetes mellitus,1
patients with history of hyperlipidemia,1
patients with history of hypertension,1
patients with history of previous coronary artery bypass graft (cabg),1
patients with history of previous percutaneous coronary intervention (pci),1
patients with ischemic heart disease,1
patients with mild and moderate hyperpigmentation,1
patients with one or more hospitalization in the previous year,1
patients with recist evaluable disease,1
patients with two or more copd exacerbation in the previous year,1
patients with/without vitamin d deficiency,1
pattern of work,1
"pbro2 (mm hg) (n=17, 22)",1
pc20 (mg/ml),1
pca-3 score,1
pca related intrusive ideation,1
pca related knowledge,1
pca related negative expectancies,1
pca related perceived risk,1
pca related positive expectancies,1
pci,1
pcl-c,1
pcs12,1
pcwp,1
pd-l1 expression level,1
pd-l1 tumor expression status,1
pd qualify of life scale,1
pd symptoms present,1
pdai index total score,1
pdq-39 total,1
peak expiratory airflow rate,1
peak expiratory flow,1
peak flow rate,1
peak historical inhibitor titre recorded,1
peak inhibitor titre,1
peak inspiratory pressure,1
peak mixed meal tolerance test (mmtt) c-peptide,1
peak oxygen consumption,1
peak oxygen consumption percentage of predicted value (vo2peak%),1
"peak oxygen consumption rate, ml/kg/min",1
peak oxygen consumption(vo2peak),1
peak oxygen uptake,1
peak stress diastolic bp,1
peak stress systolic bp,1
peak suds during exposure,1
peak transaortic jet velocity,1
peak treadmill running speed,1
peak urine flow rate,1
peak urine flow rate (qmax),1
peak vo2 (ml/kg/min),1
peanut-specific ige,1
peanut skin prick test score,1
pediatric anxiety rating scale,1
pediatric anxiety rating scale (pars),1
"pediatric anxiety rating scale, 5-item total",1
pediatric asthma score at presentation,1
pediatric crohn's disease activity index (pcdai) score,1
pediatric migriane disability assessment score (pedmidas),1
pediatric patients,1
pediatric quality of life (pedsql) summary score,1
pediatric quality of life inventory family functioning,1
pediatric quality of life inventory health related functioning,1
pediatric vs. adult donor,1
peep (positive end-expiratory pressure),1
pelvic obliquity,1
pelvic organ prolapse,1
pelvic organ prolapse quantification,1
pelvic radiation,1
pelvic radiotherapy (categorical),1
pelvic rotation,1
pelvic tilt,1
pemphigus vulgaris disease activity score: cutaneous,1
pemphigus vulgaris disease activity score: mucosal,1
pemphigus vulgaris disease activity score: other organ system,1
penetration-aspiration score,1
"penetration-aspiration, categorical",1
penicillin allergy history,1
penn alcohol craving scale score,1
penta/pactg site,1
peptide yy3-36 (pyy3-36) concentration,1
perceived control over hot flashes,1
perceived hot flash interference (hot flash related daily interference scale; hfrdis),1
perceived stress scale,1
perceived stress scale with 14 items,1
percent-predicted fevâ‚,1
"percent ""off"" time (%)",1
percent (%) toenail onychomycosis disease involvement,1
percent blast cells in bone marrow,1
percent body surface area (bsa) affected by psoriasis,1
percent body surface area (bsa) involved,1
percent body surface area (bsa) moveable sclerosis at baseline,1
percent body surface area (bsa) nonmoveable sclerosis at baseline,1
percent body surface area (bsa) of involvement,1
percent bsa to be treated at baseline,1
percent cd4,1
percent change in fev1 after bronchodilator,1
percent circulating blasts in peripheral blood,1
percent days abstinent,1
percent days of heavy drinking,1
percent drinking days per week,1
percent eosinophils in blood,1
percent heavy drinking days,1
percent heavy drinking days per week,1
percent leukemic blast cells,1
percent of body surface area (bsa) involvement of ps,1
percent of giant cells in tumor on pre-treatment biopsy,1
percent of glottic opening,1
percent of glycosylated hemoglobin,1
percent of site bleeding,1
percent of subjects with pra >/= 20% in last 12 months,1
percent of total sleep time,1
percent overweight,1
percent platelet aggregation at 0 weeks,1
percent predicted fev1 (%),1
"percent predicted fev1, categorical",1
percent predicted forced expiratory volume (fev1),1
percent predicted forced expiratory volume in 1 second (% predicted fev1),1
"percent predicted forced expiratory volume in 1 second (fev1), continuous",1
"percent predicted forced expiratory volume in 1 second (ppfev1), continuous",1
percent stenosis at baseline,1
percent stenosis at randomization,1
percent stenosis of symptomatic qualifying artery,1
percent toenail onychomycosis disease involvement,1
percent total body surface area (tbsa),1
percentage coefficient of variation,1
percentage days abstinent alcohol,1
percentage days abstinent all substances,1
percentage fat mass,1
percentage fat mass standard deviation score,1
percentage lean mass,1
percentage of body involvement,1
percentage of days abstinent,1
percentage of glycosylated hemoglobin (hba1c),1
percentage of interactions with adult clients (staff),1
percentage of lvef (left ventricular ejection fraction),1
percentage of methemoglobin,1
percentage of obese participants,1
percentage of parabasal cells at screening,1
percentage of participants at baseline who were taking a corticosteroid,1
percentage of participants at baseline who were taking thiopurine,1
percentage of participants at baseline with hai assay titers â‰¥ 1:40,1
percentage of participants given disease modifying anti-rheumatoid drugs (dmard),1
percentage of participants in each disease stage,1
percentage of participants in each eastern cooperative oncology group (ecog) status,1
percentage of participants in each epidermal growth factor receptor (egfr) mutation status category,1
percentage of participants in each histology category,1
percentage of participants in each smoking status category at study entry,1
percentage of participants per co-morbid (concomitant) diseases,1
percentage of participants per reason for choice of treatment with tigecycline,1
percentage of participants per type of infection: infection of skin and soft tissue,1
percentage of participants per type of infection: intra-abdominal,1
percentage of participants per type of infection: other infections,1
percentage of participants prescribed with antiviral courses,1
percentage of participants prescribed with concomitant antibiotics,1
percentage of participants prescribed with concomitant systemic antifungals,1
percentage of participants prescribed with immunosuppressant drugs,1
percentage of participants who had unprotected sex in the past month,1
percentage of participants who were responders,1
percentage of participants with antibiotic treatment(s) taken 30 days prior to tigecycline treatment,1
percentage of participants with asthma,1
percentage of participants with back pain,1
percentage of participants with cardiovascular disease,1
percentage of participants with creatinine clearance outside normal range,1
percentage of participants with diabetes,1
percentage of participants with disease activity score based on 28-joints count (das28) remission,1
percentage of participants with duration in health plan before first study oc prescription,1
percentage of participants with elective or emergency hospital admission,1
percentage of participants with gynecological disorders,1
percentage of participants with hyperlipidemia,1
percentage of participants with hypertension,1
percentage of participants with length of stay in health plan,1
percentage of participants with microbiological sampling results: direct examination,1
percentage of participants with microbiological sampling results: positive blood culture,1
percentage of participants with model for end-stage liver disease (meld) score,1
percentage of participants with optimal sleep assessed using mos-ss,1
percentage of participants with stage iiia vs iiib disease at baseline,1
percentage of participants with target joint present,1
percentage of participants with thyroid disease,1
percentage of participants without enthesitis,1
percentage of participants without peripheral arthritis,1
percentage of predicted fev1 (%) pre-bronchodilator,1
percentage of superficial cells at screening,1
percentile for bmi,1
percentile for height,1
percentile for weight,1
percentile of mean thigh circumference,1
percentile weight for length,1
perceptions of parenting an infant - what being the parent of a baby is like (wpl-r) scale,1
percutaneous coronary intervention during index admission,1
performance on the california verbal learning test,1
performance on the digit span subtest of the wechsler adult intelligence scale -iii,1
performance on the digit vigilance test,1
performance on the trail making test part a,1
performance on the trail making test part b,1
performance on the wisconsin card sorting test,1
performance on the wisconsin card sorting test (wcst),1
performance status - eastern cooperative oncology group scale (ecog),1
performance status - eastern cooperative oncology group scale (ecog) score,1
performance status (at start of treatment with leuplin sr 11.25 mg injection),1
performance status (at the start of treatment with leuprorelin acetate 11.25 mg for injection),1
performance status (ecog scale),1
performance status (ecog),1
performance status (p.s.),1
performance status scale for head and neck cancer (pss-hnc),1
"performance status, eastern cooperative oncology group (ecog)",1
performance status: eastern cooperative oncology group (ecog),1
performance status: ecog,1
perfusion index,1
peri-implant mucosa thickness at 1 mm,1
perineal trauma,1
period between date of first dianosis and date of informed consent,1
period between first dose dates of leuproride acetate (over-the-counter) and the study drug,1
period of prior chemotherapy,1
periodontal inflamed surface area (pisa),1
perioperative albumin levels,1
perioperative hemoglobin levels,1
perioperative temperature measurements,1
perioperative warming,1
peripheral artery disease history,1
peripheral blast,1
peripheral blast blood count,1
peripheral blood blasts (number of blasts/total white blood cell count),1
peripheral blood circulating plasma cells,1
peripheral neuropathy,1
peripheral vascular disease (pvd),1
periprocedural fluid volume,1
permanent atrial fibrillation [af] history,1
persistent vitreous hemorrhage,1
persistent/permanent atrial fibrillation,1
personal and social performance (psp) scale score,1
personal and social performance scale (psp) score,1
"personal health questionnaire depression scale, 8-items (phq-8)",1
personal history of skin cancer,1
pessary satisfaction,1
pga,1
pga - physician's global assessment.,1
pga score,1
phakic lens status on clinical exam,1
pharmacologic sleep aid needed to sleep,1
pharmacotherapy use during most recent quit attempt,1
phase i - estradiol,1
"phase i - lh, fsh",1
"phase i - testosterone, androstenedione, 17-oh progesterone",1
phase ii - estradiol,1
"phase ii - lh, fsh",1
"phase ii - testosterone, androstenedione, 17-oh progesterone",1
phfs behaviour,1
phfs total,1
phfs worry,1
philadelphia chromosome disease status,1
phosphocreatine recovery time constant,1
phosphorus serum level,1
phq-9 depression score,1
physical activity (ppaq),1
"physical activity level, categorical",1
"physical activity, number of steps daily",1
physical component summary score from sf-36,1
physical examination,1
physical examination performed at postinjection timepoint,1
physical examination performed at preinjection timepoint,1
physical exercise,1
physical function (health assessment questionnaire [haq]),1
"physical function, health assessment questionnaire disability index (haq-di)",1
physical functioning index (abbreviated short form-12),1
physical health-related quality of life,1
physical self-maintenance scale,1
physical self maintenance scale,1
physical work capacity,1
physician's assessment of peripheral neuropathy,1
physician's decision to use bevacizumab,1
physician's global assessment of disease activity,1
physician's global assessment score (pga),1
physician's global assessment visual analog scale at baseline,1
physician's global severity assessment (pgsa),1
physician assessment of peripheral neuropathy,1
physician assessment of peripheral neuropathy] [2],1
physician assessment of sensory neuropathy,1
physician clinical impression,1
physician criteria for initiating forteo therapy,1
physician global assessment (1â€“100),1
physician global assessment (pga),1
physician global assessment of disease status,1
physician global assessment of skin activity (likert),1
physician global assessment of skin activity (vas),1
physician global assessment per vas,1
physician global assessment per visual analogue scale (vas),1
physicianâ€™s global assessment score,1
"piboonniyom reu (reticular, erythematous and ulceration) severity score",1
pidd type,1
pioglitazone daily dose,1
pior mi,1
piper fatigue scale,1
pittsburgh sleep quality index (psqi),1
pittsburgh sleep quality index (psqi) sleep hours,1
pittsburgh sleep quality index (psqi) sleep quality,1
pittsburgh sleep quality index addendum for ptsd,1
pittsburgh sleep quality index global,1
pittsburgh sleep quality inventory,1
pituitary gland mri volume (v1),1
piv catheter insertion location,1
pivka-ii,1
place of residence,1
placental location,1
plan to bottle-wean by 2 years old,1
planned chemotherapy,1
planned concurrent chemotherapy,1
planned high-risk surgical procedures,1
planned number of chemotherapy cycles,1
planned taxane therapy,1
planning on using an evidence-based quitting aid,1
plaque index,1
plaque index (pi),1
plaque volume,1
plasma alt,1
plasma ast,1
plasma bnp,1
plasma cells in the bone marrow,1
plasma chitotriosidase,1
plasma cholesterol (mg/dl),1
plasma cortisol response to standardized dexamethasone/corticotropin releasing hormone (dex/crh),1
plasma creatinine,1
plasma dci (nmol/ml),1
plasma endothelin,1
plasma gb3,1
plasma gb3 (globotriaosylceramide),1
plasma glucose,1
plasma hcv rna,1
plasma hdl-c,1
plasma hepatitis c virus (hcv) ribonucleic acid (rna) (log 10),1
plasma hiv-1 rna,1
plasma hiv-1 rna level,1
plasma hiv-1 rna level at enrollment,1
plasma hiv-rna at delivery,1
plasma hiv rna,1
plasma hiv rna at entry,1
"plasma hiv rna, copies/ml",1
"plasma hiv rna, log10 copies/ml",1
plasma hiv viral load,1
plasma î³-glutamyl transferase,1
plasma insulin level,1
plasma ldl-c,1
plasma ldl cholesterol concentration,1
plasma log10 copies/ml vl hiv-1 rna,1
plasma minocycline (ng/ml),1
plasma myo-inositol (myo) (nmol/ml),1
plasma nitric oxide,1
"plasma norepinephrine, supine",1
"plasma norepinephrine, upright",1
plasma phylloquinone (nmol/l),1
plasma renin activity (pra) [uric acid],1
plasma renin activity (pra) [vitamin d],1
plasma total cholesterol,1
plasma triglycerides,1
plasma triglycerides (mg/dl),1
plasma uric acid concentration,1
plasma uric acid level,1
plasma zinc,1
plasminogen activator inhibitor 1 (pai-1),1
platelet,1
platelet (x1000 platelets/î¼l),1
platelet aggregation by adenosine diphosphate (adp),1
platelet aggregation by epinephrine,1
platelet count (plt),1
platelet count at baseline (in 1000/ul),1
platelet count at screening,1
platelets in peripheral blood,1
"platelets, continuous",1
platinum-containing regimen,1
platinum containing regimen,1
platinum therapy,1
plays video games,1
pleural effusion/ascites retention,1
pneumococcal risk factors,1
point prevalence abstinence,1
polycystic ovary syndrome,1
poms depression-dejection scale,1
poor lvef,1
pop stage,1
port access vein,1
port configuration,1
port score,1
port/psi score,1
portal vein involvement,1
positional headache,1
positive affect ratio (par) in derogatis affects balance scale (dabs),1
positive and negative panss subscales score,1
positive and negative symptom scale (panss),1
positive and negative syndrome scale-excited component,1
positive and negative syndrome scale-excited component (panss-ec) total score,1
positive and negative syndrome scale (panss) - general psychopathology subscale score,1
positive and negative syndrome scale (panss) - negative subscale,1
positive and negative syndrome scale (panss) - negative subscale score,1
positive and negative syndrome scale (panss) - positive subscale,1
positive and negative syndrome scale (panss) - positive subscale score,1
positive and negative syndrome scale (panss) - total score,1
positive and negative syndrome scale (panss) score,1
positive and negative syndrome scale positive subscale score,1
positive and negative syndromes scale (panss),1
positive and negative syndromes scale (panss) total score,1
positive antibody response,1
positive biopsy samples (continous),1
positive breath test results,1
positive cough stress test,1
positive culture,1
positive culture result for n. gonorrhoeae,1
positive end expiratory pressure,1
positive fecal occult blood test (fobt),1
positive for human papillomavirus (hpv+),1
positive hepatitis b surface antigen (hbsag),1
positive influenza test by local testing,1
positive mycological culture in toenail samples,1
positive nodes,1
positive p/q type voltage-gated calcium channel (vgcc) antibodies at screening,1
positive research urine toxicology screening at delivery,1
positive response on self -estimated treatment compliance,1
positive thick blood smear,1
positive urine culture,1
positivie and negative syndrome scale (panss) scores,1
positivity of the rheumatoid factor,1
post-anesthetic care unit time (min),1
post-bronchodilator fev1 (forced expiratory volume in 1 second),1
post-bronchodilator fev1% of predicted,1
post-bronchodilator fev1/fvc ratio,1
post-concussion symptom scores,1
post-dialysis body weight,1
post-dialysis weight,1
post-fev1,1
post-menopausal females,1
post-menopausal healthy females,1
post-menopausal status,1
post-prandial hypoglycemia treatment,1
post-prandial hypoglycemia treatment frequency,1
post-procedure target lesion percent diameter stenosis (%ds),1
post-procedure thrombolysis in myocardial infarction (timi) flow,1
post-tpa baseline/treatment nih stroke scale,1
post-traumatic stress disorder checklist-military version (pcl-m),1
post-void residual urine,1
post-void residual volume (ml),1
post-void residual volume (pvr),1
post brachytherapy,1
post bronchodilator fev1,1
post bronchodilator fev1/fvc ratio,1
post fev1 predicted,1
post traumatic growth inventory,1
post traumatic stress disorder checklist,1
post void dribbling episodes per day,1
post void residual (ml),1
post void residual urine volume,1
postâ€bronchodilator fev1 (forced expiratory volume at one second),1
posterior-wall carotid intima-media (cimt) thickness,1
posterior fossa syndrome,1
posterior vaginal - prolapse repair,1
postoperational pathomorphological diagnosis,1
postoperative ileus,1
postoperative partial pressure of arterial oxygen,1
postoperative total leucocyte count,1
postprandial plasma glucose (ppg) excursion,1
postsurgical anatomy,1
posttraumatic cognitions inventory (ptci),1
posttraumatic stress disorder checklist,1
posttraumatic stress disorder checklist - civilian (pcl-c),1
postvoid residual volume by ultrasound,1
potassium,1
potential anti-oxidant (pao),1
potential hydrogen (ph) monitoring,1
pp,1
"ppfev1, categorical",1
ppi/h2 blocker,1
pppasi - palmoplantar pustulosis area and severity index,1
pq-les-q overall score,1
"pq-les-q overall score (i.e., item 15)",1
practice type,1
prandial increment,1
pre- packed red cell units transfused per year,1
pre-art cd4,1
pre-asct response,1
pre-bleeding duration,1
pre-bleeding episodes per year,1
pre-bronchodilator fev1 (forced expiratory volume in 1 second),1
pre-bronchodilator fev1 percentage of predicted normal (pn) at randomization,1
pre-bronchodilator forced vital capacity (fvc),1
pre-bronchodilator peak flow,1
pre-dialysis weight,1
pre-dilatation performed,1
pre-dose anti-drug antibody (ada) status,1
pre-enrollment anti-hyperglycemic therapy,1
pre-enrollment disease status,1
pre-existing cardiovascular conditions,1
pre-existing hypertension,1
pre-forced expiratory volume in 1 second (fev1),1
pre-glucarpidase (arm a) or pre-lv (arm b) methotrexate plasma conc (umol/l),1
pre-insulin hypoglycemia,1
pre-intervention 25-hydroxyvitamin d3,1
pre-intervention mean arterial pressure,1
pre-intervention parathyroid hormone concentration,1
pre-intervention serum calcium concentration,1
pre-medication,1
pre-op diastolic blood pressure (dbp),1
pre-op epidural,1
pre-op heart rate (hr),1
pre-op systolic blood pressure (sbp),1
pre-operative abstinence intention,1
pre-operative alveolar bone width,1
pre-operative antiplatelet use,1
pre-operative celecoxib,1
pre-operative creatinine,1
pre-operative hemoglobin,1
pre-operative international normalized ratio (inr),1
pre-operative opioid,1
pre-operative platelet count,1
pre-operative prealbumin,1
pre-operative pregabalin,1
pre-operative retroversion,1
pre-operative serum creatinine >2.0 mg/dl,1
pre-operative treatment,1
pre-operative treatment with insulin or antidiabetics,1
"pre-operative treatment, details",1
pre-operative weight,1
pre-operative white blood cell (wbc) count,1
pre-pregnancy height,1
pre-procedural arrhythmia treatment with amiodarone,1
pre-procedural arrhythmia treatment with beta-blockers,1
pre-procedure pain,1
pre-procedure target lesion percent diameter stenosis (%ds),1
pre-randomization outpatient occupational therapy,1
pre-study treatment,1
pre-surgery participant photoguide score,1
pre-surgery physician overall opinion posas score,1
pre-surgery physician photoguide score,1
pre-surgery subject global assessment score,1
pre-transplant diabetes mellitus,1
pre-transplant dialysis,1
pre-transplant disease status,1
pre-treated with endothelin receptor antagonist,1
pre-treated with prostacyclin analogue,1
pre-treatment hcv ribonucleic acid (rna),1
pre-treatment hemoglobin level,1
pre-treatment left atrial fibrosis percentage,1
pre-treatment mucleoside analogues,1
pre-treatment saq score,1
pre-treatment scans,1
pre-treatment visual analogue score,1
pre-treatment weight,1
pre-trial insulin treatment,1
pre-trial treatment of oral antidiabetic drug,1
pre-vaccination antibody titer - b strain,1
pre-vaccination antibody titer - h1n1 strain,1
pre-vaccination antibody titer - h3n2 strain,1
pre-vaccination serum iga antirotavirus titer,1
pre fev1 predicted,1
precut biliary sphincterotomy,1
predicted fev1,1
predicted surgical mortality,1
prednisone and/or systemic oral corticosteroid,1
prednisone dosage at baseline (mg),1
prednisone use at baseline,1
prednisone use at screening,1
predominant location of disease,1
predominant race,1
preference of acupuncture,1
pregnancy,1
pregnancy status (females only),1
pregnancy status (females),1
pregnancy status <females>,1
"pregnancy, 35-37 weeks",1
pregnant,1
pregnant ever,1
prehospital hypotension,1
prehospital hypoxia,1
premature birth,1
prematurity,1
prenatal care initiation,1
prenatal multivitamin or folic acid supplements,1
preop bmi,1
preop left intraocular pressure,1
preop right intraocular pressure,1
preoperative 6-mwd,1
"preoperative and postoperative chemotherapy, customized",1
preoperative antiplatelet therapy,1
preoperative azbio sentence noise score - treated ear,1
preoperative best corrected visual acuity,1
preoperative classification of nyha assessment,1
preoperative haemoglobin,1
preoperative hematocrit,1
preoperative hemoglobin g/dl,1
preoperative hint quiet score - treated ear,1
"preoperative hss score,continuous",1
preoperative iris neovascularization or neovascular glaucoma,1
preoperative maximum temperature,1
preoperative medical condition,1
preoperative medical conditions (description),1
preoperative medications,1
preoperative opioid use,1
preoperative oral temperature,1
preoperative pain,1
preoperative platelet count,1
"preoperative thyroid function test (free t4, ng/dl)",1
"preoperative thyroid function test (t3, ng/dl)",1
"preoperative thyroid function test (tsh, uiu/ml)",1
preoperative total leucocyte count,1
preoperative white blood cell count,1
preoperative work status,1
preparing to overcome prepotency (pop) task - error rate,1
preparing to overcome prepotency (pop) task - reaction time,1
prepregnancy body mass index,1
prepregnancy body status,1
preprocedural pain intensity,1
prescribed ace inhibitors or angiotensin ii receptor blockers (abrs),1
prescribed beta blockers,1
prescribed weekly number of days on pn/iv,1
prescribed weekly pn/iv volume,1
prescribing providers,1
prescription opioid misuse,1
presence of a primary palpabletophus,1
presence of â‰¥ 2 abscesses,1
presence of all lesions,1
presence of an apolipoprotein e e4 allele,1
presence of at least 1 fcî³riiia v allele,1
presence of bleeding from tumor,1
presence of bone and brain metastases,1
presence of bone metastasis,1
presence of bone metastatic disease at enrollment,1
presence of cataract(s),1
presence of causal fbn1 mutation,1
presence of cd19 antigen,1
presence of cd20 antigen,1
presence of cd23 antigen,1
presence of cellulitis,1
presence of center-involved diabetic macular edema regardless of visual acuity,1
presence of center-involved diabetic macular edema with visual acuity impairment,1
presence of cluster of differentiation (cd) 5 antigen,1
presence of down syndrome,1
presence of end-organ dissemination (eod),1
presence of endometrial scar,1
presence of epidural hematoma,1
presence of erectile dysfunction,1
presence of estrogen hormone receptor,1
presence of hgain at entry,1
presence of igî»,1
presence of igîº,1
presence of major depressive episode diagnosed with mini international neuropsychiatric interview,1
presence of malodour,1
presence of metabolic syndrome,1
presence of metastasis,1
presence of metastatic disease at enrollment,1
presence of myometrial scar,1
presence of neuropathy,1
presence of non-target lesions,1
presence of oral ulcerations,1
presence of photoparoxysmal response,1
presence of primary palpable tophus,1
presence of progesterone hormone receptor,1
presence of psychiatric co-morbidity,1
presence of rhonorrhea,1
presence of serious bacterial infection (sbi),1
presence of shoulder subluxation,1
presence of signs and symptoms of candidemia,1
presence of sti at screening visit,1
presence of subarachnoid hemorrhage,1
presence of tbi,1
presence of visceral metastases,1
presence or absence of h. pylori infection,1
presence or absence of visceral metastases,1
presence with at least 1 lesion,1
presence/absence of previous treatment of hiv-infection,1
present smoker,1
presenting condition,1
preserved ejection fraction,1
pressors at randomization,1
pressure pain threshold,1
pressure pain threshold at the most active trigger point,1
pressure support,1
pressure symptoms,1
pressure ulcer (pru) characteristics,1
prestroke function - living at home,1
prestudy ics dose,1
pretreatment 100-millimeter visual analog scale (vas) scores,1
prevalence of hypertension,1
prevalence of hypothyroidism,1
prevalence of overweight,1
prevalence of tuberculosis (tb) in country of birth,1
prevalence of worm eggs in stool,1
prevalent fractures,1
prevalent hypertension,1
prevalent non-vertebral fragility fractures,1
prevalent vertebral fractures,1
prevention of mother-to-child transmission program m2m support group meeting attendance,1
previous (neo) adjuvant chemotherapy,1
previous abortions,1
previous acquired immunodeficiency syndrome (aids) diagnosis,1
previous adjuvant hormone therapy,1
previous alpha-blocker use,1
previous anthracycline,1
previous anti-tumor therapy,1
previous anti-tumor treatment,1
previous antiretroviral (arv) experience: non-nucleoside reverse transcriptase inhibitor (nnrti),1
previous arv experience: protease inhibitor (pi),1
previous back surgery,1
previous benign prostatic hyperplasia - lower urinary tract symptoms (bph-luts) therapy,1
previous benign prostatic hyperplasia therapy,1
previous bph therapy,1
previous bph treatment,1
"previous breast cancer (other), customized",1
previous breast feeding,1
previous cabg,1
previous cannabis use (at any time including last year),1
previous cardiovascular disease (cvd) event,1
previous cardiovascular event,1
previous cataract surgery,1
previous central nervous system treatment,1
previous cesarean deliveries,1
previous cesarean section,1
previous cesareans,1
"previous chemotherapy, no. of patients",1
"previous contraceptive use, marital status, employment,",1
previous deliveries,1
previous device,1
previous diagnosis of astrocytoma or aa before diagnosis of secondary glioblastoma multiforme,1
previous diagnosis with tick-borne illness,1
previous double-blind study treatment,1
previous ectopic pregnancies,1
previous elective terminations,1
previous episode(s) of depression,1
previous episodes of ovarian hyperstimulation syndrome (ohss),1
previous ercp,1
previous erlotinib treatment,1
previous fracture by history or x-ray,1
previous gynecologic surgeries,1
previous history of fracture,1
previous history of multiple myeloma,1
previous history of pressure injury,1
previous history of stroke,1
previous hormone treatment,1
previous hysterectomy,1
previous immunosuppressive therapy,1
previous injections,1
previous insulin at study entry,1
previous insulin treatment,1
previous interventions,1
previous intra-peritoneal (ip) chemotherapy,1
previous ischaemic stroke,1
previous ivig treatment,1
previous lamivudine experience,1
previous major depressive disorder episodes,1
previous management,1
previous medical history,1
previous medication for chronic myeloid leukemia,1
previous multiple sclerosis relapses,1
previous neurological surgical procedures,1
previous non-response type,1
previous nondrug treatment for oab,1
previous nuclear stress,1
previous number of episodes,1
previous number of transplant,1
previous or concurrent gynecological disease(s),1
previous osteoporosis drug use,1
previous osteoporosis therapy,1
previous osteoporotic fracture,1
previous overactive bladder therapy,1
previous panretinal photocoagulation,1
previous penicillin testing history,1
previous pituitary surgery,1
previous plastic stent,1
previous platinum treatment,1
previous preeclampsia,1
previous pregnancies,1
previous pregnancy loss,1
previous preterm delivery,1
previous rheumatoid arthritis treatment,1
previous skeletal-related event (sre) stratification factor,1
previous spontaneous abortion,1
previous sti,1
previous stimulant exposure,1
previous stroke / transient ischemic attack,1
previous stroke or transient ischemic attack (tia),1
previous surgery for pelvic organ prolapse,1
previous surgery for urinary incontinence,1
previous surgical abortion,1
previous systemic treatment (number of regimens),1
previous systemic treatment (six or more regimens),1
previous t2dm regimen,1
previous tamoxifen,1
previous teriparatide use,1
previous therapies,1
previous therapy - intravenous immue globulin,1
previous therapy - plasma exchange,1
previous therapy for benign prostatic hyperplasia,1
previous therapy for benign prostatic hyperplasia (bph),1
previous trastuzumab,1
previous treatment - hormone treatment,1
previous treatment - radiation,1
previous treatment for fi,1
previous treatment for mantle cell lymphoma (mcl),1
previous treatment for nldo,1
previous treatment of inclusion diagnosis,1
previous treatment of multiple myeloma,1
previous treatment received (y/n),1
"previous treatment, n (%)",1
previous treatments,1
previous urate-lowering therapy,1
previous use of antihypertensive drugs,1
previous used toothbrush (mt/pt),1
previous venipuncture,1
previous vertebral fractures,1
previouse number of regimens,1
previously diagnosed with major depressive disorder (mdd),1
previously diagnosed with neither diabetes nor pre-diabetes,1
previously diagnosed with pre-diabetes,1
previously diagnosed with type 2 diabetes,1
previously treated brain metastasis,1
previously treated for alcohol withdrawal symptoms],1
previously treated for head and neck cancer (hnc),1
previously treated history,1
"previously treated with chemotherapy and/or radiotherapy, yes/no",1
primary allergic rhinitis (ar) diagnosis,1
primary basis for diagnosis,1
primary cancer,1
primary cancer diagnosis,1
primary cancer site,1
primary care assessment survey (pcas),1
primary cause of ards,1
primary cause of chronic kidney disease,1
primary cause of chronic kidney disease (ckd),1
primary cause of end stage liver disease (esld),1
primary cause of infertility,1
primary cause of lung injury,1
primary cause of renal failure,1
primary chronic painful condition,1
primary diagnosis (diabetes type i or ii),1
primary diagnosis category (clients),1
primary diagnosis of neovascular age-related macular degeneration,1
primary diagnosis of veteran,1
"primary diagnosis, deep venous thrombosis (dvt)/pulmonary embolism (pe)",1
"primary disease (ra, jra, psa or as)",1
primary disease characteristic,1
primary disease grade,1
primary drug,1
primary focus,1
primary gleason score,1
primary haemostatic treatment,1
primary icu admission diagnosis,1
primary icu diagnosis,1
primary immunodeficiency type,1
primary in place,1
primary indication,1
primary indication for device implant,1
primary indication for permanent pacing,1
primary indication for surgery,1
primary inguinal hernia,1
primary isolated intestine transplant,1
primary osteoporosis diagnosis criteria 2012,1
primary race,1
primary reason for eligibility,1
primary reason for implant,1
primary setting,1
primary site of infection,1
"primary site, no. of patients",1
primary substance,1
primary substance of use,1
primary substance use,1
primary therapy,1
primary transportation to clinic,1
primary treatment pattern for the 6 months preceding enrolment in registry,1
primary treatment type and dose for the 6 months preceding enrolment in registry,1
primary tumor classification,1
"primary tumor estrogen receptors (er)/ progesterone receptors (pgr) status, customized",1
primary tumor resection,1
primary tumor site - ovaries,1
"primary tumor site, oropharynx&larynx/oral cavity&hypopharynx",1
primary tumor status,1
primary tumour location (number of participants),1
primary underlying disease,1
primary vs repeat cesarean section,1
"prior ""first-line"" treatment",1
prior (neo) adjuvant anthracyclines,1
prior (neo) adjuvant anti-her2/neu targeted therapy,1
prior (neo) adjuvant other chemotherapy,1
prior (neo) adjuvant other therapy,1
prior (neo) adjuvant taxane chemotherapy,1
prior (neo) adjuvant/metastatic endocrine therapy,1
prior (neo) adjuvant/metastatic radiotherapy,1
prior aat protein augmentation therapy,1
prior abortions,1
prior adjuvant oxaliplatin therapy,1
prior adjuvant tamoxifen,1
prior adjuvant taxane,1
prior adjuvant therapy was chemotherapy,1
prior adjuvant therapy was endocrine therapy,1
prior af/afl,1
prior allogeneic bone marrow transplant (bmt),1
prior allogeneic hematopoietic stem cell transplant (hcst),1
prior allogeneic hsct and prior relapses,1
prior ami,1
prior analgesic medication,1
prior analgesic use,1
prior angiotensin converting enzyme inhibitor /angiotensin ii type i receptor blocker (ace-i/arb)use,1
prior anthracyclines,1
prior anti- vascular endothelial growth factor for diabetic macular edema,1
prior anti-arrhythmic drug use,1
prior anti-cancer drug group,1
prior anti-cancer therapy,1
prior anti-epileptic medications,1
prior anti-her2 (metastatic) agents,1
prior anti-myeloma therapies,1
prior anti-tumor necrosis factor (tnf) exposure,1
prior anti-tumor necrosis factor (tnf) treatment,1
prior anti-tumor necrosis factor agent,1
prior anti-vegf for diabetic macular edema,1
prior anti-vegf for dme,1
prior anti-vegf treatment for dme,1
prior antiangiogenic therapy,1
prior antiarrhythmic drug therapy,1
"prior anticancer surgeries,",1
prior antiretroviral (arv) treatment use,1
prior aortic surgery,1
prior aromatase inhibitor (ai) therapy within 6 months of enrollment,1
prior autologous stem cell transplant,1
prior autologous transplant,1
prior back surgery,1
prior bevacizumab (as per ivrs),1
prior bevacizumab exposure for mcrc,1
prior biological treatment for this cancer,1
prior biological use for psoriasis,1
prior biological use for rheumatoid arthritis (ra),1
prior biopsy,1
prior biopsy only,1
prior bisphosphonate use,1
prior bisphosphonate user,1
prior bleeding events felt to be related to underlying disease,1
prior blood pressure â‰¥160 mm hg systolic or â‰¥110 mm hg diastolic during this pregnancy,1
prior bone marrow assessment,1
prior bortezomib exposure,1
prior cabg,1
prior cancer treatment,1
prior cancer treatments,1
prior cardioversion,1
prior catheter ablation of af,1
prior central nervous system local therapy,1
prior cetuximab exposure,1
prior chelation drug therapy,1
prior chemoradiation,1
prior chemotherapies (ct)for recurrent/metastatic disease (r/m),1
prior chemotherapy (metastatic setting),1
prior chemotherapy for this cancer,1
prior chemotherapy regimen,1
prior chemotherapy treatments,1
prior contraception use,1
prior coronary artery bypass graf (cabg),1
prior coronary artery disease,1
prior coronary intervention,1
prior corticosteroids,1
prior cva/tia,1
prior cyclosporine,1
prior cystectomy,1
prior cystectomy or nephroureterectomy,1
prior cytotoxic chemotherapy received,1
prior cytotoxic regimens,1
prior disease modifying anti-rheumatic drug (except methotrexate),1
"prior disease specific therapy (including drugs, stem cell transplant, or splenectomy)",1
prior doses (baseline),1
prior drug treatment,1
prior eeg monitoring with intracranial electrodes,1
prior egfr-tki therapy,1
prior egfr (epidermal growth factor receptor) inhibitor treatment,1
prior erythropoiesis-stimulating agent (esa) treatment,1
prior exposure to hepatitis b treatment,1
prior exposure to taxanes,1
prior external-beam radiotherapy,1
prior failed medication trials,1
prior febrile neutropenia episodes,1
prior first-line systemic therapy,1
prior focal/grid laser for dme,1
prior focal/grid laser treatment for dme,1
prior fviii treatment on-demand,1
prior glaucoma procedure,1
prior h1n1 vaccine,1
prior hcv treatment and response,1
prior hcv treatment experience with cirrhosis,1
prior hemorrhoid treatment,1
prior hepatitis c virus (hcv) non-response type,1
prior hepatitis c virus (hcv) treatment,1
prior history,1
prior history of aids,1
prior history of arterial events,1
prior history of characteristics and risk factors,1
prior history of hypertension,1
prior history of peanut anaphylaxis,1
prior history of thromboembolism,1
prior history of venous thrombotic events,1
prior hormonal treatment for this cancer,1
prior hormone therapy,1
prior hospitalization,1
prior hospitalization for af,1
prior hospitalizations,1
prior hypertension,1
prior ics/laba combination therapy dose,1
prior immunological treatment for this cancer,1
prior immunotherapy,1
prior induction therapy,1
prior influenza vaccination,1
prior interferon (ifn),1
prior interferon treatment status,1
prior interleukin-2 therapy,1
prior interventions,1
prior intracranial monitoring for seizure localization,1
prior intraocular steroids,1
prior intravesical therapy,1
prior intravitreal triamcinolone for diabetic macular edema,1
prior ipf medications,1
prior iud insertions performed,1
prior ivt for diabetic macular edema,1
prior laser,1
prior lenalidomide,1
prior lenalidomide exposure,1
prior lines of chemotherapy,1
prior lines of therapy for metastatic disease,1
prior lines of trastuzumab-containing chemotherapy for metastatic breast cancer (mbc),1
"prior lumbar fusion (n, %)",1
prior lung cancer,1
prior malignancy,1
prior mds therapy,1
prior medication with non-biologic disease-modifying antirheumatic drugs (dmards),1
prior medication with tumor necrosis factor (tnf) inhibitors,1
prior medication/therapy for dlbcl,1
prior medication/therapy for dlbcl (transplant),1
prior medications,1
"prior metastatic chemotherapy lines, # (range)",1
prior mohs micrographic surgery,1
prior multi-agent chemotherapy,1
prior myelodysplastic syndromes therapy,1
prior myocardial infarction (mi),1
prior neoadjuvant or adjuvant chemotherapy,1
prior neoadjuvant or or adjuvant chemotherapy,1
prior niacin history,1
prior non-diagnostic fna,1
prior non-haemorrhagic stroke,1
prior non-severe heart failure,1
prior nonsurgical ui,1
prior nsaid (nonsteroidal anti-inflammatory drugs) use,1
prior octreotide,1
prior oral bisphosphonate duration,1
prior oral bisphosphonate use stratification factor,1
prior osa surgery,1
prior osteoporosis drug use,1
prior other cancer medication,1
prior other treatment for dme,1
prior oxaliplatin exposure for mcrc,1
prior pci,1
prior pelvic exams,1
prior percutaneous coronary intervention (pci),1
prior ph therapy,1
prior photocoagulation for diabetic macular edema,1
prior platinum-based chemotherapy regimen,1
prior pr response,1
prior protease inhibitor use,1
prior prp,1
prior pru surgery,1
prior quit attempts lasting at least 24 hours,1
prior radiation due to nsclc,1
prior radiation therapies,1
prior radiation to prostate,1
prior radiation treatment,1
prior radioiodine treatments per patient,1
prior radiotherapy and/or chemotherapy,1
prior rectal corticosteroids,1
prior relapses,1
prior response to chemo,1
prior response to chemotherapy,1
prior revascularization (pci or cabg),1
prior rituximab,1
prior salvage therapy stratification at randomization,1
prior scatter photocoagulation,1
prior second-line systemic therapy,1
prior selective serotonin reuptake or serotonin norepinephrine reuptake inhibitor trials,1
prior sildenafil citrate use as needed (prn),1
prior skeletal related event,1
prior somatostatin analogue treatment,1
prior stem cell transplant for myeloma,1
prior stem cell transplantation (sct),1
prior stimulant exposure,1
prior stimulant exposure status,1
prior stroke or transient ischemic attack,1
prior stroke/transient ischemic attack,1
prior study medications,1
prior suicide attempts,1
prior surfactant treatment,1
prior surgeries,1
prior surgeries per patient (not including initial thyroidectomy),1
prior surgery due to nsclc,1
prior surgery history,1
prior systemic and intralesional therapies,1
prior systemic anti-cancer therapy,1
prior systemic chemotherapy (metastatic),1
prior systemic regimens,1
prior systemic treatment,1
prior systemic treatment for gist,1
prior targeted therapy,1
prior taxane interval,1
prior taxanes,1
prior thalidomide exposure,1
prior therapies since diagnosis,1
prior therapy-cytokine therapy,1
prior therapy-nephrectomy,1
prior therapy-oral vascular endothelial growth factor (vegf) receptor kinase inhibitor,1
prior therapy-radiotherapy,1
prior therapy for metastatic disease,1
prior therapy for myelofibrosis,1
prior therapy received for this cancer,1
prior therapy with fludarabine,1
prior therapy with rituximab,1
"prior therapy: attention-deficit/hyperactive disorder (adhd), oppositional defiant disorder (odd)",1
prior thoracic radiation therapy,1
prior thrombosis,1
prior thrombosis or hemorrhage,1
prior tia,1
prior tiv,1
prior tmj surgery,1
prior transient ischemic attacks,1
prior transplant,1
prior transplantation,1
prior treatment cycles,1
prior treatment for diabetic macular edema (dme),1
prior treatment for diabetic macular edema (dme) in study eye,1
prior treatment for dlbcl,1
prior treatment for head and neck cancer,1
prior treatment for m-protein,1
prior treatment for oab,1
prior treatment for prostate cancer,1
prior treatment for substance use disorder,1
prior treatment of nocturnal enuresis with drugs,1
prior treatment of nocturnal enuresis with therapy,1
prior treatment status,1
prior treatment with anti-vascular endothelial growth factor drug for diabetic macular edema,1
prior treatment with bevacizumab,1
prior treatment with irinotecan,1
prior treatment with platinum-based therapy,1
prior treatment with platinum for recurrent disease,1
prior tyrosine kinase inhibitor (tki),1
prior tyrosine kinase inhibitor (tki) treatment,1
prior ui surgery,1
prior ulcer locations,1
prior ulcer surgery locations,1
prior use of adv,1
prior use of arb or acei,1
prior use of beta-blocker,1
prior use of desferal (deferoxamine mesylate),1
prior use of exjade (deferasirox),1
prior use of famciclovir,1
prior use of hydroxyruea,1
prior use of interferon alpha,1
prior use of lamivudine,1
prior use of lenalidomide during induction therapy,1
prior use of non-nucleoside reverse transcriptase inhibitors (nnrti),1
prior use of other hepatitis b medications,1
prior use of sulfonylurea (su),1
prior use of thalidomide during induction,1
prior use of varenicline,1
prior use of vasodilator,1
prior vaginal deliveries,1
prior vardenafil hcl use,1
prior vegf inhibitor treatment,1
prior whole pelvic radiation,1
prior yoga exposure,1
prism,1
prism iii score,1
private insurance,1
pro-bnp,1
pro-insulin auc(0:30-4:30h),1
probing depht,1
probing depth,1
probing depth (pd),1
problems related to alcohol,1
procedural characteristics: number of non-target lesion treated,1
procedural characteristics: number of participants currently taking medication,1
procedural characteristics: number of participants with additional vascular procedures performed,1
procedural characteristics: number of participants with other devices used,1
procedural characteristics: number of participants with stent placement performed,1
procedural characteristics: primary diagnosis,1
procedural characteristics: puncture site,1
procedural characteristics: time from artery access to sheath removal,1
procedural characteristics: total amount of contrast used,1
procedural characteristics: total fluoroscopy time,1
procedural characteristics: urgency of intervention,1
procedural time,1
procedure details,1
procedure time,1
procedures,1
procedures after primary diagnosis,1
procedures used for age-related macular degeneration (amd) diagnosis,1
product of bsa and spga,1
profession,1
profilactic antibiotics,1
profile of mood states (poms) brief total score,1
profiles of mood states total score,1
progesterone-receptor (pr) status,1
progesterone-receptor status,1
progesterone level on day of surgery (ng/ml),1
progesterone receptor (pgr) status of the isolated local or regional recurrence,1
progesterone receptor (pr),1
progesterone receptor (pr) result,1
progesterone receptor (pr) status,1
progesterone receptor status at metastatic diagnosis,1
progesterone serum level,1
prognostic factors at screening â€“ 11q,1
prognostic factors at screening â€“ 17p,1
prognostic factors at screening â€“ 6q- or +12q or 13q - deletion,1
prognostic factors at screening â€“ b2 microglobulin,1
prognostic factors at screening â€“ ighv homology,1
prognostic risk group,1
programmed cell death ligand 1 (pd-l1) expression status,1
progression after initial diagnosis,1
"progression setting (adjuvant, metastatic)",1
prokinetic taken in last month,1
prolactin level,1
prolactin level female,1
prolactin level male,1
promis anxiety t-score,1
promis composite t-score,1
promis depression t-score,1
promis fatigue,1
promis fatigue t-score,1
promis pain t-score,1
promis physical functioning,1
promis sleep t-score,1
promyelocytes in bone marrow,1
propionibacterium acne counts,1
propofol,1
propofol use,1
proportion at educational level,1
proportion days heavy drinking,1
proportion heavy drinking days preceding screening visit,1
proportion of abstinent days,1
proportion of patients undergoing revision surgery,1
proportion of patients with polyps,1
prosocial intervening,1
prospective-retrospective memory questionnaire,1
prostate-specific antigen (psa) â‰¥ 8.0 ng/ml,1
prostate-specific antigen (psa) concentration,1
prostate-specific antigen (psa) doubling time,1
prostate-specific antigen (psa) stratification factor,1
prostate-specific antigen on study,1
prostate cancer,1
prostate radiotherapy dose (categorical),1
prostate radiotherapy dose (continous),1
prostate rt,1
prostate size (g) via trus,1
prostate specific antigen (psa) concentration,1
prostate specific antigen (psa) level,1
prostate volume (cc),1
prostatectomy,1
prostatic specific antigen psa,1
protein-to-creatinine ratio,1
protein blood levels,1
protein c level,1
protein/creatinine ratio,1
proteinuria,1
proteinuria (g/day),1
prothrombin time,1
prothrombin time-international normalized ratio (pt-inr),1
prothrombin time (international normalized ratio) (pt[inr]),1
prothrombin time (seconds),1
proton-pump inhibitor taken in last month,1
proton pump inhibitor (ppi) usage,1
protoporphyria type,1
provider-collected cervical cytology (current),1
provider-collected cervical hpv dna (current),1
provider status,1
pru duration for largest pru,1
pru size of largest ulcer,1
pruritus at baseline,1
pruritus numerical rating scale (nrs) score,1
pruritus score,1
psa (categorical),1
psa (continous),1
psa at entry,1
psa doubling time,1
psa level,1
"psa level, ng/ml",1
psa status at registration,1
pseudocyst diameter,1
pseudomonas aeruginosa tobramycin minimal inhibitory concentration (mic),1
psoriasis body surface area(bsa),1
"psoriasis scalp severity index (pssi) (n=393, 413, 393)",1
psoriasis scalp severity index (pssi) score,1
psoriatic arthritis,1
psqi,1
psqi score,1
pss normalcy of diet,1
pstat3 positive status,1
psychiatric comorbid condition,1
psychiatric comorbidity,1
psychiatric diagnosis,1
psychiatric diagnosis (scid),1
psychiatric diagnosis category,1
psychiatric history for response to lithium treatment for bipolar 1 disorder,1
psychiatric history for response to valproic acid treatment of bipolar 1 disorder,1
psychiatric illness,1
psychological global well-being index (pgwbi),1
psychomotor function domain z-score,1
psychopathy checklist-revised - factor one (f1),1
psychosis,1
psychotic symptoms,1
"psychotic symptoms, brief psychiatric rating scale",1
psychotropic medications by weight gain potential,1
pt,1
ptcl subtype based on central diagnosis,1
pten status at registration via central path review,1
ptga â€“ pain,1
pth (1-84) dosing frequency,1
pth concentration,1
ptsd-related insomnia duration,1
ptsd check-list (pcl) military version,1
ptsd checklist-specific,1
ptsd checklist score,1
"ptsd checklist, military version",1
ptsd checklistâ€“military version,1
ptsd current diagnosis,1
ptsd diagnosis,1
ptsd duration,1
ptsd symptom checklist-m,1
ptsd symptom duration,1
ptsd symptom scale interview,1
ptsd symptom severity (used posttraumatic diagnostic scale (pds)),1
ptsd symptoms,1
pubertal,1
pubertal status,1
pud,1
pulmonary arterial hypertension etiology,1
pulmonary arterial hypertension present,1
pulmonary arterial hypertension stratification,1
pulmonary arterial hypertension treatment,1
pulmonary artery pressure 1 minute pre-dose,1
pulmonary artery wedge pressure,1
pulmonary capillary wedge pressure,1
pulmonary capillary wedge pressure (pcwp),1
pulmonary function,1
pulmonary function (fev1/fvc),1
"pulmonary function measures, percent predicted",1
pulmonary function test at baseline.,1
pulmonary hypertension (ph) subtype (nice clinical classification),1
pulmonary vascular resistance (pvr),1
pulmonary vein peak diastolic velocity,1
pulmonary vein peak systolic velocity,1
pulse (bpm),1
pulse oximetry (spo2),1
pupil diameter - cataractous eye,1
pupil diameter - fellow eye,1
pupil reactivity,1
pure-tone average,1
pure tone sensitivity,1
purpose for low-dose aspirin use,1
purpose of non-steroidal anti-inflammatory drug (nsaid) treatment,1
pushup,1
pwv (pulse wave velocity),1
pyramids and palm trees - pictures,1
pyramids and palm trees - words,1
pyrazinamide susceptibility,1
q-les-q,1
qmax result,1
qmg score,1
qrs,1
qrs (electrocardiogram complex),1
qrs duration (ms),1
qrs interval,1
qrs morphology,1
qrs width (msec),1
quadriceps,1
qualified for medicaid,1
qualifying condition,1
qualifying diagnosis,1
"qualifying ejection fraction, %",1
qualifying event,1
qualifying index venous thromboembolic embolism,1
qualifying sbp,1
qualifying triglyceride level (mg/dl),1
qualitative visual assessment of diffuse uptake of 99m technetium methylene diphosphonate,1
qualitative visual score of focal uptake of 99m technetium methylene diphosphonate (99m tc-mdp),1
quality-of-life,1
quality of life (qol) - scales,1
quality of life (qol) using the rotterdam symptom scale checklist (rssc),1
quality of life (sf-36),1
quality of life as assessed by the eq-5d,1
quality of life enjoyment & satisfaction questionnaire,1
quality of life enjoyment and satisfaction questionnaire (q-les-q),1
quality of life enjoyment and satisfaction scale,1
quality of life inventory,1
quality of life questionnaire,1
quality of life questionnaire of the european foundation for osteoporosis (qualeffo) score,1
quality of life sf-36,1
quality of life specific to male erection difficulties (qol-med),1
quality of life(fact-g),1
quality of well-being scale mean daily score,1
quantifiable programmed death-ligand 1 (pd-l1) expression,1
"quantitative extent of lung fibrosis on hrct, for lobe of maximum involvement",1
"quantitative extent of lung fibrosis on hrct, for whole lung",1
"quantitative extent of total insterstitial lung disease on hrct, for lobe of maximum involvement",1
"quantitative extent of total insterstitial lung disease on hrct, for whole lung",1
quantitative insulin sensitivity check index (quicki),1
quantitative myasthenia gravis (qmg) at screening,1
quantitative pcr viral shedding,1
quebec task force on spinal disorders,1
quick inventory of depressive symptomatology-self reported (qids16sr) total score,1
"quick inventory of depressive symptomatology-self reported 16 items (qids-sr16) (n=430, 431, 431)",1
quick inventory of depressive symptomatology (qids-sr) total score,1
quick inventory of depressive symptoms,1
quicksin snr-50 score (db),1
quit attempts,1
quit history : main reasons for relapses after previous attempts,1
quit history : reasons motivated participant to quit smoking,1
quitting confidence,1
quitting importance,1
r-glutamyl transpeptidase (r-gt),1
r2* values,1
ra functional class,1
race-ethnicity,1
race - peru,1
race - puerto rico,1
race - south africa,1
race - thailand,1
race - u.s.a.,1
race / ethnicity,1
race [caucasian / white],1
race or ethnicity,1
"race, compliant participants",1
race/ethnicity*language,1
race: extension phase,1
racial origin,1
radiation boost planned,1
radiation indication,1
radiation modality,1
"radiation, customized",1
radical prostatectomy,1
radiographic osteoarthritis severity,1
radiological joint deterioration,1
radiologist,1
radiolucency of stones,1
"rage (receptor for advanced glycation end-products) gene expression ""rt-pcr""",1
rai stage group,1
raloxifene therapy,1
ramsay sedation scale (rss),1
randomization allocation,1
randomization nih stroke scale,1
randomization strata,1
randomization strata of insulin,1
randomization strata of main meal of the day,1
randomization stratification factors per crf,1
randot preschool stereoacuity,1
range of motion (neck): extension,1
range of motion (neck): flexion,1
range of motion (neck): inclination left,1
range of motion (neck): inclination rigth,1
range of motion (neck): rotation left,1
range of motion (neck): rotation rigth,1
range of motion (rom),1
range of motion (rom) of the glenohumeral joint,1
range of motion of cervical spine,1
range of motion of knee,1
range of prior therapies,1
rape myth acceptance,1
rapid antigen test (rat) results,1
rapid antigen test result,1
rapid assessment of physical activity (rapa) score,1
rapid cyclers,1
rapid cycling course,1
rapid estimate of adult literacy in medicine (realm),1
rapid eye movement sleep (rem),1
ras and braf mutation status,1
rasagiline/selegiline use,1
rash,1
rate of compliance with exercise regimen at the start of treatment with metact combination tablets,1
rate of compliance with the diet regimen at the start of treatment with metact combination tablets,1
rating of aggression against people and/or property scale,1
rating of management quality,1
ratio of amyloid beta 1-42 to 1-40,1
ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2),1
ratio of minute ventilation to co2 output,1
ratio of tc:hdl-c,1
ravlt: baseline total score,1
raw intraocular pressure,1
rbc transfusion burden,1
rca coronary vessel,1
rdq score at baseline,1
re-admission,1
re-excision,1
reaction time,1
reactive hyperemia index (rhi),1
readiness to quit smoking,1
realm-r,1
"reason for administration, treatment/prophylaxis",1
reason for appointment,1
reason for end stage renal disease,1
reason for excision,1
reason for hospitalization,1
reason for inadequate prior chelation therapy,1
reason for intubation,1
reason for not eligible for hematopoietic stem cell transplantation,1
reason for pessary,1
reason for picc placement,1
reason for prophylaxis,1
reason for stopping injection,1
reason for the use of instanyl,1
reason off study therapy,1
reasons for prescription of study drug,1
reasons for quitting smoking,1
reasons for surgery,1
reasons for vitrectomy: unresponsive to other therapies,1
reasons for vitrectomy: vitreomacular interface abnormality,1
reasons of cirrhosis,1
recalcitrant psoriasis history,1
receipt of antibiotics prior to admission,1
receipt of bronchodilators prior to admission,1
receipt of oral corticosteroids before admission,1
receive regular assistance from:,1
received androgen-deprivation therapy (adt),1
received baseline ultrasound,1
received duramorph,1
received epidural,1
received excess days supply of 20% or greater in any of past 4 quarters,1
received hiv care in last 6 months,1
received iud per protocol,1
received prenatal care,1
received previous therapy for current episode,1
received previous treatment,1
received prior bevacizumab,1
received prior focal photocoagulation,1
received prior nonnucleoside reverse transcriptase inhibitor (nnrti),1
received prior nucleoside/nucleotide reverse transcriptase inhibitor (nrti),1
received prior protease inhibitor (pi),1
received prior scatter (panretinal) photocoagulation,1
received prior treatments for melasma,1
received traditional chinese medicine therapies,1
received transfusion in preceding year but > 120 days before protocol therapy,1
received treatment in heart failure specialty clinic,1
receiving dialysis,1
receiving government benefit,1
receiving hydroxyurea (hu) therapy,1
recent condomless anal sex,1
recent surgery,1
receptor status,1
receptor status (all her2/neu negative),1
recession,1
recipient-donor cytomegalovirus status,1
recipient to first cbu hla match,1
recist evaluable soft tissue metastases,1
"recorded migraine days/past 3m, median (interquartile range)",1
recruited at site in asia,1
recruitment settings,1
rectal soft tissue scarring,1
recurrence,1
recurrence prior to start of treatment with leuprorelin acetate 11.25 mg for injection,1
recurrent,1
recurrent disease,1
recurrent major depressive episode status,1
recurrent vs secondary primary,1
recurrent/persistent disease,1
recurring and/or persistent disease,1
recursive partitioning analysis (rpa) score,1
red blood cell (rbc) transfusion dependence,1
red blood cell count,1
red blood cell pre-planned (yes/no),1
red blood cell/plasma epa,1
red cell transfusion-dependent,1
reduce hcv recurrent post liver transplant,1
reduced-glutathione,1
reducible inguinal hernia,1
reference diameter,1
reference vessel diameter (rvd),1
referral source,1
referral source category,1
reflux screening,1
reflux symptom index (rsi) score,1
reflux symptoms,1
refractive error - fellow eye,1
refractive error in amblyopic eye (spherical equivalent,1
refractive error in amblyopic eye (spherical equivalent),1
refractive error in amblyopic eye at enrollment,1
refractive error in fellow eye,1
refractive error in fellow eye (spherical equivalent),1
refractive error in fellow eye (spherical equivalent/diopters),1
refractive error in fellow eye at enrollment,1
"refractive error in more myopic eye (spherical equivalent, d)",1
refractive error in sound eye (spherical equivalent/diopters),1
refractory,1
refractory to frontline therapy,1
refractory to most recent therapy,1
refractory to pi/imid,1
refractory to proteasome inhibitor (pi)/immunomodulatory agent (imid),1
refractory to proteasome inhibitor (pi)/immunomodulatory drug (imid),1
regimen complexity,1
region (crf [case report form]),1
region enroll (united states of america),1
"region of enrollment, customized",1
"region of enrollment: period 2 (trial enrollment, induction art)",1
region of enrollment: period 3 (randomization to once vs twice daily abc+3tc),1
region of enrollment: period 4 (randomization to stop versus continue cotrimoxazole),1
region of enrollment: united states,1
region of enrolment,1
region of recruitment,1
region treated,1
region: continent,1
regional lymph node stage,1
regions of greece,1
regular alcohol consumption,1
regular doctor (primary care physician),1
regular medication,1
regular use of opioid,1
regular use of sedation drugs,1
reimbursement type,1
relapse and/or progression,1
relapsed,1
relapsed / refractory status,1
relapsed or refractory lymphoma,1
relapsed/refractory status to last prior treatment,1
relationship,1
relationship between donor and recepient,1
relationship of patient to his or her caregiver,1
relationship to patient,1
relationship to patients,1
relationship to recipient,1
relationship to timing of immune tolerance induction (iti),1
relationship type to care recipient,1
relative fmd,1
relative gingival margin position (rgmp),1
relative horizontal clinical attachment level (rhcal),1
relative reinforcing value high energy dense foods (rrv hed),1
relative reinforcing value low energy dense foods (rrv led),1
relative vertical clinical attachment level (rvcal),1
"relative wall thickness, mean (sd)",1
religions denomination indicated,1
religious denomination,1
religious preference,1
rem latency,1
remaining wound area (rwaâ€”mm2 ),1
remission status prior to autologous stem cell transplant,1
remote history of venous thromboembolism,1
renal and peripheral history,1
renal artery stenosis,1
renal cell carcinoma (rcc) subtype,1
renal cell carcinoma subtype,1
renal dysfunction,1
renal functione categor: normal or mild impairment/moderate impairment/severe impairment,1
renal graft function,1
renal history,1
renal history (modification of diet in renal disease [mdrd]),1
renal history based on creatinine clearance,1
renal impairment category,1
renal insufficiency,1
renal sequential organ failure assessment (sofa) score,1
renal status,1
repeatable battery for the assessment of neuropsychological status: rbans delayed memory subindex,1
repeatable battery for the assessment of neuropsychological status: rbans total score,1
reported ptsd diagnosis,1
reported receiving all childhood vaccines,1
reproductive status,1
required to attend treatment (clients),1
resection location,1
residence at diagnosis,1
resident area,1
resident year of postgraduate education,1
residual disease,1
resistance patterns at baseline: percentage of participants with resistant pathogens,1
resistance self-efficacy,1
resistance to prior therapy-len refractory,1
resistance to prior therapy-len+bortezomib refractory,1
resistance to the three first-line drugs,1
respiratory conditions,1
respiratory disease,1
respiratory distress assessment instrument score,1
respiratory disturbance index,1
respiratory disturbance index (rdi),1
respiratory exchange ratio,1
respiratory function,1
respiratory rate (bpm),1
respiratory sequential organ failure assessment (sofa) score,1
respiratory support @ randomization: conventional mechanical ventilation,1
respiratory support @ randomization: high-frequency ventilation,1
respiratory support @ randomization: inhaled nitric oxide,1
respiratory support @ randomization: non-invasive ventilation,1
respiratory symptoms,1
respiratory trauma or distress at baseline,1
responder group to transcatheter arterial chemoembolization (tace),1
response assessment,1
response evaluation,1
response of mantle cell lymphoma (mcl) to chemotherapy at enrollment,1
response to 1st line therapy,1
response to first-line therapy,1
response to induction chemotherapy,1
response to last prior hcv treatment regimen,1
response to pioglitazone in pioglitazone monotherapy prior to dosing of metact combination tablets,1
response to prior chemotherapy,1
response to prior induction therapy,1
response to prior treatment,1
response to second-line therapy,1
restenosis,1
"resting ankle brachial index, leg with target lesion",1
resting cardiac output,1
resting diastolic bp,1
resting ejection fraction (ef),1
resting extensor tone (modified ashworth scale),1
resting heart rate (hr),1
resting respiratory rate (rr),1
resting stroke volume,1
resting systolic bp,1
result of hcg pregnancy screen - negative,1
result of influenza test by local testing,1
results of initial transurethral resection of a bladder tumor (tur-bt): number of visible lesions,1
results of transurethral resection of bladder tumor (tur-bt): final pathological disease stage,1
results of transurethral resection on a bladder tumor (tur-bt): final disease grade,1
retentive fecal incontinence,1
retinal nerve fiber layer thickness,1
retinal thickness plus subfoveal-fluid thickness at fovea,1
retinal volume,1
retinal volume on oct,1
retinopathy,1
retinopathy severity (etdrs severity scale),1
revascularization,1
reverse total shoulder arthroplasty,1
reversibility,1
revised heart failure self-care behavior scale (hfscb),1
revised quantified denver scale of communication function (qds),1
revised trauma score (rts),1
revised university of california los angeles (ucla) loneliness scale,1
rey auditory verbal learning scale,1
rgcl/ipl thickness in the affected eye at baseline,1
rheumatoid arthritis disease activity index (radai),1
rheumatoid arthritis duration,1
rheumatoid factor (rf),1
rhinoconjunctivitis quality-of-life questionnaire (rqlq) overall score,1
rhinoconjunctivitis quality of life score,1
rhythm at enrollment,1
rhythm on 12-lead ecg,1
rib fracture,1
rickets severity scale - rss,1
right-handed,1
right femoral artery site,1
right handedness,1
right heart catheterization,1
right lower extremity strength,1
right ventricular ejection fraction of blood,1
right ventricular function,1
rilpivirine csf concentration,1
riluzole usage at screening,1
rim area,1
rim volume,1
ring finger circumference,1
risk class,1
risk factor--lower respiratory tract infections,1
risk factor--upper respiratory tract infections,1
risk factor [cerebral vascular disease],1
risk factor [chronic lung disease],1
risk factor [congestive heart failure by nyha classification],1
risk factor [current cigarette smoker],1
risk factor [diabetes],1
risk factor [ejection fraction],1
risk factor [hypertension],1
risk factor [left main disease],1
risk factor [peripheral artery disease],1
risk factor [previous myocardial infarction],1
risk factor [previous sternotomy],1
risk factor [renal failure],1
risk factor at enrollment: age >= 75 years,1
risk factor at enrollment: left ventricle ejection fraction (lvef) <=40%,1
risk factor at enrollment: prior stroke,1
risk factor at enrollment: prior transient ischemic attack (tia),1
risk factor at enrollment: symptomatic chronic heart failure (chf),1
risk factor: smoking status,1
risk factors for developing diabetes,1
risk level for opioid misuse or abuse,1
risk of coronary artery disease,1
risk scores for ponv,1
risk subgroup (intermediate vs. high),1
risky decision making as assessed by score on the risky decision making task,1
risser grade,1
rna group,1
"rna polymerase iii-positive, n (%)",1
rna polymerase(+),1
roland-morris disability questionnaire (rmdq),1
roland-morris disability questionnaire score,1
roland-morris disability questionnaire total score,1
roland morris disability questionnaire,1
roland morris disability questionnaire (rdq) score,1
rosacea severity score,1
rosenberg score of 2 or more,1
rotavirus anti-immunoglobulin a (iga) serum antibody level,1
rotavirus vaccination,1
rotavirus vaccination received,1
rothschild scale for antidepressant tachyphylaxis (rsat) total score,1
rp duration,1
rs12979860 single nucleotide polymorphism in the interleukin-28b gene,1
rss at entry,1
rt3,1
rupture of membraned duration,1
rurality,1
rutherford,1
rutherford class,1
rv (l) - % predicted,1
rv (l) (residual volume) observed,1
rv/tlc,1
rv/tlc percent predicted,1
rvo subtype,1
s.aureus susceptible to fusidic acid,1
sacroiliac joint pain intensity,1
sad,1
safety and immunogenicity assessment.,1
safety assessment,1
safety scales,1
sagittal abdominal diameter,1
saint louis university mental status score,1
salary per month,1
saliva weight,1
salzburg pru risk score,1
sara at screening visit,1
sarcoma grade,1
sarcoma histology,1
sarcoma location,1
satiety,1
satisfaction with life scale,1
saving inventory revised,1
sbeta+thalassemia,1
sbms,1
sbp (systolic blood pressure),1
sbp < 90 or lactate >= 4 mmol/l,1
scale for the assessment of negative,1
scaling and dryness,1
scarring,1
schiff air scale,1
schirmer test â± sd,1
schizophrenia duration,1
schober's test,1
school grade average (sga) language score,1
school grade average (sga) math score,1
school grade average (sga) total score,1
school grade score (sga) science score,1
school speech questionnaire (ssq),1
schooling,1
schwab and england activities of daily living scale (seadl),1
"schwab/england activities of daily living score (""on"")",1
scleroderma classification,1
scleroderma health assessment questionnaire (shaq) individual domain score,1
scoliosis,1
scorad,1
scorad - score atopic dermatitis,1
score for performance iq,1
score for the overall scale intelligence,1
score for verbal iq,1
score of patient assessment of constipation quality of life(pac-qol),1
score of stool consistency (bristol stool form scale),1
score on epworth sleepiness scale (ess),1
score stress,1
score to question #3 on udi-6,1
scores on the adhd rating scale-iv,1
screen cd4,1
screen for child anxiety and related emotional disorders - child version,1
screen for child anxiety and related emotional disorders - parent version,1
screening blood pressure,1
screening cd4 count,1
screening cd4 count categorical,1
screening cd4 count continuous,1
screening cd4 percent (%),1
screening cd4%,1
screening copd severity (gold) n (%),1
screening fasting plasma glucose,1
screening fev1,1
screening glycated hemoglobin (hba1c),1
screening heart rate,1
screening height,1
screening hiv-1 rna,1
screening hiv-1 rna categorical,1
screening hiv-1 rna continuous,1
screening ldl-c level,1
screening lens opacities classification system (locs) iii status,1
screening lymphocytes,1
screening neutrophils,1
screening peak gh values,1
screening ppfev1,1
screening score on beck depression inventory-ii,1
screening score on folstein mini mental status exam,1
screening serum albumin,1
screening serum ctx,1
screening testosterone,1
screening weight,1
sds: social subscale,1
sds: work subscale,1
se refractive error in amblyopic eye at randomization,1
se refractive error in fellow eye at randomization,1
seasonal allergies,1
seasonality (time of vaccination),1
seated sbp in subjects with baseline seated sbp â‰¥130 mmhg,1
seattle angina questionnaire,1
seborrheic dermatitis,1
second oad use at screening by class,1
second or greater salvage,1
second oral anti-diabetic drug (oad) use,1
secondary acute myeloid leukemia (aml) at baseline,1
secondary gleason score,1
segmented neutrophil,1
seizure,1
seizure type,1
seizures with auras in past 2 months,1
seizures with auras in the past 2 months,1
selected serious infections,1
selective serotonin reuptake inhibitor taken in last month,1
selena-sledai score,1
self-assessment of mouth odor,1
self-collected vaginal hpv dna (current),1
self-comfort with men's inappropriate behaviors,1
self-efficacy (diabetes empowerment scale),1
self-efficacy for engaging in physical activity (ese),1
self-efficacy for managing chronic disease (semcd),1
self-efficacy related to eating patterns (wel) - global score,1
self-efficacy score,1
self-efficacy to communicate with physician,1
self-efficacy to intervene,1
self-efficacy to manage stroke,1
self-perceived financial status,1
self-rated general health status - fair or poor health,1
self-rated health,1
self-rated quality of health,1
self-reported anger,1
self-reported anxiety,1
self-reported average pain level in the past week via nrs-1,1
self-reported depression,1
self-reported health rating,1
self-reported pain score,1
self-reported physical activity,1
self-reported symptoms,1
self-reported visual analog scale (vas) for menstrual pain intensity,1
self-reported weekly substance use,1
self-reported years with arthritis symptoms,1
self-selected overground walking speed,1
self assessed level of competency in english,1
semantic fluency (7 categories),1
semsob,1
senic score,1
sensation,1
sensitivity of the face evaluated by subject,1
sensory gating ratio,1
sentinel lymph node biopsy,1
"septal e/e' ratio, mean (sd)",1
"septal tissue doppler early velocity (e'), mm/s, mean (sd)",1
septic shock characteristic: primary infection location,1
septic shock characteristic: primary infection type,1
sequencing urotypes at baseline,1
sequential organ failure assessment (sofa) score,1
sequential organ failure assessment(sofa),1
sequential organ functional assessment (sofa),1
serial computer tomography imaging,1
serious mental illness,1
serious mental illness duration,1
seropositivity status at baseline,1
seroprotected at baseline â€“ influenza b,1
seroprotected at baseline â€“ influenza h1n1,1
seroprotected at baseline â€“ influenza h3n2,1
"serum 1,25-dihydroxyvitamin d",1
serum 17-hydroxyprogesterone,1
serum 17-ohp,1
"serum 25-hydroxy vitamin d (25-oh-d), categorical",1
serum 25-oh-d,1
serum 25 ohd (serum 25-hydroxyvitamin d),1
serum add,1
serum anti-mullerian hormone (amh),1
serum beta 2 microglobulin,1
serum bone-type alkaline phosphatase (bap),1
serum c-reactive protein (crp),1
serum c-telopeptide (ctx),1
serum c-telopeptide of type 1 collagen (ctx),1
serum ca-125 after 3rd chemotherapy cycle,1
serum calcium (mg/dl),1
serum carboxyterminal cross-linking telopeptide of collagen type i (ctx),1
serum chemistry: creatinine,1
serum chemistry: lactate,1
serum chemistry: troponin i,1
serum chloride (meq/l),1
serum complement test c3,1
serum complement test c4,1
serum complement test ch50,1
serum corrected calcium,1
serum cotinine,1
serum creatinine (scr),1
serum creatinine at enrollment,1
serum creatinine category,1
serum creatinine clearance,1
serum creatinine clearance category,1
serum creatinine concentration,1
serum ctx,1
serum dhea,1
serum dht,1
serum dihydrotestosterone concentration,1
serum e2,1
"serum e2 concentration (pretreatment), customized",1
serum erythropoietin level,1
serum estradiol,1
serum estradiol (e2),1
serum estradiol (e2) concentration (pretreatment),1
serum estradiole level,1
serum ferritin,1
serum ferritin concentration at baseline,1
serum follicle-stimulating hormone (fsh),1
serum follicle simulating hormone (fsh),1
serum fructosamine concentration,1
serum fsh level,1
serum glutamate oxaloacetate transaminase(ast) (u/l),1
serum glutamate pyruvate transaminase (alt) (u/l),1
serum glutamic oxaloacetic transaminase sgot (ast),1
"serum glutamic pyruvate transaminase, sgpt (alt)",1
serum hcv rna concentration,1
serum hormone binding globulin (shbg),1
serum î²2m in clinical stage,1
serum ige,1
serum ldl cholesterol beta quantification,1
serum levels of 25(oh)d,1
serum lh level,1
serum luteinizing hormone (lh),1
serum m-protein,1
serum m-spike at study entry,1
serum magnesium,1
serum monoclonal (m) protein,1
serum monoclonal protein >1g/dl,1
serum oestradiol concentration,1
serum oestradiol levels,1
"serum osmolarity, mosm/l",1
serum osteocalcin,1
serum parathyroid hormone,1
serum parathyroid hormone (pg/ml),1
serum phosphorus level,1
serum procollagen 1 n-terminal peptide (p1np),1
serum procollagen type 1 n-terminal propeptide (p1np),1
serum procollagen type i n-terminal propeptide (pinp),1
serum progesterone (p4),1
serum progesterone level,1
serum prolactin level,1
serum prostate-specific antigen (psa),1
serum prostate specific antigen (psa) level (ng/ml),1
serum prostate specific antigen levels,1
serum pth (parathyroid hormone),1
"serum sodium, mmol/l",1
serum specific ige egg white,1
serum specific ige ovalbumin,1
serum specific ige ovomucoid,1
serum tartrate-resistant acid phosphatase 5b (tracp-5b),1
serum testosterone concentration,1
serum total alpha-1 antitrypsin concentration,1
serum total prostate-specific antigen level (psa),1
serum type i collagen c-telopeptide (ctx-1),1
serum urate categories,1
serum urate in men,1
serum urate in women,1
serum urea nitrogen,1
serum uric acid (sua),1
serum vitamin d 25-hydroxy (ng/ml),1
service-connected 100%,1
service-connected benefits for sci recipient,1
service branch,1
service connected disability rating,1
service connection,1
service era,1
setting of non-steroidal aromatase inhibitor,1
"severe baseline symptoms, dryness",1
"severe baseline symptoms, dyspareunia",1
"severe baseline symptoms, itching",1
severe chronic neutropenia (scn) diagnosis,1
severe eczema,1
severe micturition-related urgency episodes per 24 hours,1
severely incontinent men post rarp,1
severity,1
severity grading of oral mucosa,1
severity of abdominal pain,1
severity of active bleeding,1
severity of atopic dermatitis,1
severity of atopic dermatitis (ad) using scorad index,1
severity of belching,1
severity of bloating,1
severity of chronic obstructive lung disease (copd),1
severity of cirrhosis (child-pugh score),1
severity of copd at baseline,1
severity of diarrhea,1
severity of endometriosis,1
severity of flatulence,1
severity of heart burn,1
severity of hemophilia,1
severity of hot flashes,1
severity of lack of appetite,1
severity of less than 2 bowel movements per week,1
severity of more than 2 bowel movements per day,1
severity of nausea,1
severity of podoconioisis based on a staging systeme,1
severity of sui rated by amount of urine leakage measured by 1-hour pad test,1
severity of symptoms of dementia,1
severity of symptoms score,1
severity of vaginal symptoms,1
severity of vertebral fracture,1
severity of vomiting,1
sex hormon binding globulin,1
sex hormone,1
sex hormone-binding globulin,1
sex hormone binding globulin,1
sex hormone binding globulin (shbg),1
sex hormone binding globulin (shbg) (nmol/l),1
sex of the infant,1
sexual activity,1
sexual activity with female partner,1
sexual coercion perpetration,1
sexual encounter profile (sep),1
sexual encounter profile diary question number 1,1
sexual encounter profile diary question number 2,1
sexual encounter profile diary question number 3,1
sexual encounter profile diary question number 4,1
sexual encounter profile diary question number 5,1
sexual function,1
sexual function as assessed by international index of erectile function (iief),1
sexual orientation,1
sexual orientation (casi),1
sexual orientation disclosure,1
sexual risk group,1
sexually active and erectile dysfunction (ed),1
sexually active during study,1
sexually active prior to study,1
sexually transmitted diseases within 8 weeks prior to diagnosis,1
sexually transmitted infection diagnosed-ever,1
sf-12 mental component score,1
sf-12 physical component score,1
sf-36 mcs,1
sf-36 mental component score,1
sf-36 mental health score,1
sf-36 physical activity score,1
sf-36 physical component (quality of life),1
sf-36 physical component score,1
sf-36 physical health score,1
sf-36 quality of life - physical component,1
sf-36 quality of life -mental component,1
sf-36 quality of life: mental component summary,1
sf-36 quality of life: physical component summary,1
sf-36 score- mental component,1
sf-36 score- physical component,1
sf-36 score; summary mental component at baseline,1
sf-36 score; summary physical component at baseline,1
sf-36 vitality,1
"sf-36, mean",1
sf-36v physical scale,1
sgaw (lps/cmh2o/l) (specific airway conductance),1
sgrq-hkc total,1
sgrq hk-activity,1
sgrq hkc-impact,1
sgrq hkc symptom,1
shape discrimination,1
shbg,1
sheehan disability scale,1
"sheehan disability scale-item 1 (sds-item 1), n=187, 193, 380",1
"sheehan disability scale-item 1 (sds-item 1), n=196,200,396",1
sheehan disability scale-item 2 (sds-item 2),1
"sheehan disability scale-item 2 (sds-item 2), n=262,265,527",1
sheehan disability scale-item 3 (sds-item 3),1
"sheehan disability scale-item 3 (sds-item 3), n=262,265,527",1
sheehan disability scale - total score (sds total),1
sheehan disability scale -total score (sds total),1
"sheehan disability scale -total score (sds total), n=262,265,527",1
sheehan disability scale (sds) global functional impairment score,1
sheehan disability scale (sds) global functional impairment total score,1
sheehan disability scale (sds) item 1: symptoms disrupted work/school,1
sheehan disability scale (sds) item 2: symptoms disrupted social life/leisure activities,1
sheehan disability scale (sds) item 3: symptoms disrupted family life/home responsibilities,1
sheehan disability scale (sds): family subscale,1
shiff sensitivity score at baseline,1
shock,1
short-form-36 (sf-36) summary scores,1
short-form 36 (general health status),1
short acting beta agonist,1
short form-12 health survey (sf-12) questionnaire,1
short form-36 health status surveyâ„¢ version 2 (sf-36â„¢v2) physical component score (pcs),1
short form-36 health survey scores,1
"short form-mcgill pain questionnaire (sf-mpq), sensory portion total score",1
short form - 36 (sf) -36 mental component (quality of life),1
"short form 36 (range 0 [worst] -100 [best]), continuous",1
short form 36 health survey (sf-36),1
short form health survey-12-veterans (sf-12 v) mental composite score,1
short form health survey version 2 - mental health,1
short form health survey version 2 - physical health,1
short index of problems,1
short nutritional assessment questionnaire (snaq) score,1
short performance physical battery (sppb),1
short performance physical test,1
short physical performance battery (sppb),1
short physical performance battery score (sppb),1
short portable mental status questionnaire score,1
sick node dysfunction,1
sickle-cell genotype,1
sickle cell disease hb ss,1
sickle cell genotype,1
side,1
side & position of flail,1
side dominance,1
side of donation (left),1
side of dvt,1
side of hemianopia,1
side of hemiparesis,1
side of involvement,1
side of the breast cancer,1
sigh-ads depression score,1
sighads29,1
signs of psoriasis at baseline (erythema),1
signs of psoriasis at baseline (plaque elevation),1
signs of psoriasis at baseline (scaling),1
simple hospitalization costs,1
simplified acute physiology score (saps ii) score,1
"simultaneous vaccination of diphtheria, tetanus, pertussis-inactivated polio vaccine (dpt-ipv)",1
simultaneous vaccination of measles-rubella (mr) vaccine,1
simultaneous vaccination of pneumococcal vaccine,1
simultaneous vaccination of rotavirus vaccine,1
single-breath diffusing capacity,1
single largest daily insulin dose,1
single leg stance,1
sino-nasal outcome test (snot-20) overall score,1
sinonasal outcome test score (snot-20),1
sinonasal questionnaire (snq-6),1
sinus arrhythmias,1
sinus atrioventricular (av) junctional arrhythmias and blocks,1
sinusitis category 1,1
sinusitis category 2,1
sinusitis category 3,1
sirtuin,1
"sirtuin-1 gene expression by real time polimerase chain reaction ""rt-pcr""",1
sit-to-stand test,1
sit-up,1
sit and reach,1
sit and reach flexibility,1
site of enrollment,1
site of head and neck carcinoma,1
site of invasive candida infection,1
site of lesion,1
site of metastatic disease was bone,1
site of metastatic disease was distant lymph nodes,1
site of metastatic disease was liver,1
site of metastatic disease was loco-regional,1
site of metastatic disease was lung,1
site of onset,1
site of origin,1
site of origin of tumor,1
site of pain,1
site of primary lesion,1
site of primary tumour reported in >5% patients,1
site of stone (180 ureterorenal units),1
site of subacromial injection,1
site of surgery,1
site of target/nontarget lesions at baseline - organ class,1
site of tumor,1
site of uveitis,1
sites of primary tumor,1
sitting systolic blood pressure (sisbp),1
six-minute walk test (6mwt),1
six mile walk test (6mwt),1
six minute hall walk,1
six minute walk,1
six minute walk test,1
six minute walk test (6 mwt),1
six minute walk test (6mwt),1
size of burn,1
size of disease by recist criteria,1
size of fibroid or polyp,1
size of hcc,1
size of in situ component,1
size of in situ component (dcis patients),1
size of incision,1
size of invasive component,1
size of lesions,1
size of residual disease,1
size of stone,1
skeletal muscle citrate synthase activity,1
skeletal plasma clearance of 99m technetium methylene diphosphonate (99m tc-mdp),1
skeletal survey,1
skeletal survey for osteolytic lesions/fractures,1
skeletal uptake of 99m technetium methylene diphosphonate (99m tc-mdp),1
skin aging measured with photonumeric scale,1
skin disease,1
skin elasticity,1
skin hydration (conductance),1
skin prick test score,1
skin reaction to the sun,1
skin thickness (mm),1
skin ulcer size,1
skin volume (cc),1
sle patients,1
sledai total score,1
sleep-specific ptsd symptoms,1
sleep (pittsburgh sleep quality index),1
sleep aids,1
sleep disturbance,1
sleep latency,1
sleep norm area under the curve average by group,1
sleep onset latency on multiple sleep latency test,1
sleep scores,1
sleep spindle density,1
sleep study apnea hypopnea index (ahi),1
slept under any bednet prior night,1
slept under itn prior night,1
slope,1
slow vital capacity (max %-predicted),1
slow vital capacity (max % predicted),1
small for gestational age,1
small ldl particles,1
smoke-free household,1
smoke exposure,1
smoke menthol cigarettes,1
smokeless tobacco,1
smokeless tobacco quantity,1
smokeless tobacco use,1
smoker (yes/now),1
smoker in household-yes,1
smokers in household,1
smoking-related concurrent illnesses and cardiovascular risk factors,1
smoking (packs per year),1
smoking classificaiton,1
smoking classification (non-smoker),1
"smoking classification, customized",1
smoking history - pack years,1
smoking history : did participant have frequent contact with someone who smoked,1
smoking history : did participant live with someone who smoked,1
smoking history : number of times the participant has attempted to quit in past year,1
smoking history : participant categorized based on number of attempt to quit in the past year,1
smoking history or current,1
smoking history: average number of cigarettes smoked per day in the last year,1
smoking history: lifetime serious quit attempts,1
smoking history: longest period of abstinence in the last year,1
smoking history: total number of years participant smoked,1
smoking pack years,1
smoking prevalence,1
smoking rate,1
smoking related cancer,1
smoking related cardiovascular disease,1
smoking related concurrent diseases,1
smoking related respiratory disease,1
smoking status - dependent (n=124),1
smoking status - participant,1
smoking status - smoker,1
"smoking status (n, %)",1
smoking status n (%),1
smoking use at baseline,1
smoking within 4 weeks preoperation,1
snaith cas,1
social adaptation self-evaluation scale (sass),1
social and occupational functioning assessment scale (sofas),1
social interaction anxiety scale,1
social phobia,1
social phobia scale,1
social reciprocity scale,1
social responsiveness scale total score,1
social security disability insurance recipient,1
social security income recipient,1
social support,1
"social support from ""special person""",1
social support from family,1
social support from friends,1
society of thoracic surgeons (sts) score,1
socioeconomic status (ses),1
socket width (buccopalatal),1
socket width (meiodistal),1
sof-adl score at baseline,1
sofa,1
sofa score,1
soft tissue thickness,1
soluble fibrin at baseline n=(53;16;23;88;27;29;92;30;25;65;448),1
somatic hypermutation (shm) analysis of immunoglobulin heavy chain variable (igvh) genes,1
some secondary school education or higher,1
somoking status,1
sore throat scale (sts) score,1
sos,1
source of assistance,1
source of assistance with adls at baseline,1
source of contact,1
source of reimbursement,1
south oaks gambling screen (sogs),1
southwestern oncology group performance status,1
spasticity level of wrist,1
spatial qrs-t angle,1
specific dermatophyte species in mycological culture,1
specific site(s) of metastasis/relapse,1
specific surgical procedure,1
spectacle wear (single vision lenses),1
speed score,1
sperm cell count,1
sperm cell motility (%),1
sperm cells with abnormal morphology (%),1
sperm morphology,1
spherical equivalent in amblyopic eye,1
spherical equivalent in fellow eye,1
spherical equivalent refractive error in amblyopic eye at enrollment,1
spherical equivalent refractive error in fellow eye,1
spherical equivalent refractive error in fellow eye at enrollment,1
spica cast,1
spider phobia questionnaire,1
spinal cord injury (sci) etiology,1
spinal cord syndrome at onset,1
spinal deformity index,1
spinal injury at baseline,1
spinal pain intensity,1
"spine (average of spine lumbar 1, lumbar 2, lumbar 3, lumbar 4 ) t-score â‰¤ -2.5",1
spine agility function by ott test,1
spine agility function by schober test,1
spine bone mineral density (bmd),1
spine t-score,1
spine volumetric bone mineral density (qct),1
spine z-score,1
spirometry,1
spleen involvement,1
spleen/kidney laceration at baseline,1
splenectomy status,1
splenectomy status at baseline,1
spo2 (oxygen saturation),1
spo2 at rest while breathing ambient air,1
spondyloarthritis research consortium of canada (sparcc) enthesitis score,1
spontaneous bowel movement (sbm) frequency per week,1
spontaneous bowel movement weekly rate,1
spontaneous bowel movements (csbms) per week,1
sport concussion assessment tool- second edition (scat 2),1
sputum density of p. aeruginosa - sum of all biotypes,1
sputum eosinophils,1
sputum eosinophils (%),1
sputum tuberculosis culture,1
sputum volume,1
srt: baseline total score,1
ssc classification,1
ssi classification,1
ssri history,1
st george's respiratory questionnaire (sgrq),1
st george's respiratory questionnaire (sgrq) score,1
st george's respiratory questionnaire total score,1
st georges respiratory questionnaire,1
st use,1
stable angina,1
stable daily dose of metformin,1
stable daily dose of pioglitazone,1
stage-iv disease,1
stage (figo 2009),1
stage (tmn),1
stage at breast cancer diagnosis,1
stage at enrolment,1
stage at first diagnosis (international federation of gynecology and obstetrics (figo) ),1
stage at first diagnosis (international federation of gynecology and obstetrics (figo)),1
stage at initial diagnosis of breast cancer,1
stage at randomization,1
stage grouping,1
stage ii or greater prolapse: anterior,1
stage ii or greater prolapse: apical,1
stage ii or greater prolapse: posterior,1
stage iv disease at study entry,1
stage of cancer,1
stage of cancer diagnosis,1
stage of change,1
stage of chronic kidney disease,1
stage of disease [international staging system (iss),1
stage of disease at entry to study,1
stage of disease at entry to the study,1
stage of disease at study entry (tnm classification),1
"stage of disease at study entry (tnm classification, stage iv)",1
"stage of disease at study entry (tumor, nodules, metastasis (tnm) classification)",1
stage of disease at the time of entry into this study,1
stage of disease at time of diagnosis,1
stage of disease prior to tumor resection,1
stage of lung cancer,1
stage of malignancy at screening diagnosis,1
stage of melanoma,1
stage of multiple myeloma at initial diagnosis,1
stage of primary lesion,1
stage of prostate cancer at diagnosis,1
stage of prostate cancer at enrolment,1
stage of prus at randomization,1
stage on the nurnberger-muller scale (nms),1
stages of cardiac failure (new york heart association [nyha] classification),1
staging at diagnosis,1
stai state anxiety subtest,1
stai trait anxiety subtest,1
staic - state anxiety,1
staic - trait anxiety,1
"stair total (climb, descend)",1
standard deviation,1
standard drinks/day over the past 2 weeks,1
standard of care,1
standard of care chemotherapy regimen received,1
standard of care received (crf),1
standardized dyspnea score at isotime at the beginning of fluticasone,1
standardized dyspnea score at isotime at the beginning of placebo,1
standing height,1
standing height sds,1
stanford health assessment questionnaire (haq),1
star excursion balance test- anterior reach,1
star excursion balance test- posteriolateral reach,1
star excursion balance test- posteriomedial reach,1
start of en,1
starting bmi,1
starting wound dimension,1
stat category,1
state-trait anxiety inventories (stai),1
state-trait anxiety inventory state scale (stai-s),1
state-trait anxiety inventory state subscale,1
state of inclusion diagnosis,1
state of patient relative to menopause,1
state trait anger expression inventory,1
state trait anxiety,1
state trait anxiety inventory- state anxiety score,1
state trait anxiety inventory- trait anxiety score,1
static beta-cell sensitivity to glucose index,1
static field strength of mri scans,1
static physician's global assessment (spga),1
static physician global assessment (spga),1
static physician global assessment (spga) of psoriasis,1
static physician global assessment of psoriasis (spga),1
static physicianâ€™s global assessment (spga),1
static physicianâ€™s global assessment (spga) score,1
statin administration before entry,1
statin status,1
statins,1
stature,1
stature z-score,1
status,1
status of administration of pioglitazone and metformin prior to dosing of metact combination tablets,1
status of the vitreous,1
status of underlying disease,1
staxi anger expression subtest,1
steatosis grade,1
stem cell type,1
stemi,1
stenosed lesion length,1
stent diameter,1
stent in situ,1
stent length,1
stent to apex of socket,1
stent to buccal plate,1
stent to distal osseous crest,1
stent to mesial osseous crest,1
stent to midosseous crest,1
step-length asymmetry,1
step height,1
step length,1
steroid use at baseline,1
steroids,1
steroids administered,1
stimulated salivary flow rate,1
stinging/burning,1
stockholm criteria for mild cognitive impairment,1
stockholm joint score,1
stone volume,1
stool consistency score,1
stool frequency,1
stool frequency/day,1
straining during defecation,1
straining score,1
strata,1
stratification based on antiretroviral (arv) use,1
stratification factor 2: disease population,1
stratification factor 3: number of prior anti-mm therapies,1
stratification factor case report form (crf),1
stratification factor: age,1
stratification factor: albumin-corrected calcium level,1
stratification factor: baseline ezetimibe use,1
stratification factor: baseline statin use,1
stratification factor: baseline use of ezetimibe,1
stratification factor: baseline use of statin,1
stratification factor: diagnosis of heterozygous familial hypercholesterolemia (hefh),1
stratification factor: entry statin therapy,1
stratification factor: insulin at randomization,1
stratification factor: international staging system (iss) stag at screening,1
stratification factor: ldl level,1
stratification factor: lines of prior therapy,1
stratification factor: lines of prior treatment,1
stratification factor: low-density lipoprotein cholesterol (ldl-c),1
stratification factor: mean screening serum parathyroid hormone (pth),1
stratification factor: prior aromatase inhibitor use,1
stratification factor: prior proteasome inhibitor treatment,1
stratification factor: proteasome inhibitor,1
stratification factor: region of enrollment,1
stratification factor: screening ldl-c level,1
stratification factor: screening serum parathroid hormone,1
stratification factor: total lumbar spine bone mineral density t-score,1
stratification factor: type of hospital,1
stratification group,1
stratification groups,1
stratification programmed cell death ligand 1 status,1
stratification variable,1
stratification variable 1 - csf viral load (vl) - pre-baseline,1
stratification variable 2 - objective or subjective neuropsychological test - pre-baseline,1
stratification: hormone receptor status (this stratification information iis based on crf data).,1
stratification: prior chemotherapy (this stratification information iis based on crf data).,1
stratification: prior taxane (this stratification information iis based on crf data).,1
streptococcus pneumoniae (s pneumoniae) sensitivity in nasopharyngeal cultures,1
stress (pss-4),1
stress cardiac output,1
stress ef,1
stress heart rate,1
stress incontinence,1
stress stroke volume,1
"stressful life events (e.g. hospitalization, loss of employment or family member) in past 6 months",1
"stressful occlusion, categorical",1
stricture etiology,1
stridor,1
stroke impact scale-hand subscale,1
stroke impact scale - communication,1
stroke impact scale - daily activities,1
stroke impact scale - emotion,1
stroke impact scale - general rating of recovery,1
stroke impact scale - hand function,1
stroke impact scale - memory and thinking,1
stroke impact scale - mobility,1
stroke impact scale - physical strength,1
stroke impact scale - social activity,1
stroke impact scale (sis),1
stroke or transient ischaemic attack,1
stroke severity,1
"stroke severity, nihss",1
"stroke severity, nihss (national institutes of health stroke scale)",1
stroke specific health related quality of life perceived energy,1
"stroke specific, health-related quality of life",1
stroke upper limb capacity scale (sulcs),1
stroke volume index,1
stroke/transient ischemic attack (tia),1
stroop color-word test,1
stroop congruent: baseline total score,1
stroop incongruent: baseline total score,1
stroop interference test - congruent (sit-c): baseline efficacy scores,1
stroop interference test - incongruent (sit-i): baseline efficacy scores,1
structured clinical interview for dms-iv (scid),1
structured clinical interview for dsm-iv axis i disorders,1
structured clinical interview for separation anxiety disorder,1
study arm - diagnosis,1
study cohort,1
study day body weight,1
study day postmenstrual age,1
study drug formulation,1
study entry: m,1
study entry: n,1
study eye best-corrected visual acuity score (etdrs chart),1
study knee,1
study participants,1
study specific characteristic,1
study specific characteristic [kansas city cardiomyopathy questionnaire: symptom frequency scale,1
study specific characteristic [plasma gb3],1
study specific characteristic [urine gb3],1
study specific measure [tumor location],1
study specific race/ethnicity,1
study stents implanted per patient,1
study stratification: disease classification,1
stunted,1
subarachnoid and/or subdural bleeding at baseline,1
subcutaneous adipose tissue area,1
subcutaneous insulin catheter,1
subcutaneous thickness,1
subject's assessment of disease related pain,1
subject's satisfaction with previous treatment,1
subject characteristics (bmi),1
subject characteristics (height),1
subject characteristics (weight),1
subject drinking status,1
subject given radiation therapy,1
subject global health assessment,1
subject of child-bearing potential (y/n),1
subject of child bearing potential,1
subject on dialysis at baseline,1
subject on mechanical ventilation at baseline,1
subject on vasopressors at baseline,1
subject pain assessment per vas,1
subject pain assessment per visual analogue scale(vas),1
subject population,1
subject reached puberty,1
subject self rating scale (ssrs),1
subjective appetite (visual analog scale),1
"subjective effects as assessed by score on ""feel high"" subscale of the drug effects questionnaire",1
subjective effects as assessed by score on the vigor subscale of the profile of mood states (poms),1
"subjective effects as assessed by the ""elated"" subscale of the visual analogue scale (vas)",1
subjective mood,1
subjective numeracy (sns),1
subjective numeracy scale (sns),1
subjective sleep efficiency,1
subjective well-being under neuroleptic (swn-20) scale score,1
subjective well-being under neuroleptic treatment - short form,1
subjects receiving t-pa then minocycline,1
subjects requiring narcotic pain control,1
subjects taking antiparkinson medication,1
subjects who received antivirals prior to treatment,1
subjects with baseline venous thromboembolic (vte) disease per site-reported medical history,1
subjects with central iv catheter in place,1
subjects with diabetic retinopathy,1
subjects with embryo transferred,1
subjects with haemorrhagic history,1
subjects with medical history of splenectomy,1
subjects with metabolic syndrome based on point of care analyses,1
sublevel ib dissection,1
subluxed or dislocated,1
submandibular gland excision,1
subretinal fluid on ocular coherence tomography (oct),1
subretinal fluid on optical coherence tomography (oct),1
substance abuse,1
substance use (clients),1
substance use days (past 30 days),1
substance use diagnoses,1
substance use disorders,1
substance used,1
subtotal hysterectomy,1
subtype of disease,1
subtype of functional dyspepsia (fd),1
subtype of myeloma,1
successful sexual intercourse in sexual encounter profile (sep),1
sudbp,1
"suicide attempts in lifetime (n=335, n=159, n=301)",1
suicide ideation,1
sulfonylurea treatment duration,1
sum glasgow coma score,1
sum of product diameters,1
sum of the longest diameter of target lesions,1
sum sizes of target lesions,1
summary of adhd diagnosis,1
summary of locations of crohn's disease at screening (all treated subjects),1
summary of odd diagnosis,1
summary of participants' living arrangements,1
summary of previous treatment,1
summary of prior therapy by type of therapy,1
summed symptom severity,1
supine blood pressure (mmhg),1
supine diastolic blood pressure,1
supine heart rate,1
supine heart rate (bpm),1
supine systolic blood pressure,1
supplemental fluid administration for vomiting,1
supplemental oxygen at enrollment,1
surgeon,1
surgeon's experience,1
surgeon type,1
surgery characteristic: focal/grid laser to diabetic macular edema used,1
surgery characteristic: laser used with endoprobe,1
surgery characteristic: laser used with indirect ophthalmoscope,1
"surgery characteristic: panretinal photocoagulation, history of prior use",1
"surgery characteristic: panretinal photocoagulation, with none used prior",1
surgery characteristic: scatter laser over peripheral schisis or barrier laser used,1
"surgery duration, min",1
surgery for primary tumor,1
surgery for recurrence for current progression prior to enrollment,1
surgery on admission,1
surgery performed,1
surgery type,1
surgical bed inspection,1
surgical charachteristic:epiretinal membrane peeled,1
surgical characteristic: focal to grid breaks laser used,1
surgical characteristic: internal limiting membrane removed,1
surgical characteristic: vitrectomy system,1
surgical complexity scores,1
surgical cytoreduction,1
surgical duration,1
surgical indication: incontinence,1
surgical indication: prolapse,1
surgical lung biopsy (slb) to confirm diagnosis of ipf (per ivrs),1
surgical procedure performed,1
surgical procedure performed: concomitant incontinence procedure,1
surgical procedure performed: prolapse repair with abdominal hysterectomy,1
surgical procedure performed: prolapse repair with laparoscopic hysterectomy,1
surgical procedure performed: prolapse repair with vaginal hysterectomy,1
surgical procedure performed: prolapse repair without hysterectomy,1
"surgical procedure, customized",1
surgical proceedure,1
surgical risk [rand score],1
surgical site classification,1
surgical time,1
surgical type,1
survey language,1
susceptibility score,1
sustained attention to response task,1
"swallow response time (thin liquids), categorical",1
"swanson, nolan & pelham rating scale-revised (snap-iv): adhd combined score",1
"swanson, nolan & pelham rating scale - revised (snap-iv): adhd inattention subscale score",1
"swanson, nolan & pelham rating scale - revised (snap-iv): hyperactivity/impulsivity score",1
"swanson, nolan & pelham rating scale - revised (snap-iv): odd score",1
"swanson, nolan, and pelham rating scale revised (snap-iv)",1
sweat chloride test,1
switch from metformin (> 500 mg/day) to metact combination tablets,1
swollen and tender joints,1
swollen joint count (76 joints),1
swollen joint count (out of 66 joints),1
swollen joint counts (sjc),1
symbol digit,1
symptom assessment in dry eye (sande),1
symptom assessment in dry eye (sande) frequency score,1
symptom assessment in dry eye (sande) severity score,1
symptom checklist 90-r (scl90-r),1
symptom complexes at baseline,1
symptom duration,1
symptom onset to nicardipine infusion time,1
"symptom onset to randomization time, minutes",1
symptom onset to study drug infusion time,1
symptom score (afternoon and evening),1
symptom score (morning),1
symptom score for olp,1
symptom severity (ss) score,1
symptomatic,1
symptomatic (operated) spinal level,1
symptomatic [1],1
symptomatic bone disease,1
symptomatic qualifying artery,1
symptomatic splenomegaly,1
symptomatology,1
symptoms duration (years),1
symptoms of acute hepatitis b,1
symptoms of hypogonadism,1
syncope,1
syphilis infection,1
syphilis positive,1
"syphilis, #",1
systematic anti-cancer therapy stratification factor,1
systemic corticosteroids in past 12 monts,1
systemic glucocorticoid or antibiotic use within previous 12 mo,1
systemic lupus international collaborative clinics/american college of rheumatology(slicc/acc) score,1
systemic symptoms (b symptoms) (ann arbor staging),1
systemic urticaria,1
systemic vascular resistance,1
systolic and diastolic blood pressure,1
systolic blood pressure (bp),1
systolic blood pressure (mean),1
systolic blood pressure (sbp) at time of baseline,1
systolic blood pressure (sbp) pre-induction,1
systolic blood pressure at presentation in hospital emergency department (ed),1
systolic blood pressure categories,1
systolic blood pressure percentile,1
systolic blood pressure(sbp),1
"systolic blood pressure, mm mg",1
"systolic blood pressure, mmhg",1
"systolic bp, supine",1
"systolic bp, upright",1
systolic pressure,1
t-cell immunosuppressant use,1
t-score,1
t-score classification by inclusion criteria: a fracture in spine lumbar 1-4 and t-score â‰¤ -2.0],1
t-score classification by inclusion criteria: femoral neck t-score â‰¤ -2.5,1
t-score classification by inclusion criteria: femoral total t-score â‰¤ -2.5,1
t-score classification by inclusion criteria: spine (average of spine lumbar 1-4 ) t-score â‰¤-2.5,1
t-stage at study entry,1
t stage (categorical),1
t stage of tumor at diagnosis,1
t staging,1
t status,1
t1 enhancing lesions at baseline,1
t1 hypointense lesions volume at baseline,1
t1 lesion volume at baseline,1
t2 lesion volume at baseline,1
t2 lesions at screening,1
t2 lesions volume at baseline,1
t25fw at screening visit,1
t2dm,1
t2dm disease duration,1
t2dm duration,1
t3,1
t4,1
tachypnea for age,1
tacrolimus daily dose,1
tacrolimus trough level,1
taking antidepressant meds at baseline,1
taking biguanides,1
taking escitalopram 3 months prior to study entry,1
taking medications for chronic pain,1
taking opiods,1
taking psychotropic medication,1
taking ts prophylaxis,1
tamoxifen indication,1
tamoxifen therapy,1
tamoxifen treatment,1
tamoxifen use,1
tampon test,1
tanner adolescent pubertal self-assessment: breast (females),1
tanner adolescent pubertal self-assessment: genitalia (males),1
tanner adolescent pubertal self-assessment: pubic hair (females and males),1
tanner classification,1
tanner classification at randomization,1
tanner stage 1,1
tanner stage 3 or greater,1
tanner stage by physical examination,1
target diseases,1
target height,1
target height standard deviation score (sds),1
target induced astigmatism(tia),1
target joint,1
target joint for bleeds,1
target joints presence,1
target lesion location,1
target medication use,1
"target trough range (high), ng/ml",1
"target trough range (low), ng/ml",1
target vessel,1
target vessel location,1
targeted vision function,1
taxane regiment,1
tb diagnosis level at entry,1
tb treatment status,1
tbi severity,1
tc,1
tc / hdl-c ratio,1
tchol,1
tear break-up time (tbut),1
tear break-up time â± sd,1
tear film break-up time (tbut),1
teeth,1
teeth number,1
teg act (activated clotting time),1
teg angle,1
teg ly30,1
teg ma (maximal amplitude),1
temperature (celcius),1
temperature of room,1
tender joint count (78 joints),1
tender joint count (out of 68 joints),1
tender joint count at baseline,1
tender joint counts (tjc),1
tender point count (tpc),1
tender/painful joint count,1
"tendon friction rubs, n (%)",1
tenure with current cell phone number (months),1
testis volume,1
testosterone (t),1
testosterone (t) concentration,1
testosterone level,1
testosterone serum level,1
"testosterone, total",1
tg,1
"tg levels, continuous",1
thalamic localization,1
the aberrant behavior checklist,1
the adult patients with coronary artry disease,1
the barcelona-clinic liver cancer (bclc) stage at study entry,1
the cambridge pulmonary hypertension outcome review (camphor),1
the children's depression inventory (cdi),1
the clinical global impressions scale-severity,1
the concomitant surgery,1
the eastern cooperative oncology group (ecog) performance status,1
"the eastern cooperative oncology group performance status (ecog p.s.), customized",1
the executive interview (exit-25),1
the massachusetts general hospital cognitive and physical functioning questionnaire (mgh-cpfq) total,1
the mean number of years elapsed since graduation from dental school,1
the mean of patient bpi (brief pain inventory) scores,1
the mean of patient womac ( western ontario and mcmaster universities osteoarthritis index) subscale,1
the measure is of what contraceptive method the participants chose to use,1
the milwaukee inventory for styles of trichotillomania (mist) - child version,1
the multidimensional fatigue inventory (mfi) dimension scores,1
"the multidimensional scale of perceived social support : social support from ""special person""",1
the multidimensional scale of perceived social support: social support from family,1
the neurobehavioral symptom inventory,1
the number of participants at each stage of prostate cancer,1
the number of participants randomized to each treatment panel,1
the number of participants with an mva(motor vehicle accident) of a particular duration,1
the number of participants with detectable positive circulating tumor cells (ctcs=>1) at baseline,1
the number of participants with vertebral fractures,1
the number of subjects engaged in treatment at baseline,1
the numbers of valves implanted simultaneously,1
the patients were required to have received a prior iv bortezomib containing combination regimen tha,1
the patients with coronary artery disease,1
"the percentage of platelets that are ""coated-platelets"" as measured by dual-agonist stimulation",1
the rosenberg self-esteem scale score,1
the social responsiveness scale,1
the time for extracorporeal circulation and cross clamp in surgery,1
the trichotillomania scale for children (tsc)-child report,1
the trichotillomania scale for children (tsc)-parent report,1
the vineland adaptive behavior scales (vabs) - maladaptive behavior domain,1
the wide range achievement test-iv,1
therapeutic biliary sphincterotomy,1
therapeutic pancreatic sphincterotomy,1
therapy,1
therapy at enrollment - glucocorticoid,1
therapy at enrollment - pyridostigimine,1
therapy status,1
thiamine level,1
thiazolidinedione use,1
thigh circumference,1
thigh coronal angular velocity,1
those with and w/o mental health concerns as identified by each investigator,1
thought about getting help for pms,1
three factor eating questionnaire - disinhibition subscale,1
three factor eating questionnaire - hunger subscale,1
three factor eating questionnaire - restraint subscale,1
three item severity score,1
throat itching,1
throat swelling,1
thromboembolic disease assessment,1
thrombolysis in myocardial infarction (timi) flow,1
thromboxane b2 (txb2) measured at baseline n=(53;20;23;93;30;30;90;31;30;67;467),1
thrombus present (post-procedure),1
thrombus present (pre-procedure),1
thymic reactivity - investigator-based assessment,1
thymidylate synthase enhancer region (tser) genotype,1
thyroid-stimulating hormone,1
thyroid disease,1
thyroid hormone substitution,1
thyroid peroxidase antibody,1
thyroid stimulating hormone (tsh),1
thyrotropin,1
"tick bites in previous year, continuous",1
time (in months) from current pathological diagnosis to enrollment,1
time (years) from first attack to study day 1,1
time after injury in days,1
time asleep (habitual and desired),1
time between completion of chemo to randomization,1
time between diagnosis of primary and metastatic disease,1
time between symptom onset and diagnosis,1
time between the 2 loading doses,1
time between visits,1
time constant 1 (t1) cerebral volume,1
time constant 2 (t2) lesion volume,1
"time elapsed from stroke, years",1
time from 1st documented metastasis/relapse to study entry,1
time from admission to the hospital to admission to icu,1
time from advanced ncslc diagnosis to consent,1
time from allogeneic stem cell transplant,1
time from cancer diagnosis to start of study therapy,1
time from chronic gvhd onsent,1
"time from current kidney transplant to enrolment, months",1
time from current transplantation to randomization,1
time from diagnosis of chronic colonization of p. aeruginosa,1
time from diagnosis of rheumatoid arthritis,1
time from diagnosis to first dosing,1
time from diagnosis to radiotherapy,1
time from diagnosis to randomization,1
time from diagnosis to v-beam transplant,1
time from diagnosis to vns therapy,1
time from dispatch call to first intravenous/intraosseous access (iv/io),1
time from drug administration to parental separation (minutes),1
time from dvt diagnosis to randomization,1
time from end of surgery to first dose,1
time from endometriosis diagnosis,1
time from first clinical event to randomization,1
time from first crt implant,1
time from first cystic fibrosis diagnosis,1
time from first diagnosis,1
time from first documented metastatic disease to study entry,1
time from first multiple sclerosis (ms) symptom,1
time from first pathological diagnosis,1
time from index acs event to randomization,1
time from index stroke to randomization,1
time from initial cancer diagnosis to enrollment,1
time from initial diagnosis of bone metastasis,1
time from initial diagnosis of nsclc to randomization,1
time from initial diagnosis to randomization,1
time from initial diagnosis to registration,1
time from initial documented hiv infection,1
time from initial gastrointestinal stromal tumor (gist) diagnosis to consent,1
time from initial pathological diagnosis to enrollment,1
time from initial prostate cancer diagnosis,1
time from initial scleroderma diagnosis to start of study,1
time from initial tumor diagnosis,1
time from injury,1
time from injury to surgery for revision patients,1
time from injury to surgery for traumatic/pathologic patients,1
time from last chemotherapy,1
time from last diagnosis to enrollment,1
time from last dose of bevacizumab,1
time from last menstruation to first dose,1
"time from last menstruation to first dose, customized",1
time from last prior therapy,1
time from metastatic/unresectable gist diagnosis to consent,1
time from onset/diagnosis of focal segmental glomerulosclerosis to study enrollment/consent,1
time from primary diagnosis and from first metastasis/relapse to study entry,1
time from primary diagnosis to metastatic disease,1
time from primary surgery to isolated loco-regional recurrence (ilrr) surgery,1
time from prior treatment,1
time from qualifying event to randomization,1
time from qualifying to randomization,1
time from radiotherapy to study enrollment,1
time from shunt palliation to randomization,1
time from stroke onset to initiation of iv rt-pa,1
time from stroke to randomization,1
time from study qualification to study drug start,1
time from surgery or previous postoperative adjuvant therapy to administration of study drug,1
time from surgery to first treatment dose,1
time from surgery to lymphedema diagnosis,1
time from surgery to the start of treatment,1
time from symptom onset,1
time from the dry eye diagnosis,1
time from the first allergic rhinitis symptom to visit 1,1
time from transplant to first dose,1
"time homeless, current episode",1
time hub in place,1
time in dialysis,1
time in haart,1
time in icu before qualifying,1
time in years since diagnosis of hypertension,1
time insulin free,1
time interval between episodes,1
"time of first diagnosis of aa who grade iii (years) (descriptive analysis, only)",1
time of first study medication since first progression,1
time of first study medication since initial diagnosis,1
time of first study medication since most recent progression,1
time of latest chemotherapy completion,1
time of onset of second organ dysfunction to start of drug infusion,1
time of prior antiretroviral therapy use,1
time of treatment resistance,1
time off immunosuppression before protocol enrollment,1
time on antiretroviral treatment (art),1
time on background therapy,1
time on current antiretroviral regimen,1
time on dialysis,1
time on enfuvirtide therapy,1
time on opioids,1
time on treadmill constant workrate test,1
time post-stroke,1
time post onset of stroke,1
time post tbi,1
time poststroke,1
time since acromegaly diagnosis,1
time since af diagnosis,1
time since art initiation,1
time since asthma diagnosis,1
time since central retinal vein occlusion (crvo) diagnosis,1
time since chronic kidney disease diagnosis,1
time since current cancer diagnosis,1
time since diagnosis (years),1
time since diagnosis of cancer,1
time since diagnosis of chronic hand dermatitis (years),1
time since diagnosis of chronic hepatitis b,1
time since diagnosis of copd,1
time since diagnosis of essential hypertension,1
time since diagnosis of neuropathic pain,1
time since diagnosis of secondary hyperparathyroidism,1
"time since diagnosis, y",1
"time since end of first cancer treatment, weeks",1
time since first antipsychotic treatment (years),1
time since first diagnosis of primary cancer,1
time since first ms diagnosis,1
time since first ms symptoms,1
time since first transplant,1
time since first treatment for cancer,1
time since hbv diagnosis,1
time since histological diagnosis,1
time since hiv-infection diagnosis,1
time since hiv diagnosis (days),1
time since hiv infection,1
time since human immunodeficiency virus (hiv) infection diagnosis,1
time since initial cancer diagnosis,1
time since initial diagnosis (years),1
time since initial diagnosis of adhd,1
time since initial pathological diagnosis,1
time since initial treatment with radium-223 dichloride,1
time since injury,1
time since last cannabis use,1
time since last gout flare,1
time since last ibd flare-up (months),1
time since last ofp dose (months),1
time since last pituitary surgery,1
time since last relapse,1
time since last somatostatin analogue treatment,1
time since last suicide attempt,1
time since mds diagnosis,1
time since myelofibrosis diagnosis,1
time since onset of adhd,1
time since onset of adhd symptoms,1
time since onset of ibs symptoms,1
time since onset of multiple sclerosis,1
time since onset of symptoms,1
time since patient stopped smoking,1
time since pd diagnosis,1
time since pd diagnosis (years),1
time since postmenopausal osteoarthritis diagnosis,1
time since primary diagnosis to first dose,1
time since schizophrenia diagnosis (years),1
time since smoking cessation,1
time since start of dialysis,1
time since start of esa therapy,1
time since starting haemodialysis,1
time since starting pth(1-84),1
time since stroke to randomization - days,1
time since tamoxifen ended,1
time since transplant,1
time since transplantation,1
time since treatment,1
time to active phase,1
time to art start from start of tb medications,1
time to complete modified emory functional ambulation profile (mefap) in seconds,1
time to disease progression on completion of the previous platinum therapy,1
time to fall asleep (habitual and desired),1
time to first analgesic on unit (min),1
"time to first cigarette,< or = 30 minutes",1
"time to first diagnosis of secondary gbm (years) (descriptive analysis, only)",1
time to first morning cigarette,1
time to first ms symptom,1
"time to first vaccine (from day 0 of hct), mo",1
"time to hct to relapse, mo",1
time to positivity on mgit sputum culture,1
time to progression,1
time to progression from first transplant,1
time to recovery,1
time to recovery from maximal percent fall in fev1 after exercise challenge,1
time to recurrence,1
time to screening,1
time until admission,1
time until treatment,1
time with suppressed hiv-1 rna prior to study entry,1
timed get up and go,1
timed stair climb,1
timed up and go,1
timed up and go time,1
timed walking speed,1
timeline followback,1
timi risk score,1
timi score,1
timing of delivery,1
timing of initial delayed release (dr) tablet administration on awakening,1
timing of initiation of glimepiride before the start of study treatment,1
timing of initiation of pioglitazone and glimepiride before the start of study treatment,1
timing of initiation of pioglitazone before the start of study treatment,1
timing of symptom onset,1
tinnitus functional index,1
tinnitus functional index (tfi),1
tinnitus loudness,1
tinnitus pitch,1
tired of hearing about hiv prevention information,1
tissue echogenecity,1
tissue reconstruction with the neurocutaneous island flap,1
tissue thickness,1
tissue type,1
tlc (l) (total lung capacity) observed,1
tlc percent of liters predicted,1
tls risk,1
tmt a: baseline total score,1
tmt b: baseline total score,1
tnf-î± (pg/ml),1
tnf-î± secretion by ex vivo lps-stimulated peripheral blood mononuclear cells,1
tnf alpha,1
tnm classification at diagnosis: m,1
tnm classification at diagnosis: n,1
tnm classification at study entry,1
"tnm classification: clinical tumor stage t, customized",1
tnm classification: m0,1
"tnm classification: regional lymph node stage n, customized",1
"tnm staging (stage), customized",1
tobacco,1
tobacco abuse,1
tobacco cigarette smokers,1
tobacco classification,1
tobacco consumption status,1
tobacco history,1
tobacco pack years,1
"tobacco use disorder diagnosis, past 36 months",1
tobacco use status,1
tobacco use status at baseline,1
"tobacco use, pack-years",1
tobramycin minimal inhibitory concentration (mic) value,1
tolerability of cls,1
tolerance evaluated by investigator,1
tongue dose,1
"tongue strength, continuous",1
tooth,1
tooth area scheduled for surgery,1
tooth extraction,1
tooth type,1
topoisomerase-1(+),1
torsion adapter stiffness,1
total-fmean,1
total-fpeak,1
total-glutathione,1
total-imax,1
total-imean,1
total-si,1
total alcohol dependence scale (ads) score,1
total annual household income,1
total auditory hallucination rate scale (ahrs) score,1
total bilirubin (umol/l),1
total bilirubin level,1
total bilirubin(tbil),1
total blood volume (ml),1
total blood volume (tbv),1
total body fat percent,1
total body surface area burned,1
total body surface area surgically injured,1
total burn surface area,1
total cases using an open approach,1
total cholesterol (mg/dl),1
total cholesterol (tc):high density lipoprotein-c (hdl-c) ratio,1
total cholesterol concentration,1
total cholesterol risk,1
total cholesterol(normal values range from 3.1-5.2 mmol/l),1
total cholesterol(tc),1
"total cholesterol, continuous",1
total cholesterol/hdl cholesterol,1
total cholesterol/high density lipoprotein-cholesterol (hdl-c) ratio,1
total cholesterol:high-density lipoprotein-c ratio,1
total cholesterol:high density lipoprotein-cholesterol (hdl-c) ratio,1
total cholesterol:high density lipoprotein cholesterol (hdl-c) ratio,1
total circumference measurement,1
total couples with sensitive skin,1
total daily actual insulin dose-continuous subcutaneous insulin infusion,1
total daily actual insulin dose - multiple daily injections,1
total daily basal insulin infusion,1
total daily bolus insulin dose,1
total daily dose hydrocortisone treatment prior to randomization,1
"total daily dose of 3,4-dap at randomization",1
total daily dose of basal insulin injection at baseline,1
total daily dose of bolus insulin injection at baseline,1
total daily dose of inhaled glucocorticosteroids (ics),1
total daily dose of loop diuretic,1
total daily steps,1
total danish prostatic symptom score (dan-pss-1),1
total days of current bleeding episode,1
total donor-specific antibodies (dsa),1
total dysmenorrhea score,1
total dysmenorrhea score (vrs; verbal rating scale),1
total energy expenditure,1
total enrollment numbers,1
total enthesitis count,1
total facial actinic keratosis count,1
total fat mass,1
total function capacity,1
total genant-modified sharp score,1
total geriatric depression scale (gds) score,1
total gleason score,1
total gleason score at initial diagnosis,1
total hamilton depression rating scale (ham-d17) score,1
total hand eczema severity index (hesi),1
total hemoglobin,1
total high order aberration (hoa) changes â± sd,1
total hip bmd t-score,1
total hip bone mineral density (bmd),1
total home daily insulin dose,1
total household income,1
total hysterectomy,1
total international index of erectile function (iief) score,1
total international index of erectile function score - all domains,1
total international prostate symptom score (i-pss),1
total international prostate symptom score (ipss) storage score,1
total international prostate symptom score (ipss) voiding score,1
total kidney stones passed,1
total lesion counts at baseline,1
total limb fat,1
total milk bacterial count (initial),1
total mini-mental state examination (mmse) score,1
total montgomery-ã…sberg depression rating scale (madrs) score,1
total mutuality (continuous),1
total nasal (tnss) and total ocular (toss) symptom scores,1
total nasal symptom score (am + pm),1
total neuropsychiatric inventory score,1
total no. of acute bipolar mania episodes over lifetime,1
total nonalcoholic fatty liver disease (nafld) activity score,1
total norm auc average,1
total number ak lesions (grade 1/2),1
total number covering,1
total number of disease recurrences,1
total number of injections per day,1
total number of lesions per subject,1
total number of prior interventions at the target lesions,1
total number of prior interventions to the current prosthetic graft or circuit,1
total number of prior lines of treatment,1
total number of prior treatment regimens,1
total number of psychotherapy mental health visits,1
total number of relapses,1
total number of sites (maxilla vs mandible),1
total occlusion,1
total occlusion (per patient),1
total out-of-hospital time,1
total participants,1
total pelvic pain score (using modified mccormack score),1
total percentage of monitoring time esophageal ph <4,1
total peripheral blood eosinophils,1
total plasma bilirubin concentration,1
total plasma homocysteine,1
total plasma protein concentration,1
total positive and negative syndrome scale (panss) score,1
total protein,1
total proximal femur bmd,1
total proximal femur bmd t-score,1
total psa,1
total radiation dose prescribed,1
total range of motion (rom) worse hip,1
total retinal volume (mm^3),1
total sequential organ failure assessment (sofa) score,1
total serum immunoglobulin e (ige),1
total serum immunoglobulin e (ige; ku/l),1
total serum testosterone,1
total size of target lesions,1
total sppb score,1
total stage shifts,1
total stent length (per-patient),1
total strength (kg),1
total sum score of the short physical performance battery test,1
total surface area (length x width),1
total syntax score,1
total testosteron serum level,1
total testosterone (ng/ml),1
total testosterone level,1
total testosterone level <250 ng/dl,1
total thickness at fovea,1
total urgency frequency score (tufs) (previous known as total urgency score (tus),1
total urgency frequency score (tufs) (previously known as total urgency score ([tus]),1
total vessel volume,1
total voriconazole plasma concentration,1
total walking distance,1
total years of smoking,1
tourette's disorder duration,1
tq-score,1
trail making test - a,1
trail making test - b,1
trained sentence probes,1
trainee involvement,1
tramadol,1
trans-atlantic inter-society consensus (tasc ii) type,1
transcutaneous oxygen saturation at randomization,1
transepidermal water loss (tewl),1
transformed disease from prior non-hodgkin lymphoma,1
transfusion dependence - platelets,1
transfusion dependence status - rbcs,1
transfusion dependency,1
transfusion required,1
transfusions,1
transient ischaemic attack,1
transient ischemic attack (tia) or stroke,1
transplant donor type,1
transplant number,1
transplantation patients,1
transplantation type,1
trap 5b,1
trauma as primary reason for hospital admission,1
traumatic brain injury at baseline,1
treated by basal insulin at baseline,1
treated by bolus insulin at baseline,1
treated by mixed (bolus & basal) insulin at baseline,1
treated for prior recurrence,1
treated vessel,1
treating institutions,1
treatment,1
treatment adherence,1
treatment cohort,1
treatment failure prior to baseline,1
treatment for pd - catechol o-methyltransferase inhibitor,1
treatment given for previous episodes,1
treatment modalities,1
treatment naive,1
treatment of pd - agonist,1
treatment of pd - amantadine,1
treatment of pd - anticholinergic,1
treatment of pd - levodopa,1
treatment period,1
treatment received in previous trial (nct00558467),1
treatment satisfaction questionnaire for medication (tsqm),1
treatment satisfaction score (diabetes treatment satisfaction questionnaire [dtsq]),1
treatment setting,1
treatment site,1
treatment stage (excluding posteroperative adjuvant chemotherapy),1
treatment with long-acting î²2 agonist (laba) at baseline.,1
treatment(s) for prior infections,1
tremors,1
triacylglycerol,1
triage fever >= 38 degrees celsius,1
triage vitals: blood pressure (diastolic),1
triage vitals: blood pressure (systolic),1
triage vitals: heart rate,1
triage vitals: oxygen saturation,1
trial of labor,1
triamcinolone acetonide used to improve visualization,1
trichiasis,1
"trichomoniasis, #",1
tricuspid annular plane systolic excursion (tapse),1
tricuspid regurgitant jet velocity (trv),1
tricuspid regurgitation,1
triglyceride (mg/dl,1
triglyceride (tg),1
triglyceride (tg) level,1
triglyceride levels,1
triglyceride levels â‰¥150 mg/dl,1
triglyceride risk,1
triglyceride(normal values range from 0-1.7 mmol/l),1
triglyceride(tg),1
"triglyceride, continuous",1
triglycerides (mmol/l),1
triglycerides concentration,1
triglycerides fractional clearance rate,1
triiodothyronine (t3),1
triple negative,1
triptans for acute migraine,1
trochanter bmd,1
troponin i,1
trough clinic dbp categories (mmhg),1
trough clinic diastolic blood pressure (dbp),1
trough clinic sbp category (mmhg),1
trough clinic systolic blood pressure (sbp),1
trough forced expiratory value (fev1),1
trunk-to-limb fat ratio,1
"trunk fat, limb fat, total body fat",1
trunk lean,1
trunk to limb fat ratio,1
trypan blue used to improve visualization,1
tsat% at baseline,1
tsb at birth,1
tser genotypes,1
tsqm (treatment satisfaction questionnaire for medication )domain scores,1
tss,1
tumor-node-metastasis (tnm) classification at diagnosis: t,1
tumor-node-metastasis (tnm) stage of disease,1
tumor anatomical location,1
tumor burden in skin,1
tumor burden: extrahepatic spread,1
tumor burden: macroscopic vascular invasion,1
tumor cell type,1
tumor characteristic,1
tumor diagnosis,1
tumor diagnosis (malignant neop-lasms icd10),1
tumor diameter,1
tumor diameter (1),1
tumor diameter (2),1
tumor differentiation grade,1
tumor distance from anal verge (cm),1
tumor histological type,1
tumor histology and grade,1
tumor hormone receptor status,1
tumor location (siewert type),1
tumor location: number of sites involved,1
tumor necrosis factor-alpha (tnf-alpha),1
tumor necrosis factor-alpha (tnf-î±),1
tumor necrosis factor alpha,1
tumor node metastasis(tnm) classification (at start of treatment with leuplin sr 11.25 mg injection),1
tumor node metastatis (tnm) stage,1
tumor response,1
tumor size (cm),1
tumor size (cm) mean,1
tumor size (cm) median,1
tumor size after debulking surgery,1
tumor stage at randomization,1
tumor stage at study start - primary tumor stage (t),1
tumor stage at study start - regional metastasis (n),1
tumor stage iv,1
tumor subsite,1
tumor type at initial pathological diagnosis,1
tumor type for initial disease diagnosis,1
tumor type stratification factor,1
tumor volume,1
tumour-related pain,1
tumour enhancement,1
tumour grade,1
tumour histology,1
tumour history,1
tumour location,1
twin pregnancy,1
two-hour glucose,1
two hour glucose,1
two or more fractures in spine (lumbar 1-4),1
two prior aromatase inhibitor therapy,1
twstrs severity (toronto western spasmodic torticollis rating scale),1
tympanic temperature,1
tympanogram type in worst ear,1
type-4 titer,1
type-7 titer,1
type 1 diabetes,1
type 1 diabetes mellitus,1
type 2 diabetes duration,1
type 2 diabetes mellitus,1
type ii diabetes mellitus,1
type of acute bacterial skin and skin structure infections (absssi) infection,1
type of acute myeloid leukemia (aml),1
type of adenocarcinoma,1
type of allergic rhinitis,1
type of analgesia:peripheral nerve blocks analgesia,1
type of anti-thymocyte globulin administered,1
type of cancer-gastrointestinal stromal tumor,1
type of care-giving: patient lives at nursing home,1
type of cerebral palsy,1
type of chemotherapy,1
type of crystalloid therapy,1
type of disease,1
type of disease progression,1
type of donation,1
type of dvt treatment,1
type of fibroid present,1
type of hae,1
type of health insurance,1
type of hematologic malignancy,1
type of hydronephrosis,1
type of infection,1
"type of infection, pre-treatment",1
type of infertility,1
type of initial shunt palliation,1
type of injury leading to suspected dti,1
type of insulin at first overnight visit,1
type of insurance (public/private),1
type of kidney donor,1
type of last erythropoiesis stimulating agent (esa) therapy prior,1
type of leukemia,1
type of malignancy,1
type of mastectomy (antisepsis side),1
type of mastectomy (control side),1
type of menopause,1
type of mental health disorder,1
type of metastatic disease,1
type of ms,1
type of myeloma,1
type of needle sensation ever experienced,1
type of non-melanoma skin cancer,1
type of nonproteinuric hypertension,1
type of nrti in background regimen,1
type of oab,1
type of onset of disease (classification of first demyelinating event),1
type of operation,1
type of operation (antisepsis side),1
type of operation (control side),1
type of orthopedic surgery,1
type of pci,1
type of periodontal surgical intervention,1
type of pessary,1
type of pi in background regimen (excluding ritonavir),1
type of preeclampsia,1
type of pregnancy,1
type of preoperative antibiotic,1
type of pretransplant conditioning regimen,1
type of previous attacks at enrollment,1
"type of prior therapy, no.",1
type of progression at study entry,1
type of radiation,1
type of radiotherapy,1
type of reconstruction (antisepsis side),1
type of reconstruction (control side),1
type of resection,1
type of residence,1
type of risk factor,1
type of seizures,1
type of sickle cell disease,1
type of sleep disorder (major symptoms),1
type of sleep disorders (major symptoms),1
type of stroke: ischemic/hemorrhagic,1
type of supplemental oxygen,1
type of surgery:calcaneal osteotomy,1
type of surveying method after vaccination,1
type of systemic-to-pulmonary artery shunt palliation,1
type of therapy,1
type of third-space fluid,1
type of tissue,1
type of tobacco use,1
type of transplantation,1
type of trauma,1
type of trauma (for trauma subjects),1
type of treatment,1
type of trials participants were enrolled,1
type of unit,1
type of urinary diversion,1
types of conventional treatment,1
types of diabetes mellitus,1
types of hypertension,1
types of lesions,1
types of oral antidiabetic medication combinations administered at baseline,1
types of trauma,1
typing speed,1
ùage,1
uci myo (ml/min),1
ucla sani score,1
udi score,1
ulcer duration,1
ulcer duration (weeks),1
ulcer location,1
ulceration,1
ulceration of primary tumor,1
ultrafiltration,1
ultrasound completed to assess eligibility,1
ultrasound examination,1
um-qol eating score,1
umbilical cord cross-sectional area,1
unaided acceptable noise level test,1
unaided words-in-noise test,1
unbound voriconazole plasma concentration,1
uncomplicated urinary tract infection symptom score,1
uncontrolled malignancy,1
uncontrolled malignancy status,1
uncope,1
uncorrected distance visual acuity,1
uncorrected visual acuity (logmar) â± sd,1
under the knee cast,1
underlying cause of hyponatremia,1
underlying conditions,1
underlying diagnosis,1
underlying disease:dm,1
undetectable hiv-1 rna (< 50 copies/ml),1
undetectable viral load (<48),1
unexplained syncope,1
unfavorable cytogenetics (at initial diagnosis),1
unified parkinson's disease rating scale (updrs) activities of daily living (adl),1
unified parkinson's disease rating scale (updrs) adl subsection (mean),1
unified parkinson's disease rating scale (updrs) mental,1
unified parkinson's disease rating scale (updrs) motor,1
unified parkinson's disease rating scale (updrs) motor subsection (part iii),1
unified parkinson's disease rating scale (updrs) total,1
unified parkinson's disease rating scale (updrs) total score,1
unified parkinson's disease rating scale (updrs) total score for period 1,1
unified parkinson disease rating scale part 3 motor evaluation,1
unified parkinsons disease rating scale-motor subsection (updrs iii),1
unilateral inguinal hernia,1
unilateral obstruction,1
unipolar or bipolar depression,1
unique patients/yr,1
unit placement,1
united kingdom scleroderma functional score (ukfs),1
united network for organ sharing (unos) status,1
united parkinson's disease rating scale (updrs) score total,1
units of packed red blood cell pre planned (number),1
"university of california, los angeles hoarding severity scale",1
university of pennsylvania smell inventory test (upsit),1
unprotected anal or vaginal sex with woman,1
unprotected anal sex with man in past 30 days,1
unrelated donor,1
unresectable disease,1
untrained sentence probe,1
untreated disease burden,1
untx/cr,1
updrs- section iii score,1
updrs (part iii),1
updrs (part iii) total score,1
updrs adl,1
updrs iii scores at baseline,1
updrs mental,1
updrs motor,1
updrs motor score for period 1,1
updrs motor score for period 2,1
updrs motor score for period 3,1
updrs parts ii and iii score,1
updrs score,1
updrs total score for period 2,1
updrs total score for period 3,1
upper gi abnormalities at diagnosis,1
upper incisors status,1
urbanicity,1
urea reduction ratio,1
ureteral stent at transplant,1
urge-to-cough,1
urge incontinence,1
urgency,1
urgency episodes per day,1
urgency episodes/24 hours,1
urgency incontinence episodes /24 hour,1
urgency incontinence episodes/24 hours,1
urgency of picc order,1
urgent care or ed visits in prior year,1
urinalysis - blood,1
urinalysis - glucose,1
urinalysis - ketones,1
urinalysis - leukocytes esterase,1
urinalysis - ph,1
urinalysis - values - nitrite,1
urinalysis - values - protein,1
urinary albumin ratio(normal values range from 0-30 mg/g),1
urinary albumin to creatinine ratio,1
urinary aldosterone excretion rate at baseline,1
urinary catheter type,1
urinary clearance (ucl) dci (ml/min),1
urinary continence status at baseline,1
urinary frequency,1
urinary incontinence (positive pad test),1
urinary incontinence (prevalence),1
urinary keratan sulfate measures,1
urinary management,1
urinary n-telopeptide (untx) level,1
urinary n-telopeptide (untx)value from baseline,1
urinary peak flow rate (qmax),1
urinary protein,1
urinary protein: creatinine ratio,1
urinary sugar,1
urinary tract infection,1
urinary tract infection (uti) history in the last 3 months,1
urinary tract infection (uti) history within the last 3 months,1
urine-m protein,1
urine albumin,1
urine albumin-to-creatinine ration,1
urine albumin creatinine ratio,1
urine albumin to creatinine ratio,1
urine albumin/creatinine at enrollment,1
urine calcium/creatinine,1
urine creatinine (24 hour collection),1
urine gb3,1
urine leakage measured by 1-hour pad test,1
urine lte4,1
urine m protein,1
urine n-telopeptide cross linked,1
urine n-telopeptides/creatinine ratio,1
urine protein,1
urine protein-to-creatinine ratio,1
urine protein-to-creatinine ratio (24 hour collection),1
urine protein (24 hour collection),1
urine toxicology screenings during treatment,1
urine type 1 collagen cross-linked n-telopeptide (ntx),1
urine uric acid,1
uroflowmetry (ufr) measure of maximum flow rate (qmax),1
usage of cardiac medication,1
usage of incontinence aids,1
usage of tamoxifen/aromatase inhibitors,1
use of ace inhibitors,1
use of antibiotics,1
use of anticoagulants,1
use of daily proton-pump inhibitors (ppis),1
use of diabetes medications,1
use of hearing aid,1
use of idiopathic thrombocytopenic purpura medication at baseline,1
use of insulin,1
use of kidney stone drug,1
use of lipid-lowering agent,1
use of mechanical dvt preventive devices,1
use of nicotine,1
use of nicotine products,1
use of other measures by participants,1
use of other treatments during intervention phase,1
use of pharmacological assistance to sleep,1
use of photons for <20% radiation dose,1
use of prior pis,1
use of proton pump inhibitor (ppi),1
use of respiratory medications in prior 2 weeks,1
use of rhdnase,1
use of self-applied permethrin on clothing,1
use of statins,1
use of supplemental oxygen within previous 12 mo,1
use of systemic antibiotics prophylaxis,1
use of tenofovir,1
use of tick bite prevention measures,1
use of tobacco products,1
use of trastuzumab at time of registration,1
use of vasopressor,1
use oral contraceptives,1
use sunscreen daily,1
used beta agonist in past 3 days,1
used diabetic supplies,1
using a medication reminder tool,1
using botulinum toxin for migraine prevention,1
using psychotropic medication,1
usual gait speed,1
uterine volume,1
uui episodes per 24 hours,1
v02 max - maximal oxygen consumption,1
vaccine naive,1
vaginal atrophy,1
vaginal bleeding before study drug administered,1
vaginal erosions,1
vaginal parity,1
vaginal ph at screening,1
vaginal sex in the past month,1
vaginal swab test,1
variceal bleeding,1
varicocele,1
vas baseline (cm),1
vas for leg pain preoperatively,1
vas for lumbar pain preoperatively,1
vas pain (0-100),1
vas pain score,1
vas score at baseline - continuous,1
vas score at baseline stratified by pain intensity,1
vas scores range from 0 (no pain) to 10 (severe pain),1
"vas sij pain score, mean",1
vascular access type,1
vascular injuries,1
vascular involvement,1
vascular risk factors (eg. hypertension),1
vascular/splenectomy/aaa,1
vasomotor symptom (vms) number of participants with number of hot flashes / day,1
vasomotor symptoms (vms) as number of hot flashes,1
vasopressor infusion,1
vasopressor score,1
vasopressor use,1
vcss,1
vdi,1
veines-sym score,1
venous thrombosis risk factors,1
ventilator mandatory rate,1
ventricular arrhythmia history,1
ventricular arrhythmias,1
ventricular depolarization (qrs) duration,1
ventricular ejection fraction,1
ventricular gradient,1
ventricular rate during af,1
ventriculoperitoneal shunt,1
verb naming,1
verbal learning - 1st immediate list a,1
verbal learning - list b immediate recall,1
verbal learning - long delay cued recall,1
verbal learning - long delay free recall,1
verbal learning - total trials 1-5,1
verbal memory domain z-score,1
verbal rating scale,1
vertebral fracture at baseline,1
vertical cup to disc ratio,1
vertical thickness,1
very-low-density lipoprotein cholesterol (vldl-c) concentration,1
very-low density lipoprotein (vldl),1
very low-density lipoprotein cholesterol (vldl-c),1
very low density lipoprotein cholesterol (vldl-c) concentration,1
vessel tortuosity,1
vf induction amount of participants,1
villalta score at baseline,1
vineland adaptive behavior composite score,1
vineland adaptive behavior scales-ii (vabs-ii) communication domain,1
viral load <50 copies/ml,1
viral load >10^3/mm^3 plasma,1
virus type identification,1
visceral abdominal tissue (vat) mass,1
visceral adipose tissue area,1
visceral disease at baseline,1
visceral disease in liver and/or lung,1
visceral disease site,1
visceral metastasis,1
visceral/subcutaneous adipose tissue area ratio,1
visual acuity (va) score,1
visual acuity 20/200 or worse,1
visual acuity 20/40 or better,1
visual acuity categorized by randomization strata,1
visual acuity during head movements,1
visual acuity in the amblyopic eye at randomization,1
visual acuity in the fellow eye at randomization,1
visual acuity letter score,1
visual acuity letter score (approximate snellen equivalent) by randomization strata,1
visual acuity score (letters correct),1
visual acuity score (vas) of the study eyes,1
visual analog scale (vas) degree of low back pain rating,1
visual analog scale (vas) degree of ulcer pain rating,1
visual analog scale (vas) overall pain severity,1
visual analog scale (vas) pain score,1
visual analog scale (vas) pain scores,1
visual analog scale (vas) score,1
visual analogue pain scale,1
visual analogue scale (vas) for primary dysmenorrhea,1
visual analogue scale for pain,1
visual analogue scale for pain (vas-pain),1
vit d,1
vital capacity,1
vital capacity percent predicted,1
vital signs: diastolic,1
vital signs: pulse,1
vital signs: systolic,1
vitamin a,1
vitamin b12 level,1
vitamin d-deficient: defined as serum 25(oh)d <20 ng/ml,1
vitamin d at baseline,1
vitiligo area scoring index,1
vldl cholesterol,1
vo2 peak,1
vo2 peak (% predicted),1
vo2max,1
vo2max (ml/kg/min),1
void volume,1
voided volume,1
voids per day,1
volatile sulfur compound,1
volume,1
volume of brain t2 lesions before first dose,1
volume of drug administered,1
volume of oxygen,1
volume of oxygen (vo2) at anaerobic threshold,1
volume of preparation: 4l,1
volume of residual tumor following debulking surgery,1
volume status/ underlying cause of hyponatremia,1
voriconazole daily dose,1
vorinostat treatment (schedule a/schedule b),1
vvsymq score,1
wagner classification,1
waist-hip ratio,1
waist-to-hip ratio (whr),1
waist abdominal circumference,1
waist and hip circumference,1
waist circumference (in cm),1
waist circumference (wc),1
waist circumference category,1
"waist circumference, centimeters",1
waist size,1
waist to height ratio,1
waist to hip ratio,1
waist to hip ratio (whr),1
waist:hip ratio,1
waistline circumference,1
wake norm area under the curve average by group,1
walked distance,1
walking distance,1
walking speed,1
walking speed (m/sec),1
wants to attend treatment (clients),1
warfarin,1
warfarin dose,1
warfarin use,1
was patient/relative/helper instructed in pth(1-84) (self) injection technique?,1
washout required,1
wasted,1
watch bp office minus doppler ankle-brachial index (abi) difference,1
waveform change in valsalva's maneuver,1
ways of diagnose,1
wbc,1
wbc (cells/ml),1
wbc at baseline,1
wbc count,1
wechsler abbreviated scale of intelligence (wais),1
wechsler abbreviated scale of intelligence (wasi),1
wechsler adult intelligence scaleâ€“digit span,1
week 0/day 1 psoriasis area severity index (pasi) score,1
weekly 24-hour average pain,1
weekly 24-hour average pain rating,1
weekly alcohol intake at baseline,1
weekly average of peak daily pruritus numerical rating scale (nrs),1
weekly average pain intensity score,1
weekly average pain score,1
weekly dose,1
weekly fecal incontinent days,1
weekly fecal incontinent episodes,1
weekly mean blood glucose,1
weekly mean of 24-hour average pain,1
weekly mean of 24-hour average pain rating using an 11-point numerical scale patient diary,1
weekly mean of 24-hour worst pain severity,1
weekly mean of nighttime pain severity,1
weekly mean of the daily worst pain severity,1
"weekly means of 24-hour average pain, worst pain, and night pain diary scores",1
weekly peak averaged pruritus numeric rating scale (nrs),1
"weekly rating of evening & morning behavior-revised-investigator rated, total & subscores",1
weekly topical estrogen,1
weekly urgent fecal incontinent episodes,1
weeks from achei initiation to randomization,1
weeks of gestation,1
weeks post partum,1
"weight-for-age z-score: period 1 (trial enrollment, cdm vs lcm)",1
"weight-for-age z-score: period 2 (trial enrollment, induction art)",1
weight-for-age z-score: period 3 (randomization to once vs twice daily abc+3tc),1
weight-for-age z-score: period 4 (randomization to stop versus continue cotrimoxazole),1
weight-for-stature z-score,1
weight-kg,1
weight (in kgs),1
"weight (kg) (descriptive analysis, only)",1
weight (kgs),1
weight (n=32),1
"weight 39-169 kg, inclusive",1
weight and height percentiles overall,1
weight at day 0,1
weight at day 1,1
weight at enrollment,1
weight at inclusion,1
weight at infusion,1
weight at pretreatment,1
weight at randomisation,1
weight at screening,1
weight at study entry,1
weight at time of study,1
weight at transplant,1
weight at visit 2 (week 0),1
weight category by body mass index (bmi),1
weight current,1
weight customized,1
weight in kgs,1
weight in kilograms (kg),1
weight loss during initiation phase,1
weight loss during last 3 months,1
weight loss over last 3 months,1
weight loss past 6 months,1
weight loss prior 6 months,1
weight mean score,1
weight percentile,1
weight quartile,1
weight sd score,1
weight z-score,1
weight z score,1
weight(female),1
weight(kg),1
weight(male),1
"weight, categorized",1
"weight, group",1
"weight, kilogram (kg)",1
"weight, kilograms",1
weight: adult population,1
weight: pediatric population,1
weighted pinprick stimulator-induced mechanical pain,1
"weihgt, kg",1
wender-reimherr adult attention deficit disorder scale,1
western aphasia battery,1
western ontario and mcmaster universities arthritis index (womac),1
western ontario and mcmaster universities index of osteoarthritis physical function score,1
western ontario and mcmasters universities osteoarthritis index (womac),1
western ontario mcmaster universities osteoarthritis index (womac) scores,1
what is your highest education level?,1
what is your household(s) average monthly income?,1
wheat ige,1
wheat igg4,1
wheat ofc dose at first symptom,1
wheat ofc successfully consumed dose,1
wheat skin prick test,1
wheezing,1
wheezing episodes in prior year,1
when is patient anxious at baseline?,1
when most recent suicide death,1
white,1
white blood cell,1
white blood cell (wbc),1
white blood cell count (10^9/l),1
white blood cell count (wbc),1
white blood cell counts,1
white blood cells,1
white blood cells (wbc),1
white blood cells at first diagnosis,1
white blood cells in peripheral blood,1
white race,1
who-ucla auditory verbal learning test (avlt): delayed,1
who-ucla auditory verbal learning test (avlt): trials total,1
who clinical staging,1
who do you live with?,1
who do you usually live with?,1
who functional class,1
who functional classification,1
who functional classification of pah,1
who functional health class,1
who is your primary caregiver?,1
who/ ecog performance status,1
whodas-ii disability score,1
whole body (with head) bmd (g/cm^2),1
whole body insulin sensitivity index,1
whole mouth average lobene modified gingival index,1
why-mpi general activity,1
why-mpi: pain severity score,1
widespread pain index (wpi),1
widest open,1
widest ridge width,1
wire-localization target,1
wire cannulation of pancreatic duct,1
wish to have more self-respect,1
with prior defect,1
withdrawal symptoms,1
wlq: percentage of productivity loss,1
womac a,1
womac disability scale,1
womac function score,1
womac index,1
womac pain subscale,1
womac physical-function score,1
womac physical function score,1
womac stiffness,1
womac va 3.1 a score (total pain),1
women and ischemia syndrome evaluation-number (wise),1
women and ischemia syndrome evaluation-severity (wise),1
women with live offspring,1
women: hdl cholesterol,1
wong-baker faces rating scale (frs) pain scores,1
wood smoke expossure,1
woodcock johnson achievement tests,1
word recognition score,1
word recognition score of target ear,1
"work division, categorical",1
work involves contact with persons with ebola,1
work limitations questionnaire (wlq),1
work productivity activity impairment questionnaire-psoriasis (wpai-pso),1
work productivity and activity impairment: psoriasis (wpai:pso),1
work situation,1
work status,1
"work status (n, %)",1
worker's compensation case,1
working alliance inventory short form,1
working currently,1
working status,1
workload (watts),1
world health organisation (who) functional class,1
world health organisation (who) performance status,1
world health organisation functional class,1
world health organization (who) classification of mds,1
world health organization (who) classification of pah,1
world health organization (who) functional classification,1
world health organization (who) functional classification for pah,1
world health organization (who) performance,1
world health organization acute myeloid leukemia (aml) classification,1
world health organization class,1
world health organization classification 2008 of mds by central review,1
world health organization classification of mds,1
world health organization functional class (who fc),1
world health organization functional class in participants with pulmonary arterial hypertension,1
world health organization grade (staging),1
world health organization grading for gliomas,1
"world health organization health and work performance questionnaire (hpq), absolute absenteeism",1
"world health organization health and work performance questionnaire (hpq), absolute presenteeism",1
world health organization performance status,1
world heath organization (who) class,1
worst numeric pain rating scale (nprs),1
worst pain intensity,1
worst pain intensity (wpi) score,1
wound age at randomization,1
wound area,1
wound area at randomization,1
wound classification,1
wound location,1
wound size at enrolment (cm^2),1
wrist's active range of motion,1
wrist's passive range of motion,1
wt z score,1
x ray lesions severity,1
x ray showing cavitation,1
xanthine consumption,1
xanthine/caffeine history,1
y-bocs baseline score,1
yale-brown obsessive compulsive scale,1
yale-brown obsessive compulsive scale (y-bocs),1
yale-brown obsessive compulsive scale (ybocs),1
yale-brown obsessive compulsive scale modified for bdd (bdd-ybocs),1
yale global tic severity scale,1
yale physical activity scale - index summary score,1
year diagnosed with hiv,1
year in college,1
year in residency,1
year since stroke,1
years at agency (staff),1
years diagnosed,1
years from diagnosis to screening,1
years from symptom onset to diagnosis,1
years from symptom onset to screening,1
years implanted with interstim therapy,1
"years in current position, continuous",1
years in field (staff),1
years in north america,1
years in position (staff),1
years living with diabetes,1
years living with hiv,1
years of alcohol use,1
years of antiretroviral treatment,1
years of atrial fibrillation,1
years of caregiving given or received,1
years of cognitive symptoms,1
years of diabetes,1
years of dm treatment,1
"years of education, continuous",1
years of injection,1
"years of pain, mean (range)",1
years of practice,1
years of proton-pump inhibitor use,1
years of regular smoking,1
years of residence in norway,1
years of running experience,1
years of tampon use,1
years on parkinson's disease medications,1
years on zidovudine (azt)/lamivudine (3tc),1
years post-amputation,1
years post-transplant,1
years post graduate trainee level,1
years post menopause,1
years postmenopausal,1
years pulmonary arterial hypertension (pah) present,1
years reported use of substances,1
years since asthma diagnosis,1
years since bipolar diagnosis,1
years since chronic graft-versus-host disease,1
years since copd diagnosis,1
years since diabetes diagnosis,1
years since employment,1
years since final menstrual period (postmenopausal only),1
years since hiv diagnosis,1
years since last hospitalization,1
years since last menstrual period (lmp),1
years since menopause,1
years since onset of generalized anxiety disorder (gad),1
years since parkinson's disease diagnosis,1
years since pd diagnosis,1
years since pd onset,1
years since renal diagnosis,1
years since rheumatoid arthritis (ra) diagnosis,1
years since scleroderma diagnosis,1
years since ssc diagnosis,1
years since start of pn/iv dependecy,1
years since started smoking daily,1
years since symptom onset,1
years since the first mdd episode,1
years since the first rosacea diagnosis,1
years since the most recent mdd episode,1
years with diabetes,1
years with hiv,1
years with hiv-associated diarrhea,1
years with hypertension,1
years with pms,1
years with rheumatoid arthritis,1
years with rheumatoid arthritis at baseline,1
years with systemic lupus erythematosus (sle) at baseline,1
ymrs,1
young-mania rating scale (y-mrs) total score,1
young mania rating scale,1
young mania rating scale (y-mrs) total score,1
young mania rating scale score (y-mrs),1
zap-70 expression,1
zarit burden scale,1
zarit caregiver burden scale at baseline,1
zcq,1
zheight,1
zubbrod performance status,1
zubrod performance score,1
zubrod score,1
zweight,1
